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Copy Number Variation (CNV) is a major source of genetic variation in the 
human genome, and contributes to human genetic diversity, diseases susceptibility 
and evolution. Elucidating their role requires understanding the distribution of CNV 
polymorphisms. This study has established a CNV catalogue for three Singapore 
populations using the Affymetrix SNP Array 6.0 and detection algorithm Birdsuite. A 
total of 2,227 CNV regions (CNVRs) were identified from 281 samples (100 
Chinese, 95 Malays, 86 Indians), and the various characteristics of CNVR, 
distribution, frequency, type, gene content, were studied. Quantitative PCR was used 
to validate array hybridisation-based genotypes. Common CNVRs that were 
population-specific or with high population differentiation were identified and the 
possibility of their high diversity due to natural selection were explored. This led to 
the identification of a locus near NEGR1 where the deletion CNVR is highly enriched 
in Chinese and Malays. The distribution of CNVRs among the three populations 
confirms the genetic relationship between Chinese and Malays are closer than that 
between Indians and either of the two groups. 
The Amylase genes, AMY1 and AMY2A, were studied as examples of 
multiallelic CNV. We developed an improved method of genotyping copy numbers 
by qPCR and digital PCR, allowing discovery of a novel distribution pattern of AMY1 
diploid copy number with even:odd copy number imbalance, due to underlying 
haplotype structures. Using this improved method, the population diversity of AMY1 
and AMY2A CNVs in the three populations was studied. I also applied this improved 
method to validate a recently reported association between AMY1 copy number and 
obesity in European and Singapore Chinese cohort, showing no evidence of 
association and reflecting genotyping error might have led to spurious result in the 
early study. This study highlighted the technical challenges faced in the field, and 





   
1.1 Introduction to Copy Number Variation (CNV) 
The central goal of human genetics is to understand the inherited basis of 
variation in phenotypes, elucidating human physiology, disease and evolution. To 
uncover the genetic basis of phenotypic differences, the study of phenotype-genotype 
correlation has been a main approach. Therefore, the availability of informative 
genetic markers is crucial and a comprehensive understanding of all forms of genetic 
variations is fundamental. 
Genetic variation in the human genome is now known to take many forms, 
ranging from single nucleotide change to large chromosomal events. Figure 1.1 
summarised the different type of variants, ranging from the ubiquitous single 
nucleotide polymorphisms (SNPs), to fine-scale changes such as small insertions and 
deletions (INDELs), microsatellite and minisatellite tandem repeats (STRs, VNTRs), 
retroelement insertions (LINEs & SINEs), larger scale structural variations such as 
inversions, translocations and Copy Number Variations (CNVs), to large microscopic 
chromosomal anomalies and even aneuploidy. These variations and polymorphisms 
constitute the dynamic human genome architecture and underlie the differences 
between individuals. 
 
1.1.1 Copy Number Variation as a Sub-class of Structural Variation  
Over the past decade, the sequencing of the human genome, as well as 
initiatives like the HapMap project (http://www.hapmap.org) and the 1000 Genomes 
project (http://www.1000genomes.org/); have greatly advanced our knowledge of 
human genetic variation. Just a decade ago, Single Nucleotide Polymorphisms 
(SNPs) were thought to be the most prevalent form of genetic variation in the human 
2 
 
genome. It is now realized that the millions of SNPs are not the only major 
contributor of genetic variation. Rather, much of the naturally occurring genetic 
variation consists of large-scale differences in genome structure, generally termed as 
Structural Variant (SV). These SVs comprise of several sub-classes; the most 
common being Copy Number Variation (CNV). Other SVs include genomic 
rearrangements such as inversions and translocations. Therefore, on top of SNP, SV / 
CNV add another dimension of variation to the genome. 
Structural variation (SV) is a broad term for genetic variants that alter 
chromosomal structure. It encompasses both cytogenetically visible and more 
commonly, submicroscopic variants, typically involving DNA segment >1 kb. SV 
may be quantitative like Copy Number Variant (CNV) (comprising deletion, insertion 
and duplication), or balanced changes involving position (translocation) or orientation 
(inversion) (Feuk et al. 2006a; Scherer et al. 2007; Sharp et al. 2006a). In short, CNV 
is unbalanced chromosomal rearrangement, while inversion and translocation are 
copy number neutral events, or balanced chromosomal rearrangement.   
CNV is a major subclass of SV. It is better understood because it is more 
amenable to genome-wide survey. Traditionally, an operational definition of CNV is 
a DNA segment that is 1 kb or larger, and present at variable copy numbers in 
comparison with a reference genome (Scherer et al. 2007). Recently with the advent 
of Next-Generation-Sequencing (NGS), the operational spectrum of SVs and CNVs 
has widened to include much smaller events (for example, those >50 bp in length) 
(Mills et al. 2011). In this thesis, the conventional definition of ≥1kb is adopted since 
this work was based on microarray technology. The focus of this thesis is CNVs 
between 1 kb and ~3 Mb. 
In this thesis, CNV is taken as singular and CNVs are in plural. CNV Region 
(CNVR) is the result of merging overlapping CNVs which creates the representation 
of a CNV locus. CNVR is a widely used term in CNV research. It measures the 






2 bp to 1,000 bp
• Microsatellites, minisatellites (STR, VNTR)
• Indel
• Inversion
• Repeat Elements (eg. SINEs, LINEs)
1 kb to submicroscopic (~3 Mb)
• Copy number variant (CNV)
• Segmental duplication (SD/LCR)
• Inversion, translocation
• Microdeletion, microduplication
Microscopic (~5 Mb) to submicroscopic (~3 Mb)
• Segmental aneusomy
• Chromosomal deletion – losses

































CNVR, this will be a discrete cassette of DNA; while in others, it will be a multiplex 
arrangement of variant units in close proximity forming a CNV region. A Copy 
Number Polymorphism (CNP) is a CNV that occurs in more than 1% of a population. 
Table 1.1 summarises other common terms used in literature for various types of SV.  
CNV being a quantitative variant can be genomic copy number gains 
(insertions or duplications), losses (deletions or null genotypes), or multi-allelic (gain 
& loss) relative to a designated reference genome sequence. There are several types 
of insertion CNVs depending on the relative position and nature of the events. These 
can be Mobile element insertions via retrotransposition, or insertions of novel DNA 
sequences such as those that did not exist in the human reference genome. 
Duplication CNVs can involve repeat events in tandem to each other or be dispersed 















Figure 1.1  The continuum of genetic variation in human genome. (Adapted from 




Structural variant (SV) A genomic alteration (eg. a CNV, an inversion) that 
involves segments of DNA >1 kb
Feuk et al. 2006
Copy number varaint (CNV) A genomic duplication or deletion involving >1 kb DNA Feuk et al. 2006
CNV region (CNVR) Merging of independently ascertained, but overlapping 
CNV regions
Scherer et al. 2007
Intermediate-sized structural 
variant (ISV)
A structural variant that is ~8 to 40 kb in size. This can 
be a CNV or a balanced structural rearrangement (eg. 
an inversion)
Tuzun et al. 2005
Segmental duplication (SD) A segment of DNA >1kb that occurs in 2 or more copies 
per haploid genome, with the different copies sharing 
>95% homology
Eichler 2001
Low Copy Repeat (LCR) similar to segmantal duplication Lupski 1998
Insertion/deletion (Indel) Variation from insertion or deletion event involving <1kb 
DNA
Genome-wide CNV was not discovered earlier due to the lack of suitable 
technology. Early methods such as cytogenetic and Sanger-sequencing technologies 
have facilitated the detailed characterization of genetic variation at karyotype and 
nucleotide level respectively, but the knowledge of medium-size structural variants 
was lagging. However technology advancement in the last decade, initially starting 
with genome-array scanning and more recently whole genome sequence technologies, 
have begun to reveal this group of DNA variation that involves segments that are 
smaller than those recognized microscopically, but larger than those that are detected 
by conventional sequence analysis (Figure 1.1).  
Table 1.1  Some terminology in the literature on Structural Variants. 
 
 
Although genome-wide CNV is discovered only in the last decade, some 
specific CNV has long been studied as gene copy number difference among 
individuals at specific locus. For example, in the α- and β- gene loci deletion in 
thalassaemia, or as genomic imbalance resulting in diseases such as Prader-Willi and 
Angelman Syndrome, or the duplication of the gene PMP22 that causes the dominant 
and sporadic neuropathy Charcot-Marie disease type 1. Until recently, such 
rearrangements in the human genome were assumed to be limited in scale, and were 
always assumed to cause diseases.  
It was the advance in microarray technologies and the availability of a 
complete human genome sequence that make it possible to obtain genome-wide CNV 
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maps with locations and frequencies. The first two seminal reports on wide-spread 
abundance of CNVs in humans appeared in 2004. Two groups independently 
surveyed the human genome for copy number changes, revealing the extent of this 
source of human genetic variation at a previously unanticipated level (Iafrate et al. 
2004; Sebat et al. 2004). The two microarray based CNV studies detected a total of 
476 CNV loci from 75 individuals. Soon after 2004, studies on copy number changes 
were also mined from SNP genotyping data and clone paired-end sequencing data 
(Conrad et al. 2010b; McCarroll et al. 2008b; Tuzun et al. 2005).  
The first generation map of genome-wide CNV was published in 2006 
(Redon et al. 2006). This map was based on 270 individuals from four different 
ethnic populations originally used in the HapMap1 Project. They reported a total of 
1447 CNVRs, corresponding to 360 Mb of human DNA sequences or 12% of the 
human genome which was an over-estimation due to use of BAC clones in the then 
array technology. Successive CNV studies have helped to further characterize general 
CNV architecture (Pinto et al. 2007; Shaikh et al. 2009; Zogopoulos et al. 2007). 
Also, studies on fine-scale CNV detection based on sequencing technologies and 
genome comparisons provided other perspectives on CNVs and SVs (Khaja et al. 
2006; Kidd et al. 2008; Korbel et al. 2007). This initial wave of studies in normal 
individuals confirmed CNVs as a major source of human genetic variation.  
The next comprehensive genome-wide CNV map was published in 2010 by 
the Structural Variation Consortium (Conrad et al. 2010b). They studied 41 
individuals of European and African descent using an ultra-high density oligo-
microarray with 42 million probes on CGH platform (more on CGH in Section 
1.4.2.1). They reported 11,700 CNVs of which 8,599 were validated, and estimated 
that two diploid human genomes typically differed in >1000 CNVs covering a length 
of 24 Mb (0.8%) of the genome. This figure remains as a plausible estimation even 
after the introduction of NGS which is capable of uncovering many smaller CNVs.  
The capabilities of NGS were demonstrated in the recent publications from the 1000 
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Genome Project (Abecasis et al. 2010; Abecasis et al. 2012; Mills et al. 2011). 
However, there is an ascertainment bias towards deletion CNVs and a depletion of 
duplication and multi-copy CNVs particularly those in the larger size range. This is 
due to the technical limitations of NGS (Section 1.4.3), and hence a combination of 
both array and NGS approaches are still necessary for a comprehensive range of CNV 
analysis. 
When this study commenced, there was no CNV data for Southeast Asian 
populations. In the last few years, CNV information for Singapore populations 
became available (Ku et al. 2010; Xu et al. 2011). However, the CNV dataset 
generated from this study still provide additional value as an independent validation 
to the published CNVs. Also, as demonstrated in Chapter 2, the dominance of rare 
CNVs means additional CNV information will always be useful as many rare CNVs 
are likely to be novel even in the same populations. 
The phenomenon of copy number variations is not unique to the human 
genome. CNVs have been shown to be widespread in a variety of organisms, 
including the great apes (Perry et al. 2008), rat and mouse (Guryev et al. 2008; She et 
al. 2008), dogs (Chen et al. 2009), chickens (Griffin et al. 2008), cow (Liu et al. 
2010), Drosophila (Emerson et al. 2008), maize (Springer et al. 2009), Arabidopsis 
thaliana (Ossowski et al. 2008), Caenorhabditis elegans (Maydan et al. 2010) and 
Saccharomyces cerevisiae (Carreto et al. 2008). This confirms CNV as a major class 
of genetic variation. 
 
1.1.2 Prevalence and Distribution of CNV in the Human Genome 
Appreciation of the extent of CNV in the human genome has increased 
dramatically as a result of various studies as described above. However the proportion 
of the genome believed to be copy-number variable is not exactly clear. The figures 
reported by Conrad et al. remains commonly quoted (Section 1.1.1) (Conrad et al. 
2010b).  According to the current version of Database of Genomic Variants (DGV, 
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http://dgv.tcag.ca/dgv/app/home/ Accessed on March 2015), the proportion of the 
genome showing CNV is reported to be 68.7% from a combination of 62 published 
studies. This is likely to be an overestimation due to severe bias introduced through 
the BAC-arrays which were commonly used in the early days. DGV is a database that 
curates published CNV results from various detection platforms for healthy 
individuals. 
CNVs are found throughout the human genome. The distribution of CNVs is 
reported to be non-random and is enriched in telomeres and centromeres, and shown 
to be associated with genomic features such as segmental duplications (SDs) (Cooper 
et al. 2007). SDs is defined as duplicated sequences of ≥1 kb with ≥90% sequence 
identity (Table 1.1). Multi-allelic and complex CNVs are especially enriched in these 
SD regions. SDs are associated with the mutation mechanism NAHR (Non-Allelic 
Homologous Recombination, Section 1.3.1)  (Lupski 1998), which would explain the 
association of CNV hotspots with SDs.   
 
1.2  Biological Significance of Copy Number Variation 
Genetic variation can account for phenotypic differences between 
individuals, which include susceptibility to disease and different reactions to drugs 
and environmental stimuli. Genetic variations also form the substrates for evolution. 
CNV, like other better known genetic variations such as SNP, would have functional 
consequences depending on the genetic sequence context it occurs. A CNV can be 
phenotypically benign or affecting physical traits that vary in normal populations, or 







1.2.1 Phenotypic Effect of CNV 
The mechanisms by which CNV contributes to disease are numerous. Figure 
1.2 illustrates some ways that CNV may influence gene dosage, expression and 
diseases (Feuk et al. 2006b; Stankiewicz and Lupski 2006):  
a) Gene dosage alteration. CNV may act on a gene or multiple 
contiguous genes that are dosage-sensitive, and affecting gene expression;  
b) Direct gene disruption, e.g. interrupting coding sequence causing 
protein functional loss or modification; 
c) Gene fusion at junction, generating novel fusion products. For 
example, by fusing different protein domains, or by deleting exons generating 
novel splice variants; 
d) Position effects in which the rearrangement alters the regulation of a 
nearby  gene, via deletion of the regulatory element from a gene or by 
inserting new protein coding sequences to the proximity of regulatory 
elements;  
e) Unmasking of recessive mutation or functional SNP on the remaining 
allele, where a deletion results in hemizygous expression of a recessive 
mutation or; 
f) further uncovers/exacerbates effects of a functional polymorphism; 
g) Potentially interrupting effects of transvection, where the deletion of 
a gene and its surrounding regulatory sequences affects the communication 
between alleles. 
There are known CNVs to exemplify the above molecular mechanisms. The 
effect of CNV on gene dosage is most obvious in genomic disorders. The Charcot-
Marie-Tooth disease type 1A (CMT1A) locus at chromosome 17p12 encompasses the 
dosage-sensitive gene Peripheral myelin protein 22 (PMP22). Duplication of this 
region results in trisomic expression of PMP22 leading to the neuropathy CMT1A, 




liability to Pressure Palsies (HNPP) (Chance et al. 1994; Lupski et al. 1991). Further 
examples include the Smith-Mageins Syndrome (SMS) and Potocki-Lupski 
Syndrome which result from reciprocal deletion and duplication, respectively, at 









Figure 1.2  Molecular mechanisms by which CNV can affect phenotypes. 
Chromosome homologs are depicted as horizontal lines. The rearranged genomic 
interval is enclosed by brackets—dashed lines indicate genomic regions either deleted 
or duplicated, an absent line indicates deletion with phenotypic effects from the 
remaining allele unmasked because of the rearrangement, and a dotted line represents 
deletion but where phenotypic effects result from the absence of interactions between 
alleles (i.e., transvection effects). Gene is depicted by filled horizontal rectangle, 
while regulatory region is shown as a hatch-marked rectangle. Asterisks denote point 
mutations. (Adapted from Stankiewicz and Lupski 2006) 
 
 
The position effect of CNV on gene expression can be demonstrated in a 
pathological example of CNV associated with susceptibility to Crohn’s Disease (CD). 
At chromosome locus 5q33.1, a 20 kb deletion CNV immediately upstream of the 
Immunity-related family, M gene (IRGM) is in perfect linkage disequilibrium with 
the most strongly CD-associated SNP, and is the cause for the IRGM gene to 
segregate in the population with two distinct upstream haplotypes. The deletion allele 
and the reference allele showed distinct expression patterns, and these expression 
patterns modulated a biological process implicated in CD. This work suggests that the 
CD association at IRGM locus arises from a CNV in the upstream regulatory region 
of the IRGM gene that likely affects the gene expression in such a way that causes the 
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CD phenotype, and hence the 20kb deletion CNV is a likely casual variant 
(McCarroll et al. 2008b). The association of CD with this CNV has later been 
replicated in a large scale CNV association study (Craddock et al. 2010). 
There is also evidence for the role of CNV in gene expression. Stranger et al 
surveyed the impact of CNV on expression patterns by examining mRNA levels in 
lymphoblastoid cell lines from 210 HapMap individuals of four ethnic groups 
(Stranger et al. 2007), in combination with CNV data generated from the same 
sample set (Redon et al. 2006). They interrogated 15,000 transcripts and found that 
~18% of the variation in expression could be explained by CNVs, while 80% was due 
to SNPs. Distant regulation or position effect was reported to be as far as 2 Mb away. 
Also reporting similar conclusions was a study using a mouse model system which 
showed that CNVs shaped tissue transcriptomes and phenotypic variation. The 
genome-wide expression data generated from 6 major mouse organs confirmed the 
influence that CNVs have on the expression of genes within the CNV and their 
vicinity, an effect that could be extended to half a megabase (Henrichsen et al. 2009).  
However, a simple direct model of proportional relationship between CNV 
gene copy number and expression level may not hold for all CNVs. It does explain 
the effect of some CNVs. For instance, in the case of human salivary amylase gene, 
AMY1, a multi-allelic CNV, the diploid copy number of this starch hydrolysis gene 
varies from 2 to >15 (Sudmant et al. 2010). It has been demonstrated that this CNV 
affects gene expression at both transcriptional and translational levels, with copy 
number dosage shown to correlate directly with mRNA and AMY1 protein level in 
human saliva samples (Falchi et al. 2014; Perry et al. 2007).   
On the contrary, a contrasting example is the red and green opsin pigment 
genes, OPN1LW (‘opsin 1 long-wave-sensitive’ for the red photopigment) and 
OPN1MW (‘opsin1 medium-wave-sensitive’ for the green photopigment) which are 
located head-to-tail in a tandem array on chromosome Xq23. This locus is susceptible 
to genomic rearrangement resulting in fusion of red and green gene pigments and 
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copy number variation of the green pigment gene. Although mutations in the copy 
number variable OPN1MW gene may result in colour blindness, only the copy nearest 
the locus control region is expressed to an appreciable extent, such that a male with a 
disrupted first gene but intact subsequent genes will have colour blindness. In short, 
only the first two copies of OPN1LW and OPN1MW exert stronger phenotypic 
influence. Besides copy number, other factors including allelic states that differ by 
single-nucleotide change, gene order and the status of nearby sequence element will 
also influence colour-vision phenotype (Cooper et al. 2007; Deeb 2005). This showed 
that a proper understanding of the molecular basis of CNV effect will need 
information on copy number, local sequence and structure context. 
For the above two examples, part of the difference can be attributed to the 
location of the gene-containing CNV with respect to that of the gene regulatory 
machinery. For AMY1, each duplicated segment of the AMY1 gene contains the 
regulatory sequence necessary for salivary-specific expression. Whereas there is only 
a single regulatory ‘locus control region’ upstream of the red (OPN1LW) and green 
(OPN1MW) opsin genes on the X chromosome, therefore the second copy of 
OPN1MW onwards will not display much functional effect. 
CNVs can also predispose to disease by altering the genome architecture such 
that it is more prone to further changes in subsequent mitosis or meiosis (Feuk et al. 
2006a). One of the best known examples is a 900 kb inversion polymorphism at 
chromosome 17q21.31 (Stefansson et al. 2005). The inverted haplotype appear at 
increased frequency in the European population (21%) but at very low frequency in 
Africans (6%) and Asians (1%), with female carriers of the inversion showing a small 
increase in fertility. Interestingly, although the inversion polymorphism itself may not 
be a direct cause of phenotypic variation, many of them can confer susceptibility or 
are the substrate to further chromosomal rearrangements in the following generations 
(Sharp et al. 2006b). Inversion polymorphisms are frequently observed in parents of 
deletion carriers that confer different disease phenotypes, such as Angelman 
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syndrome, Sotos syndrome or Williams-Beuren syndrome (Boettger et al. 2012). 
Therefore, higher-order genomic architecture such as nearby inversion polymorphism 
may predispose the disease locus to further chromosomal rearrangement in the 
following generations and confer disease phenotypes. 
Nevertheless, it is noted that despite the deleterious effect some CNVs have 
shown on disease phenotypes, CNVs as a class of genetic variation is widespread in 
apparently healthy normal populations (Conrad et al. 2010b; Redon et al. 2006); 
Chapter 2 of this thesis). This suggests that copy number changes may not necessarily 
translate into phenotypic outcomes. These apparently ‘neutral’ CNVs may be 
explained by (i) the genomic location of CNV (e.g. located in gene-poor regions); (ii) 
the insensitivity of the CNV genes to dosage; or (iii) the effect of dosage 
compensation or redundancy in molecular pathway. In conclusion, the severity of 
phenotypes caused by a given CNV via gene expression is a combination of dosage 
sensitivities of genes affected by CNV, plus their interaction with other genetic and 
environmental variants. 
 
1.2.2 CNV and Human Traits 
One example of CNV and human traits is the deletion of the RHD gene 
responsible for the rhesus negative blood group. The Rh (Rhesus) blood group 
antigens are products of two genes, RHD and RHCE, which lie in tandem on 
chromosome 1p34-p36. RHD encodes the D antigen, a highly immunologic blood 
group. The RHD and RHCE genes are structural homologs and result from a 
duplication of a common gene ancestor. The RHD gene is flanked by two 9-kb 
"Rhesus boxes" with 98% sequence homology. It is thought that unequal homologous 
recombination confined to the Rhesus boxes (NAHR) is a common cause of the 
deletion of the entire RHD gene, which is found in up to 40% in Caucasians (Wagner 
and Flegel 2000). 
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A second example comes from the X-linked opsin gene locus dictating red-
green colour vision (Deeb 2005). The locus comprises red (L-opsin) and green (M-
opsin) photopigment genes and a “locus control region” regulating gene expression. 
Variable copy numbers were detected in the L-opsin gene (OPN1LW, 0-4 haploid 
copy), M-opsin gene (OPN1MW, 0-7 haploid copy) and the locus control region unit 
(0 or 1 haploid copy). It is a combination of the copy number of these three units, 
sequence variation and unequal cross-over between the homologous L-opsin and M-
opsin that determines the phenotype of colour vision, even to the extreme of colour 
blindness (Cooper et al. 2007; Deeb 2005).  
Another example is the aforementioned AMY1 locus, in which copy number 
was shown to correlate with the amount of starch-digesting amylase protein in human 
saliva. The geographical variation of copy numbers at this locus was proposed to be 
shaped by the evolution of diet of different populations, with a higher copy number 
range found in populations consuming a high-starch diet (such as Japanese) compared 
to a lower copy range in populations with customary low-starch diet (such as Biaka) 
(Perry et al. 2007). 
CNVs have also shown to be associated with other physical traits including 
height (Dauber et al. 2011), body mass index (Wheeler et al. 2013; Willer et al. 
2009), and in the extreme pathological case of early onset extreme obesity (Jarick et 
al. 2011), all were reported in European populations. Interestingly, very recently, 
AMY1 high copy-number has been reported to be associated with lower body mass 
index (Falchi et al. 2014) in both European and Singapore Chinese cohorts. I have 
attempted to verify this finding and the results are summarised in Chapter 4. 
 
1.2.3 CNV and Natural Selection  
Copy number variations, either deletions or duplications, can provide the raw 
materials for evolutionary forces to act. Therefore, natural selection may have 
affected at least some CNVs. Duplications have long been suggested as substrates on 
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which selection processes can act. A duplicated gene could subsequently be modified 
for new functions, facilitating a species’ diversification and evolution (Ohno et al. 
1968). Some of these innovations may have been favoured in positive selection. An 
example of positive selection on CNV is that the variable copy of AMY1 in different 
human populations was suggested to be a result of adaptive evolution in response to 
changing diet (Perry et al. 2007). On the other hand, negative selection could also 
have shaped the characteristics of CNVs. This can be envisaged in the deletion 
scenarios where deleterious loss-of-function alleles are generated. In support of this, 
an enrichment of common CNVs (particularly those that do not overlap with SDs) in 
gene-poor regions was reported (Cooper et al. 2007). Further support comes from the 
observation that deletions in the genome are more biased away from the morbid 
OMIM (Online Mendelian Inheritance in Man) genes than duplications are (Conrad et 
al. 2010b; Mills et al. 2011).  
Examining the functional categories of contemporary CNV gene content may 
provide a glimpse into the underlying selection pressure. Many studies have shown 
that CNVs co-localize with genes that have environmentally responsive functions, 
such as sensory perception and immunity (Conrad et al. 2010b; Redon et al. 2006). 
While such enrichment could be interpreted as evidence of positive selection since 
these proteins are within the biological categories documented in mammalian 
adaptive evolutions (Cooper et al. 2007), it could also be consistent with an 
alternative ‘neutral hypothesis’ that such enrichment actually reflects these functional 
classes of CNV-genes being less deleterious, therefore remaining in the genome by 
reduced purifying selection (Nguyen et al. 2008).  
The ‘neutral hypothesis’ was supported by a study which compared the 
proportion of functional olfactory receptor genes that are copy number variable to 
that for olfactory receptor pseudogenes, which are expected to reflect neutral patterns 
of diversity. A similar number of genes and pseudogenes were copy number variable, 
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which is consistent with the neutral evolution (e.g. genetic drift) on the copy numbers 
of functional olfactory receptors (Nozawa et al. 2007).  
On the other hand, CNVs affecting environmental response genes have been 
associated with a number of infectious and autoimmune diseases, such as 
susceptibility to systemic autoimmunity diseases, psoriasis, and HIV-1 susceptibility 
(Gonzalez et al. 2005; Hollox et al. 2008; Yang et al. 2007). This appears to align 
better to the adaptive selection hypothesis. 
The other line of evidence of CNV involvement in natural selection comes 
from CNVs that are highly stratified among global populations. A handful of studies 
on some of these CNVs documented an adaptive advantage conferred by CNVs. One 
example is AMY1 where populations with a higher average copy number have a 
history of starch-rich diets (Perry et al. 2007). A deletion in APOBEC3 gene which 
functions in innate retroviral immunity is rare in Africans and Europeans but common 
in Asians (Kidd et al. 2007). Another population differentiated CNV overlap 
UGT2B17 which is involved in steroid and xenobiotic metabolism. Its deletion CNV 
has been shown to be ancient and its dominance in Asia was suggested to be 
maintained by selection (Xue et al. 2008). 
There is also an example of CNV involvement in balancing selection. It 
involves the deletion polymorphisms of α-globin genes (HBA1 and HBA2) which 
result in α-thalassemia. Alpha-globin is copy number variable, with most individuals 
having four copies per diploid genome, two copies each of HBA1 and HBA2. 
Homozygotes for α-globin deletion alleles (two copies per diploid genome) have α+-
thalassemia. The diploid copy number correlated to distinct clinical features with a 
clear gene dosage effect: the fewer the genes, the more severe the symptoms, with 
fatality in complete homozygous deletion (zero copy per diploid). The frequencies of 
alleles with HBA single or double gene deletions are frequent in populations endemic 
with malaria, with ~1% in non-malaria region while reaching 20% in malaria regions 
like sub-Saharan Africa. This is due to the protective effects of the deletion alleles 
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against severe malaria. As a result, α-thalassemia frequency is strongly correlated 
with malaria prevalence, down to very local levels. This is a classic example of 
balancing selection in human (Hollox and Hoh 2014).  
Therefore, it could be hypothesized that the current distribution of CNVs in 
the human genome has been driven by past selection forces and adaptive evolution. 
Alternatively, from a neutralist’s point of view, CNVs could be under reduced 
purifying selection (Nguyen et al. 2008). This model suggests that variants are 
enriched in nonessential genes, with fixation of slightly deleterious substitutions, 
while the neutral CNVs were under genetic drift.  
In summary, both these two models (selection versus neutral) might be true. 
Different set of forces may be present in different CNV loci resulting in CNV pattern 
in contemporary human genome.  
 
1.2.4 CNV and Diseases 
1.2.4.1  Genomic Disorders 
Large chromosomal abnormalities have been known to cause human diseases 
long before the discovery of the genome-wide prevalence of CNVs in the general 
population. A common example is trisomy of chromosome 21 resulting in Down’s 
syndrome. Other early evidence that showed copy number alterations influencing 
human phenotypes come from a group of diseases known as ‘genomic disorders’, 
which are caused by genomic rearrangements affecting dosage-sensitive genes 
(Lupski 2009). They are usually due to local genomic architecture such as flanking 
long segmental duplications that predispose the region to recurrent rearrangements 
mediated by Non-Allelic Homologous Recombination (NAHR). Well-known 
examples include the 22q11.2 deletion which is responsible for the 
Velocardiofacial/Di-George syndrome (VCFS/DGS, OMIM192430/188400); the 
7q11.23 deletion for William Beuren Syndrome (WBS, OMIM194050); the 17p11.2 
duplication and its reciprocal duplication which are responsible for Charcot-Marie-
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Tooth Syndrome Type1A (CMT1A, OMIM118220) and Hereditary Neuropathy with 
Liability to Pressure Palsies (HNPP, OMIM162500), respectively (Stankiewicz and 
Lupski 2010). 
Traditionally, genomic disorders are usually clinically recognized first by 
their typical constellation of clinical features, and were tested for by karyotyping or 
fluorescence in-situ hybridisation (FISH) using DNA probes specific to the suspected 
genomic regions. In the last decade, advances in chromosomal microarray 
technologies (CMA, including array comparative genomic hybridisation aCGH and 
single nucleotide polymorphism array SNP array) have allowed their widespread use 
not only in research setting but also as a clinically diagnostic modality in many 
human diseases. It has been shown that high resolution CMA analysis allows the 
detection of pathogenic CNVs in nearly 15-20% of patients with developmental delay 
or intellectual disability who had a normal G-banded chromosome analysis (Miller et 
al. 2010). Because of their high diagnostic yield, CMAs were recommended in 2010 
by the American College of Medical Genetics and Genomics (ACMG) as the 
preferred first-tier clinical diagnostic test for individuals with developmental delay, 
intellectual disability or multiple congenital anomalies (Miller et al. 2010). 
The improved diagnostic yield increases the discovery rate of chromosomal 
aberrations. These clinical findings documenting chromosomal aberrations associated 
with diseases have been steadily catalogued in online public databases such as the 
DECIPHER database (https://decipher.sanger.ac.uk/). As of January 2015, more than 
44,000 cases have been archived representing ~70 submicroscopic chromosomal 
rearrangement-associated syndromes. It has become a useful resource in aiding the 
interpretation of the pathogenic significance of SVs/CNVs. 
 
1.2.4.2  ‘Simple’ Common CNVs and Common diseases 
Following the discovery of widespread CNVs in the general population 
(Conrad et al. 2010b; Redon et al. 2006), their functional impact was fervently sought 
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after with the hope that some of the CNVs might explain part of the ‘missing 
heritability’ left by SNP GWAS (Genome-Wide Association Study). In the period 
2006 to 2010, many CNV-disease association studies were carried out using either the 
GWAS or a locus-specific approach. A number of disease associations with common 
CNVs were reported, although several of them were later proved to be controversial. 
Nevertheless, some of the replicated positive associations included a deletion CNV 
upstream of IRGM which is associated with Crohn’s disease (McCarroll et al. 2008a), 
and a ~43kb deletion upstream of NEGR1 which is associated with increased body 
mass index (Willer et al. 2009).  
A comprehensive study of disease association of 3,432 common CNVs (>500 
bp in size) on the UK population undertaken by the WTCCC (Welcome Trust Case 
Control Consortium) reported that except for a limited number of loci, the vast 
majority of common CNVs that could be genotyped using microarray technology do 
not associate with the eight diseases studied (bipolar disorder, breast cancer, coronary 
artery disease, Crohn’s disease, hypertension, rheumatoid arthritis, type 1 and type 2 
diabetes). WTCCC concluded that common CNVs are unlikely to have a large impact 
on common diseases in general, and as for the small number of loci that do exhibit 
association, the CNVs are typically well-tagged by common SNPs and have been 
captured by previous SNP GWAS, indicating that common CNVs are unlikely to 
explain the ‘missing heritability’ for common diseases (Craddock et al. 2010).  
However, it is important to note that the >3k common CNVs that WTCCC 
reported were CNVs that could be genotyped in distinct copy-number classes on 
aCGH platform. Hence WTCCC conclusion should only apply to ‘simple’ CNVs, in 
which unique genomic regions are deleted or duplicated. These ‘simple’ CNVs are 
usually biallelic and are generally well-tagged by flanking SNPs, as in the findings of 
WTCCC. Much has yet to be discovered for multi-allelic and complex CNVs. 
Nevertheless, the WTCCC study did provide important validation for several reported 
CNV-disease associations, and two of them are mentioned above.  
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1.2.4.3 Models of CNV Diseases Associations 
After the WTCCC study, much attention was shifted towards rare CNVs in 
diseases, wherein variants were thought to have larger effect sizes and the rare CNVs 
are unlikely to be fully captured by common SNPs which are often adopted in most 
microarray platforms. Through insights gained from those studies, two distinct 
models of CNV disease association have been proposed (Girirajan et al. 2011; 
Mikhail 2014).  
The first model involves CNVs that are individually rare (<1% frequency) 
but typically involve larger chromosomal segments (>100 kb) and exist in fewer copy 
number states (segmental monosomy/ hemizygous or trisomy). These CNVs are 
under strong selection pressure, their frequency in the population is largely 
contributed by de novo events, and they can only persist for a few generations. This 
aligns to the mutation-selection model of diseases. These CNVs can be individually 
rare in the population, but collectively as a group can account for a large fraction of 
disease, as seen for some neurological and neuro-cognitive diseases as discussed in 
the next section. Rare CNVs can either be recurrent with a common size and 
breakpoint clustering, or non-recurrent with different sizes and variable breakpoints. 
The non-recurrent rare CNVs typically share a common genomic region of overlap 
that encompasses the gene(s) associated with the observed phenotype (Figure 1.3).  
The second model involves CNPs that occur at a population frequency of 
>1% but often exists in multicopy number states ranging from 0 to 30 copies per 
diploid genome (Sudmant et al. 2010). For these, variation in copy, content, or 
structure of sequences is important for understanding disease etiology. These 
multicopy CNPs are enriched for multicopy gene families that are commonly copy-
number variable and contribute to disease susceptibility, as seen for diseases/traits 
related to immune gene functions and environmental responses (Table 1.2) (Campbell 











Figure 1.3  Recurrent and non-recurrent CNVs. (Adapted from Mikhail 2014). Black 
box represents dosage sensitive gene. Hatched box represents Segmental Duplication. 
Grey box represents CNV.  
 
1.2.4.4  Rare CNVs, Variable Human Disease Phenotypes, and the ‘Two-hit’ Model 
Some themes have emerged in the studies of rare CNVs in human diseases. 
The first is the recognition of flanking segmental duplications of human genome 
predisposed certain individuals to recurrent CNVs. Second, two types of recurrent 
CNVs could be distinguished: (i) the syndromic forms in which phenotypic features 
are relatively constant, and (ii) those in which the same CNV can be associated with a 
diverse set of phenotypes (Girirajan et al. 2011; Mikhail 2014). 
The syndromic forms of recurrent CNV are exemplified by those genomic 
disorders described in Section 1.2.4.1. They are usually relatively large 
microdeletions or microduplications that are highly penetrant. They are mostly de 
novo in origin, and can occur on different haplotype backgrounds in multiple 
unrelated individuals. They are thought to be under strong negative selection and 
hence mostly de novo.  
On the other hand, the more recently discovered recurrent CNVs tend to 
show incomplete penetrance and variable expressivity. Some examples included 
1q21.1, 15q13.3, 16p11.2, 16p12.1, and 16q13.11 microdeletions and 
microduplications. They have been associated with, but not limited to, developmental 
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delay, intellectual disability, autism, schizophrenia, seizures, and other congenital 
anomalies (Girirajan et al. 2011; Mikhail 2014).  
A ‘Two-hit’ model has been proposed to explain the variable phenotypes. It 
was originally used to explain the variable phenotypes observed for a 520 kb 
microdeletion in 16p11.2, which was non-syndromic and was inherited from a parent 
in 95% of the cases (Girirajan et al. 2010). Within the affected family, the carrier 
parents showed sub-clinical manifestations of mild neuropsychiatric symptoms, while 
the proband was affected to a higher degree. Further studies suggested that the 
differences in phenotypic variability were due to the presence of additional large 
deletion or duplication (second hit) in the probands that resulted in a sensitized 
genetic background and consequently a more pronounced phenotype. Therefore, the 
two-hit theory hypothesized that one hit (first CNV) is sufficient to reach a threshold 
to induce features of a given phenotype while the second hit (e.g. a second CNV) 
pushes toward a more severe manifestation. 
Further examination of other recurrent CNVs associated with either 
syndromic or variable phenotypes have showed evidence of the clustering of two hits 
in the CNVs with variable phenotypes as compared with the syndromic forms. Also, a 
strong correlation was observed between the proportion of inherited first CNV and 
the frequency of the second CNV (Girirajan et al. 2010). This implies that variable 
expressivity are more likely to be inherited from less severely affected parents, which 
suggested that they are by themselves not sufficient to determine the disease outcome 
(Cooper et al 2010). Although the two-hit theory was initially applied to large CNVs, 
it has been proposed that the second hit could also be a smaller CNV or a SNP 
involving a related gene or risk allele inherited from a parent. 
In addition to recurrent CNV, a large fraction of CNVs observed in human 
genetic disease are non-recurrent CNV arising via other mutation mechanisms like 
NHEJ or FoSTeS. Although individually these non-recurrent CNVs occur at a lower 
frequency at the individual locus level, but collectively as a group, they are common 
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and can account for a substantial portion of the disease they associated with. Several 
non-recurrent CNVs have been reported in neuropsychiatric diseases, including 
ASTN2 and NRXN1 CNVs in both autism and schizophrenia, SHANK2, SHANK3 and 
PTCHD1 CNVs in autism, and MYT1L and CTNND2 disruption in schizophrenia 
(Marshall and Scherer 2012; Vrijenhoek et al. 2008). Intriguingly, there is an 
emerging pattern of certain genes implicated by rare CNVs across clinically distinct 
disorders, and these genetic overlaps could be consistent with comorbidity and shared 
traits. This hints at common underlying biological processes. A general theme that 
emerged from the study of CNVs in neurodevelopmental phenotypes is  that they tend 
to involve gene networks related to neuronal signaling and development, synapse 
function and chromatin regulation. 
A challenge in rare CNV study, particularly non-recurrent CNVs which occur 
at a lower frequency, is the requirement to screen thousands of patients and controls 
to establish pathogenicity. New models / approaches have been adopted in the study 
of rare CNVs. For instance, focusing on CNV of de novo origin with enrichment in 
simplex families, or enrichment of de novo CNV in affected siblings compared to 
unaffected siblings in multiplex families. Other strategies included focusing on the 
overall CNV burden or increased CNV size burden in patients, using pathway-based 
analysis through inferring disease if implicated CNVs interrupted related genes in one 
common pathway. Take the study of schizophrenia for example, there were reports of 
increased genome wide burden of large and rare CNVs that disproportionally disrupt 
neurodevelopmental pathways in patients compared to controls, and associations 
involving de novo or recurrent CNVs at specific loci, including deletions at 1q21.1, 
15q13.3 and 22q11.2 and duplications at 16p11.2 were discovered and replicated 
(Rethelyi et al. 2013). While some of the discovered disease-CNVs are highly 
penetrant, others may act as predisposing factors and exacerbate phenotype in 




1.2.4.5 Copy Number Polymorphisms (CNPs) 
These are CNVs present in a relatively high frequency (>1%) in the human 
population. CNPs may be distinguished in 2 types: (i) those that simply represent a 
gain or loss of a particular segment of DNA, called biallelic CNPs, and (ii) those 
where the underlying sequence can exist as a series of whole integers, termed 
multicopy CNPs.  
Surveys of CNPs in the general population have identified large numbers of 
these variants in the human genome (Campbell et al. 2011; Sudmant et al. 2010). 
CNPs are not distributed uniformly in the genome but are enriched in segmental 
duplications (SDs) (Alkan et al. 2009; Bailey et al. 2002). Studies have estimated a 
fourfold to tenfold enrichment of CNPs within regions of SD (Cooper et al. 2007). 
The enrichment of SD supports a higher rate of recurrent mutation via NAHR, likely 
contributing to its propensity to be multicopy. 
More recently, using newly developed read depth method on ‘One Thousand 
Genomes ’ project’s data, a comprehensive assessment of multi-copies CNV across 
the human genome has revealed the extent of multi-allelic gene regions ranging from 
0 to 48 copies per diploid genome in the general populations (Sudmant et al. 2010). 
The CNPs overlapping SD showed the highest variability in copy number, and most 
of the copy variation involved tandem changes in copy rather than duplication to new 
location (Alkan et al. 2009).  
In addition, a separate study on CNPs in global populations found that CNPs 
in SDs are more likely to be population differentiated than CNPs in unique genomic 
regions, and bi-allelic CNPs show greater population stratification when compared to 
frequency-matched SNPs. This observed population stratification across multiple 
ethnicities suggested an important role of multi-allelic CNPs in evolution, adaptation, 
and disease association (Campbell et al. 2011). The same study also reported that 
although biallelic CNPs show a strong correlation of copy number with flanking SNP 
genotypes (in strong linkage disequilibrium), the majority of multicopy CNPs do not. 
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This means the copy number of multiallelic CNPs, especially those in SDs, will not 
be imputable from SNP genotypes, and should be directly measured. Therefore, 
robust and cost-effective experimental assays that can accurately measure copy 
among thousands of samples are needed for CNV study in order to provide a more 
thorough assessment of relationship between locus-specific CNP to human 
phenotypes. 
CNPs can encompass genes. Genes overlapping with CNPs are enriched for 
immune and environmental response pathways (Conrad et al. 2010b; Redon et al. 
2006). This suggests CNPs are likely to play an important role in local adaptive 
selection in human populations, which may be indicated by those CNPs that show 
large differences in frequency between populations. Some CNPs that showed great 
population differentiation also contain genes that have clinical relevance. For 
example, African population tends to have higher copy-number of CCL3L1 than 
European population (Gonzalez et al. 2005). CCL3L1 encodes a chemokine ligand, 
which binds to the coreceptor of HIV. There is controversial evidence for a role of 
copy number variation of this locus in HIV infection and progression (He et al. 2009; 
Urban et al. 2009). Also a deletion in APOBEC3B, which functions in innate 
retroviral immunity, is most frequent in East Asians (Kidd et al. 2007). Another 
population differentiated CNP overlap UGT2B17, which is involved in steroid 
metabolism, its deletion CNV is found to be under positive selection and is common 
among Asian individuals (Xue et al. 2008).  
Numerous CNPs have been associated with complex human diseases. Table 
1.2 summarises a list of CNPs (including both bi-allelic and multi-allelic) known to 
associate with various complex diseases or traits. Many of these associations are to 
immune-related phenotypes, which may be due to the fact that CNPs are enriched for 
immune-related genes, and these genes are considered candidates for these 
phenotypes. CNPs in the human leukocyte antigen (HLA) region have been 
associated with multiple diseases, including Crohn’s disease, rheumatoid arthritis, 
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and type 1 diabetes (Craddock et al. 2010). SNPs in the HLA region have been 
strongly associated with many diseases (Girirajan et al. 2011) and given the strong 
LD across this locus, it is not surprising that CNPs in this region also show 
association to disease. A large proportion of the CNPs associated with disease are in 
segmental duplications highlighting the role of these regions in disease, including the 
association of high copy number of the β-defensin locus on chromosome 8p23.1 with 
psoriasis (Hollox et al. 2008; Stuart et al. 2012) and low copy number of FCGR3B 
associated with lupus and lupus glomerulonephritis (Aitman et al. 2006; Fanciulli et 
al. 2007). In general, as reflected in Table 1.2, multi-allelic CNPs appear to be more 
enriched for phenotypic associations compared to their bi-allelic counterparts (Falchi 
et al. 2014). 
Several studies of CNPs in segmental duplications have revealed the 
difficulty of conducting association studies with these multicopy variants. One 
controversial case is the association of lower copy number of CCL3L1 with 
susceptibility to HIV infection (Gonzalez et al. 2005), but other studies have failed to 
replicate this association (Field et al. 2009; Urban et al. 2009). It is unclear whether 
this lack of reproducibility is due to the original result being spurious or was caused 
by the difficulty in accurately genotyping CNPs, especially segmental duplications 
like the CNP containing CCL3L1 (He et al. 2009). Follow up analysis has also failed 
to replicate the association of β-defensin copy number with Crohn’s disease using 
different copy number genotyping methods (Craddock et al. 2010). Therefore, 
although CNPs in segmental duplications are likely important for human genetic 
diversity and diseases, accurate genotyping methods are required to test these variants 
for association to disease.  
To demonstrate the usefulness and challenges of studying CNPs, I have 
worked on the amylase genes locus at chromosome 1p21.1, and the work is described 
in detail in Chapter 4. Two amylase gene families cluster on 1p21.1; AMY1 gene 
family encodes salivary amylases while AMY2 gene family pancreatic amylases. Both 
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AMY1 and AMY2 genes are CNPs, but AMY2 behave more like biallelic CNPs while 
AMY1 is highly multiallelic (Falchi et al. 2014; Itsara et al. 2009; Sudmant et al. 
2010). AMY1 has been shown to be significantly copy-number stratified in global 
populations and was thought to demonstrate the effect of diet-induced selection forces 
acting in favor of higher copy number in populations with a traditionally high-starch 
diet (Perry et al. 2007). Interestingly very recently, low copy number of AMY1 gene 
has been reported to predispose individuals to obesity in both European populations 
and also in a Singapore Chinese cohort (Falchi et al. 2014). I have attempted to verify 
the association by studying both AMY1 and AMY2A genes in a second Singapore 
Chinese sample set. At the same time, the work also sheds light on the population 
diversity of these two genes in our local populations, and demonstrates the challenges 






Gene Loci Disease/trait Variant type Associated allele Reference
Diseases
IRGM 5q33.1 Crohn’s Upstream deletion Deletion McCarroll et al. 2008, Craddock et al. 2010 (WTCCC)
LCE3B, LCE3C 1q21.3 Psoriasis Deletion Deletion de Cid et al 2009, Li et al 2011
CFHR1, CFHR3 1q31.3 Age-related macular degeneration Deletion
a
No deletion Hughes et al. 2006
HLA 6p22.1-p21.3 Crohn’s disease, Rheumatoid arthritis, 
Type 1 diabetes
Multiple CNVs a Various Craddock et al. 2010 (WTCCC)
TSPAN8 12q15-q21.1 Type 2 Diabetes Amplificationa,b Low copy number Craddock et al. 2010 (WTCCC)
C4 6p21.32 Lupus Amplification
a,b
Low copy number Yang et al. 2007, Lv et al. 2011, Boteva et al. 2012
DEFB4, DEFB103, DEFB104 8p23.1 Psoriasis Amplificationa,b High copy number Hollox et al. 2008, Stuart et al. 2012
CCL3L1 17q12 HIV/AIDS Amplificationa,b Low copy number Gonzalez et al. 2005,  Shostakovich-Koretskaya et al. 2009
FCGR3B 1q23.3 Glomerulonephritis in Lupus patients Amplificationa,b Low copy number Aitman et al. 2006, Fanciulli M et al. 2007
FCGR3B 1q23.3 Lupus Amplificationa,b Low copy number Fanciulli et al. 2007, Morris et al. 2010
UGT2B17 4q13.2 Osteoporosis Deletion
b
No deletion Yang et al. 2008
UGT2B17 4q13.2 Graft-versus-host disease Deletion
b
Deletion McCarroll et al. 2009
CYP2D6 22q13.2 Reduced drug metabolism Deletiona Deletion Hughes et al. 2006, Spencer et al. 2008
CYP21A2 6p21.32 Congenital adrenal hyperplasis Amplificationa,b Two copies/chrom Koppens et al. 2002
LPA 6q25.3-q26 Coronary heart disease Amplificationa,b Low copy number Kraft et al. 1996
SMN2 5q13.2 Severity of spiral muscular atrophy Amplificationa,b Low copy number Wirth et al 1999
NBPF23 1q21.1 Neuroblastoma Deletion
a,b
Deletion Diskin et al 2009
Traits
NEGR1 1p31.1 Obesity/BMI Upstream deletion Deletion Willer et al 2009, Wheeler et al. 2013
GPRC5B 16p12.3 Obesity/BMI Upstream deletion Deletion Speliotes et al. 2010
AMY1 1p21.1 Obesity/BMI Amplification
a,b
Low copy number Falchi et al. 2014
AMY1 1p21.1 High starch diet Amplificationa,b High copy number Perry et al. 2007
RHD 1p36.11 Rh-negative blood group Deletiona Deletion Colin et al. 1991
HBA1, HBA2 16p13.3 alpha-thalassemia Deletiona Deletion Harteveld & Higg 2010
OPN1LW, OPN1MW Xq23 Color blindness Deletion Deletion Deeb 2006
AZFc region Yq telemoric endSpermatogenetic failure Deletion Deletion Repping et al. 2003
a Multicopy CNP, more than three diploid copy numbers observed in the population.

















Table 1.2 Selected Copy Number Polymorphisms associated with human complex diseases or traits. (Modified from Girirajan et al. 2011) 
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1.3 Mechanisms of CNV Formation 
One fundamental question in CNV studies is what mechanisms contribute to 
the generation of CNVs. Understanding the underlying mutation processes for CNV 
will yield insights into the genomic distribution, evolution and frequency of CNVs in 
the human population. CNV/SV is thought to form by recombination, replication or 
retrotransposition events. Four major mechanisms for CNV/SV formation have been 
proposed; they are non-allelic homologous recombination (NAHR), non-homologous 
end joining (NHEJ), fork stalling and template switching (FoSTeS) and L1-mediated 
retrotransposition (Zhang et al. 2009). Figure 1.3a demonstrates the models while 
1.3b highlights the characteristic features of each mechanism. NAHR and FoSTeS 
can form deletions, duplications and inversions. NHEJ can form deletions and 
duplications but not inversions. Retrotransposition can only form novel insertion. In 
addition, FoSTeS can form complex patterns of deletions, duplications and inversions 
at a single locus. 
The evidence of these CNV formation mechanisms comes from studying the 
breakpoints and sequences surrounding CNVs (Hastings et al. 2009). These mutation 
mechanisms can take place during meiosis or mitosis. Those that occur at mitosis can 
either be restricted in one tissue type or present at several or all tissues depending 
upon the development stage and the cell type when the mutation occurs. For example, 
somatic mosaicism (Piotrowski et al. 2008) and the observation of CNVs between 
monozygotic twins are the result if structural changes occur during mitosis (Bruder et 
al. 2008). 
 
1.3.1 Non-Allelic Homologous Recombination (NAHR) 
Many studies have shown that CNVs often occur in regions of repeat sequences such 
as segmental duplications (Sharp et al. 2005; Tuzun et al. 2005) or Alu repeats (de 
Smith et al. 2008). Several studies suggest that SDs are hot-spots for chromosomal 
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rearrangements, since SDs increase the chance of NAHR (Lupski 1998; Sharp et al. 
2006a). Segmental duplication (SD) is operationally defined as a sequence >1kb with 
>90% sequence homology to another region elsewhere in the genome. SD can be in 
tandem in the genome or dispersed within the same chromosomal (intra-
chromosome) or in another chromosome (inter-chromosome) (Table 1.1).  In fact, SD 
can be considered as ancient SVs that have become fixed in the genome (Kim et al. 
2008; Marques-Bonet et al. 2009). 
Figure 1.3 Comparisons and characteristics of the four major mechanisms underlying 
human genomic rearrangements and CNV formation. (From Zhang et al. 2009) 
(a) Models for Non-Allelic Homologous Recombination (NAHR) between repeat 
sequences (LCRs/SDs, Alu, or L1 elements); Non-Homologous End-Joining (NHEJ), 
recombination repair of double strand break; Fork Stalling and Template Switching 
(FoSTeS), multiple FoSTeS events (×2 or more) resulting in complex rearrangement 
and single FoSTeS event (×1) causing simple rearrangement; and retrotransposition. 
TS, target site; TSD, duplicated target site. Thick bars of different colors indicate 
different genomic fragments; completely different colors (as orange and red or 
orange/red/green in FoSTeS×2) symbolize that no homology between the two 
fragments is required. The two bars in two similar shades of blue indicate that the two 
fragments involved in NAHR should have extensive homology with each other. The 
triangles symbolize short sequences sharing microhomologies. Each group of 
triangles (either filled or empty) indicates one group of sequences sharing the same 
microhomology with each other. 
(b) Characteristic features for each rearrangement mechanism. Specific features of 
certain mechanisms are shown in red. Abbreviations: dup, duplication; del, deletion; 
inv, inversion; ins, insertion. 
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Early examples were from genomic disorders, a class of diseases caused by 
genomic rearrangements resulting in alteration of dosage-sensitive genes, usually in 
the form of large-scale microdeletions or microduplications of the genome. These 
diseases, such as William Buren Syndrome and Charcot Marie Tooth Disease, often 
have breakpoints clustering in highly homologous segmental duplications or low 
copy repeats (LCRs). It was suggested that SDs or LCRs can act as substrates for 
NAHR, and NAHR accounts for most cases of recurrent CNVs (Lee et al. 2007; 
Stankiewicz and Lupski 2006). Beside SDs, other more divergent repeats such as 
SINEs (eg. Alu), LINEs and human endogenous retrovirus (HERVs) can also act as 
substrates for NAHR, but such events are less likely to be recurrent (Cooper et al. 
2007; Hurles 2005). 
NAHR is a recombination event that occurs when highly homologous, but 
non-allelic sequences, align and undergo crossing over during meiosis. Repeat 
sequence stretches on the same chromosome in direct orientation to each other can 
recombine to produce deletion and/or duplication events. Inverted repeats in opposite 
orientation will mediate inversion of the genomic interval flanked by the repeats, 
generating copy neutral inversion. NAHR between sequence repeat from different 
chromosomes can lead to chromosomal translocation. NAHR occurring in meiosis 
results in heritable SV/CNV. NAHR can also occur in mitosis producing somatic 
rearrangement, although this class of CNV is less well-studied (Piotrowski et al. 
2008). 
 
1.3.2 Non-Homologous End Joining (NHEJ) 
NHEJ occurs when cells repair double stranded breaks (DSB) in their DNA, 
involving the modification and repairing of the two DNA break ends. To repair DNA 
ends, the ends are modified to make them compatible and ligatable, which can 
involve addition or deletion of nucleotides of the segments between the two DSBs. 
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This results in an ‘information scar’ at the joint point. Unlike NAHR, NHEJ does not 
require substrate with extended homology (Zhang et al. 2009).  
Less is known about NHEJ compared to NAHR. The mechanism of NHEJ is 
suggested to be mediated by microhomologies (<25 bp homology) (Lieber 2008). It 
was reported NHEJ events often fall in repetitive sequence elements of the genome 
such as Long terminal repeats (LTRs), Long Interpersed Elements (LINEs), and Short 
Interspersed Elements (SINEs). Many of such events are found to occur in regions of 
the genome with architectural features that promote DNA double-stranded breaks 
(Korbel et al. 2007). 
 
1.3.3 Fork Stalling and Template Switching (FoSTeS) 
FoSTeS is a replication error based mechanism that can account for complex 
non-recurrent genomic rearrangements. When a DNA replication fork stalls, the 
lagging strand can disengage from the original fork and switch to another replication 
fork, usually in close physical proximity to the original. Here the lagging strand can 
restart DNA synthesis by priming the new replication fork from the short stretches of 
homologous DNA sequence (sequence microhomology) between the original fork 
and switched new template site.  
Depending on the direction of fork progression and whether the lagging or 
leading strand of the new fork was used as the template and copied, the orientation of 
the erroneously incorporated fragment from the new fork could be in direct or 
inverted orientation to its original position. In addition, depending on the location of 
the new fork if it is located downstream or upstream of the original fork, the template 
switching results in either a deletion or duplication. This process of stalling, 
disengaging, invading/annealing and priming/extension may occur multiple times in 





1.3.4 L1-mediated Retrotransposition 
While mobile elements comprise almost half of the human genomic 
sequence, most of the formerly mobile elements are now degraded and no longer 
active. Long interspersed elelment-1 (L1) elements are a major class of 
retrotransposons. They are abundant in the human genome, covering ~17% of the 
genome, and are the only currently active autonomous transposons. However, only 
about 100 full-length L1 LINE copies are potentially active in the human genome. 
These full-length L1 elements are 6 kb in size and contain all the necessary genes for 
the L1 LINE to retrotranspose itself. Retrotransposition occurs via a RNA 
intermediate when the LINE sequence is transcribed from the genomic DNA. This 
RNA intermediary is then reverse-transcribed into DNA and inserted elsewhere into 
the genome. The reverse transcription and insertion are thought to occur by a coupled 
process known as target primed reverse transcription. The resultant insertion is 
flanked by duplicated target sites (Zhang et al. 2009). 
 
1.3.5 Insights from Breakpoint Mapping  
More recently, the use of extreme high density microarrays and importantly, 
genome-sequencing have enabled high to nucleotide resolution of CNV breakpoint 
mapping, thereby allowing more precise inference of CNV mutation mechanisms.  
An analysis of 270 CNVs larger than 7 kb using fosmid clone pair-end sequencing 
found that 38% of the events are formed by NAHR, 39% by NHEJ and ~18% by 
retrotransposition, and 4.5% were VNTRs (Kidd et al. 2008).  
In 2010, the SV Consortium reported that mutation mechanisms generating 
CNVs vary depending on the different size of the genomic alteration, with NAHR 
having more of a role in larger CNV formation. They also found that duplication 
CNVs are more likely to be formed by NAHR and retrotransposition, and are more 
enriched for breakpoint-associated sequence motifs than deletion CNVs, indicating 
the formation of duplications is more likely to be sequence-dependent than deletions 
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(Conrad et al. 2010b). A follow-up study using breakpoint sequencing on 314 
deletion CNVs (sizes 420 bp to 184 kb with bias towards small size due to capture 
method) observed two major breakpoint signatures: 70% of the deletion breakpoints 
have 1-30 bp of microhomology, while 33% contain 1-367 bp of inserted sequences. 
The co-occurence of microhomology and inserted sequence is low (10%), suggesting 
at least 2 different mutational mechanisms (Conrad et al. 2010a) that resemble NHEJ 
or FoSTeS. About 5% have more complex rearrangement at the breakpoints 
suggesting a replication-based strand switching mechanism such as FoSTeS.    
 In 2012, the 1000 Genome Consortium published an extensive effort on SVs. 
Due to short-read sequencing limitation, the focus was on >22,000 deletions, with 
less focus on ~6,000 insertions and tandem repeats. 53% of these SVs were mapped 
to nucleotide resolution to facilitate mechanism inference (Mills et al. 2011). The 
breakpoint analysis revealed that 71% of the deletions and 90% of the insertions 
exhibited microhomology/homology ranging from 2-376 bp, while 16% of the 
insertions have non-template inserted sequence at their breakpoints. They inferred 
NHEJ as the dominant deletion mechanism while mobile element insertion as the 
dominant insertion mechanism. They also reported that both NHEJ and NAHR 
occurred across a wide size range, but it was noted this study has a strong focus on 
deletion SVs. 
Although it is hard to compare the above studies due to their ascertainment 
bias using different methods, some general themes did emerge supporting the 
involvement of the four mechanisms described in this section in the formation of 
CNVs/SVs. Also, the mechanism is related to CNV/SV size, with NAHR associated 
with the formation of larger size CNV/SV, while NHEJ is associated with smaller 
CNV. In addition, the demonstration of a map of SV hot spots by Mills et al 
suggested local centres of de novo SV formation, and is consistent with the concept 




1.3.6 CNV Mutation Rate  
The mutation rate of SNP point mutation has been estimated to be 1-1.2 x10
-8
 
per base pair per generation, using de novo events of whole-genome sequencing on 
all individuals from a nuclear family or from parent-offspring trios (Campbell and 
Eichler 2013). In contrast to the relatively uniform mutation rate of SNP across the 
human genome, the mutation rates of CNVs have been shown to vary widely at 





, which are two to four orders higher than SNP mutation rate. These 
locus-specific mutation rates for some de novo CNVs (mostly for genomic disorders) 
have been estimated by different methods, including disease prevalence calculations, 
pooled sperm PCR assays, and analyses of parent-offspring trios (Lupski 2007; 
Turner et al. 2008; van Ommen 2005). The widely variable mutation rate of CNVs 
most likely reflects the differences in CNV formation mechanism and local or 
regional genome architecture inciting genomic instability. 
The overall rate of de novo CNV has been explored via genome-wide 
screening of de novo CNV in trios. More recently, a genome-wide analysis of large 
CNVs (>100kb) reported a mutation rate of 1.2x10
-2
 per genome per generation, 
based on approximately 400 trios (Itsara et al. 2010). While using high density 
microarrays and population genetics approaches, the Structural Consortium reported a 
rate of CNV formation for CNV >500 bp to be 3x10
-2
 per genome per generation 
(Conrad et al. 2010b).    
 
1.4 Detection of Copy Number Variations 
1.4.1 Classical Cytogenetic Techniques for the Detection of Structural 
Variations 
Classical cytogenetics and karyotype techniques such as Giemsa-banding (G-
banding) are traditionally used to detect large structural variations which are 
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microscopically visible (> 5Mb). One well-known example of cytogenetic application 
is the diagnosis of trisomy 21, which leads to Down syndrome. Despite the higher 
resolution of the newer array-based methods described below, karotyping remains the 
primary method to detect balanced chromosomal rearrangement such as translocation 
or inversions.  
Complementary to the genome-wide but low-resolution G-banding method, 
fluorescence in situ hybridisation (FISH) was developed as a targeted and higher 
resolution method, extending the detection to submicroscopic copy number changes 
of a few hundred kilobases. FISH is an in situ hybridisation technique in which a 
fluorescently labelled probe is hybridised to specific complementary sequences in the 
genome of metaphase chromosomes or interphase DNA. Following hybridisation, 
visualisation under a fluorescence microscope allows direct detection of deletions 
(missing signals), duplications (extra signals), or translocation (relocated signals). 
Other derivative techniques evolved from FISH. Improvement on probe 
labelling has led to the development of multi-probe FISH and spectral karyotype 
(SKY) (Schrock et al. 1996). Using multiple probes labelled in different colours 
allows visualising rearrangements involving different chromosomes, permitting 
complex rearrangement to be investigated in a single experiment. Also, the DNA 
preparation method has progressed such that extended chromatin fibres (as a 
replacement for interphase or metaphase preparation) were fixed onto glass slides for 
high-resolution detection, a technique known as Fiber-FISH, which can yield a 
resolution of a few thousands base pairs (Florijn et al. 1995). 
Along with the development of FISH, complementary techniques such as 
Comparative Genomic Hybridisation (CGH) (Kallioniemi et al. 1992) were 
developed for the detection of structural rearrangement. In CGH, differentially 
labelled test and reference DNA were simultaneously hybridized to chromosome 
spreads. The hybridisation was then detected with two fluorochromes, and genomic 
regions of gains or losses would be detected as changes in the ratio of intensities of 
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the two fluorophores along the chromosome. The major advantage of CGH is that it 
allowed whole-genome surveys of chromosomal aberrations, compared to previous 
target specific approaches as in FISH. However, such CGH approaches remained 
limited in resolution by the use of metaphase chromosomes as DNA hybridisation 
targets.  
While microscope-based techniques still remain relevant for some 
applications such as targeted studies, technology revolution has profoundly changed 
the way genomes are screened for SVs/CNVs. There are now two main technological 
approaches for detecting and mapping SV/CNV in the human genome:  
1) Hybridisation-based microarray approaches 
2) Sequencing-based computational approaches 
 
1.4.2 Hybridisation-based Microarray Approaches 
Microarrays have been the experimental workhorse for CNV discovery and 
genotyping. They are represented by array comparative genomic hybridisation 
(aCGH) and SNP microarrays. Both hybridisation-based microarray platforms can 
screen entire genome at once for CNV based on massively paralleled hybridisation of 
DNA to targeted probes attached to glass slide or other solid surface. The nature of 
probes used and experimental details differ on the two platforms. 
 
1.4.2.1 Array-based Comparative Genomic Hybridisation (BAC or 
Oligonucleotide)  
Array-based comparative genome hybridisation (aCGH) is a modification to 
the traditional CGH technique with greatly enhanced resolution.  It is achieved by 
substituting chromosome targets in a traditional CGH experiment by a matrix of 
defined nucleic acid target sequences, now typically long oligonucleotides, and in 
earlier days, bacterial artificial chromosome (BAC) clones. Uniquely labelled test and 
reference DNAs are co-hybridised, and the signal intensity ratio is normalised and 
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converted to a log2 ratio, or Log R ratio, which is used as a proxy for copy numbers. 
Significant deviation from the 1:1 test/reference for a probe (or a series of 
consecutive probes) would be interpreted as DNA copy number changes (Figure 
1.4A). An important consideration is the effect of reference sample on the copy 
number profile. For example, when only one sample is examined, a loss in the 
reference sample is indistinguishable from a gain in the test sample. Therefore, a 
well-characterized reference is important to interpretation of array CGH data. 
Many early genome-wide CNV studies were based on BAC aCGH (Iafrate et 
al. 2004; Redon et al. 2006). Although these initial studies had demonstrated the 
widespread occurrence of CNV in healthy individuals, the resolution is in the order of 
~100 kb, and the breakpoints were not sufficiently well defined at ~ 50 kb resolution, 
thereby hindered accurate assessment of proportion of genome altered by CNV and 
its gene content. This resulted in an overestimation of the extent of CNV using BAC 
aCGH (Redon et al. 2006), which was subsequently refined by oligonucleotide 
microarrays (Conrad et al. 2010b; McCarroll et al. 2008b), or sequence-based study 
for the same DNA samples (Kidd et al. 2008).   
BAC arrays have now been replaced by oligonucleotide-based arrays, which 
are mostly supplied commercially (e.g. Agilent Technologies). These arrays are 
synthesized in-situ with ~20-80-mer oligonucleotides which form the probes for CNV 
detection. Array designs can be optimized to target regions or breakpoint studies. The 
Structural Consortium study and a Korean study have used ultra-high-resolution 
arrays (24M to 42M probes) for aCGH-based SV discovery for HapMap samples 
(Conrad et al. 2010b; Park et al. 2010). They have allowed the discovery of CNV 
down to 500 bp, with breakpoints precise enough to allow identification of sequence 
motifs in a subset of variants. But it was not practical to do in large number of 
samples (30 to 40 samples done in the 2 studies). 
A main advantage of aCGH platform is that it produces better signal-to-noise 




hospitals and clinical laboratories already acquired with traditional CGH, and studies 
that proved its sensitivity over traditional G-banding (Miller et al. 2010), these factors 
have led to the widespread adoption of aCGH in clinical diagnosis, replacing 
karyotype analysis as the preferred first tier test to detect copy number alterations for 
patients with developmental delay, intellectual disability or multiple congenital 
anomalies (Miller et al. 2010).  
 
  
Figure 1.4  Array CGH versus SNP microarray detection. A) Schematic 
representations of Log R ratio in Array CGH in different copy number states and 
other biological situations. B) Log R ratio and B-allele Frequency in SNP array at 
different copy number states and during other biological situation. (Adapted from 




1.4.2.2 SNP Microarrays 
The second type of microarray platform, SNP microarray, has integrated the 
detection of SNPs and CNVs. In contrast to aCGH which hydridises both test and 
reference DNAs to the same array, SNP arrays hybridize only one sample to each 
array and compare the data in silico to a reference dataset. Currently, two major 
brands of SNP arrays are available on the market, Illumina (Illumina Inc., CA, USA), 
and Affymetrix (Affymetrix Inc., CA, USA). Each uses different approach to 
determine genotype. Illumina uses probes targeting the position adjacent to the SNP, 
discriminating the alleles using differentially labelled nucleotides in a single-base 
extension reaction (Peiffer et al. 2006). Affymetrix uses different probes to target 
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each of the alleles in a single-colour hybridisation (McCarroll et al. 2008b). Both 
allele intensities, based on two colors (Illumina), or two separate probe sets 
(Affymetrix), are then combined in a total signal, which is compared in silico to a 
normalised reference signal. The ratio between the total signal and the reference 
signal yields a log2 ratio (or Log R ratio), similar to the intensity ratio from aCGH 
results, which can be translated to copy-number information (Figure 1.4B). The 
reference used in SNP array can be a collection of reference hybridisations, or the 
same sample set that are being analysed. 
One main disadvantage of SNP array is that it has lower signal-to-noise ratio 
(SNR) than aCGH (Figure 1.4A & B). However, SNP arrays offer an additional 
metric that enables a more comprehensive assignment of copy number than does 
array CGH. This metric, termed B allele frequency (BAF) (Figure 1.4B, bottom 
panel), can be calculated as the proportion of the total allele signal (A + B) explained 
by a single allele (A). The BAF has a significantly higher per-probe SNR than the log 
ratio data and can be interpreted as follows: a BAF of 0 represents the genotype (A/A 
or A/–), whereas 0.5 represents (A/B) and 1 represents (B/B or B/–). Different BAF 
values occur for AAB and ABB genotypes or more complex genotypes (for example, 
AAAB, AABB and BBBA). Homozygous deletions result in a failure of the BAF to 
cluster. Hence, the BAF could be used to accurately assign copy numbers from 0 to 4 
in diploid regions of the genome. The BAF also allows detection of copy-neutral 
events such as segmental uniparental disomy (segmental UPD) or whole-chromosome 
UPD and identity by descent (IBD), which results when a segment of one 
chromosome is replaced by the other allele without a change in copy number (this is 
therefore not detectable by array CGH). An additional advantage of the BAF is that it 
can be used to reliably detect and type low-level mosaic gains and losses (Figure 
1.4B). 
One early version SNP array, the Affymetrix GeneChip 500K array, was used 
for CNV detection as a complementary platform to BAC array in the HapMap CNV 
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study published in 2006 (Redon et al. 2006). A major drawback of the early SNP 
arrays was uneven probe spacing, with particularly sparse probes at regions near 
segmental duplication, and at repeat-rich centromeres and telomeres. This 
disadvantage has been overcome by newer SNP genotyping platforms such as the 
Affymetrix Genome-wide Human SNP array 6.0, which has included non-
polymorphic probes specifically selected for their genomic positions to target known 
CNV regions, and to better covered SNP-poor regions such as SD and repeat regions. 
These non-polymorphic CNV probes are examined for log ratios only and not BAF. 
Examples of the more recent SNP arrays included Affymetrix Genome-wide 
Human SNP array 6.0, containing ~906,600 SNPs and ~946,000 CNV probes; and 
the Illumina Human1M-Duo Bead Chip, with ~1.2 million markers and 1.5 kb 
median marker spacing. These platforms offer a new paradigm for genome-wide 
disease association studies, integrating both SNP and CNV assessments in the work-
flow of such investigations (Korn et al. 2008). This study has adopted Affymetrix 
Genome-wide Human SNP array 6.0, the rationale and more details are discussed in 
Chapter 2. 
 
1.4.3 Sequencing-based Computational Approaches 
The advent of next-generation-sequencing (NGS) technologies provides new 
promise to structural variation studies. The main advantage of whole genome 
sequencing technologies is that they permit the simultaneous mapping of the entire 
spectrum of genetic variants present in a single genome. However, NGS approaches 
present substantial computational and bioinformatics challenges. There are three 
sequence analytical strategies, all of which focus on mapping sequence reads to the 
reference genome and subsequently identifying discordant signatures or patterns that 





1.4.3.1 Pair-End Mapping (PEM) 
Pair-End Mapping (PEM) assesses the span and orientation of paired-end 
reads and cluster ‘discordant’ pairs in which the mapping span and/or orientation of 
the read pairs are inconsistent with the reference genome (Figure 1.5, top panel). 
Most classes of variation can, in principle, be detected. Read pairs that map too far 
apart define deletions, those found too close together are indicative of insertions, and 
orientation inconsistencies can delineate inversions and a specific class of tandem 
duplications. Read pairs in which only one end clusters and the others do not map to 
the reference have been used to flag variant sequences not included in the reference 
genome (novel insertions). 
Pair-End Mapping (PEM) is used on two types of sequencing libraries. Mate 
pairs are created by circularizing size-selected fragments from randomly fragmented 
DNA using an internal ligation adapter, followed by shearing and sequencing around 
the adapter. This yields two sequences that are separated in their genomic position by 
the size of the selected fragment, typically several kilobases. Paired-end sequencing 
uses smaller fragments of only a few hundred base pairs, which are sequenced from 
both ends using ligated primer binding sites.  Read-pair methods were initially 
applied using classical Sanger sequencing, more recent NGS techniques allow 
performing this method in millions of parallel reactions (Alkan et al. 2009; Kidd et al. 
2008; Korbel et al. 2007; Mills et al. 2011; Tuzun et al. 2005).  
 
1.4.3.2 Read-Depth Analysis (RDA) 
Read-depth analysis is based on statistical analysis of read mapping density 
per a given stretch of the human genome (Alkan et al. 2011; Alkan et al. 2009). It 
detects deletions and duplication by identifying regions where the density 
significantly deviates from genome average. DNA sequencing reads are mapped onto 
the reference genome. The mapped reads are then counted in bins along the genomic 
sequence. Duplicated regions in the genome will show significant higher read depth 
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while deletions will show reduced read depth when compared to diploid regions 
(Figure 1.5, bottom panel). Based on this principle of RDA, the strength of a RDA 
signal is related to the coverage of the sequence data and the size of the CNVs. On 
the other hand, RDA may be less powerful in detecting smaller CNV and limited in 
defining breakpoints. Also, RDA cannot detect copy-neutral variations, unlike PEM.  
 
1.4.3.3 Split-Read Analysis (SRA) 
Split-Read Analysis (SRA) is capable of detecting deletions and small 
insertions down to single base-pair resolution (Alkan et al. 2011). SRA utilizes 
information from partial, i.e., split, mappings of a single read. SRA makes us of DNA 
sequencing reads that span the junction point of the two breakpoints caused by the 
occurrence of a SV. If the alignment to the reference genome is broken; a continuous 
stretch of gaps in the read indicates a deletion, while gap in the reference indicates an 
insertion (Figure. 1.5, middle panel). If the split-read spans this position in such a 
way that there is enough sequence information available on both sides of the junction 
to allow for unambiguous independent mapping of each side of the split read onto the 
reference genome, then SRA will produce a SV call that has immediate nucleotide-
level (i.e. maximal) resolution. More so than PEM and RDA, SRA is dependent on 
long read-length and deep genomic coverage of the sequencing data. However, SRA 
immediately produces SV predictions at highest resolution, which can be of great 
benefit for example if a SV has occurred within the sequence of a gene and it is of 
interest to learn which parts of the gene exactly have been preserved and which have 




Figure 1.5  The three approaches to analyse 2
nd
-genertaion, high throughput DNA 
sequencing reads to detect structural genomic variation. A) Paired-end mapping 
(PEM). B) Split-read analysis (SRA), C) Read-depth analysis (RDA). (Adapted from 




1.4.4 Validation and Detection of Locus-specific CNV   
Large scale CNV discovery experiment is usually followed by quantitative or 
semi-quantitative measurements of copy number variations at specific targeted loci. 
These quantitative measurements besides serving as independent platforms to validate 
array based CNV discoveries, they would also provide more accurate copy number 
genotype information for the targeted CNV locus, and some could precisely map 
breakpoints of CNV regions. The quantitative measurements of CNVs at targeted loci 
could also be expanded to a broader context, where a low-cost reliable assay is 
developed for high throughput genotyping in a large number of samples, for disease 
association studies or in clinical diagnostic settings. 
Traditional methods used to quantify copy number included FISH, fiber-
FISH, Southern blotting and PFGE (Pulse Field Gel Electrophoresis). However, these 
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methods require cells or large amounts of high-quality DNA. They are also laborious, 
time consuming, and low-throughput, and therefore could only be applied to validate 
small number of targeted CNVs in limited samples.  
Newer techniques have evolved along with the progress of CNV discoveries. 
The five PCR-based approaches discussed below all have higher through-put 
capabilities and better cost-effectiveness, hence the feasibility to be used in large-
scale studies.  
 
1.4.4.1 Quantitative Real-time PCR (qPCR) 
Quantitative Real-time PCR (qPCR) is a rapid method for quantifying nucleic 
acids in real time. By analyzing the sample during the exponential phase of PCR 
amplification, it is measuring the amount of PCR product generated after each cycle 
in real time, as opposed to end point detection in conventional PCR (Hoebeeck et al. 
2007). Quantification of PCR product can be achieved through two common methods 
that either measured fluorescence intensity generated by a fluorescent dye (e.g. 
SYBR-green) which binds to the double-stranded DNA amplicons, or using 
primer/dual-labelled probe-based assay such as Taqman™ chemistry (Figure 1.6A). 
Taqman™ assays draw on the 5’-3’ exonuclease activity of Taq polymerase, which 
cleaves the dual-labelled probe hybridised to the DNA template, releasing the 
reporter dye (e.g. FAM) which emits a fluorescence signal during PCR amplification. 
The analysis of result can be carried out using the standard curve method or the 
comparative CT (threshold cycle) method.  
In the absence of post-PCR manipulation, qPCR has the advantages of being 
fast, relatively simple to implement, require minimal amount of DNA (10 ng per 
sample) and scalable to high throughput screening, as demonstrated in our genotyping 
work in Chapter 4. It is a commonly used CNV validation strategy (Conrad et al. 
2010b; Redon et al. 2006). The disadvantage is multiplex assays with many loci in 
one reaction is still difficult to optimise. Also optimising target and reference assays 
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to similar PCR efficiency required some effort, although the optimising effort is much 
less than those in PRT. Also at extreme high copy number, precision becomes a 
limitation. However, extreme high copy-number will present similar challenge to 













Figure 1.6  Four PCR-based methods for detection of copy numbers. (Adapted from 
(Cantsilieris and White 2013) 
A) Real-time quantitative PCR. Amplification of double-stranded DNA with unique 
primers, used in combination with a fluorescently labelled probe.  
B) Multiplex amplifiable probe hybridisation. A unique single-stranded probe with 
universal primer ends is hybridized to single-stranded genomic DNA immobilized to 
a nylon filter.  
C) Multiplex ligation-dependent probe amplification. Two unique half probes with 
universal primer ends hybridize adjacently to genomic DNA in solution. Addition of 
DNA ligase allows ligation of adjacently annealing probe sequences and subsequent 
amplification.  
D) Paralogue ratio test. Amplification of test and interchromosomal reference 




1.4.4.2 Multiplex Amplification Probe Hybridisation (MAPH) 
Both MAPH and MLPA (discussed in next section) are cost-effective 
methods for typing large numbers of loci in a single reaction (Armour et al. 2000; 
Schouten et al. 2002). Both techniques are probe-based hybridisation assays, with the 
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main difference being in the hybridisation and post-hybridisation treatment of the 
DNA.  
MAPH requires immobilization of genomic DNA to a nylon filter. The 
hybridisation process involves single-stranded DNA probes with universal primer 
ends (Figure 1.6B). Each probe can be of different sequence length and target 
separate regions of interest in the genome. Unbound probes are removed post-
hybridisation through stringent washing. The bound probes are simultaneously 
recovered and quantitatively amplified with universal primer ends, electrophoresis on 
a capillary sequencer, and analysed. The PCR products are quantified by peak height 
or area, which are directly proportional to the copy number in the genomic DNA. 
MAPH has been applied to measure α- and β-defensin copy variable genes, which 
show a range of variation up to 12 copies (Hollox et al. 2008). Unlike MLPA which 
could be affected by SNP that will affect its ligation step, MAPH will not be affected 
by sequence polymorphism, and hence does not differentiate highly homologous 
sequences. Also, MAPH requires substantial amount of DNA (~1ug). 
 
1.4.4.3 Multiplex Ligation-dependent Probe Amplification (MLPA) 
Like MAPH, MLPH also relies on the enumeration of copy number through 
quantification of amplified probes that indirectly assesses the complementarily bound 
sequences (Schouten et al. 2002). Unlike MAPH, MLPH used half probes and 
requires only 100-200 ng of input DNA. Each probe has two halves – 5’ and 3’ 
probes. They contain the sequences complementary to the genomic region of interest. 
Each half probe also contains a universal primer along with a staffer sequence, which 
may be present on one or both half probes. This staffer sequence is of variable length, 
which aids in distinct separation of different targets. MLPH has a ligation step, after 
both half probes are hybridised properly to the target locus. (Figure 1.6C) This 
ligation step has makes MLPH sensitive for distinguishing highly homologous 
sequences, but also makes it susceptible to assay failure due to unsuspected 
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polymorphism around the ligation site. MLPH has been largely applies to detect 
common deletions and duplications in genes with clinical importance, such as genes 
for Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and 
low-density lipoprotein (LDL) receptor (Holla et al. 2005; Janssen et al. 2005). It is 
also used in diagnosis of aneuploidies and trisomies (Slater et al. 2003), but it has not 
been reported to be used to measure high copy number variants. 
The key advantage of both MAPH and MLPH techniques is that 
hybridisation is quantitative and proportional to the amount of target, and that 
amplification using a single universal primer pair eliminates bias through differential 
amplification efficiencies. But they suffer the same limitation in precision as in qPCR 
when distinguishing extremely high copy numbers. 
 
1.4.4.4 Paralogue Ratio Test (PRT) 
PRT is a comparative PCR method that relies on dual amplification of test 
and reference loci using the same primer pair via amplification of interchromosomal 
paralogous low copy repeats (Armour et al. 2007). Differentiation between test and 
reference loci is achieved through differences in fragment size (Figure 1.6D), or 
through restriction digestion of the PCR products for differentiation. By comparing 
ratios from test and reference loci, it allows inference of gene copy number. An 
advantage of PRT is that amplifying a reference and test locus in a single reaction 
using the same primer pair makes the kinetics of both amplifications similar, 
therefore removing potential experimental bias caused by differential PCR 
efficiencies when different primer pairs are used. The precision of PRT are equivalent 
to MLPA and MAPH, with the advantage of requiring smaller amount of input DNA 
(10-20 ng) (Armour et al. 2007). However, PRT is limited by the precise design of 
primer sequences that exclusively match test and reference loci but with sequence 
length difference. Nevertheless, PRT allows high throughput analysis of CNVs and 
have been successfully applied to measure different CNVs, such as β-defensin genes 
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at 8p23.1 (Armour et al. 2007; Hollox et al. 2008), CCL3L1/CCL4L1 copy number at 
17q12 (Walker et al. 2009), and the immunoglobin-receptor genes FCGR3A/FCGR3B 
at 1q23.3 (Hollox et al. 2009). 
 
1.4.4.5 Digital PCR (dPCR) 
Digital PCR provides an absolute measurement of nucleic acid concentration 
by combining limiting dilution of input DNA, end-point PCR, and Poisson statistics 
(Sykes et al. 1992). In dPCR, target reactions are performed at low template input so 
that some reaction chambers (replicates) are positive and some negative. The absolute 
concentration of target (in molecules/µl) can be calculated from the fraction of 
positive end-point reactions, after applying a correction for Poisson distribution.  
Although the concept of dPCR was first described in 1992 (Sykes et al. 
1992), implementing the thousands of partition per single experiment has not been 
easy. Recent advances in nanofabrication and microfluidics have now led to systems 
that produce hundreds to millions of nanoliter- or even picoliter-scale partitions. 
Fluidigm and Life Technolgies use reaction chambers within specifically designed 
chips or plates. Bio-Rad and RainDance sequester reagents into individual droplets. 
As dPCR relies on a binary end-point threshold to assign each replicate 
reaction as either positive or negative, it can tolerate wide variation of PCR 
efficiencies without affecting copy number estimation. Because dPCR quantifies an 
absolute measurement of the target molecule numbers (copies), there is no need to 
calibrate the results to a sample calibrator, nor the need of a standard curve. Thus, the 
relative copy number is determined by comparing the results of the target assay 
directly to the results of the reference assay (known to have 2 copies per diploid 
genome) for each sample. The number of reaction replicates, or partition chambers, 
largely defines the dynamic range of target DNA quantitation, where an order of 
magnitude increase in the number of replicates yields approximately an order of 
magnitude increase in dynamic range. Increasing the number of partitions also 
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improves precision therefore enable resolution of smaller concentration differences 
(or smaller copy number fold change) in two DNA samples. As shown in our amylase 
genes CNVs genotyping work discussed in Chapter 4, dPCR has proven its resolution 
over qPCR in multi-copy CNV, particularly for higher copy number range. 
 
1.5 Early Work that Lead to This Study 
1.5.1 Genetic Diversity in Singapore Populations using Mitochondrial DNA 
and Chromosome Y Markers 
Part of the impetus of this study comes from our previous studies using other 
DNA markers for Singapore populations. Sex-lineage markers were studied because 
of their specific advantages in different situations for forensic applications. A non-
coding highly variable region in the mitochondrial genome, the Control Region 
Sequence (CRS) of approximately 1.2 kb in size, was studied in three Singapore 
populations, Chinese, Malays and Indians (Figure 1.7). Chinese and Malays displayed 
similar polymorphism pattern. But the polymorphic pattern in Indians showed some 
obvious differences, both in term of sequence variation sites and in allele frequencies 
of many CRS positions (Yong et al. 2004).  
The genetic differentiation of Indians from Chinese and Malays was even 
more obvious using chromosome Y markers. The 2003 version of Chromosome Y 
phylogenetic tree clustered global populations into 153 haplogroups using a total of 
245 Y-SNPs. These 153 haplogroups could be grouped into 18 major clades, and each 
clade is associated with a continent-specific population (Jobling et al. 2003). For 
example, Chinese are mostly represented by Clade O. We genotyped a total of 91 Y-
SNPs and identified 87 haplogroups distributed over 14 clades in the 3 Singapore 
populations (Figure 1.8). Indians generally have distinct Y-haplogroups spread 
between Clades C, F, H. J, L, Q and R. While Chinese and Malays are mostly in 
Clade O, and Malays could also be found in Clades C and R. Furthermore, there is 
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more sharing of haplogroups between Chinese and Malays (Yong et al. 2006a).  
Besides Y-SNP markers, 12 Y-STR markers were also genotyped in the same sample 






















Figure 1.7. Distribution of mitochondrial DNA polymorphisms in 3 Singapore 
populations. CRS, Control Region Sequence. *novel or no polymorphism in specific 
CRS position in Indians compared to Chinese and Malays. ‡ CRS polymorphism with 
highly different allele frequency in Indians. (Yong et al. 2004) 
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10 Y-STR 91 Y-SNP HV1+2 seq
Chinese Malay Indian Chinese Malay Indian Chinese Malay Indian
n=210 n=186 n=183 n=209 n=181 n=174 n=99 n=70 n=95
Chinese 0.0506 0.1891 Chinese 0.1199 0.3544 Chinese 0.0068 0.0261
Malay 0.0000 0.1110 Malay 0.0000 0.2187 Malay 0.0384 0.0204
Indian 0.0000 0.0000 Indian 0.0000 0.0000 Indian 0.0000 0.0000





















































































































































































































































































































































































With the genotype information obtained from all three types of DNA 
markers, the genetic distance between each population-pair was estimated using 
Wright Fixation Index, FST (more details on FST in Section 3.1.2.1). Regardless of 
DNA markers used, all analysis consistently showed that Chinese-Malay has the 
smallest genetic distance, followed by Malay-Indian, and Chinese-Indian has the 
largest genetic distance (Table 1.3). These studies laid the impetus to look into 
autosomal DNA variants for further validation of these results. 
 
Total Haplogroups: 33  
Chinese: n=209   7 clades 18 haplogroups 
Malay:  n=181   12 clades 25 haplogroups 
Indian:  n=174   12 clades 18 haplogroups 
 
Figure 1.8 Distribution of Y-haplogroups in the 3 populations of Singapore. X-axis 
shows the respective Y-haplogroups. Y-axis is the frequency. 14 major clades are 
shown at the bottom of the figure, corresponding to their member haplogroups. 
Sample size and total number of clades and haplogroups identified in each population 
are also listed. (Yong et al. 2006a) 
 
A              B          C 
 
Table 1.3  Genetic distance between population-pair, using various types of DNA 
markers.  A) 10 Y-STRs, B) 91 Y-SNPs and C) mitochondrial DNA CRS regions. FST 




1.5.2 An example of CNV on Chromosome Y – Yp11.2 Deletion  
The second study that led to this CNV study involved the characterization of 
a 3 Mb deletion at chromosome Yp11.2 (Yong et al. 2007). A side observation on 
forensic databases noted a small percentage of genotyping failure in the sexing 
marker Amelogenin Y (AmelY) locus, leading to an erroneous classification of male 
to female. The AmelY null allele is found mainly in Indians, with a null allele 
frequency of 2.7% and 0.6% in Indians and Malays, respectively.  
Further investigation suggested a large deletion in this locus. We 
characterized this locus to molecular detail, deciphering the breakpoints to sequence 
level, demonstrating that the breakpoints were tightly linked to their Y-SNP 
haplogroups (Figure 1.9). We showed that there were 5 recurrent mutations that 
resulted in the current Yp11.2 null allele distribution in our regional populations. 
Combining genotype information from Y-SNPs and Y-STRs, the estimated age of 
each mutation events were calculated and a phylogenetic map built to account for the 
chronological orders of these deletion in our regional populations (Figure 1.10). The 
availability of breakpoint information allowed a precise determination of the affected 
genes in this locus, permitting a better assessment of their functional effects. The 
breakpoint information also inferred the deletion mechanism, Non-alleleic 
Homologous Recombination (NAHR), a mechanism often associating with large 
CNV formation. It was during this period that the widespread occurrence of CNVs in 
genome of healthy individuals became recognized. We recognized that Yp11.2 was 
an example of CNV and demonstrated the amount of insights to be culled from a 
detailed study of such candidate. This naturally led to a question of the extent of such 
CNV in other chromosome in our populations. Also, with the population-specificity 
shown in this Yp11.2 deletion, whether more of such candidate could be found, 
which could be combined and used to construct an ancestry informative panel that has 
forensic application value. This led to this study of genome-wide screening of CNVs 




















Figure 1.9  Schematic diagrams of Yp11.2 deletion haplotypes. A) Low resolution 
mapping of the Yp11.2 deletion region, flanked by TSPY repeats. B) Sequence 


















































































Figure 1.10  Deduced phylogenetic branching and estimated age of both Yp11.2 
deletion  for Singapore and Malaysia populations. (Yong et al. 2007) 
 
 
1.6 Singapore Populations  
Singapore is a relatively young country with a migratory history 
predominantly consisting of immigrants with Chinese, Malay, and Indian genetic 
ancestries from neighboring countries such as China, India, Indonesia, and Malaysia 
(Saw 2012). The Chinese in Singapore are mostly Southern Chinese, which reflect 
the origins of most first-generation Chinese migrants in Singapore, who were from 
the southern provinces of China, such as Fujian and Guangdong. Currently, Chinese 
is the dominant racial group in Singapore, accounting for 74.3% of the resident 
population (Department of Statistics, Singapore. http://www.singstat.gov.sg/home). 
While Han Chinese represents the largest ethnic group amongst the Chinese globally, 
there are a considerable number of sub-ethnicities within the Han classification with a 
diverse range of dialects and cultural diversity, with established genetic heterogeneity 
following a geographical north–south cline (Suo et al. 2012). The majority of the 
early Chinese immigrants to Singapore were mainly attributed to the dialect groups of 
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Hokkien, Teochew, Cantonese, Hakka, and Hainanese (Saw 2012) that are 
predominantly found in Southern China.  
The Malays are the native population in Singapore, with close cultural and 
migration history with Malays from neighboring Brunei, Indonesia, Malaysia and 
Southern Thailand. In a broader context, Malays are considered to be Austronesian 
peoples. Malays formed the dominant race in Singapore prior to the colonization by 
British settlers, the proportion of indigenous Malays has been surpassed by migrant 
Malays from Peninsula Malaysia, as well as Javanese and Boyanese people from 
Indonesia. Cultural and religious similarities have resulted in intermarriages between 
the immigrant and local Malays, whose descendents are now collectively known as 
Malays and account for 13.3% of the Singapore population (Department of Statistics, 
Singapore).  
The British colonization of Singapore also brought Indian migrants from the 
Indian subcontinent, with the majority consisting of Telugas and Tamils from 
southeastern India and a minority of Sikhs and Pathans from north India. The 
definition of Indians in Singapore comprises people with paternal ancestries tracing 
back to the Indian subcontinent, and, as a race, Indians represent 9.1% of the 
Singapore population (Population Trends 2014, Department of Statistics, Singapore). 
 
1.7 Aims of this Thesis and Thesis Organization 
The aims of this thesis are: 
1) To establish a CNV catalogue for three Singapore populations and to 
understand the distribution and characteristics of these genome-wide 
CNVs. 
2) To study the population diversity of CNVs in these three populations. 
3) To identify the CNVs that are highly stratified between these three 
populations and to investigate if functional inference could be 
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deciphered in relation to the high differentiation. Attempt is also made 
to study if there is any evidence of selection signal in these population 
differentiated CNVs. 
4) With the rapid growth of CNV research, one of the remaining gaps is 
the multiallelic CNVs that are difficult to genotype. This thesis elects 
to study amylase gene CNV loci as examples of multiallelic CNVs and 
optimized a method to genotype these loci. This study also attempts to 
validate a recent reported association of AMY1 copy number and 
obesity in a Singapore Chinese cohort.  
 
This thesis is organized into 5 chapters.  All chapters contain an introduction, 
materials and methods, results and discussion. Each chapter is relatively independent, 
but there is linkage and continuation between chapters 2 and 3. Some of the detailed 
information and results are presented in appendices. 
Chapter 1 provides a literature review for a general overview of CNVs, 
comprising various aspects from historical development, their biological impact, 
molecular mechanism of formation and the different methods of detection, both 
genome-wide discovery and targeted locus-specific genotyping. 
Chapter 2 documents the genome-wide screening of CNVs in the three 
Singapore populations. Different CNV calling algorithms have been examined and 
the reproducibility rate tested. Rationale of selecting specific algorithm over a 
stringent approach was discussed, and the strategy was ascertained by qPCR. QPCR 
was used to validate the false positive rate and genotyping concordance rate of 
various CNV categories. The distribution and characteristics of CNVs in the three 
populations was discussed. The CNV dataset was compared against dataset from 
similar populations such as SGVP. 
Chapter 3 examines the genetic diversity of CNVs in the three populations. 
Genetic distance between the three populations was determined. Common CNVs that 
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were population-specific or highly differentiated in frequency were identified and 
inference to functional differences was investigated. Attempt was made to explore if 
selection forces could account for the high frequency difference between populations 
for this group of CNVs, and a plausible locus identified was discussed. 
Chapter 4 studies the AMY1 and AMY2A CNV loci as examples of 
multiallelic CNVs with different range of diploid copy numbers. A genotyping 
method was optimized to combine data from qPCR and dPCR platforms. This method 
uncovered a novel distribution pattern of AMY1 diploid copy number with even:odd 
genotype imbalance, due to underlying haplotype structures. The genetic diversity of 
AMY1 and AMY2A in the three populations was studied. Finally, I carried out an 
analysis of association between AMY1 copy number and obesity to validate a recent 
claim of positive association in European populations and a Singapore Chinese 
cohort, but could not detect any association. The validity of this study results in view 
of the technical challenge in high copy number genotyping are discussed. 
Chapter 5 summarises the major findings of the earlier 3 chapters and 




















2.1.1 Significance of Copy Number Variation in Individual Populations  
Copy Number Variation has emerged as a major source of human genomic 
variation, encompassing more base pairs than SNPs (Chapter 1). A key analysis has 
reported that two diploid human genomes typically differed in >1000 CNVs of >1kb 
size, covering a length of 24Mb (~0.8% of the genome) (Conrad et al. 2010a). CNV 
as a class of ubiquitous genetic variation can play an important role in contributing to 
genetic diversity, human evolution and disease susceptibility. Like SNPs, many 
CNVs are normal genetic variants that do not contribute to clinically recognizable 
phenotypes. But some CNVs can predispose to or are significantly associated with 
conditions of medical consequence. Studies have identified CNVs of biological 
relevance, most notably as pathogenic variants in neuropsychiatric and 
neurodevelopmental diseases (Girirajan et al. 2011; Stankiewicz and Lupski 2010). 
To better understand the relationship between CNV and clinical phenotypes or 
biological outcomes, a baseline of normal variation is important to assist in vigorous 
analysis of any pathological or biological consequences of a CNV candidate. 
Therefore, a comprehensive detection and characterization of CNVs in healthy 
humans helps to lay the foundation to better decipher the role of CNVs in diseases. 
In addition, many CNVs appear to be a highly dynamic form of genetic 
variation exhibiting a relatively higher mutation rate (refer section 1.3.6). A 
significant fraction of such variation is not adequately captured by linkage 
disequilibrium (LD) to SNPs in genome-wide association studies (GWAS) (Campbell 
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et al. 2011; Redon et al. 2006). Hence, these CNVs should be directly ascertained, 
studied, and included in GWAS. 
It is also noted that CNV polymorphisms vary in frequencies in different 
populations. It was demonstrated that the four HapMap populations could be 
clustered into 3 groups that reflect their continent of origin by only 67 CNV 
genotypes (Redon et al 2006). Therefore, studies on CNV association with 
phenotypes would require ethnicity matched controls. Similarly, understanding the 
evolutionary impact of CNV will also need a more comprehensive knowledge of 
location, size and frequency distribution of these CNVs within and between 
populations. With the increasing resolution of CNV detection technologies, the 
number of CNVs identified has increased dramatically. To date, there are 62 studies 
with >350,000 CNV loci recorded in the Database of Genomic Variants 
(http://dgv.tcag.ca/dgv/app/home) (MacDonald et al. 2013). However there are not 
many Asians populations included. When this study was initiated in 2009, there was 
no CNV data for South-East Asia. Although several papers have subsequently 
published during the course of this study (Ku et al. 2010; Ku et al. 2011; Xu et al. 
2011), this study still adds information to the continuing expansion of CNV catalogue 
of our local populations, and offers an independent study to aid in the validation of 
the CNVs in existing SGVP database (http://www.statgen.nus.edu.sg/~SGVP/). 
In summary, a comprehensive CNV catalogue is useful for: 
1) A better understanding of the distribution of CNV in local populations, 
2) Genome-wide or locus-specific CNV association studies, 
3) Cytogenetic research and diagnostics as a baseline reference, 
4) Validating existing databases with similar populations, and 






2.1.2 Platform Selection 
As discussed in Section 1.4.2, a hybridisation-based platform offers cost-
effectiveness and good throughput for genome-wide CNV discovery study. There are 
several high-resolution microarrays commercially available for CNV analysis, falling 
into two main categories. The first is SNP microarrays, which can interrogate over a 
million SNP genotypes in a single individual (provided mainly by the companies 
Affymetrix and Illumina). The second type of microarray is the comparative genomic 
hybridisation arrays (aCGH) (provided by companies such as Agilent). Both 
platforms contain oligonucleotide probes that bind to fluorescently labelled genomic 
DNA and the intensities are used to interrogate copy number. The main difference 
between the two platforms is that for CGH arrays the reference DNA is hybridized to 
the array together with the test DNA allowing a direct comparison of copy number. 
For SNP microarrays, only one sample is hybridized to the array and the reference 
must be built from other experiments in order to analyze for copy number. More 
details about these two approaches can be found in section 1.4.2. 
This study has adopted SNP microarray over aCGH for several reasons; (1) 
SNP array provides both SNP and CNV genotypes, hence a cost-effective way to 
obtain two datasets simultaneously; (2) the SNP information could be used to 
determine population structure of the samples and hence to verify the NRIC-
registered ethnicity of this sample set; (3) SNPs allow for quality control checks to 
ensure no sample mix-up, determine relatedness between samples, and confirmation 
of parentage for family samples; (4) copy-neutral events such as uniparental disomy 
or copy-neutral loss of heterozygosity can be detected; (5) SNP array requires less 
starting DNA material than aCGH. Points 3 and 5 are particularly important for this 
legacy sample set where samples were collected some time ago and are limiting. 
When this study began in 2009, there were two high-resolution SNP arrays 
commercially available; Affymetrix Genome-wide Human SNP array 6.0 (Affy 6.0) 
and Illumina Human1M-Duo Bead Chip (Illumina 1M). Between these two arrays, 
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Affymetrix was selected for this study because it contains 906,600 SNP probes and 
946,000 non-polymorphic probes, translating to a better genome coverage at a median 
probe distance of 680bp, in contrast to Illumina 1M with ~1.2 million markers and 
1.5 kb median marker spacing. Also, Affymetrix SNP6.0 array contains probes 
specifically designed for the detection of 5,677 known copy number variable regions 
from the Database of Genomic Variants (DGV, 
http://www.projects.tcag.ca/variation/). Greater than 200,000 probes are used to 
interrogate copy number at these known CNVs for an average of 61 probes per loci. 
In addition, more than 744,000 non-polymorphic probes are evenly spaced along the 
genome to enable more even coverage of the genome and the SNP-poor genomic 
regions. All 1.8 million probes can be used to detect CNVs, enabling detection of 
CNVs at 2 kb breakpoint resolution (McCarroll et al. 2008b). 
As novel CNV were discovered, a subset of CNV called were validated 
experimentally by a second method, Quantitative PCR (qPCR). We used 
conventional tube-based qPCR, and also attempted to optimise a new slide-based 
qPCR platform for this validation. Further work on novel methods for multiallelic 
CNV is reported in Chapter 4. 
This chapter describes the establishment of a CNV catalogue for 3 Singapore 
populations and the characteristics of CNVs and CNVRs. The population diversity 
and population genetics aspect of CNVs will be reported and discussed in following 
chapter, Chapter 3. 
 
2.2 MATERIALS AND METHODS   
2.2.1 DNA Samples – DNA Fingerprinting Cohort  
The study sample set was a legacy sample set collected for a previous 
DMERI project entitled “DNA Fingerprinting project”, which was approved by the 
DMERI Institutional Review Board in 2002. The project was a forensic genetic study 
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and the collection was for the establishment of DNA forensic marker databases of 
local populations. The blood sample collection was carried out directly by a 
department of MINDEF (Ministry of Defence, Singapore), and samples were 
anonymised at the point of collection source. Approximately 600 peripheral blood 
samples were collected from apparently healthy SAF (Singapore Armed Forces) 
personnel representing the three main populations in Singapore; Chinese, Malays, and 
Indians. Blood samples were provided to DMERI researchers together with three 
demographic information, birthday, gender, and race. The demographic information 
had been verified by the funder against the National Registration Identity Card 
system. The information on gender had been validated with forensic sexing markers 
during the DNA Fingerprinting project. The information on race was verified in this 
project with Principal Component Analysis using SNP genotypes. DNA was 
extracted from whole blood with QIAamp DNA Mini Kit (Qiagen, Germany) and re-
quantification by Nanodrop Spectrophotometer (Thermo Fisher Scientific Inc., USA). 
The reuse of legacy samples for this study was approved by DSO-IRB in 
2008. A total of 328 samples were randomly selected for this study, with 
approximately equal representation of each population. These 310 selected samples, 
together with 1 Affymetrix reference sample (Reference 103), 12 HapMap samples 
for protocol training purpose, and 1 set of family trio samples included for QC 
purpose, were used in this study. 
 
2.2.2 Hybridisation on Genome-wide SNP Array  
Genotyping was carried out on the Affymetrix SNP6.0 array according to the 
manufacturer’s instructions (Affymetrix® Genome-wide Human SNP Nsp/Sty 6.0 
User Guide) (Affymetrix, USA). Briefly, 500 ng of genomic DNA was digested with 
Nsp1 and Sty1 restriction enzymes separately and ligated to adaptor. A generic 
primer that recognized the adaptor sequence was used to PCR-amplify the ligated 





Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 Batch 7 Batch 8 Batch 9
Processed 48 47 46 46 46 39 45 14 23 354
Failed at sample QC 1 1 0 0 0 1 1 2 0 6
Failed at Digest 0 0 0 1 1 0 0 0 0 2
Failed at PCR 0 0 1 2 1 0 0 0 0 4
Hybridised on SNP6.0 array 47 46 45 43 44 38 44 11 23 341
Failed CQC 2 0 0 1 0 0 2 1 1 7
Passed CQC 45 46 45 42 44 38 42 10 22 334
the 200 to 1,100 bp size range. Amplicon size was verified with gel electrophoresis 
before further experiment. PCR products from both digests were combined, purified, 
and quantified to ensure samples passed QC before fragmentation. Fragmented 
products were checked to be <180 bp in size on gel, before labeling and hybridisation 
onto Affymetrix SNP6.0 chips at 50ºC for 16 hrs in GeneChip® Hybridisation oven 
645. After hybridisation, washing and staining of chips were carried out in 
GeneChip® Fluidic Station 450 using GeneChip® Command Console Software 
(AGCC), and scanned in GeneChip® Scanner 3000 7G to produce an signal intensity 
data CEL file per sample. 
Laboratory quality control steps were built into every stage of the work flow. 
Samples were randomized to avoid batch or group-specific effects. A total of 341 
samples were hybridized onto Affymetrix chips in 9 batches (Table 2.1). These 
samples included reference samples from Affymetrix and Hapmap, and one family 
trio samples. Also, intra- and inter-assay sample duplicates / triplicates were 
embedded into the assays for QC purposes.   
 
 
Table 2.1  Details of samples assayed per batch. Only samples that passed CQC 




2.2.3 Quality Control Measures 
2.2.3.1 Array Quality Control Parameters  
The signal intensity files were processed by Affymetrix® Genotyping 
Console v3.0.2 (GTC). Quality measures engaged in the software GTC was as 
recommended by Affymetrix. For array quality control before full-scale SNP 
genotyping or CNV analysis, GTC established two QC metrics; (1) Contrast QC 
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(CQC) captures the ability of an assay to resolve SNP signals into three genotype 
clusters and is used to predict SNP genotyping performance. It uses 10,000 random 
SNP probes. (2) Median Absolute Pairwise Difference (MAPD). Each pair is defined 
as adjacent probes in genomic distance. Increased variability decreases the quality of 
copy number calls. Arrays with recommended values of CQC >0.4 and MAPD <0.3 
could proceed to SNP and CNV genotyping, respectively. In addition, the dataset is 
considered problematic if more than 10 % of the samples do not pass the CQC cutoff 
of 0.4 or when the mean CQC is smaller than 1.70. A flowchart of various QC and 
filters are summarised in Figure 2.1 
 
2.2.3.2 Sample QC 
Those arrays meeting a contrast QC (CQC) > 0.4 have passed initial QC and 
were SNP genotyped using the built-in algorithm Birdseed v2 in GTC.  The SNP 
summary results are useful in identifying problematic samples. Samples were 
removed on the basis of:  
(1)  High rate of missing SNP >5%,  
(2) Too high or too low rate of heterozygosity, >0.3 or <0.2. High 
heterozygosity suggests sample contamination while low heterozygosity 
could be due to sample quality,  
(3) Sample duplicate or triplicate, and related samples identified by 
excessive IBS (Identity-by-State) > 70% carried out in PLINK 
(http://pngu.mgh.harvard.edu/~purcell/plink/ibdiBirdsuite.shtml),  
(4)  Stated gender did not match genetically inferred gender,  
(5)  Identification of samples with inconsistent population membership by 
PCA (Principal Component Analysis) carried out in SNP & Variation 
Suite 7 (Golden Helix Inc., USA),  
(6)  MAPD >0.3 using a reference file generated by samples genotyped in the 









 Contrast QC ≥ 0.4
Batch QC:
 Proportion of samples with CQC < 0.4 is less than 10%
 Average CQC of samples that pass CQC is ≥ 1.7
Inclusion Criteria
Sample Inclusion Criteria
• Call rate ≥ 95%; Missingness < 5%
• Heterozygosity > 0.20 & < 0.30
• Stated gender = Inferred gender
• IBS < 70% (PLINK)
• PCA to identify admixed samples
SNP Inclusion Criteria  
• HWE p-value > 10-7
• SNP call rate ≥ 95%
• Polymorphic  SNPs
CNV Detection
Sample Inclusion Criteria
• MAPD < 0.3 using in-house ref file
• Called CNV fragments <  3SD
(7)  Sample that has called too many CNVs, with >3 SD of the batch (mean 
CNV call per individual 59.4, standard deviation 26.1). 
Of the 334 samples that passed CQC, a total of 53 were removed. Eighteen 
were foreign samples comprising Affymetrix reference sample and Hap Map samples 
which were included in a protocol training batch. Two were triplicates, four 
duplicates, four with <95% SNP call rate, one showed cryptic relatedness, the 
daughter of the family trio, fifteen admixed or misclassification of reported ethnicity, 
six with MAPD >0.3, and two with > 500 CNV fragments. A total of 281 samples 
remained, comprising of 100 Chinese, 95 Malays, and 86 Indians. The gender, age 
range and QC parameters distribution are in Table 2.2. The PCA of these 281 samples 















Figure 2.1  Flow diagram of QC and filter processes.  Inclusion criteria are shown in 
green boxes. IBIRDSUITE, Identity-By-States; HWE, Hardy-Weinberg Equilibrium; 






Chinese Malay Indian Total
(n=100) (n=95) n=86) (n=281)
Male / Female 90 / 10 94 / 1 79 / 7 263 / 18
Average Age (Std Dev) 31.6 (8.6) 27.5 (7.6) 33.2 (8.9) 30.7 (8.7)
CQC Av (Std Dev) 2.2 (0.5) 2.2 (0.5) 2.0 (0.5) 2.1 (0.5)
Min - Max 1.2 - 3.2 0.8 - 3.3 0.8-3.0 0.8 - 3.3
MAPD Av (Std Dev) 0.2 (0.0) 0.2 (0.0) 0.2 (0.0) 0.2 (0.0)
Min - Max 0.2 - 0.3 0.2 - 0.3 0.2 - 0.3 0.2 - 0.3
SNP Call Rate Av (Std Dev) 99.0 (0.7) 99.0 (0.7) 99.0 (0.7) 99.0 (0.7)
Min - Max 96.4 - 99.7 95.6 - 99.7 95.1 - 99.7 95.1 - 99.7
Heterozygosity Av (Std Dev) 23.8 (0.4) 24.4 (0.7) 25.9 (0.6) 24.6 (1.0)









Table 2.2  Demographic information of the population samples, and their genotyping 











Figure 2.2  Plot of PCA with 281 DMERI samples using SNPs. The colour is 
assigned according to the self-reported ethnicities. Red - Chinese; Green - Malays; 
Blue - Indians. 
 
2.2.3.3 SNP Genotype Concordance Rate & SNP QC 
The SNP genotype concordance rates between duplicated samples could 
provide an estimate to the accuracy of the experiments. Intra-laboratory comparison 
was made possible by obtaining intensity files of HapMap and reference samples 
from Affymetrix. Within the 11 HapMap samples genotyped, there were 2 mother-
daughter pairs, providing a parallel comparison to the internal trio samples. SNP 
genotype concordance rate for all duplicates and triplicates are above 99.45%, with 




Comparison % SNP Concordance (SD)
7 pairs of intra-lab, intra-batch duplicates 99.68 (0.31)
4 pairs of intra-lab, inter-batch (the triplicate) 99.45 (0.26)
28 pairs of inter-lab 99.49 (0.36)
Trio concordance Sample 1 Sample 2 % SNP Concordance
Mother-daughter (all chr) AFGT1073-136 AFGT1073-137 74.31
Mother-daughter (MT) AFGT1073-136 AFGT1073-137 100
Pedigree 1350 Mother-daughter (all 
chr) NA11832 NA10855 73.69
Pedigree 1350 Mother-daughter (MT) NA11832 NA10855 100
Pedigree 1341 Mother-daughter (all 
chr) NA06985 NA06991 73.26
Pedigree 1341 Mother-daughter (MT) NA06985 NA06991 100
2.3). The mitochondrial SNPs (~110) concordance of the mother-daughter pairs were 
all 100% as expected. Their autosomal SNP concordance ranged between 73.26 to 
74.31% were within acceptable level of parent-offspring or first-degree relative 







Table 2.3  SNP genotype concordance studies. Top panel: concordance rates between 
inter-laboratory, intra-laboratory, inter-batch and intra-batch. Bottom panel: 
concordance rates between mother-daughter pair. All chr, SNPs from all 




A subsequent round of QC on the entire collection of autosomal SNPs was 
performed on the remaining 281 samples with these exclusion criteria: (1) SNP 
missingness > 5%, (2) HWE (Hardy-Weinberg Equilibrium) p-value ≤ 10-7 in each 
population. A total of 843,282 SNPs passed the two filters. Of these, 77,524 SNPs 
were monomorphic in all 3 populations and were removed. The remaining 765,758 
SNPs were the final SNP set used for calculation of Selection Signal Loci using 
HaploPS (Liu et al. 2013) (Section 3.2.2). This SNP dataset was also used for the 
calculation of Wright Fixation Index (FST), a metric used to quantify genetic 
substructure in population, or to measure genetic distance between populations 
(Wright, 1950). The genetic distance estimated from SNPs for every population-pair 
could be used as a comparison to a similar parameter obtained from CNVs, as 





2.2.4 CNV Detection from Microarray Data 
To maximize specificity of CNV detection, three different CNV calling 
algorithms were used initially: (1) Birdsuite v1.5.3 (BS) (Broad Institute, USA), (2) 
Affymetrix Genotyping Console v3.0.2 (GTC) (Affymetrix Inc., USA), and (3) 
Nexus Copy Number v4.0 (NEX) (Biodiscovery Inc., USA). A standard filter was set 
for all algorithms, requiring CNVs called to be at least 1kb and span five or more 
consecutive probes. CNV discovery was restricted to autosomes and chromosome X 
due to inaccuracy in calling chromosome Y. All CNV detection and subsequent CNV 
analyses were performed using the original array coordinates based on the human 
genome assembly NCBI36 (UCSC hg18). 
 
2.2.4.1 BirdSuite v.1.5.3 
Birdsuite is a suite of methods originally developed to detect known common 
copy number polymorphism (CNP) based on prior knowledge, as well as to discover 
rare CNVs, from Affymetrix SNP 6.0 array data (Korn et al. 2008; McCarroll et al. 
2008b). Birdsuite contains two main modules; the Canary and the Birdseye 
algorithms. The Canary algorithm assigns copy number across regions of known 
common CNPs, which were obtained from a reference set with 1,319 CNPs with a 
minor allele frequency >1% created on the basis of 270 HapMap samples genotyped 
with Affy6 (McCarroll et al. 2008b). The Birdseye algorithm uses a hidden Markov 
model (HMM) approach to detect regions of variable copy number in a sample. For 
the HMM, the hidden state is the true copy number of the individual’s genome and 
the observed states are the normalised intensity measurements (means with their 
estimated variance) of each array probe. The Birdeye algorithm was used to detect 
additional CNV located outside the 1319 CNPs. CNV analysis in Canary and Birdeye 
were performed as described in Pinto et al (2011). CNV calls from the Canary and 
Birdseye algorithms were collated for each sample. For both Canary and Birdeye, 
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only CNVs called with a confidence score ≥ 10.0 were kept, which corresponded to 
an approximate FDR of ~5% (Pinto et al. 2011).   
 
2.2.4.2 Genotyping Console v3.0.2  
Genotyping Console v3.0.2 is the proprietary software provided by 
Affymetrix and contains modules for SNP genotyping (section 2.2.3.2) and CNV 
calling. Copy number analysis was performed using the Copy Number/Loss of 
Heterozygosity (CN/LOHOH) analysis tool with default settings according to the 
manufacturer’s instruction. Unpaired copy number and LOH analysis was performed 
with regional GC correction. The CN/LOH analysis tool used BRLMM-P-Plus and 
CN5 algorithms with a Hidden Markov Model. The log2 ratio between signals for 
each marker in each sample and the corresponding median value in a reference group 
was calculated.  A reference model file was built using a similar sample set but 
included all sample duplicates / triplicates. The resulting output file (.CNCHP) 
containing copy number log2 ratio data was generated for individual sample. This was 
served as input file to run the Segmental Reporting Tool in GTC, which is a CNAT 
tool to detect copy number event in a sample.  A threshold was set in Segment 
Reporting Tool to filter out CNVs with < 1Kb size and < 5 probes. 
 
2.2.4.3 Nexus Copy Number software v4.0 
Nexus Copy Number software v4.0 uses a rank segmentation algorithm for 
analyzing output files of all array platforms. The rank segmentation algorithm is 
similar to the circular binary segmentation (CBS) algorithm, with the major 
difference that rank segmentation uses the probe’s log-ratio rank as opposed to the 
actual log-ratio value (Pinto et al. 2011). The Nexus default settings were used for all 
CNV analysis, consisting of a significance threshold of 1x10
-6
 and a minimum 
number of probes per segment of 5. Nexus generates quality control (QC) scores for 
experimental results based on the statistical variance of the probe-to probe log ratios. 
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A small number (default 3%) of the outliers are excluded from this calculation to 
remove changes due to true CNVs. This QC value can be indicative of the quality of 
the sample and experiment, with lower QC scores indicating better quality results. A 
QC score less than 0.15 is considered the cut-off for best quality results for these 
arrays. A score between 0.15-0.25 is considered borderline.  
 
2.2.5 CNV Analysis 
2.2.5.1 Construction of Stringent CNV Dataset 
In an initial attempt to maximize specificity of CNV calls, a stringent set of 
CNVs was constructed. This ‘stringent’ CNV set was defined as those CNVs detected 
by Birdsuite and at least one of the other two CNV detection algorithms. Merging 
was performed for every individual sample, using a criterion of at least 50% 
reciprocal overlap between CNVs called by Birdsuite and at least another algorithm. 
If this condition was satisfied, the CNV called by Birdsuite was included into the 
stringent set. CNVs called by Birdsuite were elected as the anchor CNV because it 
had been demonstrated to produce the highest reproducibility of CNV calls, both in 
this study (Table 2.5) and in Pinto et al. (Pinto et al. 2011). Furthermore, CNVs called 
by Birdsuite tends to produce more uniform breakpoints, particularly for common 
CNVs called by Canary in Birdsuite. 
 
2.2.5.2 Construction of CNV Region (CNVR) 
Because CNVs between samples can overlap, CNVs at similar genomic 
regions were merged into a discrete locus. CNVR can measure the cumulative extent 
of CNV (Conrad et al. 2010b; Park et al. 2010; Redon et al. 2006). CNVs across 
samples that share at least 50% reciprocal overlap measured by length and position 
were merged, with the most outside probe (maximum size) defining the CNVR 
boundaries (Figure 2.3) (Redon et al. 2006). The type of CNVR was classified into 







‘deletion’, ‘duplication’ contained only duplication CNVs (CN2, 3, ≥4) (CN2 is for 
CNV on chromosome X in male), and ‘complex’ which encompassed both deletion 
and duplication CNVs. CNVR could also be classified by population frequency. 
CNVRs that contained <1% of the population were classified as ‘rare’, those with > 
5% population were termed as ‘common’, while CNVRs with population frequency 
1-5% were termed as ‘intermediate” CNVRs. 
Two sets of CNVR had been constructed, one for the stringent CNV set 
comprising 8,518 CNVs, and another for the full CNV set called by Birdsuite 







Figure 2.3  Definition of CNV Region (CNVR). CNVR composed of CNV calls that 




2.2.5.3 Annotation of CNV Region (CNVR) 
Novel CNVR – To identify CNV Regions that are novel, the CNVR dataset 
was compared to the data in DGV (MacDonald et al. 2014). A CNVR was considered 
novel if it did not share at least 50% of its length with any CNV loci catalogued in 
DGV. The version of DGV file used was the version at release date 2012-11-14 
(http://dgv.tcag.ca/dgv/docs/NCBI36_hg18_2012-11-14.txt). 
Mapping against annotated genes, Segmental Duplication, OMIM – UCSC 
gene annotation hg18 version (http://genome.ucsc.edu/) was used to map against the 
DMERI CNVR dataset. RefSeq Genes and known transcripts that are located within 
or partially overlap (defined as 1 bp overlap) with CNVR were identified. A CNVR is 
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considered overlapping segmental duplication (SD) if it shared at least 50% of its 
length with a SD. CNVR that overlapped with genes listed in OMIM (Online 
Mendelian Inheritance in Man) Morbid Map were also identified. OMIM v3 list was 
obtained from NCBI (http://www.ncbi.nlm.nih.gov/omim). 
 
2.2.6 CNV Validation with Quantitative Real-time PCR 
2.2.6.1 Real time-PCR Copy Number Assay in conventional 384-well plates 
Selected CNVRs were validated using quantitative Real-Time Polymerase 
Chain Reaction (qPCR). Quantitative real-time PCR assay for each CNVR target was 
selected from the pre-designed Taqman Copy Number Assay (P/N4400293, Applied 
Biosystems, Thermo Fisher Scientific Inc., USA). One assay was selected for every 
CNVR target, except for 2 CNVRs where 2 Taqman assays were used each to test its 
breakpoints. There were 2 assays that could each test 2 CNVRs because of 
overlapping CNVR locations. Two CNVRs could be called by one Taqman assay 
because of the size difference between the CNVRs which failed to fulfill the 50% 
reciprocal overlap criterion (Figure 2.3). Generally, the selected assay would target 
the middle of the maximum boundaries of the CNVR. 
The 5’ nuclease Taqman assay is a duplex real-time PCR utilizing 
fluorescently labeled oligonucleotide DNA probes. The FAM dye-based Taqman 
copy number assays, designed to detect the target of interest, and the VIC dye-based 
RNaseP Reference assay (P/N4403328, Thermo Fisher Scientific, USA) were run in a 
duplex real-time PCR reaction. Details of all the 80 selected assays are summarised in 
Appendix 1. 
Briefly, 10ng of genomic DNA was mixed with 1X TaqMan Genotyping 
MasterMix, 1X VIC labeled RNaseP assay mix (internal reference), and 1X FAM 
labelled target assay mix using dH2O for a final reaction volume of 10µl. Each 
sample was replicated four times for accuracy. After optimization, most subsequent 
qPCR assays were done in a final volume of 4 µl to conserve gDNA materials and to 
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save cost. Cycling conditions consisted of an initial denaturation at 95ºC for 10 
minutes, 40 cycles of denaturation at 95ºC for 15 sec, and annealing and elongation at 
60ºC for 60 sec on a QuantStudio™ 12K Flex Real-Time PCR System (Thermo 
Fisher Scientific Inc., USA) with 384-well plate. Real-time PCR data was analysed 
with QuantStudio™ 12K Flex Software version 1.1.2. All analysis settings selected 
were as recommended in the user guides. 
Raw data (CT) was exported to CopyCaller v2.0 software (Thermo Fisher 
Scientific Inc., USA) for copy number calculation. A comparative CT method was 
used in estimating diploid copy number. Copy Number calls were determined using 
the software algorithm when compared to the reference signal from RNaseP, which is 
assumed to be present at 2 copies in a diploid organism. Diploid copy number was 
estimated by ΔΔCt method using the calibrator DNA sample NA10851 (Coriell Cell 
Repositories, USA), which was also used for between-experiment normalization.  
NA10851 was chosen as a default calibrator because it was a common 
standard adopted in many CNV studies using SNP microarray. It has been included as 
one of the Hapmap samples that were run in this study. In addition, both CNV and 
CNP results were available for NA10851 from previous publications (Pinto et al. 
2008, McCarroll et al. 2008). A second sample, an in-house sample AFGT1073-268, 
which was used as a triplicate in the Affy6.0 experiments, was used as a back-up. 
  
2.2.6.2 Real time-PCR assay on OpenArray® Platform 
In an attempt to increase sample throughput, to minimize sample quantity 
requirement, and to save reagent cost, optimization effort was carried out to try to 
translate the rt-PCR from 384-well format to the Open Array® format working with 
the same instrument QuanStudio 12K. OpenArray® technology uses a microscope 
slide–sized plate with 3,072 through-holes (well is in through-hole format). Each 
plate contains 48 subarrays, each with 64 through-holes. Each through-hole is 300 μm 
in diameter and 300 μm deep and is treated with hydrophilic and hydrophobic 
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coatings. Reagents are retained in the through-holes via surface tension. Each 
through-hole accommodates 33 nl of reagent mix. One OpenArray® plate can hold as 
many samples as can eight traditional 384-well plates.  
OpenArray® (OA) chip is designed originally for digital PCR work (Thermo 
Fisher Scientific Inc., USA). This optimization work was a first attempt to try to 
optimise it for real time-PCR use. The experimental design of this first test run 
consisted of 14 target assays, one of it being the reference assay RNaseP. All primers 
and fluorescent probes were customized to be pre-spotted onto the OA chips. The 
first rt-PCR experiment was done in a singleplex format, with the reference assay 
done as a separate well from the target assay. This singleplex design was due to the 
uncertainty of QuanStudio 12K might not satisfactorily support dual fluorescent 
capture in OA chip. All target probes, including RNaseP, were labelled with 
FAM_MGB. Of the 13 target assays designed to verify CNVR, 6 had been tested in 
conventional rt-PCR, and hence could be used as gold standards to verify 
OpenArray® output. 
Each OA chip can accommodate up to 48 samples. Every sample was run in 
4 replicates. In this optimisation experiment, every OA chip would hold 45 test 
samples, 1 No-Template Control, and 2 calibrators (NA10851 & an in-house DNA 
control). A total of 3 chips were run in the singleplex format, generating CT data for 
135 samples. However, the standard deviation (Std Dev) between sample replicates 
proved to be highly variable. This variability was further compounded with reference 
being run as a separate assay from target assay. 
To reduce the well-to-well variability, a duplex reaction was carried out in 
OA. A separate reference assay RNaseP was ordered with fluorescent dye label as 
VIC_QSY (QSY is a non-fluorescing quencher). Two OA chips were used in the 
duplex experiment, generating CT data for 90 test samples. Although the duplex 
experiment did lower the variability between sample replicates somewhat, the SD still 




Original Edited Original Edited 
HS03396518_cn 24 26 26 13 1 1 2
HS03566526_cn 85 26 9 13 0 2 2
HS03724711_cn 22 20 83 15 1 1 1
HS03873630_cn 37 37 0 0 40 40 40
HS03900335_cn 24 59 19 9 4 3 2
HS03922779_cn 74 59 11 2 8 8 8








% Discordance with RT-PCR
raw CT data was carried out, by removing out-liers within the 4-replicates of every 
test sample. However, this additional step still failed to improve the precision of CT 
obtained from the OA experiment. Table 2.4 summarises the overall results of the 
first 45 samples. Percentage discordance between OA results and conventional rt-
PCR were reported. OA results from singleplex and duplex experiment were 
included, and so were the original & edited results. There were gradual improvements 
in each attempt, but the final outcome was still not precise enough to generate 
accurate & reproducible copy number data. The assay which showed better 
concordance rate was the assay with a lot of samples with CN0, which produced the 






Table 2.4  Comparison study between RT-PCR done on conventional 384-well 
format versus OpenArray®. S/plex – Singleplex, OA - OpenArray®. 
 
A reason for the extremely high CT variability in the OA chip was due to its 
small volume at 33 nl. This tiny volume would exert great effect on the chemistry and 
dynamics of PCR reaction. The small volume might also encourage competition 
between assay primers & probes in the duplex experiment. As a result, all the qPCR 










Sample Birdsuite GTC Nexus
143 61.0% 26.8% 18.2%
352 77.6% 64.7% 64.4%
321 79.6% 57.0% 57.1%
Average (Std Dev) 72.7% (10.2) 49.5% (20) 46.6% (24.8)
2.3 RESULTS  
2.3.1 CNV Calling by Different Algorithms 
Three algorithms were used to detect CNVs from intensity files of microarray 
hybridisation due to the challenge of CNV calling being less robust, as demonstrated 
in the concordance rates of intra-batch duplicates in Table 2.5. In contrast, SNP 
genotyping has shown a concordance rate of >99.5% (Table 2.3), thereby validating 
the experimental workflow of this study. The three algorithms were Birdsuite v1.5.3 
(BS), Genotyping Console v3.0.2 (GTC) and Nexus Copy Number v4.0 (Nexus). A 
standard threshold was used requiring CNVs called to be ≥ 1kb and containing at 
least 5 probes, and only CNVs on autosomes and chromosome X were studied. Of the 
three algorithms, Birdsuite showed the highest reproducibility at 72.7% with the 
lowest standard deviation (10.2%). The concordance rates of Birdsuite and GTC were 
in line to a large-scale assessment study on various microarray platforms and calling 
algorithms (Pinto et al. 2011, ~70% & 50% for Birdsuite & GTC, respectively). 
 
Table 2.5  Call reproducibility of each algorithm. Replicated sample pairs, intra-
batch. CNV (≥1kb & 5 probes) concordance in each algorithms. A CNV pair was 
considered in concordance in the replicated sample if ≥50% of their region overlaps 
with each other. 
 
An overview of the CNV genomic landscape for each algorithm is 
summarised in Table 2.6. Birdsuite called approximately 30% more CNVs than GTC 
or Nexus, giving the highest average number of CNVs per individual at 78. The 
number of CNV per individual called by Birdsuite and GTC corroborated with a large 
assessment study (~80 and 50, respectively. Pinto et al 2011). The spread of the 



























No. of samples 281 281 281
Total no. of CNVs 22,024 16,683 16,899
Ave. no. of CNVs /individual 78 59 60
Median no. of CNVs /indiv 78 53 57
Range of no. of CNVs/indiv 51 - 103 28 - 243 26 - 124
Average no. of markers/CNV 34 33 1340
Average size of CNVs  (Kb) 56.9 93.3 2,429.6
Median size of CNVs  (Kb) 14.6 19.0 34.6
Size range of CNVs  (Kb) 1 - 10,142 1 - 23,822 1 - 92,971
Total no. of Deletion 16,757 11,430 12,428
Average size  (Kb) 36.7 72.6 3248.3
Median size (Kb) 10.6 13.0 29.9
Size Range  (Kb) 1 - 6,097 1 - 21,792 1 - 92,971
Total no. of Duplication 5,267 5,253 4,471
Average size  (Kb) 121.1 138.4 153.6
Median size (Kb) 67.1 46.0 46.9
Size Range  (Kb) 1 - 10,142 1 - 23,822 1 - 6,506
Ratio of Deletion/Duplication 3.2 2.2 2.8
SD 7.8), in contrast to the wide range by GTC (range 28 – 243, SD 26.2). The 
average size of CNVs called by Nexus was generally larger than the other algorithms. 
This could be attributed primarily by a greater proportion of deletions detected by 
Nexus having ≥ 1,000kb in size (Figure 2.4 & Table 2.6). In all three algorithms, 
deletions were more common than duplications. Further, deletions were generally 






















Figure 2.4  Size distribution of Duplication/Gain and Deletion/Loss CNV events in 




2.3.2 ‘Stringent’ CNV Dataset versus the Full Birdsuite CNV Dataset 
In view of the reproducibility issue of CNV detection by various algorithms 
(Table 2.5) and to avoid false positives, a conservative approach was adopted 
initially. A stringent CNV dataset was established comprising of CNVs called by 
Birdsuite and at least one other algorithm in the same sample. Because Birdsuite 
CNVs had the highest concordance rate and had the most consistent breakpoints, it 
was elected as the anchor by which GTC and Nexus CNVs were compared against. A 
CNV is deemed ‘high confidence’ if it satisfied the following criteria; (1) it is 
detected by Birdsuite and GTC or Nexus in the same sample, and (2) if its genomic 
position in Birdsuite shared ≥ 50% reciprocal overlaps with the genomic position 
called by GTC or Nexus. This approach established a ‘stringent’ CNV set containing 
8,518 high confidence Birdsuite CNVs (Figure 2.5B). The distribution of these 
stringent CNVs in the three Singapore populations is summarised in Table 2.7. CNVs 
at similar genomic location with ≥ 50% reciprocal overlap were merged into a CNV 
Region (CNVR). These 8518 stringent CNVs could be merged into a stringent CNVR 
set containing 1618 CNVRs (Figure 2.5A).  
Because one of the main goals of this study was to investigate the population 
diversity of CNVs, population-specific CNVR candidates were of major interest. 
However, among the 1618 CNVRs, most of the population-specific CNVR were 
singletons appearing in only one sample. Being singleton reduced the confidence of 
population-specific classification. The proportion of singleton was the highest 
(65.6%) in the stringent CNVR set, and the lowest (58.6%) in the full Birdsuite set 
(Table 2.8). The full CNV set called by Birdsuite comprised 22,024 CNVs, which has 
160% more CNV than the 8,518 stringent set. However, this full Birdsuite CNV set 
produced 2,227 CNVRs, which was only 37% more CNVR than the 1,618 stringent 
CNVR set (Table 2.5). This suggested that many of the Birdsuite CNVs outside the 
stringent set could be merged to form 1 CNVR, and hence likely to be real. This also 











• per sample level
• ≥ 50% reciprocal overlap
• adopt Birdsuite breakpoints
• across samples
• merge by position
• ≥50% reciprocal overlap















GTC or NEX (hence failed to be included in the stringent CNV set), but it was 
possible to find another sample with CNV called by Birdsuite in the same genomic 
location. Considering that CNVRs comprising at least 2 samples are more likely to be 























Figure 2.5   CNV / CNVR datasets generated in this study. A) A stringent set of 8518 
CNVs was merged into 1618 CNVR stringent set, while the full Birdsuite set of 
22,024 CNVs was merged into 2,227 CNVR Birdsuite set. Red boxes are inclusion 
criteria. B) The number of CNVs called by different algorithms and the extent of 
CNVs shared across algorithms. The numbers of shared CNVs between algorithms in 




Chinese Malays Indians Total
No. of samples 100 95 86 281
Total no. of CNVs 2,818 2,871 2,829 8,518
Ave. no. of CNVs /individual 28 30 33 30
Median no. of CNVs /indiv 28 30 32 30
Range of no. of CNVs/indiv 13 - 44 16 - 45 18 - 47 13 - 47
Average size of CNVs  (Kb) 63.0 65.5 70.2 66.2
Median size of CNVs  (Kb) 21.4 22.3 24.1 22.3
Size range of CNVs  (Kb) 1 - 3,244 1 - 2,410 1 - 1,251 1 - 3,244
Total no. of Deletion 2,320 2,378 2,305 7,003
Ave. size of Deletion (Kb) 44.4 47.8 53.1 48.4
Median size of CNVs  (Kb) 14.1 18.8 18.6 18.6
Size range of CNVs  (Kb) 1 - 1,499 1 - 1,136 1 - 1,251 1 - 1,499
Total no. of Duplication 498 493 524 1,515
Ave. size of Duplication (Kb) 152.8 154.1 145.6 150.8
Median size of CNVs  (Kb) 67.1 71.9 93.2 73.4
Size range of CNVs  (Kb) 1 - 3,244 1 - 2,410 1 - 1,072 1 - 3,244
Ratio of Del / Dup 4.7 4.8 4.4 4.6
CNV
Total number of CNV 22,024 16,683 16,899 8,518
Total number of CNVR 2,227 100% 4,082 100% 4,016 100% 1,618 100%
No. of of singletons 1,305 58.6% 2,647 64.8% 2,611 65.0% 1,061 65.6%
No. of CNP (n≥2) 922 41.4% 1,435 35.2% 1,405 35.0% 557 34.4%
No. of CNP (≥1% or n≥3) 652 29.3% 919 22.5% 933 23.2% 380 23.5%
No. of Common CNP (≥5% or n≥15) 267 12.0% 219 5.4% 231 5.8% 145 9.0%
No. of C-Specific CNVR (n≥5) 8 2 5 3
No. of M-Specific CNVR (n≥5) 3 3 5 2
No. of I-Specific CNVR (n≥5) 21 25 20 15
CNVR
Total number of CNVR 2,227 100% 4,082 100% 4,016 100% 1,618 100%
C only 498 22.4% 1,103 27.0% 1,038 25.8% 389 24.0%
M only 482 21.6% 970 23.8% 939 23.4% 393 24.3%
I only 584 26.2% 967 23.7% 1,006 25.0% 466 28.8%
C+M only 126 5.7% 304 7.4% 230 5.7% 88 5.4%
C+I only 58 2.6% 102 2.5% 123 3.1% 30 1.9%
M+I only 101 4.5% 184 4.5% 180 4.5% 59 3.6%
C+M+I 378 17.0% 452 11.1% 500 12.5% 193 11.9%
≥2C only 62 124 106 39
≥2M only 76 114 99 59
≥2I only 121 155 167 89
BS GTC NEX Stringent set 
BS GTC NEX Stringent set 
Table 2.7  Summary of high confidence CNVs characteristic in the ‘Stringent set’. 
 
 
Table 2.8  Comparison of CNV/CNVR datasets called by individual algorithm and 




Realizing that the stringent set of 8518 CNVs might be over conservative, 
CNV datasets called by individual algorithm were re-examined. Each CNV dataset 
called by individual algorithms was merged independently to form their respective 
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CNVR set. Table 2.8 summarises the total number of CNV / CNVR called by each 
algorithm and their distribution in the 3 local populations. If CNVRs with at least 2 
samples were likely to represent real CNVs, the number of population-specific 
CNVRs (CNVR with ≥ 2 samples)  was almost 2x more in Birdsuite CNVR set 
compared to the CNVR stringent set (last 3 rows of Table 2.8). 
Since this study sought to identify CNVR candidates that are population-
specific or highly differentiated across populations, a high false negative rate in 
CNVR discovery would reduce the total CNVR number to be studied, decreasing the 
success rate of finding any interesting CNVR candidate. As a result, it was decided to 
adopt a full CNV dataset, rather than a trimmed stringent set for all subsequent work 
in this study. 
This study has shown Birdsuite CNV calls produced the highest concordance 
rate and have the most consistent breakpoints. It called the highest number of CNV 
per individual. The average number of CNVs per individual called by Birdsuite 
numbering 78 (Table 2.6) was consistent with a large-scale microarray assessment 
study (Pinto et al. 2011). The same study also reported Birdsuite on Affy6.0 produced 
a high concordance rate (~70%) amongst various SNP-array platforms & CNV 
calling algorithms tested. In addition, a separate study has reported that Birdsuite has 
a sensitivity of 76% for CNVs >10kb (McCarroll et al. 2008b). As a result, the full 
Birdsuite set (22,024 CNVs merged into 2,227 CNVRs) was elected to be the dataset 
for all CNV analysis work reported in this thesis. This strategy was later re-affirmed 
by qPCR validation study as this approach reduced false negatives (Section 2.3.5).  
 
2.3.3 Characteristics of CNVs and CNVRs  
2.3.3.1 Characteristics of CNVs  
Analyzing the full Birdsuite dataset of 22,024 CNVs identified from 281 
samples, there was an average of 78 CNVs in every individual with a ratio of 
deletions to duplications of approximately 3.2 (Table 2.9). The majority of the 
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Chinese Malays Indians Total
No. of samples 100 95 86 281
Total no. of CNVs 7,785 7,436 6,803 22,024
Ave. no. of CNVs /individual 78 78 79 78
Median no. of CNVs /indiv 78 78 80 78
Range of no. of CNVs/indiv 51 - 103 60 - 99 54 - 94 51 - 103
Average no. of markers/CNV 32 33 37 34
Average size of CNVs  (Kb) 55.0 54.3 61.8 56.9
Median size of CNVs  (Kb) 14.5 14.9 15.8 14.6
Size range of CNVs  (Kb) 1 - 10,142 1 - 2,410 1 - 6,098 1 - 10,142
Proportion of CNV <50Kb 0.75 0.74 0.72 0.74
Total no. of Deletion 5,975 5,689 5,093 16,757
Ave. size of Deletion (Kb) 33.6 34.8 42.4 36.7
Med. size of Deletion (Kb) 10.4 10.8 10.6 10.6
Size range of Deletion (Kb) 1 - 5,940 1 - 1,631 1 - 6,098 1 - 6,098
Total no. of Duplication 1,810 1,747 1,710 5,267
Ave. size of Duplication (Kb) 125.6 118.0 119.6 121.1
Med. size of Duplication (Kb) 67.1 67.1 67.1 67.1
Size range of Duplication (Kb) 1 - 10,142 1 - 2,410 1- 1,072 1 - 1,0142















































Number of CNVs per individual
Indian 
individuals have 65 to 95 CNVs in their genome (Figure 2.6). There was no 
significant difference in the average number of CNVs per individual in the three 
populations (ANOVA, p=0.6853). There were 3-fold more deletions than duplication 
CNVs, and duplication CNVs were generally larger in size than deletion CNVs 
(Table 2.9, Figure 2.7). About 74% of the CNV were <50kb in size, and majority 
(86% of CNV <50kb) were of the deletion type. About 39% of the CNVs are <10kb 
in size. In contrast, duplication CNVs have a large proportion (41%) in the size range 




Table 2.9  Summary of CNVs characteristic in the full Birdsuite CNV dataset. 
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P=0.0193*
P=0.0023*P=0.7841
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 Figure 2.7   Characteristic of CNV distribution by type and size. A) Distribution of 
CNV type by size. B) Distribution of CNV sizes in deletion and duplication CNVs. 
 
 
The distribution of the type (deletion or duplication) and sizes of CNVs were 
slightly different in Indians compared to Chinese and Malays. The percentage of 
deletion is slightly lower at 74.9% in Indians compared to >76.5% in Chinese or 
Malays. This difference in deletion/duplication ratio is statistically significant 
between Chinese-Indians and Malay-Indians, but not for Chinese-Malay comparison 
(Chi-sq test, Figure 2.8A). Similarly, the average size of the CNVs found in the three 
populations are significantly different in Chinese-Indians and Malay-Indians, but not 
for Chinese-Malay comparison (Mann-Whitney test, Figure 2.8B) (Average size 
difference for Chinese-Indians -6.9 ± 2.9 kb, Malays-Indians -7.5 ± 2.5 kb, Chinese-
Malays 0.6 ± 2.3 kb).  





Figure 2.8   Distribution of CNV characteristics in each population. A) Percentage of 
deletion and duplication CNVs in each population. P-values from Chi-sq test.  B) 
Distribution of CNVs in different size range in each population. P-values from 
unpaired Mann-Whitney test. P-values were p-value (two-tailed). Asterisk represents 




2.3.3.2 Characteristics of CNV Regions (CNVRs) 
CNVs located in similar genomic position were merged into a CNV region 
(CNVR). A criterion of ≥ 50% reciprocal overlap was adopted for merging as in 
Conrad et al (2010b). The maximum & minimum breakpoints of each CNVR were 
recorded, and maximum breakpoints are used in all subsequent analysis. The full 
Birdsuite set with 22,024 CNVs was merged into 2,227 CNVRs (Figure 2.5). In total, 
these 22,024 CNVs covered 161,627,331 bp of unique region, representing 
approximately 5.4% of the human genome. 
CNVRs can be classified into 3 types: Deletion, Duplication and Complex 
(Both deletions and duplication in same locus). CNVR can also be classified by its 
population frequency: Rare, Intermediate or Common (Section 2.2.5.2). ‘Rare’ 
CNVR occurs in ≤ 1% of the population. ‘Intermediate’ 1-5%, and ‘Common’ ≥ 5% 
population frequency. In this study comprising 281 samples, these frequencies would 
translate into n ≤ 3 for rare, intermediate would be n = 4-14, while common would be 
n ≥ 15 samples.  
In this CNVR dataset, 58.6% (1,305) of the CNVRs were singleton, and 
represented rare or private polymorphisms. A total of 29.3% (652) of the CNVRs 
occurred at a frequency ≥ 1% (n ≥3 individuals) across 3 populations, and were 
considered copy number polymorphisms (CNPs). While 12% (267) occurred at a 
frequency ≥ 5% (n ≥15 individuals), and are termed common CNPs (Table 2.8).  
Classifying CNVRs by type, deletions were the most common at 50% (1113), 
followed by duplication at 37% (831), and complex CNVRs at 13% (283) (Table 
2.10A). If CNVRs were classified by population frequency, the majority were rare 
CNVRs (76%), while intermediate and common CNVRs were both at 12% (Table 
2.10A). Between the three CNVR types, deletions and duplications were mostly rare 
(>81%, Table 2.10B), while many of the complex CNVRs were common in the 
population (44% of complex CNVRs has ≥5% frequency, Table 2.10B). Classifying 




CNVR by Frequency Del Dup Complex Total
Rare (n≤3) 901 731 71 1703 76%
Intermediate (n=4-14) 103 66 88 257 12%
Common (n≥15) 109 34 124 267 12%
Total 1113 831 283 2227 100%













































































CNVR by Frequency Del Dup Complex Total
Rare 81% 88% 25% 76%
Intermediate 9% 8% 31% 12%
Common 10% 4% 44% 12%
Total 100% 100% 100%
CNVR Type
CNVR by Frequency Del Dup Complex Total
Rare 53% 43% 4% 100%
Intermediate 40% 26% 34% 100%
Common 41% 13% 46% 100%
Total 134% 81% 85%
(total 96%, Table 2.10C). On the other hand, many of the common CNVR were either 
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Table 2.10  Distribution of CNVRs by type and by population frequency. A) 
Overview of the distribution. B) Percentage of CNVR by frequency in deletion, 
duplication and complex CNVRs. C) Percentage of CNVR by type in rare, 




Most of the CNVRs (66% or 1456 counts) were of size < 50kb (Figure 2.9). 
Among the different CNVR type, 75% of deletion CNVRs (840/1113) were of 
smaller size of < 50kb, while 49% of duplication CNVRs (406/831) have sizes > 
50kb (Figure 2.9A). The proportion of deletion CNVRs decreased with size. In 
contrast, the proportion of duplications increased with size (Figure 2.9B). The 
proportion of complex CNVR also showed an increase in size range > 1Mb (Figure 
2.9B). 
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The distribution of CNVR number and type on each autosome and 
chromosome X is summarised in Figure 2.10A. The number of CNVR was 
normalised against chromosome sizes (Figure 2.10B). CNVRs were distributed across 
all chromosomes, with chromosome 16 and 19 showing the highest density of CNVR 
number per Mb genome, while chromosome 18 and 13 harboring the lowest density 
of CNVRs. The proportion of complex CNVRs were higher in chromosomes 15, 19 
and 22, with 23 - 29% of the CNVRs were complex in these chromosomes. CNVRs 
that were common, intermediate or rare in frequency were also distributed across all 
studied chromosome (Figure 2.11). Some chromosomes, such as X, 20 and 21, 
harbored the lowest percentage of common CNVRs. As for distribution of various 
size ranges across chromosome, chromosome 15, 16 and X harbored the highest 













Figure 2.10   Distribution of CNVRs by count and type in 22 autosomes and 
chromosome X. A) By count. B) The number of CNVR on each chromosome has 
been normalised against respective chromosome size. C) Distribution in percentage of 
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Figure 2.11   Distribution of common, intermediate and rare CNVRs in 22 autosomes 









Figure 2.12   Distribution of CNVRs by size range in 22 autosomes and chromosome 
X. A) By count. B) By percentage. 
 
2.3.3.3 Novel CNVRs and Annotation Results  
About 30% (671/2227) of the CNVRs were novel having ≤ 50% overlap with 
CNVs in DGV. Approximately 47% (1036/2227) of the CNVRs encompassed 
gene(s), and 7% (160/2227) encompassed OMIM genes. In addition, about 21% of 
the CNVRs overlap with segmental duplications (SDs) with ≥ 50% overlap (Table 
2.11).  
None of the common CNVRs were novel, as expected (Table 2.11A). 
Common CNVRs would have been discovered earlier and hence less likely to be 
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novel. In contrast, rare CNVRs were more likely to be novel, with 38.6% of the rare 
CNVRs in this dataset being novel.  The proportion overlapping genes or OMIM 
genes were similar across rare, intermediate and complex CNVR. A higher proportion 
of common and intermediate CNVRs overlapped with segmental duplication (SD). 
SDs are known to be genomic substrates that sponsor mutation via the mechanism 
Non Allelic Homologous Recombination (NAHR, section 1.3.1), increasing the 
frequency of CNV in those regions.  
Similarly, complex CNVRs, which tends to be common (Table 2.10), were 
not novel (Table 2.11B). Deletion CNVRs were much less likely to harbor genes 
compared to duplication or complex CNVRs. This is consistent with previous 
findings (Conrad et al. 2010b; Ku et al. 2010; Redon et al. 2006). Complex CNVRs 
were more likely to overlap SD. The relationship of complex and common CNVRs 
are known to be related to SD, whose genomic architecture encourages recurrent 
mutations via NAHR, resulting in a higher mutation rate and hence higher population 
frequency (section 1.3.1).  It has been reported that CNVs in SD are highly variable 
in copy number in human (Alkan et al. 2009; Sudmant et al. 2010), and more likely to 
be population differentiated (Campbell et al. 2011).  
Interestingly, CNVRs that overlap SD (defined as ≥ 50% overlap) are more 
likely to encompass genes compared to CNVRs that do not overlap SD (≤50% 
overlap). This difference was statistically significant (Table 2.12A). Furthermore, 
CNVRs that overlap SD are also significantly larger in size and have higher 
population frequency (Table 2.12A). The correlation with population frequency can 
be explained by the biological effect of SD in relation to mutation mechanism 
NAHR, as seen in common CNVRs in Table 2.11A. The correlation with size is in 
line with a study which reported NAHR being a major mediator for CNV formation, 









overlap gene 307 (66%) 729 (41%) <0.0001*
overlap OMIM 36 (8%) 124 (7%) 0.6728
CNVR size (bp)
Average size 142,053 75,874
Std Dev 207,412 330,447
Median 71,069 20,696 <0.0001*
Popn freq (%)
Average 5.9% 2.9%
Std Dev 12.9% 8.9%
Median 1.1% 0.4% <0.0001*
Novel (≤50%) Not novel (>50%) P-value
N 671 1556
Population-specific 648 (97%) 916 (59%) <0.0001*
Shared ≥2 populations 23 (3%) 640 (41%)
overlap gene 314 (47%) 722 (46%) 0.9005
overlap OMIM 56 (8%) 104 (7%) 0.1922
CNVR size (bp)
Av size (bp) 113,584 79,389
Std Dev 494,166 178,784
Median 36,427 23,461 <0.0001*
Popn freq (%)
Av 0.4% 4.9%
Std Dev 0.3% 11.6%
Median 0.4% 0.7% <0.0001*
On the other hand, almost all novel CNVRs (98%) were population-specific 
(Table 2.12B). Both novel and known CNVRs have a similar proportion overlapping 












Table 2.11  Distribution of CNVRs by population frequency and by type, and the 
proportion of each CNVR type that overlapped with genes, OMIM, and segmental 
duplication. ‡ indicates Fisher exact test p (two-tailed) values <0.01 between the three 
CNVR types. Percentages in green boxes were calculated by row, while other 
percentages were calculated by respective columns. A) CNVR by frequency; rare, 
intermediate and common. B) CNVR by type; deletion, duplication, and complex. 
 
A              B 
 
Table 2.12  Correlation of CNVR characteristics. Statistical test for proportion 
difference was carried out in Fisher exact test, while median difference was done with 
Mann-Whitney test. Reported are two-tailed p-values. * denotes significant different.   
A) CNVRs that overlap segmental duplication versus those which do not. B) 
Characteristics of novel CNVRs versus those CNVRs that were already known. 
 
Rare Intermediate Common Total
(≤1% or n≤3) (1-5%, n=4-14) (≥5% or n≥15)
Total no. of each group 1703 (76.5%) 257 (11.5%) 267 (12%) 2227 (100%)
Attributes 
Novel (≤50% overlap dgv)
ǂ
657 (38.6%) 13 (5.1%) 0 (0%) 671 (30.1%)
Overlap genes 793 (46.6%) 121 (47.1%) 122 (45.7%) 1036 (46.5%)
Overlap OMIM 126 (7.4%) 18 (7%) 16 (6%) 160 (7.2%)
Overlap SD (≥50%)ǂ 270 (15.9%) 102 (39.7%) 93 (34.8%) 465 (20.9%)
Complex Deletion Duplication Total
Total no. of each type 283 (12.7%) 1113 (50%) 831 (37.3%) 2227 (100%)
Attributes 
Novel (≤50% overlap dgv)ǂ 2 (0.7%) 376 (33.8%) 293 (35.3%) 671 (30.1%)
Overlap genes
ǂ
149 (52.7%) 430 (38.6%) 457 (55%) 1036 (46.5%)
Overlap OMIMǂ 23 (8.1%) 62 (5.6%) 75 (9%) 160 (7.2%)
Overlap SD (≥50%)ǂ 134 (47.3%) 129 (11.6%) 202 (24.3%) 465 (20.9%)
CNVR Type (N=2227)
CNVR by Frequency (N=2227) 
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2.3.3.4 Genomic Content of CNVRs  
About 47% of the CNVRs in DMERI dataset overlapped to known genes and 
uncharacterized transcripts in UCSC hg18 database (Table 2.11).  Comparing 
deletion, duplication and complex CNVRs, there was a significantly lower percentage 
of gene content in deletion CNVRs (39% vs 55% & 53%, p<0.0001) (Table 2.11B).  
Gene ontology analysis with Metacore™ (Thomson Reuters, Inc. USA) 
investigating the full 2,227 CNVR dataset showed an enrichment of genes involved in 
biological processes such as cell adhesion, immune response, signaling pathways and 
regulation of secretion (Table 2.13A). Notably, neurophysiological processes such as 
neurogenesis and synapse assembly were also in the highly enriched GO category. 
Gene ontology analysis for the 267 common CNVRs with ≥ 5% frequency showed 
that they were highly enriched for immune functions (Table 2.13B). In addition, the 
other enriched categories in common CNVRs included gluthathione metabolism and 
olfactory transduction. These enrichments are similar to previous studies which 
reported an enrichment of genes involving extracellular biological processes such as 
adhesion, recognition and communication, but deficient in genes involving in 
intracellular processes such as metabolic pathways (Conrad et al. 2010b; Park et al. 
2010; Redon et al. 2006). In line with past reports, there were many pharmacogenetic 











Enrichment by Pathway Maps p-value FDR
Cytoskeleton remodeling_Reverse signaling by ephrin B 2.18E-06 0.001395
Development_S1P1 signaling pathway 4.08E-06 0.001395
Development_S1P3 receptor signaling pathway 2.96E-05 0.004875
Cell cycle_Role of Nek in cell cycle regulation 3.12E-05 0.004875
Development_Ligand-independent activation of ESR1 and ESR2 4.18E-05 0.004875
Immune response_CCR5 signaling in macrophages and T lymphocytes 4.28E-05 0.004875
Chemotaxis_CCR1 signaling 6.78E-05 0.006388
Development_Thromboxane A2 signaling pathway 7.89E-05 0.006388
Development_Delta-type opioid receptor mediated cardioprotection 8.42E-05 0.006388
Development_ERBB-family signaling 0.00012 0.008168
Enrichment by Process Networks p-value FDR
Cell adhesion_Synaptic contact 1.69E-07 2.63E-05
Cell adhesion_Attractive and repulsive receptors 3.06E-05 0.002015
Development_Neurogenesis_Axonal guidance 3.87E-05 0.002015
Cytoskeleton_Regulation of cytoskeleton rearrangement 6.11E-05 0.002384
Cell adhesion_Cadherins 0.000139 0.004321
Development_Neurogenesis_Synaptogenesis 0.000384 0.009974
Signal transduction_ERBB-family signaling 0.00084 0.017835
Reproduction_GnRH signaling pathway 0.000994 0.017835
Development_Regulation of angiogenesis 0.001029 0.017835
Cell adhesion_Cell junctions 0.001951 0.03044
Enrichment by GO Processes p-value FDR
cell adhesion 1.53E-14 7.44E-11
biological adhesion 2.43E-14 7.44E-11
regulation of secretion 1.53E-11 3.12E-08
regulation of system process 5.56E-10 5.87E-07
positive regulation of nervous system development 5.75E-10 5.87E-07
positive regulation of synapse assembly 5.75E-10 5.87E-07
positive regulation of cellular component biogenesis 8.84E-10 7.73E-07
regulation of heart rate 1.09E-09 8.33E-07
regulation of ion transmembrane transporter activity 1.86E-09 1.21E-06
cell-cell adhesion 1.97E-09 1.21E-06
























    
 
Table 2.13  Over-representated Gene Ontology categories. These biological processes 
were enriched in two CNVR datasets. A) Genes enriched in the full dataset 
containing 2,227 CNVRs. B) Genes enriched in the 267 common CNVRs. 
   
Enrichment by Pathway Maps p-value FDR
Glutathione metabolism 0.0004 0.008675
Glutathione metabolism / Human version 0.000418 0.008675
Glutathione metabolism / Rodent version 0.00052 0.008675
Immune response_Antiviral actions of Interferons 0.006239 0.067141
Immune response_Role of DAP12 receptors in NK cells 0.006714 0.067141
Transport_RAB3 regulation pathway 0.031757 0.147132
G-protein signaling_RhoB regulation pathway 0.036215 0.147132
Schema: Initiation of T cell recruitment in allergic contact dermatitis 0.040653 0.147132
Neurophysiological process_Olfactory transduction 0.045071 0.147132
LRRK2 and immune function in Parkinson's disease 0.04947 0.147132
Enrichment by Process Networks p-value FDR
Immune response_Antigen presentation 4.51E-06 0.000162
Inflammation_NK cell cytotoxicity 0.00127 0.022852
Reproduction_FSH-beta signaling pathway 0.008163 0.09796
Response to hypoxia and oxidative stress 0.048043 0.432389
Neurophysiological process_Olfactory transduction 0.09161 0.541794
Development_ERK5 in cell proliferation and neuronal survival 0.114328 0.541794
Proteolysis_Connective tissue degradation 0.120263 0.541794
Immune response_Phagosome in antigen presentation 0.122337 0.541794
Transcription_Chromatin modification 0.135449 0.541794
Development_Skeletal muscle development 0.163428 0.588339
Enrichment by GO Processes p-value FDR
detection of bacterium 1.51E-16 2.35E-13
detection of biotic stimulus 5.38E-15 4.18E-12
interferon-gamma-mediated signaling pathway 2.62E-12 1.36E-09
cellular response to interferon-gamma 1.8E-10 6.99E-08
response to interferon-gamma 1.3E-09 4.05E-07
antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent2.39E-09 6.18E-07
regulation of interleukin-10 secretion 1.58E-08 3.51E-06
antigen processing and presentation of peptide antigen 2.62E-08 5.09E-06
defense response 3.59E-08 6.19E-06





















1 110,025,907 110,058,147 32,240 Del GSTM1,GSTM2,GSTM5 3 - 100 100 30 26 50 90.6%
4 69,021,057 69,234,339 213,282 Del UGT2B15,UGT2B17,TMPRSS11E 3 - 76 100 99 89 70 99.3%
4 69,168,575 69,234,339 65,764 Del UGT2B15 1 - 97 100 0 2 0 ND
4 70,162,233 70,273,689 111,456 Del UGT2B28 1 - 97 100 22 29 47 ND
4 187,166,418 187,374,152 207,734 Dup TLR3,CYP4V2,FAM149A 3 TLR3,CYP4V2 - 97 0 0 5 100.0%




9 PLA2G7 5 7 0 1 0 ND
10 96,548,713 96,596,764 48,051 Del CYP2C19 1 CYP2C19 - 5 0 1 0 100%
10 135,081,984 135,239,886 157,902 Dup
CYP2E1,MTG1,SYCE1,SPRN,LOC6192
07,SPRNP1
6 - 17 100 1 7 1 97.5%
10 135,184,288 135,284,541 100,253 Dup SYCE1,SPRNP1,CYP2E1 3 - 16 100 0 2 0 ND
16 54,353,890 54,387,091 33,201 Del CES1P1 1 - 100 100 72 61 40 95.7%
16 54,387,058 54,560,676 173,618 Dup CES1,CES5A 2 CES1 39 22 0 1 0 49.8%
16 65,534,672 65,613,452 78,780 Dup CES3,CES2,CES4A 3 - 3 84 0 0 1 ND
19 46,040,709 46,072,786 32,077 Complex CYP2A6 1 CYP2A6 82 100 19 23 5 96.8%
19 46,143,504 46,205,185 61,681 Dup CYP2B7P1,CYP2B6 2 - 49 100 0 1 0 ND
22 22,613,016 22,680,528 67,512 Complex DDTL,GSTTP1,GSTT2B,GSTT2,DDT 5 - 97 100 25 21 40 failed
22 22,670,786 22,734,830 64,044 Complex GSTTP1,GSTTP2,GSTT1,LOC391322 4 - 62 100 45 36 22 78.2%
 
Table 2.14  Examples of CNVRs containing pharmacogenetic genes. 
Pharmacogenetic genes are in red font. Nine CNVRs have been validated by qPCR. 
One qPCR assay failed. ND, Not done. 
 
 
2.3.4 Comparison with SGVP Database 
A comparison was made between this DMERI dataset and SGVP since both 
datasets were established from populations residing in Singapore with three similar 
ethnic ancestries; Chinese, Malays and Indians. The SGVP database of CNV loci was 
downloaded from http://www.statgen.nus.edu.sg/~SGVP/download.html, while some 
CNV information was obtained from Ku et al 2010. The anchor dataset of SGVP was 
generated using Illumina 1M microarray and the CNVs were called by PenCNV (Ku 
et al. 2010).  SGVP merged overlapping CNVs using a 1bp overlap criterion to 
establish a CNV loci, a term similar to the ‘CNVR’ used in this thesis. The complete 
set of CNV loci generated from Illumina was used in this comparison, containing a 
total of 2,573 CNV locus comprising 1,841 deletion and 732 duplication CNV loci.  
A larger number of CNVs were detected in Affy6.0 platform compared to 
Illumina 1M, resulting in a higher average number of CNV per individual in DMERI 
data (78) over SGVP (42) (Table 2.15). However, the CNVR dataset in SGVP was 
slightly larger than DMERI’s, indicating that in the DMERI dataset, there were a 
higher number of CNVs being merged into a CNVR. This could be attributed to the 
Canary algorithm in Birdsuite which is optimized to detect common CNVs. The 




Microarray Affy6.0 Illumina 1M
CNV calling algorithm Birdsuite PenCNV
No. of samples 281 266
Total no. of CNVs 22,024 11,282
Total no. of CNVR 2,227 2,573
Ave. no. of CNVs /individual 78 42
Range of no. of CNVs/indiv 51 - 103 27 - 110
Proportion of CNV <50Kb 0.74 0.69
Average size of CNVs  (Kb) 56.9 57.6
Median size of CNVs  (Kb) 14.6 ~ 21.8
Ratio of Deletion/Duplication 3.2 4.3
Proportion of Deletions 0.76 0.81
Ave. size of Deletion (Kb) 36.7 42.8
Med. size of Deletion (Kb) 10.6 ~ 14.8
Proportion of Duplications 0.24 0.19
Ave. size of Duplication (Kb) 121.1 118.6
Med. size of Duplication (Kb) 67.1 ~ 63.3
but duplication loci slightly larger in size in DMERI data. But DMERI has a higher 
proportion of CNVs <50kb. In both datasets, deletion greatly outnumbered 
duplications, but SGVP showed a larger deletion/duplication ratio.  In both datasets, 

















Of the list of novel CNVRs that were reported to be common in at least one 
population in Ku et al. (Ku et al. 2010), all 7 CNVRs could be found in the DMERI 
dataset as well (Table 2.16). In addition, this study has detected another novel Malay-
specific common CNVR in chromosome 9, which has been validated by qPCR 
(Section 2.3.5). The nature of these 7 CNVRs (deletion or duplication) were in full 
agreement between the two datasets, although the sizes varied in some. The definition 
of novelty differed in these 2 datasets as SGVP data was mapped against an earlier 
version of DGV (2009 vs 2012), resulting in more novel CNVRs. The population 
frequencies of each CNVR could differ in the 2 datasets, but the general trend of 




Count of CNVR by 
Frequency
Overlap (≥50%) No Overlap (<50%) Total Count of CNVR by 
Type
Overlap (≥50%) No Overlap (<50%) Total
Common 146 (18.0%) 121 (8.5%) 267 Complex 142 (17.6%) 141 (9.9%) 283
Intermediate 147 (18.2%) 110 (7.8%) 257 Del 396 (48.9%) 717 (50.6%) 1113
Rare 516 (63.8%) 1187 (83.7%) 1703 Dup 271 (33.5%) 560 (39.5%) 831
Total 809 1418 2227 Total 809 1418 2227
Fisher Exact Test, p (two-tailed)= <0.0001* Fisher Exact Test, p (two-tailed)= <0.0001*
DMERI SGVP 
Chr Start End Size (kb) Type Chi Mal Ind Novel Chr Start End Size (kb) Type Chi Mal Ind Novel
(n=100) (n=95) (n=86) (n=93) (n=88) (n=85)
1 173,061,601 173,069,074 7.5 Del 13 8 5 No 1 173,064,490 173,135,447 71.0 Del 34 13 13 Yes
2 49,389,272 49,394,694 5.4 Del 6 3 0 No 2 49,387,002 49,401,059 14.1 Del 8 4 0 Yes
2 72,103,499 72,124,997 21.5 Del 4 10 0 Yes 2 72,102,919 72,133,022 30.1 Del 2 7 0 Yes
2 137,761,562 137,782,241 20.7 Del 0 0 9 Yes 2 137,759,660 137,783,206 23.5 Del 0 1 6 Yes
6 40,174,188 40,211,285 37.1 Del 0 0 5 Yes 6 40,174,655 40,204,896 30.2 Del 0 0 5 Yes
7 52,911 197,438 144.5 Dup 1 2 3 No 7 37,124 164,003 126.9 Dup 13 9 14 Yes
8 9,091,324 9,099,936 8.6 Del 0 0 3 No 8 9,091,324 9,099,900 8.6 Del 0 0 7 Yes
9 27,220,509 27,242,785 22.3 Del 0 5 0 Yes
 
CNVR size overlap (≥50%) No overlap (<50%)
N 809 1418
Average size (bp) 95,619 86,310
Std Dev 170,362 366,534
Median size (bp) 40,170 21,322
Mann-Whitney Test, p (two-tailed)= <0.0001*
Mean difference = 9,309 ± 13,659 bp
 
Table 2.16  List of novel CNVRs common to at least one population in SGVP as 
compared to DMERI dataset.  
 
 
The 2,227 CNVR dataset from DMERI was merged against the 2,573 CNV 
loci of SGVP. Adopting a ≥ 50% overlap criterion, 36.3% (809) of the CNVRs from 
DMERI dataset overlapped with at least one CNV locus from SGVP. As expected, 
there was a significantly higher percentage of common CNVRs that were shared, but 
a deficit of rare CNVRs shared across the two datasets (Fisher exact test, p<0.0001. 
Table 2.17A). Likewise, there was significantly more sharing of complex CNVRs 
since complex CNVRs are more likely to be common (Tables 2.17B & 2.10). In 
addition, CNVRs that were shared across datasets were of significantly larger size 
compared to CNVRs not shared between the two datasets, confirming a higher true 
positive rate of discovery for CNVs of larger sizes (Table 2.17C).  
A          B 
 
 C               
 
 
Table 2.17  Characteristics of CNVRs that were shared with SGVP (defined as ≥ 50% 
overlap) versus those that were not shared (< 50% overlap) between the 2 datasets.  
A) By frequency. B) By type. C) By size. 
 
2.3.5 Validation of CNVR with Quantitative PCR 
Selected CNVRs were validated using quantitative Real-Time Polymerase 
Chain Reaction (qPCR). There were two objectives for the validation: (1) to validate 
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the existence of the target CNVR, (2) to compare the CNV copy number calls by 
microarray and qPCR platforms for the same sample so that a concordance rate could 
be calculated. Because one of the objectives of this thesis is to study the population 
diversity / differentiation of CNV between Singapore populations (Chapter 3), three 
categories of CNVRs were selected for validation;  
(1) Common CNVRs that have shown high population differentiation from 
microarray CNV calls (≥5% frequency, or n ≥15 in this study),  
(2) Common CNVRs that are population-specific (≥5% or n ≥5 in one 
population only), and  
(3) Rare CNVRs (≤1% frequency). 
Selected CNVRs for validation are of various sizes. Some of these selected 
CNVRs were called by one algorithm (Birdsuite) only (therefore not in the stringent 
set of CNVs, section 2.2.5.1). 
 
2.3.5.1 False Positive Rate 
A total of 71 CNVRs were successfully tested by qPCR, comprising of 26 
population-differentiated common CNVRs, 30 population-specific common CNVRs, 
and 15 rare CNVRs. A total of 28 qPCR assays were used for the 26 common 
CNVRs, as 2 of the common CNVRs were tested with 2 assays each in order to 
assess their breakpoints. Two assays could simultaneously tested 2 CNVRs at their 
overlapping positions. Therefore, a total of 71 assays were employed for the selected 
71 CNVRs. Another 8 assays failed to run successfully due to high variability in the 
results output. The technical details of these 79 assays could be found in Appendix 1.  
The detailed results of the validation study are summarised in Table 2.18. 
The attributes of each CNVR defined by their microarray calls were included. Any 
changes to these attributes after qPCR are highlighted in pink boxes. The delta value 
of each population-pair is akin to Fixation index FST, which is a measure of 
population differentiation due to genetic structure (delta-value defined in Section 
97 
 
3.2.1). Delta values ≥ 95 percentile have been highlighted in red (Delta at 95 
percentile for Chinese-Malays, Malays-Indians, Chinese-Indian are 0.0199, 0.0424 
and 0.0531, respectively). Many of the common CNVRs in the population-
differentiated and population-specific categories are of high delta-values.  
Of the 71 CNVRs validated by qPCR, three CNVRs were confirmed to be 
not real and should be classified as false positives. Among them, two were from the 
rare CNVR category and 1 from the population-specific category. This translated into 
an overall False Positive Rate (FPR) of approximately 4.2%. The FPR differs 
between the 3 CNVR categories, with 0% FPR in common CNVRs, 3.3% FPR in the 
population-specific group, and the highest FPR, 13.3%, was found in the rare CNVR 
category as expected.  
Among the 71 CNVRs, 8 of them were called by single algorithm Birdsuite 
only (these will not be present in the stringent set), 5 are in the rare CNVR category 
and 3 in the population-specific category (Table 2.18B & C). Of these 8, 3 could not 
be validated by qPCR, suggesting CNVRs called by only one algorithm Birdsuite 
could harbor ~37.5% of false positives. On the other hand, all the CNVRs in this 
validation study called by ≥2 algorithms could be validated by qPCR (51 called by 3 
algorithms and 12 called by 2 algorithms), lending support to the report of CNVs 
detected by multiple algorithms have a low false-positive rate, validating at a rate of 
>95% by qPCR (Marshall and Scherer 2012). However, the disadvantage of the 
stringent approach is the high false negative rate, which was proven by the validation 
study in the population-specific CNVR category. Of all the 30 population-specific 
CNVRs from the full Birdsuite CNVR list, 29 were validated by qPCR, and with 
good concordance rate (99%) between the 2 platforms (Table 2.18C, Figure 2.13C). 
If the stringent set was adopted, 13 of the validated CNVRs would have been 
excluded in the population-specific list because they were either not detected by a 
second algorithm or the population frequency fell below 5% (see section 3.3.2.1, 
Table 3.6). Therefore, this validation study for population-specific common CNVRs 
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clearly demonstrated that the stringent approach would have resulted in many false 
negatives. 
In this validation study, 17 CNVRs are smaller than 10kb; 5 in common 
category and 12 in population specific category. Of these, 9 are smaller than 5 kb; 2 
in common and 7 in population-specific category. A total of 16 could be validated 
except one with size of 4.7 kb proved to be false positive (Table 2.18C). The other 2 
false positives have sizes above 20kb (Table 2.18B). The smallest size CNVR 
validated was an Indian-specific CNVRs of 1.7kb. The successful validation of 8 out 
of the 9 CNVRs < 5kb suggested that many of the small size CNVRs likely to be real 
since they were detected by at least 5 probes. 
Interestingly, it was noted that all 3 false positives are duplication CNVRs. 
This is in line with the inherent character of microarray being able to detect deletion 










































Popn(s) CNVR freq 
in 1 popn 
(≥5)
CNVR freq 
in 3 popns 
(≥15)
CNV Type Popn(s) CNVR freq 
in 1 popn 
(≥5)
CNVR freq 






Delta M_I Delta C_I
7 11 135 1 25,465,715 25,534,592 68.9 RHD 1 100 100 3 4 0 7 2 Com. Intermed. Complex 3 Comm. Comm. Del 27.0% 0.0204 0.0424 0.0075
20 225 154 1 72,522,941 72,583,736 60.8 5' of NEGR1 0 - 100 3 89 83 53 3 Com. Com. Del 3 Comm. Comm. Del 82.0% 0.0006 0.0872 0.1007
21 9 161 1 103,910,761 103,960,907 50.1 AMY2A 2 67 100 2 1 2 6 3 Com. Intermed. Dup 3 Comm. Comm. Complex 93.2% 0.0020 0.0137 0.0233
28 106 177 1 110,025,907 110,058,147 32.2 GSTM1 3 100 100 3 30 26 50 3 Com. Com. Del 3 Comm. Comm. Complex 90.6% 0.0008 0.0967 0.0803
34 71 214 1 173,062,498 173,069,074 6.6 RABGAP1L 1 - 91 3 37 17 17 3 Com. Com. Del 3 Comm. Comm. Del 96.0% 0.0458 0.0006 0.0365
32 71 226 1 194,994,473 195,083,353 88.9 CFHR3 2 97 100 3 11 11 49 3 Com. Com. Complex 3 Comm. Comm. Complex 98.6% 0.0001 0.2287 0.2355
33 71 226 1 194,994,473 195,083,353 88.9 CFHR1 0 97 100 3 11 11 49 3 Comm. Comm. Complex 95.7% 0.0001 0.2287 0.2355
47 12 228 1 195,023,645 195,183,422 159.8 CFHR2,CFHR3,CFHR1,CFHR4 4 67 100 3 7 2 3 3 Com. Intermed. Complex 3 Comm. Intermed. Complex 99.6% 0.0138 0.0018 0.0062
35 19 287 2 40,779,595 40,803,110 23.5 - 0 - 100 3 1 16 2 3 Com. Com. Del 3 Comm. Comm. Del 98.9% 0.0772 0.0608 0.0027
61 14 314 2 72,103,499 72,124,997 21.5 - 0 - 0 2 4 10 0 2 Com. Intermed. Del 2 Comm. Intermed. Del 100.0% 0.0158 0.0556 0.0204
43 76 393 2 146,580,874 146,583,404 2.5 - 0 - 100 3 46 19 11 3 Com. Com. Del 3 Comm. Comm. Complex 74.5% 0.0764 0.0095 0.1328
26 249 547 3 163,989,224 164,127,661 138.4 - 0 - 100 3 98 93 58 3 Com. Com. Del 3 Comm. Comm. Del 100.0% 0.0000 0.1618 0.1633
23 258 639 4 69,021,057 69,234,339 213.3 UGT2B15 3 76 100 3 99 89 70 3 Com. Com. Del 3 Comm. Comm. Complex 99.3% 0.0200 0.0346 0.0876
22 9 1439 10 135,081,984 135,239,886 157.9 CYP2E1 6 17 100 3 1 7 1 3 Com. Intermed. Dup 3 Comm. Intermed. Dup 97.5% 0.0253 0.0236 0.0001
5 52 1488 11 58,566,573 58,615,474 48.9 LOC283194 1 99 100 3 30 10 12 3 Com. Com. Complex 3 Comm. Comm. Complex 93.5% 0.0587 0.0027 0.0375
40 31 1659 13 42,497,548 42,501,093 3.5 DNAJC15 1 - 100 2 19 12 0 2 Com. Com. Dup 2 Comm. Comm. Dup 86.6% 0.0076 0.0674 0.1050
4 129 1754 14 73,070,876 73,090,732 19.9 HEATR4, ACOT1 2 97 100 2 74 47 8 3 Com. Com. Complex 3 Comm. Comm. Complex 83.5% 0.0637 0.1944 0.4306
27 127 1875 16 14,844,825 15,023,758 178.9 NPIP 11 94 100 3 48 37 42 3 Com. Com. Complex 3 Comm. Comm. Complex 83.8% 0.0083 0.0099 0.0001
29 173 1921 16 54,353,890 54,387,091 33.2 CES1P1 1 100 100 3 72 61 40 3 Com. Com. Del 3 Comm. Comm. Del 95.7% 0.0070 0.0317 0.0673
15 11 1938 16 76,929,941 76,942,266 12.3 WWOX 1 - 100 3 1 0 10 2 Com. Intermed. Complex 3 Comm. Comm. Del 15.8% 0.0050 0.0617 0.0477
45 13 1940 16 77,319,838 77,327,934 8.1 WWOX 1 - 100 3 1 9 3 3 Com. Intermed. Del 3 Comm. Intermed. Complex 99.6% 0.0362 0.0148 0.0071
24 64 1991 17 41,006,741 41,015,665 8.9 - 0 100 100 2 37 25 2 3 Com. Com. Complex 3 Comm. Comm. Complex 2.5% 0.0132 0.1173 0.1903
25 66 1993 17 41,517,686 41,750,195 232.5 KANSL1 4 52 100 3 1 6 59 3 Com. Com. Complex 3 Comm. Comm. Complex 77.7% 0.0200 0.4140 0.5036
36 176 2027 18 36,512,703 36,523,810 11.1 - 0 - 72 3 45 65 66 3 Com. Com. Complex 3 Comm. Comm. Complex 93.9% 0.0559 0.0087 0.1058
30 47 2076 19 46,040,709 46,072,786 32.1 CYP2A6 1 82 100 3 19 23 5 3 Com. Com. Complex 3 Comm. Comm. Complex 96.8% 0.0040 0.0663 0.0400
39 114 2078 19 48,388,815 48,460,022 71.2 LOC284344 3 91 100 3 51 52 11 3 Com. Com. Del 3 Comm. Comm. Del 97.5% 0.0014 0.1967 0.1680
37 103 2204 22 22,670,786 22,734,830 64.0 GSTTP1 4 62 100 3 45 36 22 3 Com. Com. Complex 3 Comm. Comm. Complex 78.3% 0.0052 0.0175 0.0413
38 103 2204 22 22,670,786 22,734,830 64.0 GSTT1 4 62 100 3 45 36 22 3 Comm. Comm. Del 78.0% 0.0052 0.0175 0.0413
65 2 237 1 223,501,418 223,512,861 11.4 DNAH14 1 - 0 2 0 2 0 M-sp Intermed. Rare Del 2 Intermed. Rare Del 98.9% 0.0106 0.0106 -
53 1 367(or368) 2 108,642,559 109,819,785 1,177.2SH3RF3,LOC100287216,CCDC138,SEPT10,ANKRD57,LIMS1,EDAR,MIR4266,MIR4265,RANBP210 9 6 3 1 0 0 C-sp Rare Rare Dup 2 Rare Rare Complex 99.3% 0.0050 - 0.0050
64 1 367 2 108,642,559 109,819,785 1,177.2SH3RF3,LOC100287216,CCDC138,SEPT10,ANKRD57,LIMS1,EDAR,MIR4266,MIR4265,RANBP210 9 6 3 1 0 0 C-sp Rare Rare Dup C-sp Rare Rare Dup 100.0% 0.0050 - 0.0050
70 1 493 3 41,229,838 41,255,648 25.8 CTNNB1 1 - 0 1 1 0 0 C-sp Rare Rare Dup No CNV 98.9% 0.0050 - 0.0050
60 1 556 3 180,365,866 180,389,211 23.3 PIK3CA 1 - 3 1 0 1 0 M-sp Rare Rare Dup No CNV 99.6% 0.0053 0.0053 -
69 1 652 4 84,352,524 84,448,376 95.9 HPSE,COQ2 2 - 0 1 0 1 0 C-sp Rare Rare Dup C-sp Rare Rare Dup 100.0% 0.0053 0.0053 -
10b 1 763 5 9,799,299 10,053,817 254.5 LOC285692 1 - 53 3 0 0 1 M-sp Rare Rare Del M-sp Rare Rare Del 100.0% 0.0053 0.0053 -
63 1 1426 10 96,548,713 96,596,764 48.1 CYP2C19 1 - 5 3 0 1 0 M-sp Rare Rare Del M-sp Rare Rare Del 100.0% 0.0053 0.0053 -
41 2 1468 11 35,200,620 35,215,983 15.4 CD44 1 - 0 2 2 0 0 C-sp Intermed. Rare Dup C-sp Comm. Intermed. Dup 97.1% 0.0101 - 0.0101
66 2 1505 11 83,237,190 83,272,311 35.1 DLG2 1 - 0 3 2 0 0 C-sp Intermed. Rare Dup C-sp Intermed. Rare Dup 99.0% 0.0101 - 0.0101
68 1 1548 12 5,000,615 5,033,564 32.9 KCNA5 1 - 10 3 0 1 0 M-sp Rare Rare Del M-sp Rare Rare Del 100.0% 0.0053 0.0053 -
62 2 1817 15 30,027,161 30,248,706 221.5 CHRNA7 1 7 100 1 1 1 0 2 Rare Rare Dup 2 Rare Rare Complex 98.9% 0.0000 0.0053 0.0050
42 1 1922 16 54,387,058 54,560,676 173.6 CES1 2 39 22 2 0 1 0 M-sp Rare Rare Dup 3 Comm. Comm. Complex 49.8% 0.0053 0.0053 -
44 1 1939 16 77,208,496 77,251,710 43.2 WWOX 1 - 0 3 1 0 0 C-sp Rare Rare Del C-sp Rare Rare Del 100.0% 0.0050 - 0.0050
19b 1 2196 22 17,004,365 17,150,527 146.2 USP18,GGT3P 2 88 100 1 0 0 1 I-sp Rare Rare Dup I-sp Rare Rare Dup 100.0% - 0.0058 0.0058
as above
as above
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Delta M_I Delta C_I
6 7 111 1 696,962 840,550 143.6LOC643837,FAM41C,LOC100288069,NCRNA001154 87 100 3 7 0 0 C-sp Com. Intermed. Dup 3 Comm. Comm. Dup 92.1% 0.0363 - 0.0363
31 5 249 1 243,505,830 243,509,160 3.3 KIF26B 1 - 100 1 5 0 0 C-sp Com. Intermed. Complex 2 Comm. Intermed. Del 98.9% 0.0256 - 0.0256
67 7 286 2 40,617,671 40,622,406 4.7 - 0 - 100 1 0 0 7 I-sp Com. Intermed. Dup No CNV (2 assays showed all CN2) 97.1% - 0.0424 0.0424
50 5 355 2 95,094,701 95,099,193 4.5 - 0 - 100 1 5 0 0 C-sp Com. Intermed. Del C-sp Comm. Intermed. Del 97.8% 0.0256 - 0.0256
8 9 390 2 137,761,562 137,782,241 20.7 THSD7B 1 - - 3 0 0 9 I-sp Com. Intermed. Del 3 Comm. Intermed. Del 98.9% - 0.0552 0.0552
17 5 392 2 141,971,752 141,973,472 1.7 LRP1B 1 - 100 2 5 0 0 C-sp Com. Intermed. Del C-sp Comm. Intermed. Del 99.6% 0.0256 - 0.0256
71 8 420 2 212,889,560 212,900,070 10.5 ERBB4 1 - 100 3 0 0 8 I-sp Com. Intermed. Del I-sp Comm. Intermed. Del 100.0% - 0.0488 0.0488
9 5 732 4 187,166,418 187,374,152 207.7 TLR3,CYP4V2,FAM149A 3 - 97 3 0 0 5 I-sp Com. Intermed. Dup I-sp Comm. Intermed. Dup 100.0% - 0.0299 0.0299
10a 9 762 5 9,954,952 9,982,909 28.0 LOC285692 1 - 100 3 0 0 9 I-sp Com. Intermed. Del I-sp Comm. Intermed. Del 100.0% - 0.0552 0.0552
1 7 789 5 41,267,255 41,277,150 9.9 C6 1 - 100 3 7 0 0 C-sp Com. Intermed. Del C-sp Comm. Intermed. Del 100.0% 0.0363 - 0.0363
48 11 840 5 155,407,677 155,415,307 7.6 - 0 - 100 2 0 0 11 I-sp Com. Intermed. Del 2 Comm. Intermed. Complex 98.5% - 0.0683 0.0683
52 5 883 6 40,174,188 40,211,285 37.1 - 0 - - 3 0 0 5 I-sp Com. Intermed. Del I-sp Comm. Intermed. Del 100.0% - 0.0299 0.0299
11 7 984 7 8,792,410 8,832,522 40.1 - 0 - 100 3 0 0 7 I-sp Com. Intermed. Del I-sp Comm. Intermed. Del 100.0% - 0.0424 0.0424
57 5 1016 7 53,433,670 53,563,109 129.4 - 0 - 96 3 0 0 5 I-sp Com. Intermed. Del I-sp Comm. Intermed. Del 100.0% - 0.0299 0.0299
3 5 1273 9 27,220,509 27,242,785 22.3 NCRNA00032 1 - - 3 0 5 0 M-sp Com. Intermed. Del M-sp Comm. Intermed. Del 99.6% 0.0270 0.0270 -
16 9 1357 10 27,265,910 27,268,479 2.6 LINC00202 1 100 100 3 0 0 9 I-sp Com. Intermed. Dup 3 Comm. Comm. Complex 94.6% - 0.0552 0.0552
54 7 1385 10 58,186,381 58,196,843 10.5 - 0 - 100 3 0 0 7 I-sp Com. Intermed. Del I-sp Comm. Intermed. Del 100.0% - 0.0424 0.0424
49 7 1411 10 82,871,310 82,879,763 8.5 - 0 - 100 3 0 0 7 I-sp Com. Intermed. Complex I-sp Comm. Intermed. Del 99.6% - 0.0424 0.0424
12 7 1540 11 133,857,095 133,977,420 120.3 LOC283177 1 - 100 3 0 7 0 M-sp Com. Intermed. Del M-sp Comm. Intermed. Del 100.0% 0.0383 0.0383 -
13 6 1547 12 2,105,889 2,128,667 22.8 CACNA1C 1 - 100 3 0 0 6 I-sp Com. Intermed. Del I-sp Comm. Intermed. Del 100.0% - 0.0361 0.0361
56 5 1624 12 79,349,306 79,352,244 2.9 - 0 - 100 2 5 0 0 C-sp Com. Intermed. Del 2 Comm. Intermed. Del 99.3% 0.0256 - 0.0256
58 5 1650 13 22,185,775 22,192,245 6.5 - 0 - 100 3 0 0 5 I-sp Com. Intermed. Del I-sp Comm. Intermed. Del 99.6% - 0.0299 0.0299
51 6 1726 14 27,536,375 27,591,214 54.8 - 0 - 96 3 0 0 6 I-sp Com. Intermed. Del I-sp Comm. Intermed. Del 100.0% - 0.0361 0.0361
2 18 1834 15 45,992,538 46,001,995 9.5 - 0 - 80 3 18 0 0 C-sp Com. Com. Del C-sp Comm. Comm. Del 100.0% 0.0989 - 0.0989
14 9 1854 15 95,618,796 95,633,191 14.4 - 0 - 100 3 0 0 9 I-sp Com. Intermed. Del I-sp Comm. Intermed. Del 96.8% - 0.0552 0.0552
18 8 1899 16 22,612,023 22,694,640 82.6 - 0 - 89 3 0 8 0 M-sp Com. Intermed. Dup M-sp Comm. Intermed. Dup 99.3% 0.0440 0.0440 -
46 10 1925 16 58,640,103 58,654,487 14.4 - 0 - 100 2 10 0 0 C-sp Com. Intermed. Del C-sp Comm. Intermed. Del 100.0% 0.0526 - 0.0526
55 5 2064 19 21,179,648 21,191,982 12.3 - 0 - 67 3 0 0 5 I-sp Com. Intermed. Del 2 Comm. Intermed. Del 98.9% - 0.0299 0.0299
19a 8 2194 22 17,006,129 17,009,153 3.0 - 0 - 100 3 0 0 8 I-sp Com. Intermed. Del I-sp Comm. Intermed. Del 100.0% - 0.0488 0.0488
59 5 2201 22 21,048,635 21,082,880 34.2 - 0 - 100 3 0 0 5 I-sp Com. Intermed. Complex 2 Comm. Intermed. Complex 97.4% - 0.0299 0.0299
Microarray Calls Microarray RT-PCR
 
 
Table 2.18  Attributes of CNVRs obtained from microarray versus qPCR. Percentage of overlap to segmental duplication and DGV CNV are included. Any 
changes in attribute of a CNVR after qPCR validation would be highlighted in pink boxes. Concordance rates below 90% are hightlighted in orange boxes. 
Number of algorithm called; 1 means CNV called by Birdsuite only; 2 would be called by Birdsuite and GTC or Nexus; 3 would be called in all 3 algorithms. 
Delta of population-pair represents the extent of CNV frequency differentiation between the two populations. Delta above 95 percentile is in red font. 
Abbreviation; C, Chinese; M, Malays; I, Indians; sp, specific; com., common; intermed., intermediate; del, deletion; dup, duplication. A) Validation results of 
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2.3.5.2 Concordance Rate 
To estimate the concordance rate of CNV copy number calls between the two 
platforms, a total of 18,474 genotypes were compiled from the 71 assays. The overall 
concordance rate between microarray and qPCR platforms was approximately 91.7% 
(Figure 2.13A). However, there were obvious differences in concordance rate 
between the 3 CNVR categories. The common CNVRs have a higher proportion of 
complex CNVRs, and as a group was the most challenging to call copy-number 
accurately, as reflected in the lowest concordance rate at 83.4% (Table 2.18A, Figure 
2.13B). In contrast, the category of population-specific common CNVRs are highly 
accurate, reaching a concordance of 99% (Table 2.18C, Figure 2.13C). For the rare 
CNVRs, putting aside the higher FPR of this class of CNVR, those rare CNVRs that 
were true positives showed very good concordance rate as well, at 94.3% (Table 
2.18B, Figure 2.13D). The concordance rate in rare CNVRs can reach 99.4% if one of 
the rare CNVRs is excluded. That particular CNVR, Cluster_1922, was called by 
microarray as a rare CNVR but qPCR has determined it to be a multiallelic common 
CNVR (Table 2.18B, Figure 2.14 of Section 2.3.6). A summary of the detailed copy 
number calls by microarray and qPCR platforms can be found in Appendix 2. 
 
    























































































Population-differentiated Common CNVR: Concordance rate = 6,473/7,761 = 83.4% 
 
 
















Population-specific Common CNVR: Concordance rate = 7,946/8,034 = 99% 
      
 




























































Figure 2.13   Comparison of CNV copy number calls of the same sample between 
microarray and qPCR. The size of each point is proportional to the number of 
observations, which is listed above each genotype call. The number of observations in 
red font represents the number of concordance calls by the 2 platforms. A) Overall 
comparison involving all the 71 CNVRs, amounting to 18,474 copy number calls. B) 
26 population-differentiated common CNVRs totaling 7,761 copy number calls. C) 
30 population-specific common CNVRs totaling 8,034 copy number calls. D) 15 rare 
CNVRs totaling 2,679 copy number calls. 
 
This aspect of the validation study in comparing CNV calls between the 2 
platforms on the same sample proved to be important. The FPR of common CNVRs 
by microarray appeared to be low (FPR at 0% for population-differentiated CNVRs 
and 3.3% for population-specific common CNVRs, as in Section 2.3.5.1). However, 
when assessing the concordance rate at sample level, microarray has failed to detect 
CNVs in many samples compared to qPCR, i.e. false negatives at sample level, 
resulting in a lower population frequency for that particular CNVR. This false 
negative issue of microarray was reflected in the lower concordance rate in the 
category of population-differentiated common CNVRs, and accounted for almost all 
the 1% discordant rate in the category of population-specific common CNVRs.  
 
2.3.6 Other Findings 
This was an interesting discovery in the rare CNVR category. The 
concordance rate of rare CNVRs was lower than that of population-specific CNVRs 
due to the presence of a CNVR located in chromosome 16q12.2 encompassing the 
genes CES1 and CES5A (CNVR Cluster ID 1922). In contrast to microarrays which 
detected the duplication CNV in only one Malay sample, qPCR has shown it to be a 
common duplication CNVR with higher frequency in Chinese and Malays than 
Indians (Figure 2.14A). Interestingly, this Cluster_1922 CNVR is located 
downstream of a common deletion CNVR (Cluster ID 1921) containing the 
pseudogene CES1P1, which is also enriched in Chinese and Malays (Figure 2.14).   
The carboxylesterase 1 (CES1) gene (MIM 114835) encodes for human 




































carboxylesterases (CES) are serine esterases that play an important role in phase I 
drug metabolism, governing both metabolic deactivation and activation of numerous 
therapeutic agents.  Mutations of CES1 cause carboxylesterase 1 deficiency, but all 
reported mutations involved indels or SNPs, and duplication has only been reported 
more recently (Zhu et al. 2008). The significance of this duplication is unclear, but it 
appears to display similar multi-gene family structural pattern, with genes clustering 
in one genomic location each with multiple copy number. An example of this is the 
Amylase gene family which is discussed in further details in Chapter 4. A comparison 
of the diploid copy number call per sample for the 2 adjacent qPCRs showed an 
inverse relationship of the 2 qPCRs, confirming the CES1P1 is a deletion CNV while 
CES1 is a duplication CNV (Figure 2.15). The inverse intensity of the 2 qPCRs also 
suggested they are independent qPCR. The inverse correlation of the copy numbers 
between these 2 CNV loci likely to reflect an underlying haplotype structure. A 
situation similar to the Amylase genes CNV loci as discussed in Section 4.3.1.3. In 
summary, CES1 CNV locus with high population differentiation in frequency and its 










Figure 2.15   Correlation between the diploid copy number of the 2 adjacent qPCRs 
which target CNVRs Cluster 1991 and 1992, which encompassed the genes CES1P1 




#Cluster_ID Chr Start End Size (kb) No. of 
genes
Genes Platform Chinese (n=99) Malays (n=94) Indians (n=85) Concordanc
e
CN0 CN1 CN2 CN3 CN4 CN0 CN1 CN2 CN3 CN4 CN5 CN6 CN0 CN1 CN2 CN3 CN4
1921 16 54,353,890 54,387,091 33 1 CES1P1 Microarray 16 56 27 0 0 20 41 33 0 0 0 0 8 32 45 0 0
qPCR 16 61 22 0 0 20 48 26 0 0 0 0 8 32 45 0 0 95.7%
1922 16 54,387,058 54,560,676 174 2 CES1 CES5A Microarray 0 0 0 99 0 0 0 0 92 1 0 0 0 0 0 83 0
qPCR 0 1 22 60 16 0 0 26 47 19 0 1 0 1 43 30 9 49.8%
 
Figure 2.14   Schematic representation of 2 
adjacent CNVRs in UCSC Genome 
Browser. Clusters 1921 and 1922, 
containing the genes CES1P1 and CES1 
cum CES5A, respectively. The locations of 
these genes are displayed in the lower 
panel, while CNVs in DGV are in the 
lowest panel. The qPCR assays used and 
their genomic positions in relation to each 
CNV are indicated. CNVs displayed are 
microarray data. Red –Chinese, Green – 
Malays, Blue – Indians. The copy number 
called by microarray and qPCR in 
respective populations are included for 
direct comparison. 
#1922
Hs03939200_cn,  position 54,422,466
#1921





2.4.1 Characteristics of CNV dataset 
Using Affymetrix SNP6.0 microarray, this study has investigated the 
characteristics of Copy Number Variations of three Singapore populations. A total of 
281 samples were studied, comprising of 100 Chinese, 95 Malays and 86 Indians. 
Due to the challenge in reproducibility of CNV detection, two approaches were used 
initially.  The first was a conservative approach producing a CNV dataset that was 
called by Birdsuite and one other calling algorithm, GTC or Nexus, generating a 
stringent set containing 8,518 stringent CNVs merged into 1,618 CNVRs. The second 
approach was more liberal generating a dataset of 22,024 CNVs called by Birdsuite 
and was merged into 2,227 CNVRs. Further studies into these two datasets, and 
subsequent qPCR validation confirmed that although the stringent set has less false 
positives (63 of the CNVRs called by ≥2 algorithms in qPCR validation study showed 
0% FPR (Table 2.18), it also has a higher rate of false negatives (as demonstrated by 
the 14 population-specific CNVRs being excluded in the stringent list (Table 3.6). 
Since common CNVs are the focus of interest in studying population genetics aspect 
of CNV, the full CNVR set called by Birdsuite has been used as the anchor dataset in 
this thesis, and all work reported derived from analysis using this Birdsuite set 
comprising 2,227 CNVRs. 
Between the three CNV detection algorithms, the average reproducibility rate 
of intra-batch duplicates was the highest at 73% by Birdsuite, followed by GTC at 
50%. Both rates were close to the reported figures by a large assessment study carried 
out to test various array platforms and calling algorithms (Pinto et al. 2011). In that 
study, Birdsuite detection produced the highest CNV number called and the best 
reproducibility for Affy6.0 array, in line with the results of this study. However, 
compared to detection and genotyping of other types of genetic polymorphisms, the 
reproducibility of CNV detection is poor and methods need to be improved. 
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An average of 78 CNVs per individual was discovered in this study. In 
totality, these CNVs covered 161,627,331 bp of unique genomic region, representing 
approximately 5.4% of the human genome. The figure of 78 CNVs per genome is 
near to previous studies employing the same platform and calling algorithm 
(McCarroll et al. 2008b; Pinto et al. 2011), but was higher compared to SGVP which 
reported an average number of 42 using Illumina 1M microarray called with PenCNV 
algorithm (Ku et al. 2010). The higher detection rate in Affy6.0 versus Illumina1M 
could be attributed to higher probe density used in the Affy6.0 chip, especially the 
CNV probes placed more uniformly across the genome. The ratio of 
deletion/duplication at 3.2 in this study is lower than the reported ~4.0 in SGVP. The 
proportion of various size ranges found in this study are similar to those reported in 
Pinto et al using the same platform and algorithm (Pinto et al. 2011), but are generally 
slightly smaller in size compared to SGVP (median deletion size 12-18 kb, 
duplication 59-71 kb). The proportion of CNVs <50kb was also slightly higher in the 
DMERI dataset compared to SGVP (74% in DMERI and ~69% in SGVP). Overall, 
this DMERI dataset detected more CNVs and the CNVs are of slightly smaller size 
on average than SGVP (Table 2.15), most likely attributed to a higher density of 
probes found in Affy6.0 compared to Illumina1M. 
Of the average number of CNVs per individual at approximately 78, pairwise 
comparison between any 2 unrelated individuals showed that approximately 86% of 
the copy number differences were resulted from CNPs (i.e. CNVs with >1% 
population frequency), of which about 77% were resulted from common CNPs with 
frequency of at least 5%. This suggests that most of the CNVs found in an individual 
are common CNVs, with only about 14% being rare CNVs. This is consistent with 
previous findings, where McCarroll et al. reported ~92% were CNPs in their samples 
from HapMap (McCarroll et al. 2008b). This pattern of common variants being more 
prevalent in an individual than rare variant is also a pattern similarly observed for 
SNPs (McCarroll et al. 2008b). 
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Comparing to CNVRs in DGV, 30% (671) of the DMERI CNVRs could be 
considered novel. Of these 671 novel CNVRs, none of them are common CNVR. 
Only 2% have intermediate frequency, while 98% are rare CNVRs. The average 
population frequency is significantly lower in novel than in non-novel CNVR groups 
(Table 2.12B).  Furthermore, majority (97%) of these novel CNVRs are restricted to 
one population only (Table 2.12B), suggesting the importance of establishing CNV 
databases for different populations.  
Of the 2,227 CNVRs, 50% are deletions, 37% duplications, and 13% are 
complex CNVRs. In terms of population frequency, the majority (77%) is rare 
CNVRs, 12% have intermediate frequency and 12% are common CNVRs. Many of 
the rare CNVRs are deletion or duplication CNVRs, while common CNVRs are 
mostly complex or deletions. A higher detection percentage of deletion CNVR could 
be due to the inherent platform bias of microarray, as its signal intensity LogR ratio is 
more pronounced in deletion copy numbers compared to duplications (more details in 
next section 2.4.2). The skewness to rare CNVR has been interpreted as an indication 
of the slight deleterious effect of CNV that selection acts against changes in copy 
number (Conrad and Hurles 2007; Iskow et al. 2012). Furthermore, there is a 
significant depletion of larger CNVRs which are more likely to overlap with genes, 
hinting at purifying selection effect. The correlation of common CNVR to complex 
CNVR is mostly due to their association to segmental duplications (SDs) which is 
discussed below. 
About 20% of the 2,227 CNVRs overlap with segmental duplications (SDs) 
in the human genome. The majority (97%) of the CNVRs associated with SDs are 
known CNVs (i.e. not novel), as compared to 63% of those CNVRs not associating 
with SDs are known (Table 2.12A). The correlation of CNVRs associating with SDs 
and high population frequency lend support to the hypothesis that non-allelic 
homologous recombination (NAHR) plays a role for CNV formation in human, 
especially for common ones (Kidd et al. 2008; McCarroll et al. 2008b; Redon et al. 
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2006). This also explained why the CNVRs associating with SDs are of significantly 
larger sizes in this dataset. This corroborated with previous findings that reported 
NAHR being a major mediator for CNV formation particularly for CNVs in the 
largest decile (Conrad et al. 2010b). Interestingly, CNVRs that overlap SDs are 
significantly more likely to encompass genes (Table 2.12A). This could be due to a 
strong correlation between SDs and gene content (Bailey et al. 2002; Cooper et al. 
2007). 
Of the 2,227 CNVRs, about 47% overlapped with known genes or 
uncharacterized transcripts. Deletion CNVRs are significantly poorer in gene content, 
an observation similarly reported in previous studies (Conrad et al. 2010b; Ku et al. 
2010; Park et al. 2010; Redon et al. 2006), and was interpreted as a result of natural 
selection. Further support for the action of purifying selection may be apparent from 
the depletion of gene content in deletion CNV compared to duplication (Table 
2.11B), with gene deletion causing a stronger deleterious effect than gene duplication. 
The deleterious effect of CNVs would also explain the observation that deletions are 
generally smaller in size than duplications (Figure 2.9). Gene ontology analysis with 
the full 2,227 CNVR dataset showed an enrichment of genes involved in biological 
processes such as cell adhesion, immune response, signaling pathway and regulation 
of secretion. Neurophysiological processes such as neurogenesis and synapse 
assembly were also in the highly enriched GO category. While the 267 common 
CNVRs with ≥ 5% frequency were highly enriched for immune functions and 
olfactory transduction. These results are similar to previous studies which showed 
enrichment of genes involving extracellular biological processes such as adhesion, 
recognition and communication, but deficient in genes involving in intracellular 
processes such as metabolic pathways (Conrad et al. 2010b; Park et al. 2010; Redon 





2.4.2 Quantitative PCR Validation 
The False Positive Rate (FPR) for the three categories of CNVRs were; 0% in 
the category of population-differentiated common CNVRs, 3.3% for the population-
specific common CNVRs, and 13.3% in the rare CNVRs. A FPR of 0% in common 
CNVRs was not unexpected because the aim of qPCR for common CNVRs was to 
assess copy number call accuracy, and importantly how reliable was microarray in 
determining frequency differentiation across the three populations. The FPR of 13.3% 
in rare CNVRs should be a more representative value for the overall performance of 
microarray since the majority of CNVs discovered by microarray are rare CNVs. A 
previous large consortium study using high-density aCGH has reported a false 
discovery rate of 15% (Conrad et al. 2010b).  
We would expect the FPR to be lower if the CNVR has been called by more 
than one algorithm, since all the three false positives in this study were called by one 
algorithm Birdsuite only. It has been reported that CNVs detected by multiple 
algorithms have a low false-positive rate, validating at a rate of >95% by qPCR 
(Marshall and Scherer 2012). However, the approach to decrease false positives by 
adopting CNV detection with ≥2 algorithms comes with a trade-off of increasing 
false negatives. This was well demonstrated by the 13 false negatives in stringent set 
of population-specific CNVRs compared to the 29 validated population-specific 
common CNVRs in the full list from Birdsuite CNVR set (Table 3.6 in Section 
3.3.2.1).  
Although the FPR in rare CNVRs was relatively low at 13.3%, of the 8 
CNVRs in this study that were called by one algorithm (Birdsuite) only, 3 were 
shown to be false positives, translating to a FPR of 37.5%. Therefore, it is possible 
that the actual FPR of this study (Full 2,227 CNVR set called by Birdsuite) might lie 
between 13.3% and 37.5%.  
This study could not assess the false negative rate since there was no gold 
standard for comparison. But the concordance rate comparison (discussed below) 
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indicated some extent of false negatives in common CNVRs called by microarray at 
sample level. Hence if the false negative happened in rare CNVR, that CNVR would 
simply be missed and not recorded. A previous study comparing Affy6.0 called by 
Birdsuite to Fosmid end-sequence-pair analysis for 8 samples reported a sensitivity of 
76% for CNV >10kb (McCarroll et al. 2008b). 
While we could not assess false negatives by microarray at the population 
level, qPCR showed that the copy number calls from microarray could contain false 
negatives at sample level. Microarray also performed less satisfactorily in 
multialleleic, or complex CNVRs due to the larger range of copy number states. This 
is particularly true in the population-differentiated common CNVR category, 
resulting in the lowest concordance rate at 83.4%. Therefore, the population 
frequencies obtained from microarray data might not be accurate. But more 
importantly, this validation study has confirmed that the trend or direction of 
frequency differentiation between the three populations remains consistent between 
microarray and qPCR results. The concordance rates in the population-specific 
common, and rare CNVR categories were 99% and 94.3%, respectively. A previous 
Korean study using high-density aCGH has reported a predictive rate of 91% (Park et 
al. 2010).  
Microarray calls have been shown to be less accurate for duplication, as 
reflected in the overall concordance rate of deletion CNVRs versus duplication 
CNVRs been 99.6% and 94.2%, respectively (Table 2.18B & C). Also, microarray 
could not differentiate higher copy number (eg. between CN3 and CN4) accurately 
compared to qPCR, as reflected in more high copy number being called in qPCR 
(Figure 2.13A). This is a technical limitation of microarray, as the exponential of 
intensity data is linearly correlated with the copy number. Consequently, the signal 
intensity difference (Log R ratio) between CN1 and CN2 is more pronounced than the 
difference between CN2 and CN3 (Log R ratio is -1 for the first example, and 0.58 
for the second example). Therefore, deletion is better detected than duplication in 
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microarray. This could possibly explain the higher proportion of deletions detected 
compared to duplication CNVs. The deletion/duplication ratio in this study is 3.2. 
This would also explain why all the 3 false positives called by microarray in this 
validation study were all duplication CNVRs.  
The validation study also confirmed that the strategy of using the full CNVR 
dataset called by Birdsuite was the correct approach. All the 30 population-specific 
CNVRs, except one, were validated to be true positives. If the stringent set of CNVRs 
had been used, 5 of these population-specific CNVRs would have been missed as 
they were called by Birdsuite only, while another 9 population-specific CNVRs 
would have demonstrated lower than 5% population frequency and could not be 
classified as common.  
 
2.4.3 Summary  
In summary, this study has established a CNV dataset for three Singapore 
populations. Although CNV catalogs are now available in SGVP and SgD (Ku et al. 
2010; Xu et al. 2011), the dominance of rare CNVs in CNV databases suggests 
additional data would always be useful because many of the rare CNVs would likely 
be novel even in the same population. This is supported by the result of comparing 
the 2 datasets from DMERI and SGVP. Overlapping the two datasets showed that 
only 36.7% of DMERI CNVRs would share ≥50% with CNVRs from SGVP, 
confirming the value of additional dataset for Singapore populations. Furthermore, it 
has been shown that low-frequency variants can show an increased level of 
population differentiation (Altshuler et al. 2010; McCarroll et al. 2008b; Mills et al. 
2011). Hence this additional dataset shall add information to existing CNV map. 
In addition, extensive qPCR validation has been carried out in this dataset to 
better understand the FPRs of different categories of CNVRs. The qPCR work has 
helped to better assess the characteristics and accuracy of CNV detection and copy 




The discovery of CES1 as a novel multallelic CNV demonstrated the 
potential of this dataset for further exploration and as a hypothesis-generating tool. 
This dataset should serve to expand CNV resources for Southeast Asian populations 
and contribute to building a global CNV map. These catalogs of CNV in healthy 
individuals will aid in understanding the role of CNVs in human physiology and 

























POPULATION GENETICS OF COPY NUMBER VARIATIONS IN 
SINGAPORE POPULATIONS  
 
3.1 INTRODUCTION 
3.1.1 Significance of Population Genetics  
Population genetics is the study of the distribution and changes of allele 
frequency in a population, and is important to the understanding of human variation. 
Population genetics helps to link the medical and evolutionary aspects of genetics, 
leading to a better understanding of the origins and impacts of genomic differences in 
humans.  
Genomic variants of various types and sizes can contribute to genetic 
diseases, and also serve as potential substrates for natural selection resulting in 
phenotypic differences between individuals and populations. To better understand the 
medical and evolutionary impact of CNVs, an understanding of the distribution of 
such variation within a species and the factors that influence this variation is needed.  
The general factors that influence the distribution of variations within a species are 
common to all classes of genetic variants. These factors include: mutation, natural 
selection, genetic drift and gene flow (Jobling et al. 2014). Gene flow includes 
migration and population demographic events.  
Each genetic variant has its own specific evolutionary history, but it is 
through the analysis of many variants that the general properties of a class of 
variations can be elucidated. Population genetics studies both variant-specific 
histories and the general properties of variation, both of which are pertinent to 
medical and evolutionary issues. Variants that appear to be population genetic 
outliers relative to a background of ‘normal’ variation are often enriched for 
medically relevant mutations (Conrad and Hurles 2007). For example, the frequency 
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of alpha-globin gene deletion within a population varies between geographical 
locations to an unusually high extent. This is because the deletion confers both 
resistance to malarial infection and susceptibility to mild thalassemia. Thus, the 
deletion has increased in frequency in regions where Malaria is endemic, but remains 
low in frequency in regions without Malaria (Flint et al. 1986). This is a classic 
example of natural selection. Another example is the highly copy number variable 
salivary amylase (AMY1) CNV locus (Perry et al. 2007).  Populations consuming 
high quantities of starch, such as Japanese and Europeans, are thought to have 
significantly more copies of the AMY1 gene than do those consume lower quantities, 
such as Yakut and Biaka pygmy, suggesting that copy number variation at AMY1 is 
under positive selection in response to cultural changes (This locus is studied in detail 
in Chapter 4).  Selection can distort the population distribution of a variant so that it is 
markedly differentiated from the average. Therefore, identifying unusual patterns of 
population differentiation can highlight CNVs that have been under recent selective 
pressures.  
CNVs that differ greatly in frequency between populations are candidate 
variants for population-specific natural selection, and could provide new insight into 
recent human evolutionary history (Campbell et al. 2011). These CNVs tend to have 
>1% population frequency and are also termed Copy Number Polymorphisms 
(CNPs). As we have noted in our database work (Chapter 2, Table 2.13B), and as 
reported by other studies, genes overlapping with CNPs are enriched for immune and 
environmental response pathways (Conrad et al. 2010b; Cooper et al. 2007; Redon et 
al. 2006). This enrichment suggests that these CNPs could be candidates for local 
adaptive selection in human populations. Potentially interesting differentiated CNPs 
include a deletion that removes APOBEC3B (apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide-like 3B) (MIM 607110) which is involved in innate 
immunity and is more prevalent in East Asian and Oceanic populations (Kidd et al. 
2007), and the deletion of UGT2B17 (UDP glucuronosyltransferase 2 family, 
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polypeptide B17) (MIM 601903) which has been associated with osteoporosis and is 
more common in East Asians (Xue et al. 2008; Yang et al. 2008). In some studies, 
high population frequency differentiation alone was taken as an empirical evidence of 
positive selection (Iskow et al. 2012).  
This chapter studied the population genetics of CNVs. First, the distribution 
and genetic diversity of CNVRs in the 3 Singapore populations were investigated. 
Second, those CNVRs that are common (≥5% population frequency) and population-
specific were identified, as well as the CNVRs that showed high population 
differentiation. Some of these CNVR candidates were validated by qPCR to confirm 
the frequency differentiation. Population-specific CNVRs from our data were 
validated against a larger published CNV dataset, SgD, established from similar 
Singapore populations with each group containing ≥ 1,900 individuals (Xu et al. 
2011). Third, population-specific and population-differentiated CNVRs could arise 
from adaptive selection rather than genetic drift. To identify such CNVR candidates, 
we identified population-differentiated CNVRs in genomic regions likely to be under 
selection force. These selection loci were either obtained from publication, or 
calculated from a recently published algorithm HaploPS (Liu et al. 2013), using SNP 
dataset generated in this study. The overlap of selection locus with a population-
differentiated CNVR suggests that selection force, rather than simply genetic drift, 
resulted in frequency differentiation between populations. 
 
3.1.2 Tests of Selection Signals 
DNA variants are generally described as being neutral, under negative 
selection, under positive selection or, occasionally, under balancing selection. Most 
empirical tests for selection examine potential deviations from neutrality (Iskow et al. 
2012). Positive selection causes the allele frequency of a variant to rise, and it can 
drive sequence divergence and alter the relationship of the selected variant with 
nearby variants. These signatures can be used to detect positive selection. The types 
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of signatures that are examined can be broadly classified as frequency-based (e.g. 
population differentiation) and linkage-based (e.g. extended homozygosity, linkage 
disequilibrium and extended haplotype). Generally, these tests of selection need to be 
compared to a null model of neutrality. This null model is usually created from one of 
two sources: (1) primarily neutral regions of the genome, such as introns or processed 
pseudogenes, are compared to the variant(s) of interest, or (2) a genome-wide 
distribution of statistics can be calculated, and this is used to determine whether the 
variants of interest are outliers in the distribution. 
Generally, bioinformatic approaches designed to discover evidence of local 
adaption predominantly focus on identifying the following two genomic features that 
accompany the introduction of an evolutionarily advantageous allele (Iskow et al. 
2012):  
(a) stretches in the human genome that are highly differentiated between 
populations as a result of positive selection on the genetic backgrounds 
associated with the beneficial alleles compared to neutrally evolving regions; 
(b)  the presence of a long-range haplotype (extended haplotype) on which the 
selected allele resides, given that this variant increases in frequency very 
rapidly and brings along neighbouring variants (on the same haplotype) that 
recombination does not have sufficient time to break down. 
This study has adopted both the above approaches to test the signature of 
selection; (1) FST to test for population differentiation, and (2) extended haplotypes 
calculated from HaploPS. 
 
3.1.2.1 Wright Fixation Index, FST 
Differences in allele frequency between populations are a potential signal of 
recent positive selection (Campbell et al. 2011). Hence we studied CNVRs whose 




FST, or Wright Fixation Index, is a common parameter used in SNP dataset to 
quantify the genetic substructure in population, or to measure genetic distance 
between population pairs (Holsinger and Weir 2009). It can be estimated as the 
standardised variance of allele frequencies among populations:  
FST = σ
2
 / π(1-π) 
where σ2 and π being the variance and mean, respectively, of the allele frequencies. 
FST, ranges from 0, when all sub-populations are identical, to 1, when 
different alleles are fixed in different sub-populations. Figure 3.1 provides an 
example. The mean allele frequency is the same in both cases, at 0.46. But the 
variance is 10 times as large as in group (b) as in (a), and so is the FST. Large FST 
values are consistent with either geographically restricted selection (local adaptation) 
or demographic history (e.g. population bottlenecks and founder effects). To 
distinguish these two possibilities, we can look at the FST of other SNPs. 
Demographic events will affect other genomic markers similarly, while local 







Figure 3.1 Schematic representation of allele frequencies in two subdivided 
populations, and how they affect FST. 
 
In this study, FST was used as the parameter to measure genetic differentiation 
for SNP data. However, as FST could not be used for CNV since the allele frequencies 
of multialleleic or complex CNVRs could not be determined accurately, we used a 




3.1.2.2 Screening of Genomic Loci that Showed Selection Signals by HaploPS 
Positive selection can cause the allele frequency of a variant to rise quickly, 
and drags along the frequency of nearby variants before recombination can separate 
the linkage of the neighbouring variants. This could result in an extended haplotype, 
and if this feature reaches fixation, can be detected in a population as a selective 
sweep signature. These signatures can be used to screen the genome for positive 
selection, and have been exploited by a recently published algorithm, HaploPS (Liu et 
al. 2013). 
In this study, we used HaploPS on our SNP dataset generated together with 
the CNV dataset from Affy6.0, as described in Section 2.2.3.3. For a genomic site 
that is under positive selection, the haplotype on which the advantageous allele 
resides tends to be significantly longer than other haplotypes at the same frequency in 
the population when adjusted for the recombination background. HaploPS maps 
genomic regions that are likely to have experienced selection pressure in each 
population. 
HaploPS leverages on two sources of information to discover genomic 
regions that are positively selected. The first source of information is the local SNP 
and compares the length of the longest haplotypes found at different frequencies 
around the same focal site. The second source of information is global and is obtained 
by a comparison of the length of the longest haplotype at a particular frequency to all 
other haplotypes across the genome at the same frequency. Besides providing the 
genomic location that was subjected to selection pressure, HaploPS can also locate 
the haplotype patterns on which the selected alleles reside. The construction of the 
method allows the frequency of a selected allele to be estimated, as well as identifies 






3.2 MATERIALS AND METHODS  
3.2.1 Calculation of Population Differentiation 
SNP-level FST measures genetic differentiation based on allele frequencies in 
2 populations, as a metric of variation within a population in relation to that between 
populations (Suo et al. 2012). 
SNP-level  FST  = (p1-p2)
2
 / (p1+p2)(2-p1-p2) 
where p1 & p2 denote the frequencies of a particular allele in population 1 and 
population 2, respectively. 
The SNP-level FST was calculated for all the 765,758 polymorphic SNPs in 
the dataset derived from Section 2.2.3.3. This provided a genome-wide distribution of 
calculated FST, from which the average, median and various percentiles of FST were 
computed. These values reflected the distribution statistics and could be used to 
determine whether any variant of interest are outliers in the distribution. 
A related parameter to FST, Delta (∆), was used to measure population 
differentiation for CNVs. The same equation as in SNP-level FST was used, except p1 
and p2 now denote the population frequencies of CNVR in population 1 and 
population 2, respectively. The Delta (∆) values were calculated for each of the 2,227 
CNVRs. Many of the highly population-differentiated common CNVRs demonstrated 
high ∆ values, so were the population-specific common CNVRs. The average, 
median and various percentiles of ∆ were computed, and these values were used as 
the null model of neutrality and for comparison against outliers. 
 
3.2.2 Calculation of Selection Loci from HaploPS 
In this study, 2 sources of selection loci were used. First, we used published 
selection loci calculated by a recently published algorithm, HaploPS, using related 
populations from HapMap and SGVP (Liu et al. 2013). Second, we also used 
















DMERI CNV dataset in Affy6.0. The construction and QC of this SNP dataset 
comprising 843,282 SNPs has been described in Section 2.2.3.3. These SNPs were 
phased per chromosome for every sample using BEAGLE version 3.3.2 
(https://faculty.washington.edu/browning/beagle/b3.html) (Browning 2006), before 
calculation of selection loci in HaploPS (Liu et al. 2013). 
 
3.3 RESULTS  
3.3.1 Population Diversity of CNVRs in Three Singapore Populations 
The distribution of CNVs across three Singapore populations has previously 
been described in Section 2.3.3.1 of Chapter 2. There was no difference in the 
number of CNVs discovered per individual across the 3 populations. However, there 
was a significant difference in the ratio of deletion/duplication CNVs in Indians 
compared to Chinese or Malays (Figure 2.8A, Section 2.3.3.1), with Indians 
possessing more duplication CNVs than Chinese or Malays (Table 2.9).  Indians also 
had CNVs of slightly larger sizes than Chinese or Malays (Figure 2.8B). These initial 
indicators from the CNV data suggest Indians are genetically more distant from 
Chinese and Malays, a observation similarly noted when genetic distance between 
these populations were estimated using other genetic markers (refer to prior work 
with mitochondrial & Y-markers, Section 1.5). 






Figure 3.2 Number of CNVRs that are population-specific, shared between 2 
populations and shared across 3 populations.  A) From the full CNVR dataset 


























The dataset of 22,024 CNVs called by Birdsuite was merged by genomic 
location (using ≥50% reciprocal overlap as the criterion), yielding 2,227 CNV 
Regions (CNVRs). CNVR therefore map the cumulative coverage of CNVs. The 
distribution of CNVRs across the 3 populations showed that Indians have the highest 
number of population-specific CNVRs at 26.2%, while Chinese and Malays have a 
rather similar number of population-specific CNVRs at 22.4% and 21.6%, 
respectively) (Figure 3.2A). Similarly, like SNPs, there are more common CNVRs 
between Chinese and Malays (5.7%) as compared to Malays-Indians (4.5%), Chinese 
and Indians had fewest CNVRs in common (2.6%) (Figure 3.2A). 
Of the 2,227 CNVRs, 671 (30.1%) were novel, having ≤ 50% overlap with 
CNVs recorded in DGV. If a stringent criterion of 0% overlap was used, 397 (17.8%) 
would be novel. The distribution of these 671 novel CNVRs across the 3 populations 
is similar to the full dataset of 2,227 CNVRs, except there are a deficit of novel 
CNVRs that are shared across ≥2 populations (Figure 3.2B). About 30% of the 2,227 
CNVRs are shared in ≥2 populations but only 1% of the 671 novel CNVRs were 
shared in ≥2 populations. This is to be expected because CNVRs shared across 
populations are more likely to be common and hence less likely to be novel CNVs.  









Figure 3.3  Distribution of CNVRs by frequency in individual populations or shared 





C M I CM CI MI CMI Total
Total n 498 (22.4%) 482 (21.6%) 584 (26.2%) 126 (5.7%) 58 (2.6%) 101 (4.5%) 378 (17%) 2227 (100%)
Novel (≤50% overlap DGV) 208 (41.8%) 219 (45.4%) 221 (37.8%) 11 (8.7%) 5 (8.6%) 4 (4%) 3 (0.8%) 671 (30.1%)
overlap genes 235 (47.2%) 216 (44.8%) 265 (45.4%) 51 (40.5%) 35 (60.3%) 48 (47.5%) 186 (49.2%) 1036 (46.5%)
overlap OMIM 41 (8.2%) 35 (7.3%) 42 (7.2%) 6 (4.8%) 6 (10.3%) 5 (5%) 25 (6.6%) 160 (7.2%)
overlap SD (≥50%) 69 (13.9%) 65 (13.5%) 71 (12.2%) 35 (27.8%) 29 (50%) 38 (37.6%) 158 (41.8%) 465 (20.9%)
The majority of the population-specific CNVRs are rare in frequency (Figure 
3.3). On the contrary, most of the CNVRs shared across 3 populations are common, 
and those CNVRs shared by 2 populations are more likely to have intermediate 
frequency. 
The attributes of CNVRs in various population groups are summarised (Table 
3.1). There are no significant differences in these attributes between the 3 population-
specific groups (Table 3.1A), but differences exist in certain attributes between the 
population-specific CNVRs and those that are shared across populations (Table 
3.1B). The proportion of novel CNVR is significantly lower while the proportion of 
CNVRs that overlap with segmental duplications (SDs) is significantly higher in 
shared CNVRs. The latter could be attributed to the association of SDs with the 
mutation mechanism NAHR (Non Allelic Homologous Recombination, refer Section 
1.3.1), resulting in recurrent mutations in these genomic regions which render these 
CNVs to be common across populations (Lupski 1998; Sharp et al. 2006a). The 
average size of CNVRs is larger in the population-specific group. On the other hand, 









Table 3.1  Comparison of CNVR attributes in various population groups. ‡ represents 
statistical significant difference in Fisher Exact test with p<0.0001. † represents 
statistical significant difference in Mann-Whitney test with p<0.0001. A) Between 
individual population groups and shared across 2 or 3 populations. B) Between 2 
major groups, population-specific versus shared across ≥2 populations. 
Popn-specific Shared across ≥2 popns p-value
Total n 1564 (70.2%) 663 (29.8%)
Novel (≤50% overlap DGV)‡ 648 (41.4%) 23 (3.5%) <0.0001
overlap genes 716 (45.8% 320 (48.3%) 0.286
overlap OMIM 118 (7.5%) 42 (6.3%) 0.31
overlap SD (≥50%)‡ 205 (13.1%) 260 (39.2%) <0.0001
Average Size (kb)‡ 91.8 84.8 <0.0001
Median size (kb)† 31.7 17.2 <0.0001





CNVR Frequency Chinese Malay Indian
(n=100) (n=95) (n=86)
Rare (≤1%, n=1) 609 (57.5%) 597 (54.9%) 612 (54.6%)
Novel (<50% overlap dgv) 220 (36.1%) 229 (38.4%) 225 (36.8%)
Overlap genes 295 (48.4%) 286 (47.9%) 322 (52.6%)
Overlap OMIM 47 (7.7%) 43 (7.2%) 48 (7.8%)
Overlap SD (>50%) 114 (18.7%) 117 (19.6%) 116 (19%)
Intermediate (1-5%, n=2-4) 182 (17.2%) 227 (20.9%) 227 (20.2%)
Novel (<50% overlap dgv) 7 (3.8%) 8 (3.5%) 8 (3.5%)
Overlap genes 91 (50%) 94 (41.4%) 91 (40.1%)
Overlap OMIM 15 (8.2%) 12 (5.3%) 14 (6.2%)
Overlap SD (>50%) 85 (46.7%) 86 (37.9%) 87 (38.3%)
Common (≥5% or n≥5) 269 (25.4%) 263 (24.2%) 282 (25.2%)
Novel (<50% overlap dgv) 0 (0%) 0 (0%) 0 (0%)
Overlap genes 121 (45%) 121 (46%) 121 (42.9%)
Overlap OMIM 16 (5.9%) 16 (6.1%) 16 (5.7%)
Overlap SD (>50%) 92 (34.2%) 93 (35.4%) 93 (33%)
CNVR Frequency
Population Rare Intermediate Common Total
(≤1% or n=1) (1-5% or n=2-4) (≥5% or n≥5)
Chinese (n=100) 609 (57.5%) 182 (17.2%) 269 (25.4%) 1060 (100%)
Malay (n=95) 597 (54.9%) 227 (20.9%) 263 (24.2%) 1087 (100%)
Indian (n=86) 612 (54.6%) 227 (20.2%) 282 (25.2%) 1121 (100%)
(≤1% or n≤3) (1-5% or n=4-14) (≥5% or n≥15)
Total (n=281) 1703 (76.5%) 257 (11.5%) 267 (12%) 2227 (100%)
 
We also examined CNVR on a per population basis. In every population, rare 
CNVR dominate. There is no significant difference in the distribution of CNVR 
frequency classes between the 3 populations (Table 3.2, Fisher Exact test, p=1.0). 
Table 3.3 summarises the attributes of CNVRs in various frequency classes of each 
population. There is no significant difference in each CNVR attribute when compared 

















Table 3.3  The attributes of CNVRs within each frequency class for every population. 
 
3.3.2 CNVRs with High Population Differentiation 
CNVRs that differ greatly in frequency between populations are candidate 
variants for population-specific natural selection, and could provide new insight into 
recent human evolutionary history. Since population differentiation could be caused 
by genetic drift or by natural selection pressure, we wished to investigate if any 




Total Number of CNVR 2,227 (100%)
Number of Singleton (n=1) 1,305 (58.6%)
Number of CNVR (n≥2) 922 (41.4%)
Number of CNP (≥ 1% or n≥3) 652 (29.3%)
Number of Common CNVR (≥5% or n≥15) 267 (12.0%)
Population Groups C-specific M-specific I-specific Total
Total (n) 498 482 584 1,564
Population-specific, singleton, n=1 436 406 463 1,305
Population-specific, n≥2 62 76 121 259
Population-specific, common, n≥5 8 3 21 32
differentiation. Two methods were used in defining CNVRs that are highly 
population-differentiated; 
(1) Population-specific common CNVRs - occurring in one population 
only and with a population frequency ≥5%, or n≥5 in one population, and 
(2) Highly population-differentiated common CNVRs – top percentile of 
Delta value and ≥5%, or n≥15 across 3 populations 
 
3.3.2.1 Population-specific Common CNVRs 
Although 70% (1,564) of the 2,227 CNVRs are population-specific, many of 
them are singleton (1305) (Table 3.4). Such individually occurring CNVR may not be 
truly population-specific, if sample sizes were increased. The number of population-
specific, yet common (frequency ≥ 5%, or n ≥ 5 per population) were few, totalling 







Table 3.4  Distribution of population-specific CNVRs in the 3 Singapore populations. 
Abbreviations; C – Chinese, M – Malays, I – Indians. 
 
As the power to establish population-specificity is dependent on sample size, 
we also used a second Singapore database, SgD. SgD is a collection of CNV data 
gathered from the microarray results of several Singapore GWAS studies using 
various Illumina arrays (Xu et al. 2011). Its combined sample size comprised 1,917 
Chinese, 2,399 Malays, and 2,217 Indians. 
CNVs were firstly analysed within each of the 2 datasets (DMERI and SgD). 




Population C M I C M I
Sample size (n) 100 95 86 1,917 2,399 2,217
Total CNV call 7,785 7,436 6,803 30,520 34,101 35,591
Popn-Specific CNVa 562 510 769 3,567 2,775 2,776
Overlap with 2nd datasetsb 86 89 130 181 124 265
Popn-specific CNVRc 77 74 76 137 96 123
a Population-specific within own dataset
b CNV containing ≥ 50% overlap when merged with 2nd dataset
c Population-specific CNV merged into CNVR
populations. Any CNV from population 1 was removed if it had > 50% overlap with 
CNVs from any of the other 2 populations. This produced a set of population-specific 
CNVs from each of the 2 datasets, with >500 CNVs per population from the DMERI 
dataset and >2,700 CNVs per population from the SgD set (Table 3.5). The 
population-specific DMERI CNV set (totalling 1,864) was overlapped with the 
population-specific SgD set (totalling 9,118). Any DMERI CNV with an overlap of 
≥50% to SgD’s was considered replicated, thereby adding support for that particular 
CNV to be considered population-specific. Using this approach, the number of 
population-specific CNVs in the DMERI dataset that could obtain support from the 
corresponding SgD dataset were 86 CNVs in Chinese, 89 in Malays, and 130 in 
Indians. These CNVs were further merged to form population-specific CNVRs, 
comprising 77 CNVRs in Chinese, 74 in Malays and 76 in Indians (Table 3.5). Most 




Table 3.5  Number of population-specific CNVs within DMERI or SgD datasets. 
Also included are the final numbers of population-specific CNVs in each dataset that 
overlap ≥ 50% with at least one CNV from the 2nd dataset. 
 
In the group of 32 population-specific common CNVRs determined from the 
DMERI dataset (Table 3.4), only 5 found supporting evidences from SgD data (Table 
3.6). These 5 CNVRs are Cluster IDs 1273 (Malay-specific), and 286, 420, 1357, and 
1726 (the latter 4 are all Indian-specific). This paucity of replication between the 2 
datasets suggests that very few common CNVRs are limited to one population. 
Whether the remaining 27 non-validated CNVRs have overlapping counterparts in 
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SgD that are in multiple populations could not be ascertained as we only have data for 
population-specific CNVRs from the SgD.  Nevertheless, the paucity of replicates 
between the 2 datasets could also mean the false positive rate of the population-
specific CNVRs could be high due to small sample set. Increasing the sample size 
might find additional CNVRs in the same locus in other populations. This observation 
of few population-specific yet common CNVRs is also similar as in SNP, that 
common SNPs are generally shared across populations, while low-frequency SNPs 
show substantial geographical differentiation (Abecasis et al. 2012). 
The characteristics of these 32 population-specific common CNVRs are 
summarised in Table 3.6. Many of them have been reported in DGV since they are 
common CNVRs. Only 3 are novel with 0% overlap to DGV, one is Malay-specific 
and 2 Indian-specific (Clusters 1273, 390, 883). All these 3 novel CNVRs were 
validated by qPCR. QPCR also showed that CNVR cluster 390 could be found in one 
additional Chinese and Malay sample, rendering it no longer Indian-specific (Table 
3.6). Although 29 of these 32 have been reported in DGV, 12 of them are not found 
in SGVP (Table 3.6), reaffirming the value of this DMERI dataset as additional 
information to the growing CNV map for Asian populations. 
A total of 30 of these 32 population-specific CNVRs had been further 
validated by qPCR. Twenty nine were confirmed to be true positives, while one 
(cluster 286) was confirmed to be a false positive after 2 qPCR assays. The qPCR 
validation work on this group of population-specific common CNVRs has confirmed 
the strategy of adopting the full Birdsuite CNV set was appropriate. If the stringent 
CNVR set had been adopted, 14 of the CNVRs would be excluded from this list, 
either due to CNVs (5) not been called by a second algorithm, or due to false 
negatives at the sample level resulting in lower frequency for that particular CNVR 
(9) hence excluding it from the common category (Table 3.6, Clusters with † or *). 
The qPCR validation also demonstrated the existence of false negatives in microarray 
analysis at the individual sample level. 
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Twelve of the 31 true positive CNVRs overlapped genes or transcripts. Five 
are non-coding RNAs of unknown function, and 6 CNVRs overlap within introns, 
hence with no evidence of any effect on protein coding. There is one CNVR (Indian-
specific Cluster 732) that fully overlaps with 2 genes, TLC3 & CYP4V2. Both genes 
are involved in cellular responses to external stimulus. TLC3 is a member of Toll-like 
receptor family which plays a fundamental role in pathogen recognition and 
activation of innate immunity. It is thought to play a role in host defence against 
viruses. CYP4V2 encodes a member of the cytochrome P450 protein superfamily 
which is involved in oxidizing various substrates in the metabolic pathway. It is 
implicated in the metabolism of fatty acid precursors into n-3 polyunsaturated fatty 
acids. Cluster 732 is a duplication CNV, suggesting the possibility that increased 
gene dosage could result in functional changes in immunological and metabolic 
pathways. 
Six CNVRs overlap introns of various genes, some with interesting functions 
(Table 3.6, genes with §). These intronic CNVRs may have a functional effect via 
regulatory elements. For example, CACNA1C is a calcium ion channel gene 
implicated for cardiac arrhythmias. ERBB4 is a receptor tyrosine kinase that is a 
member of the epidermal growth factor receptor subfamily. It has been implicated in 
cancer and is related to ERBB2 or HER2, a target gene for breast cancer treatment. C6 
is Complement component 6 and has a role in immunity. LRP1B belongs to the low 
density lipoprotein (LDL) receptor gene family. A summary of the gene functions for 










































Delta M_I Delta C_I
111 1 696,962 840,550 143.6 Dup LOC643837,FAM41C,
LOC100288069,NCR
NA00115
- 87 100 100 7 0 0 22 4 3 92.1% 0.036 - 0.036
249
†
1 243,505,830 243,509,160 3.3 Complex KIF26B
§
- - 100 - 5 0 0 5 1 0 98.9% 0.026 - 0.026
355† 2 95,094,701 95,099,193 4.5 Del - - - 100 - 5 0 0 11 0 0 97.8% C 0.026 - 0.026
392* 2 141,971,752 141,973,472 1.7 Del LRP1B § - - 100 - 5 0 0 6 0 0 99.6% C 0.026 - 0.026
789 5 41,267,255 41,277,150 9.9 Del C6 § C6§ - 100 100 7 0 0 7 0 0 100.0% C 0.036 - 0.036
1624* 12 79,349,306 79,352,244 2.9 Del - - - 100 - 5 0 0 7 0 0 99.2% C 0.026 - 0.026
1834 15 45,992,538 46,001,995 9.5 Del - - - 80 60 18 0 0 18 0 0 100.0% C 0.099 - 0.099
1925* 16 58,640,103 58,654,487 14.4 Del - - - 100 56 10 0 0 10 0 0 100.0% C 0.053 - 0.053
1273 9 27,220,509 27,242,785 22.3 Del NCRNA00032 - - - 90 0 5 0 0 6 0 99.6% M 0.027 0.027 -
1540 11 133,857,095 133,977,420 120.3 Del LOC283177 - - 100 97 0 7 0 0 7 0 100.0% M 0.038 0.038 -
1899* 16 22,612,023 22,694,640 82.6 Dup - - - 89 89 0 8 0 0 7 0 99.3% M 0.044 0.044 -
286† 2 40,617,671 40,622,406 4.7 Dup - - - 100 - 0 0 7 0 0 0 no CNV no CNV - 0.042 0.042
390 2 137,761,562 137,782,241 20.7 Del THSD7B
§
- - - 100 0 0 9 1 1 10 98.9% - 0.055 0.055
420 2 212,889,560 212,900,070 10.5 Del ERBB4 § - - 100 41 0 0 8 0 0 8 100.0% I - 0.049 0.049




- 97 - 0 0 5 0 0 5 100.0% I - 0.030 0.030
762 5 9,954,952 9,982,909 28.0 Del LOC285692 - - 100 100 0 0 9 0 0 9 99.6% I - 0.055 0.055
840* 5 155,407,677 155,415,307 7.6 Del - - - 100 64 0 0 11 1 0 14 98.5% - 0.068 0.068
883 6 40,174,188 40,211,285 37.1 Del - - - - 82 0 0 5 0 0 5 100.0% I - 0.030 0.030
890† 6 58,534,011 58,535,028 1.0 Complex - - 100 100 - 0 0 7 - - 0.042 0.042
984 7 8,792,410 8,832,522 40.1 Del - - - 100 71 0 0 7 0 0 7 100.0% I - 0.042 0.042
1016 7 53,433,670 53,563,109 129.4 Del - - - 96 96 0 0 5 0 0 5 100.0% I - 0.030 0.030
1357* 10 27,265,910 27,268,479 2.6 Dup NCRNA00202 - 100 100 - 0 0 9 4 3 15 94.6% - 0.055 0.055
1385 10 58,186,381 58,196,843 10.5 Del - - - 100 100 0 0 7 0 0 7 100.0% I - 0.042 0.042
1391* 10 61,034,136 61,035,270 1.1 Del - - - 100 100 0 0 11 - - 0.068 0.068
1411* 10 82,871,310 82,879,763 8.5 Complex - - - 100 78 0 0 7 0 0 6 99.3% I - 0.042 0.042
1547 12 2,105,889 2,128,667 22.8 Del CACNA1C § CACNA1C§ - 100 52 0 0 6 0 0 6 100.0% I - 0.036 0.036
1650 13 22,185,775 22,192,245 6.5 Del - - - 100 - 0 0 5 0 0 6 99.6% I - 0.030 0.030
1726 14 27,536,375 27,591,214 54.8 Del - - - 96 96 0 0 6 0 0 6 100.0% I - 0.036 0.036
1854 15 95,618,796 95,633,191 14.4 Del - - - 100 100 0 0 9 0 0 17 96.8% I - 0.055 0.055
2064 19 21,179,648 21,191,982 12.3 Del - - - 67 19 0 0 5 1 0 7 98.9% - 0.030 0.030
2194* 22 17,006,129 17,009,153 3.0 Del - - - 100 - 0 0 8 0 0 8 99.6% I - 0.049 0.049
2201† 22 21,048,635 21,082,880 34.2 Complex - - - 100 76 0 0 5 0 1 11 97.4% - 0.030 0.030
† CNVR not found in Stringent set. * CNVR is population-specific in Stringent set, but did not reach population frequency ≥ 5%, hence cannot be termed as common CNVR in stringent set. § CNVR locates in intron of gene.
Abbreviations: SD overlap (%), % of CNVR overlap to Segmental Duplication. DGV overlap (%), % of CNVR overlap to CNV reported in DGV. % overlap SGVP, % of DMERI CNVR overlapping to SGVP CNVR.
CNVR cluster ID highlighted in red font, population-specific in both DMERI & Sg-D datasets. 











Table 3.6  Population-specific common CNVRs in three Singapore populations. 
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 C_M  M_I C_I  C_M  M_I C_I
Average 0.007 0.012 0.013 0.007 0.025 0.033
Std Dev 0.008 0.022 0.027 0.011 0.034 0.044
Min 2.862E-07 2.176E-08 2.08E-07 0.000 0.000 0.000
Max 0.099 0.414 0.504 0.210 0.529 0.711
10th percentile 0.001 0.002 0.003 0.000 0.000 0.001
25
th
 percentile 0.005 0.005 0.005 0.001 0.003 0.004
Median 0.005 0.006 0.006 0.003 0.012 0.016
75
th
 percentile 0.005 0.011 0.010 0.010 0.034 0.045
90th percentile 0.012 0.023 0.024 0.020 0.068 0.088
95
th
 percentile 0.020 0.042 0.053 0.028 0.094 0.122
99th percentile 0.040 0.100 0.132 0.050 0.158 0.205
99.5
th
 percentile 0.053 0.140 0.167 0.059 0.187 0.242
99.9th percentile 0.077 0.216 0.285 0.081 0.255 0.324
99.99
th
 percentile 0.095 0.382 0.491 0.127 0.365 0.458
Total no. 1,643 1,729 1,745 765,758 765,758 765,758
Delta (∆) of CNVR FST of SNP
3.3.2.2 Highly Differentiated CNVRs  
Next, we studied the CNVRs that showed high differentiation in population 
frequencies. The Wright Fixation index, FST, is often used as the parameter to 
quantify population differentiation for SNPs where allelic frequencies are known. A 
parameter similar to FST, Delta (∆), was used for CNVR genotype frequencies in each 
of the 3 population-pairs; Chinese-Malay, Malay-Indian, and Chinese-Indian. The 
genome-wide distribution of delta-values provided information to assess neutrality 
and permits the identification of extremely differentiated CNVR candidates.  
The distribution of delta-values in CNVR dataset generally mirrored the FST 
obtained from the SNP dataset (Table 3.7). Both FST and ∆ are highly skewed toward 
smaller values. The skewness is more extreme in CNVRs compared to SNPs. This is 
because ~59% of the CNVRs are singletons, and many are of lower frequencies.  
With this high number of singletons, many CNVRs do not produce meaningful delta-
values for some population-pairs. Therefore, the non-informative CNVRs were 
excluded from delta calculation for specific population-pairs (Table 3.7). As in SNP, 
CNVRs similarly showed that the genetic distance between Chinese and Malays is 
the smallest, followed by Malay-Indian, and the largest genetic distance is found 





Table 3.7  A genome-wide distribution of delta-values for CNVRs in each 
population-pairs. The genome-wide distribution of FST for SNP is provided for 




The CNVRs were ranked by their delta-values, and CNVRs in the top 1 
percentile of each population-pair are listed in Table 3.8A, B & C. Four of 
population-specific common CNVRs (Table 3.6) also have high delta-values (Table 
3.8) as well. Some of these high population-differentiated CNVRs overlapped genes, 
and the known functions of these genes have been summarised in Appendix 4. 
The CNVR with the highest delta-value in both the Malay-Indian and 
Chinese-Indian population-pairs was validated by qPCR (Cluster 1993, Table 3.8B & 
C, Figure 3.4). This CNVR is mostly duplicated and is highly enriched in Indians. 
This region at 17q21.31 overlapping the KANSL1 gene (aka KIAA1267) has been 
reported to be more common in populations of European origins but is almost non-
existent or very low frequency in other populations (Sudmant et al. 2010). This 
corroborates with our data, and Singaporean Indians are known to be genetically 
related to European (Teo et al. 2009). 
KANSL1 (KAT8 Regulatory NSL complex, Subunit 1) gene encodes a 
nuclear protein that plays a role in chromatin modification. It is a member of a 
histone acetyltransferase (HAT) complex. Truncating mutations in the KANSL1 has 
been shown to present phenotypes similar to classic features of chromosome 
17q21.31 deletion which includes developmental disorder and intellectual disability. 
These findings indicated that haploinsufficiency of KANSL1 is sufficient to cause the 
classic 17q21.31 microdeletion syndrome phenotype, and provided evidence that the 
histone acetyltransferase complex may have a role in human cognitive function and 

























I (n=86) Delta 
C_M
Delta M_I Delta C_I qPCR 
Concorda
nce 
C_M 1834 15 45,992,538 46,001,995 9.5 Del - - - 80 0 0 18 0 0 0.099 0.000 0.099 100.0%
287 2 40,779,595 40,803,110 23.5 Del - - - 100 0 0 1 16 2 0.077 0.061 0.003 98.9%
393 2 146,580,874 146,583,404 2.5 Del - - - 100 0 0 46 19 11 0.076 0.009 0.133 74.5%
1837 15 54,577,995 54,588,269 10.3 Complex - - - 100 0 0 21 4 4 0.064 0.000 0.060 -
1754 14 73,070,876 73,090,732 19.9 Complex HEATR4,ACOT1 - 97 100 2 1 74 47 8 0.064 0.194 0.431 83.5%
1047 7 90,867,404 90,878,663 11.3 Complex - - - 100 0 0 30 10 1 0.059 0.040 0.158 -
1488 11 58,566,573 58,615,474 48.9 Complex LOC283194 - 99 100 1 1 30 10 12 0.059 0.003 0.038 93.5%
2027 18 36,512,703 36,523,810 11.1 Complex - - - 72 0 0 45 65 66 0.056 0.009 0.106 93.9%
1563 12 11,111,991 11,143,141 31.2 Del TAS2R43,PRH1-PRR4 - 95 100 2 1 1 12 2 0.053 0.038 0.003 -
1925 16 58,640,103 58,654,487 14.4 Del - - - 100 0 0 10 0 0 0.053 0.000 0.053 100.0%
192 1 147,291,426 147,606,824 315.4 Complex LOC388692 - 99 100 1 1 17 35 24 0.050 0.009 0.017 -
214 1 173,062,498 173,069,074 6.6 Del RABGAP1L - - 91 1 0 37 17 17 0.046 0.001 0.037 96.0%
231 1 197,378,049 197,380,463 2.4 Del - - - 100 0 0 0 8 13 0.044 0.011 0.082 -
1899 16 22,612,023 22,694,640 82.6 Dup - - - 89 0 0 0 8 0 0.044 0.044 0.000 99.3%
362 2 97,507,179 97,528,142 21.0 Complex ANKRD36B - 100 100 1 1 15 3 5 0.042 0.004 0.023 -
234 1 213,560,092 213,565,727 5.6 Del - - - 100 0 0 25 9 3 0.042 0.015 0.095 -
1707 14 19,170,042 19,505,226 335.2 Dup OR4K5,OR4K1,OR4K2,OR4Q3,O
R11H2,OR4M1,OR4N2
- 76 100 7 7 58 73 48 0.040 0.049 0.000 -
682 4 122,501,918 122,504,766 2.8 Del QRFPR - - 100 1 0 23 8 10 0.040 0.003 0.023 -
1088 7 143,504,310 143,697,880 193.6 Complex OR2A20P,ARHGEF35,OR2A42,O
R2A9P,ARHGEF5,CTAGE4,LOC72
8377,OR2A1,OR2A7
- 98 100 9 9 10 1 6 0.038 0.023 0.003 -
1540 11 133,857,095 133,977,420 120.3 Del LOC283177 - - 100 1 1 0 7 0 0.038 0.038 0.000 100.0%
M_I 1993 17 41,517,686 41,750,195 232.5 Dup LOC644246,LRRC37A,KIAA1267,
ARL17B
- 52 100 4 4 1 6 59 0.020 0.414 0.504 77.7%
226 1 194,994,473 195,083,353 88.9 Complex CFHR3,CFHR1 CFHR3,CF
HR1
97 100 2 2 11 11 49 0.000 0.229 0.236 98.6%,95.
7%
894 6 66,456,203 66,463,931 7.7 Complex EYS EYS - 100 1 0 62 58 14 0.000 0.211 0.219 failed
2078 19 48,388,815 48,460,022 71.2 Del PSG4,LOC284344,PSG9 - 91 100 3 3 51 52 11 0.001 0.197 0.168 97.5%
1754 14 73,070,876 73,090,732 19.9 Complex HEATR4,ACOT1 - 97 100 2 1 74 47 8 0.064 0.194 0.431 83.5%
1847 15 82,331,742 82,334,554 2.8 Complex ADAMTSL3 - - 100 1 0 48 47 8 0.000 0.194 0.183 -
547 3 163,989,224 164,127,661 138.4 Del - - - 100 0 0 98 93 58 0.000 0.162 0.163 100.0%
607 4 32,122,898 32,126,696 3.8 Complex - - - 100 0 0 80 71 32 0.004 0.143 0.189 -
283 2 36,189,099 36,193,058 4.0 Complex - - - 100 0 0 20 26 1 0.008 0.140 0.094 -
545 3 163,699,323 163,709,653 10.3 Del - - - 100 0 0 32 26 1 0.003 0.140 0.172 failed
236 1 221,083,948 221,090,227 6.3 Del DISP1 - - 100 1 0 6 0 21 0.031 0.139 0.066 failed
565 3 194,356,185 194,365,597 9.4 Del - - 2 100 0 0 12 12 39 0.000 0.130 0.136 -
1220 8 135,130,437 135,135,890 5.5 Del - - - 100 0 0 15 26 2 0.023 0.124 0.051 -
788 5 38,180,803 38,184,645 3.8 Complex - - - 100 0 0 25 32 5 0.009 0.123 0.071 -
1991 17 41,006,741 41,015,665 8.9 Complex - - 100 100 0 0 37 25 2 0.013 0.117 0.190 2.5%
1992 17 41,750,187 42,144,468 394.3 Complex NSF,ARL17B,NSFP1,LRRC37A2,L
RRC37A,ARL17A
- 99 100 6 6 28 30 55 0.002 0.105 0.130 failed
912 6 79,012,575 79,098,528 86.0 Del - - - 100 0 0 7 6 27 0.000 0.103 0.096 -
467 3 6,626,128 6,628,332 2.2 Del - - - 100 0 0 0 1 18 0.005 0.101 0.117 -
179 1 111,178,889 111,189,749 10.9 Complex - - - 100 0 0 3 4 23 0.001 0.097 0.111 -




































I (n=86) Delta 
C_M
Delta M_I Delta C_I qPCR 
Concorda
nce 
C_I 1993 17 41,517,686 41,750,195 232.5 Dup LOC644246,LRRC37A,KIAA1267,
ARL17B
- 52 100 4 4 1 6 59 0.020 0.414 0.504 77.7%
1754 14 73,070,876 73,090,732 19.9 Complex HEATR4,ACOT1 - 97 100 2 1 74 47 8 0.064 0.194 0.431 83.5%
226 1 194,994,473 195,083,353 88.9 Complex CFHR3,CFHR1 CFHR3,CF
HR1
97 100 2 2 11 11 49 0.000 0.229 0.236 98.6%,95.
7%
894 6 66,456,203 66,463,931 7.7 Complex EYS EYS - 100 1 0 62 58 14 0.000 0.211 0.219 failed
1991 17 41,006,741 41,015,665 8.9 Complex - - 100 100 0 0 37 25 2 0.013 0.117 0.190 2.5%
607 4 32,122,898 32,126,696 3.8 Complex - - - 100 0 0 80 71 32 0.004 0.143 0.189 -
1847 15 82,331,742 82,334,554 2.8 Complex ADAMTSL3 - - 100 1 0 48 47 8 0.000 0.194 0.183 -
545 3 163,699,323 163,709,653 10.3 Del - - - 100 0 0 32 26 1 0.003 0.140 0.172 failed
2078 19 48,388,815 48,460,022 71.2 Del PSG4,LOC284344,PSG9 - 91 100 3 3 51 52 11 0.001 0.197 0.168 97.5%
1031 7 66,266,764 66,282,667 15.9 Complex TYW1 - 100 100 1 0 9 21 39 0.033 0.060 0.167 -
547 3 163,989,224 164,127,661 138.4 Del - - - 100 0 0 98 93 58 0.000 0.162 0.163 100.0%
1047 7 90,867,404 90,878,663 11.3 Complex - - - 100 0 0 30 10 1 0.059 0.040 0.158 -
295 2 49,389,272 49,394,694 5.4 Complex - - - 100 0 0 38 26 5 0.013 0.084 0.151 -
908 6 77,492,878 77,509,523 16.6 Complex - - - 100 0 0 4 13 28 0.029 0.050 0.136 -
565 3 194,356,185 194,365,597 9.4 Del - - 2 100 0 0 12 12 39 0.000 0.130 0.136 -
393 2 146,580,874 146,583,404 2.5 Del - - - 100 0 0 46 19 11 0.076 0.009 0.133 74.5%
182 1 112,497,197 112,498,913 1.7 Del - - - 100 0 0 45 53 69 0.012 0.069 0.133 -
1501 11 81,189,919 81,194,913 5.0 Del - - - 100 0 0 5 8 29 0.005 0.096 0.132 -
1964 17 14,975,566 14,995,227 19.7 Complex - - - 100 0 0 33 23 4 0.009 0.077 0.131 -
1086 7 143,341,029 143,342,084 1.1 Del - - - 100 0 0 37 26 6 0.011 0.073 0.131 -
1992 17 41,750,187 42,144,468 394.3 Complex NSF,ARL17B,NSFP1,LRRC37A2,L
RRC37A,ARL17A
- 99 100 6 6 28 30 55 0.002 0.105 0.130 failed











Table 3.8  The first 20 highly differentiated CNVRs between population-pairs. Rank from the highest delta-value. Delta-values of the top 1 percentile are 
highlighted in red. Delta values of the 99
th
 percentile are 0.040, 0.100, and 0.132 for Chinese-Malays, Malays-Indians, and Chinese-Indians, respectively. The 
number of samples called in each population was from microarray data. The concordance rate between microarray and qPCR is listed in the last column. – 
means qPCR not done. Cluster ID in red font are population-specific common CNVRs, which has been listed in Table 3.6. A) Top 20 most differentiated 











Chr Start End Size (kb) No. of 
genes
Genes Platform Chinese (n=99) Malays (n=94) Indians (n=85) qPCR 
Concordan
ce
CN0 CN1 CN2 CN3 CN4 CN0 CN1 CN2 CN3 CN4 CN0 CN1 CN2 CN3 CN4 CN5 CN6 CN7
1993 17 41,517,686 41,750,195 232.5 4 KANSL1 Microarray 0 0 99 0 0 0 0 89 5 0 0 0 28 27 30 0 0 0
qPCR 0 1 98 0 0 0 0 87 3 4 0 0 10 24 21 25 4 1 77.7%
 
Figure 3.4  Schematic representation of 2 CNVRs, 
Clusters 1992 and 1993, in UCSC Genome 
Browser. Cluster 1993 encompasses the gene 
KANSL1 (aka KIAA1267) and Cluster 1992 
contains the gene NSF. Middle panel lists 
Reference genes while lower panel shows the 
CNVs recorded in DGV. The diploid copy 
number for Cluster 1993 called by microarray and 













In addition, a neighbouring CNVR (Cluster 1992) overlapping the NSF gene 
(N-Ethylmaleimide-Sensitive Factor 1) is also highly differentiated in Malay-Indian 
and Chinese-Indian in our data (Figure 3.4). This locus has also been reported to have 
increased copy number in Asians (Sudmant et al. 2010). We attempted to validate this 
by qPCR but unfortunately the assay targeting NSF failed. NSF is known to be 
preferentially expressed in the human nervous system, and reduction in its expression 
is associated with schizophrenia (Mirnics et al. 2000), and disruptions of its 
Drosophila ortholog lead to defective synaptic transmission (Pallanck et al. 1995). 
As a whole, the genomic region at 17q21.31 that encompass Clusters 1992 
and 1993 is complex and has been associated with positive selection, rapid 
evolutionary turnover, and neurological diseases (Sudmant et al. 2010). The structural 
haplotypes in the human 17q21.31 region and their recent evolution has recently been 
reported for the European population (Boettger et al. 2012). 
The CNVR with the highest delta between Chinese-Malays is Cluster 1834 
on chromosome 15q21.1 (Table 3.8A). It is also a Chinese-specific common CNVR 
(Table 3.6) and showed a heterozygous deletion in 18% of the Chinese samples. The 
copy number call per sample obtained from microarray was in 100% concordance 
with qPCR. There is no gene in this region, and the nearest genes are about 200kb 
away, SEMA6D and SLC24A5. Other CNVRs that are highly differentiated between 
Chinese and Malays contained genes such as bitter taste receptor TAS2R43 and 
olfactory receptor gene family members OR4K5, OR2A20P etc (Table 3.8A). The 
bitter taste receptor family cluster has been reported to be highly enriched in non-
Africans compared to Africans (Campbell et al. 2011). The identification of taste 
receptor and olfactory receptor genes in these highly differentiated CNVRs between 
Chinese and Malays who are genetically close suggested a cultural or diet selection. 
This also parallels the gene ontology analysis that CNVs are enriched with genes 
involved in external communication and environmental adaptation (Section 2.3.3.4). 
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There was also an interesting CNVR that showed high differentiation 
between all 3 populations, demonstrating high delta-values for all 3 population-pairs 
comparison. Cluster 1754, a 20kb CNV on chromosome 14q24.3, is located in an 
intron of the gene HEATR4 but overlapped the entire gene ACOT1 (Figure 3.5). The 
frequency of homozygous deletion is 74% in Chinese, 47% in Malays, and 9% in 
Indians, and was validated by qPCR. ACOT1 encodes Acyl-CoA thioesterases 1, a 
member of the protein family Acyl-CoA thioesterases. They are a group of enzymes 
that catalyze the hydrolysis of acyl-CoAs to the free fatty acid and coenzyme A 
(CoASH), providing the potential to regulate intracellular levels of acyl-CoAs, free 
fatty acids and CoASH. The maintenance of cellular levels of free fatty acids and 
acyl-CoAs, the activated form of free fatty acids, is important, as imbalances in lipid 
metabolism have serious consequences for human health. There are 4 ACOT family 
gene members in the cluster of 14q24.3, ACOT1, ACOT2, ACOT4 and ACOT6, 
which suggests functional redundancy would explain the tolerance of homozygous 
deletion of ACOT1 with high frequency in Chinese. ACOT1 and ACOT2 have been 
reported to have similar substrate specificities (Hunt et al. 2006).  
Another high ranking CNVR between Chinese-Indian and Malay-Indian is 
Cluster 226 located on chromosome 1q31.3, a 89kb deletion encompassing both 
CFHR3 and CFHR1 (Complement Factor H-related 3, and 1, respectively). The 
heterozygous deletion is enriched in Indians with 52%, and about 10% in Malays and 
Chinese (Figure 3.6). The population frequencies obtained from microarray and 
qPCR for this locus were in good concordance. Both CFHR3 and CFHR1 encode 
secreted proteins belonging to the complement factor H protein family. They may be 
involved in complement regulation. Mutations in this gene are associated with 
decreased risk of age-related macular degeneration, and with an increased risk of 
atypical hemolytic-uremic syndrome (Hughes et al. 2006; Zipfel et al. 2007). 
Interestingly, an adjacent CNVR, cluster 228, overlaps CFHR4 and is more common 
in Chinese compared to Malays or Indians (Figure 3.6). 
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 #1754  Hs03873630_cn, position 73, 072, 554
 
Figure 3.5  Schematic representation of a 
CNVR, Cluster 1754, in UCSC Genome 
Browser. Cluster 1754 is located in an 
intron of HEATR4 and encompasses the 
whole gene of ACOT1. QPCR validation 
result is shown. Middle panel lists 
Reference genes while lower panel shows 













Chr Start End Size (kb) Genes Platform Chinese (n=99) Malays (n=94) Indians (n=85) qPCR 
Concordan
ceCN0 CN1 CN2 CN3 CN4 CN0 CN1 CN2 CN3 CN4 CN0 CN1 CN2 CN3 CN4
1754 14 73,070,876 73,090,732 19.9 ACOT1, Microarray 73 26 0 0 0 45 48 1 0 0 7 77 0 1 0




#226 Hs04197581_cn  position 195,065,926 CFHR1
#228  Hs03350272_cn  position 195,146,779 CFHR4
#226 Hs04206213_cn  position 195,024,436 CFHR3
#Cluster_ID Chr Start End Size (kb) Genes Platform Chinese (n=99) Malays (n=94) Indians (n=85) qPCR 
Concordanc
eCN0 CN1 CN2 CN3 CN4 CN5 CN0 CN1 CN2 CN3 CN4 CN0 CN1 CN2 CN3 CN4
226 1 194,994,473 195,083,353 88.9 Microarray 0 10 89 0 0 0 2 7 83 2 0 6 42 37 0 0
CFHR3 qPCR 1 9 88 0 0 1 2 7 84 1 0 6 43 36 0 0 98.6%
CFHR1 qPCR 0 15 82 2 0 0 2 9 82 1 0 6 44 35 0 0 95.7%
228 1 195,023,645 195,183,422 159.8 CFHR4 Microarray 0 5 92 1 1 0 2 91 0 0 0 2 81 1 0







Figure 3.6  Schematic representation of 2 
CNVRs, Clusters 226 and 228, in UCSC 
Genome Browser. Cluster 226 encompasses 
the genes CFHR3 & CFHR1 and Cluster 
1992 contains the gene CFHR4. QPCR 
validation results for both clusters are 
shown. Middle panel lists Reference genes 
while lower panel shows the CNVs 


















162 CNP76 1 103,960,908 104,069,745 108,837 Complex AMY1, AMY2A 0.01 0.05 0.05
177 CNP88 1 110,025,907 110,058,147 32,240 Del GSTM1,GSTM2 0.30 0.27 0.58
208 CNP118 1 159,778,034 159,906,183 128,149 Dup FCGR3B 0.89 0.77 0.83
226 CNP147 1 194,994,473 195,083,353 88,880 Complex (mostly Del) CFHR3,CFHR1 0.11 0.12 0.57
420 CNP340 2 212,889,560 212,900,070 10,510 Del ERBB4 0.00 0.00 0.09
562 CNP530 3 190,842,972 190,847,332 4,360 Del TP63 0.01 0.00 0.00
839 CNP603 4 69,021,057 69,234,339 213,282 Del UGT2B17 0.99 0.94 0.81
1133 CNP1244 8 7,237,790 7,836,261 598,471 Dup Beta-defensins 0.09 0.09 0.16
1847 CNP2118 15 82,331,742 82,334,554 2,812 Complex (mostly Del) ADAMTSL3 0.48 0.49 0.09
1938 CNP2203 16 76,929,941 76,942,266 12,325 Complex (mostly Del) WWOX 0.01 0.00 0.12
1979 CNP2252 17 31,459,625 31,509,204 49,579 Dup CCL3L1 0.29 0.22 0.22
2076 CNP2415 19 46,040,709 46,072,786 32,077 Complex (mostly Del) CYP2A6 0.19 0.24 0.06
2204 CNP2560 22 22,670,786 22,734,830 64,044 Complex (mostly Del) GSTT1 0.45 0.38 0.26
2216 CNP2576 22 37,693,565 37,705,253 11,688 Del APOBEC3 0.58 0.59 0.31
Other CNVs known to show global population differentiation and 
overlapping genes associated to diseases or traits were also found in our list of highly 
differentiated CNVRs. Those within the top 10 percentile of this dataset in at least 
one population-pair comparison included: CFHR3, CFHR1 (age-related macular 
degeneration) (Hughes et al. 2006), FCGR3B (renal disease) (Fanciulli et al. 2007), 
beta-defensin (psoriasis) (Hollox et al. 2008), UGT2B17 (osteoporosis) (Yang et al. 
2008), CCL3L1 (HIV susceptibility) (Gonzalez et al. 2005), C6 and APOBEC3 
(immunity) (Kidd et al. 2007), WWOX, ERBB4 and TP63 (cancers) (Su et al. 2010), 
ADAMTSL3 (height) (Weedon et al. 2008), and AMY1 (diet) (Perry et al. 2007). There 
were also several pharmacogenetic genes that overlapped CNVRs with strong 
population differentiation. These included; CYP2A6, UGT2B17, UGT2B28, GSTT1, 
GSTM1. The distribution of population frequencies of the CNVRs overlapping these 




Table 3.9  Population frequency distribution of CNVRs that overlapped Known 
disease-associated or pharmacogenetic genes. CNP is CNP ID from (McCarroll et al. 
2008b). Frequencies obtained from microarray data. Population frequency = deletion 
frequency + duplication frequency, when applicable.  
 
 
Gene ontology analysis was carried out for the top 200 CNVRs 
(approximately top 10 percentile) with the highest delta-values from every 
population-pair (Table 3.10A, B & C). For CNVRs that showed the highest 
population differentiation between Chinese and Malays, the enrichment of genes are 
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Enrichment by Pathway Maps p-value FDR
Immune response_T cell subsets: secreted signals 8.44E-04 2.42E-02
Immune response_HMGB1/TLR signaling pathway 1.75E-03 2.42E-02
HIV-1 signaling via CCR5 in macrophages and T lymphocytes 2.06E-03 2.42E-02
PDE4 regulation of cyto/chemokine expression in arthritis 3.23E-03 2.42E-02
Immune response_Histamine signaling in dendritic cells 3.36E-03 2.42E-02
Immune response_T regulatory cell-mediated modulation of effector T cell and NK cell functions 3.77E-03 2.42E-02
Immune response_HMGB1/RAGE signaling pathway 3.77E-03 2.42E-02
Immune response_CCR5 signaling in macrophages and T lymphocytes 4.50E-03 2.53E-02
G-protein signaling_RhoB regulation pathway 2.77E-02 1.09E-01
Multiple myeloma (general schema) 3.11E-02 1.09E-01
Enrichment by Process Networks p-value FDR
Inflammation_Complement system 3.28E-02 6.19E-01
Inflammation_Interferon signaling 6.85E-02 6.19E-01
Neurophysiological process_Olfactory transduction 7.20E-02 6.19E-01
Proteolysis_Connective tissue degradation 7.85E-02 6.19E-01
Chemotaxis 9.98E-02 6.19E-01
Signal transduction_Neuropeptide signaling pathways 1.23E-01 6.19E-01
Reproduction_FSH-beta signaling pathway 1.29E-01 6.19E-01
Inflammation_Innate inflammatory response 1.58E-01 6.19E-01
Neurophysiological process_Corticoliberin signaling 1.76E-01 6.19E-01
Immune response_Antigen presentation 1.80E-01 6.19E-01
Enrichment by GO Processes p-value FDR
regulation of interleukin-10 secretion 1.08E-08 1.70E-05
negative regulation of retinoic acid receptor signaling pathway 3.43E-08 2.72E-05
regulation of interleukin-4 production 5.46E-08 2.88E-05
regulation of retinoic acid receptor signaling pathway 1.25E-07 4.93E-05
positive regulation of insulin secretion involved in cellular response to glucose stimulus 2.78E-07 8.81E-05
T cell costimulation 4.62E-07 1.08E-04
lymphocyte costimulation 4.96E-07 1.08E-04
T-helper 1 type immune response 5.47E-07 1.08E-04
humoral immune response 7.65E-07 1.35E-04
humoral immune response mediated by circulating immunoglobulin 9.08E-07 1.44E-04
 
found in immune response related cellular processes (Table 3.10A). For CNVRs that 
are highly differentiated between Malays and Indians, the gene enrichment is found in 
glutathione metabolism, immunity related processes and olfactory transduction (Table 
3.10B). These cellular processes are similarly found in the top 200 CNVRs highly 
differentiated between Chinese and Indians (Table 3.10C). The enrichment of these 
environmental-responsive genes enriched in population-differentiated CNVRs 
suggest that there are functional effects of CNVR and adaptive forces play a role in 
differentiating them in different populations, even in some populations that are 















   
 
Table 3.10  Over-represented Gene Ontology categories found in the top 200 CNVRs 
with the highest delta-values (top 10 percentile of delta-values) that showed strong 
population differentiation in population-pair comparison. A) Comparison between 






Enrichment by Pathway Maps p-value FDR
Glutathione metabolism / Rodent version 0.000406 0.05686
Glutathione metabolism 0.004027 0.156
Glutathione metabolism / Human version 0.004207 0.156
Neurophysiological process_Olfactory transduction 0.004457 0.156
DNA damage_Nucleotide excision repair 0.01404 0.3111
Transcription_Role of heterochromatin protein 1 (HP1) family in transcriptional silencing 0.01716 0.3111
Pentose phosphate pathway/ Rodent version 0.01968 0.3111
Immune response_Function of MEF2 in T lymphocytes 0.0271 0.3111
Immune response_Role of DAP12 receptors in NK cells 0.03012 0.3111
Development_Role of HDAC and calcium/calmodulin-dependent kinase (CaMK) in control of skeletal myogenesis0.03012 0.3111
Enrichment by Process Networks p-value FDR
Neurophysiological process_Olfactory transduction 0.00947 0.4336
Inflammation_Protein C signaling 0.00992 0.4336
Inflammation_Innate inflammatory response 0.01327 0.4336
Immune response_Antigen presentation 0.01854 0.4542
Immune response_Innate immune response to RNA viral infection 0.02865 0.4861
Development_Regulation of angiogenesis 0.02976 0.4861
Cell adhesion_Synaptic contact 0.05544 0.7761
Inflammation_Inflammasome 0.06474 0.793
Development_Blood  vessel morphogenesis 0.1026 0.8404
Development_Skeletal muscle development 0.1028 0.8404
Enrichment by GO Processes p-value FDR
regulation of interleukin-10 secretion 8.97E-08 0.000291
inflammatory response to antigenic stimulus 2.17E-06 0.002441
positive regulation of insulin secretion involved in cellular response to glucose stimulus 2.25E-06 0.002441
T-helper 1 type immune response 4.4E-06 0.003571
T cell costimulation 7.81E-06 0.004409
lymphocyte costimulation 8.36E-06 0.004409
detection of bacterium 1.32E-05 0.004409
negative regulation of interferon-gamma production 1.32E-05 0.004409
smooth muscle contraction involved in micturition 1.41E-05 0.004409




























       
    
 
Enrichment by Pathway Maps p-value FDR
Glutathione metabolism 0.0003997 0.01666
Glutathione metabolism / Human version 0.0004184 0.01666
Glutathione metabolism / Rodent version 0.0005205 0.01666
Immune response_T cell subsets: secreted signals 0.001465 0.03517
Immune response_HMGB1/TLR signaling pathway 0.00303 0.04604
HIV-1 signaling via CCR5 in macrophages and T lymphocytes 0.00355 0.04604
PDE4 regulation of cyto/chemokine expression in arthritis 0.005556 0.04604
Immune response_Histamine signaling in dendritic cells 0.005779 0.04604
Neurophysiological process_Corticoliberin signaling via CRHR1 0.005779 0.04604
Immune response_Function of MEF2 in T lymphocytes 0.006007 0.04604
Enrichment by Process Networks p-value FDR
Inflammation_Interferon signaling 0.007131 0.2472
Neurophysiological process_Corticoliberin signaling 0.01348 0.2472
Development_Skeletal muscle development 0.01484 0.2472
Response to hypoxia and oxidative stress 0.02062 0.2472
Inflammation_NK cell cytotoxicity 0.02095 0.2472
Inflammation_Innate inflammatory response 0.02709 0.2664
Immune response_Antigen presentation 0.03367 0.2837
Neurophysiological process_Olfactory transduction 0.06699 0.4917
Transcription_Chromatin modification 0.07826 0.4917
Chemotaxis 0.08796 0.4917
Enrichment by GO Processes p-value FDR
rhodopsin metabolic process 1.075E-05 0.01926
defense response 5.585E-05 0.02302
regulation of cardiac muscle contraction by calcium ion signaling 5.822E-05 0.02302
nitrobenzene metabolic process 6.423E-05 0.02302
calcium-mediated signaling using extracellular calcium source 6.423E-05 0.02302
glutathione derivative metabolic process 0.0001064 0.02725
glutathione derivative biosynthetic process 0.0001064 0.02725
positive regulation of natural killer cell chemotaxis 0.0001599 0.03096
pigment metabolic process involved in pigmentation 0.0002234 0.03096




3.3.3 Overlapping CNVR Dataset to Selection Signal Loci Identified by 
HaploPS 
3.3.3.1 Merging of CNVR to Selection Loci Identified in 14 Populations from 
HapMap3 and SGVP 
In the first analysis, published autosomal loci under selection identified by 
HaploPS (Liu et al. 2013) were used. A total of 1070 genomic regions were identified 
by HaploPS to be positively selected in 14 populations, comprising 11 from 
HapMap3 and 3 from SGVP. These 14 populations included; CHB, CHD, JPT, GIH, 
CEU, TSI, MEX, MKK, YRI, ASW & LWK of HapMap3 (Han from Beijing, 
Chinese from Denver USA, Japanese from Tokyo, Gujarati Indians from Houston 
USA, CEPH European, Toscani from Italia, Mexican from LA USA, Maasai from 
Kinyawa Kenya, Yoruba from Ibadan Nigera, African ancestry from southwest USA, 
and Luhya from Webuye Kenya, respectively), and CHS, MAS, & INS of SGVP 
(Singapore Chinese, Singapore Malays, and Singapore Indians, respectively). These 
1070 loci were merged according to their genomic positions with a liberal condition 
of ≥1bp overlap, producing a total of 415 unique loci distributed across the 22 
autosomes (Table 3.11). 
Overlapping these 415 unique loci to the DMERI CNVR dataset containing 
2,227 CNVRs identified 100 loci with ≥1bp overlap criterion (Table 3.11). However, 
a positive selection locus should reflect as high CNVR frequency in related 
populations (indicating the CNVR allele being the selected candidate), or in the 
reverse direction, deprived of CNVR (indicating the non-CNVR allele being the 
selection candidate). Therefore, a directional effect of the selection loci in related 
populations was considered as a second condition. Many of these 100 unique 
selection loci overlapped with rare CNVRs, and at low population frequencies, it was 
difficult to interpret the effect of selection at population level. For those selection loci 
that overlapped common CNVRs, many did not satisfy the second condition which 
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35 49 33 27 17 18 26 18 20 26 16 25 8 10 14 19 20 8 5 8 1 12 415
#Selection loci that 
overlapped with 
CNVR from DMERI 
data set
8 14 6 4 6 7 3 6 3 4 6 6 3 2 4 9 3 1 2 0 0 3 100
 
required a concordant directional effect for the selection locus and 









The sole population-differentiated CNVR candidate under selection pressure 
was Cluster 154 (Figure 3.7). It is a deletion CNV highly enriched in Chinese and 
Malay, and the copy number called by microarray was validated by qPCR. The 
population frequencies of homozygous deletion for this CNVR are 81%, 83% & 40%, 
while heterozygous deletion are 19%, 16% and 48% in Chinese, Malays, and Indians, 
respectively. This CNV is located within a selection loci detected in CHB, CHD, 
CHS, MAS, and JPT, all are populations of Asian ancestry (Liu et al. 2013). It is a 
plausible hypothesis that the deletion CNV in this locus provided some form of 
selective advantage in Asians which led to its enrichment in many Asian populations. 
Interestingly, Cluster 154 is located ~40 kb upstream of the gene NEGR1 (neuronal 
growth regulator 1). Both this deletion CNV and some flanking SNPs around NEGR1 
have been shown to be positively associated with obesity in several European cohorts 
(Speliotes et al. 2010; Wheeler et al. 2013; Willer et al. 2009), but have not been 
reported in Asian studies, possibly because of the low informativeness of this CNV 











Chr Start End Size (kb) Genes Platform Chinese (n=99) Malays (n=94) Indians (n=85) qPCR 
Concordan
ceCN0 CN1 CN2 CN3 CN4 CN0 CN1 CN2 CN3 CN4 CN0 CN1 CN2 CN3 CN4
154 1 72,522,941 72,583,736 60.8 5' NEGR1 Microarray 80 8 11 0 0 78 5 11 0 0 34 19 32 0 0
qPCR 80 19 0 0 0 78 15 1 0 0 34 38 13 0 0 85.6%
 
Figure 3.7Schematic representation of a 
CNVR, Cluster 154, in UCSC Genome 
Browser. Cluster 154 is located ~40kb 
upstream of the gene NEGR1. QPCR 
validation showed homozygous deletions in 
full concordance. Middle panel lists 
Reference genes while lower panel shows 
the CNVs recorded in DGV. HaploPS 
identified a selection locus in Chinese (C) 
and Malays (M) from DMERI SNP dataset, 
a 1.48 Mb region overlapping cluster 154. 
Similar selection locus, albeit smaller at 
497 kb was identified by HaploPS in 
related populations from HapMap3 and 
SGVP. HapMap3 populations: CHB, Han 
from Beijing, CHD, Chinese from Denver 
USA, JPT, Japanese from Tokyo. SGVP 
populations: CHS, Singapore Chinese, 






Selection locus in C & M
Chr1:72,430,802 – 73,914,426
Also in
CHB, CHD, CHS, MAS, JPT











Selection loci Shared with 
DMERI
Chinese 100 80 51 (63.8%) 93 103 51 (49.5%)
Malays 96 80 45 (56.3%) 88 111 48 (43.2%)
Indians 85 54 20 (37%) 85 64 22 (34.4%)
Total 281 214 266 271
Merged into unique loci 129
DMERI SGVP
3.3.3.2 Merging of DMERI CNVR Dataset to Selection Loci Identified by HaploPS 
using DMERI SNP Dataset 
Due to the paucity of CNVR candidates that demonstrated both population 
differentiation and strong selection signal using published selection loci, we 
performed a second analysis to directly identify genomic regions that have positive 
selection signals from the DMERI dataset itself. The input dataset was the SNP 
dataset obtained from the same Affy6.0 microarray experiments as the CNVR dataset 
(Section 2.2.3.3), containing a total of 843,282 SNPs generated from the same 281 
samples. HaploPS identified a total of 214 selection loci; 80 in Chinese, 80 in Malays, 
and 54 in Indians. These 214 loci from DMERI dataset were compared to the 
published data identified from the SGVP populations which are of similar 3 
populations as in DMERI’s (Liu et al. 2013). Using ≥1 bp overlap as criterion, the 
concordance of selection loci between the 2 databases for similar populations was 
shown to be low between 37% and 63.8% (Table 3.12). 
 
Table 3.12  Selection loci identified by HaploPS using SNP datasets from DMERI or 
SGVP. Loci were considered shared if they satisfied the criterion of ≥ 1bp overlap. 
 
The 214 selection loci identified in the DMERI samples were merged by 
genomic position using 1 bp overlap criterion, generating a total of 129 unique loci 
(i.e. no sequence overlap between these unique loci). The distribution of these unique 
loci across chromosome, and also in terms of their distribution across populations are 
summarised in Table 3.13. These 129 merged selection loci unique by their genomic 
position were overlapped with the full 2,227 CNVR dataset. Twenty six of them 
overlapped one or more CNVRs. The distribution of these overlap region in various 
chromosomes are summarised in Table 3.13.  
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Chromosome 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Total
C 6 4 1 2 1 - 2 - - 1 1 1 - - 1 2 1 1 - 1 - - 25
M 3 3 2 1 - 1 - 3 - 1 - 1 - - 1 - - - - - - - 16
I 1 2 2 1 1 3 2 1 - 3 2 1 1 - - 1 2 1 - 1 - - 25
C_M 2 5 3 1 2 - 2 4 2 5 1 1 2 - 2 1 - 1 - - - - 34
M_I 1 1 - - - - - - - 2 - 1 1 - 1 - 1 - - - - - 8
C_M_I 1 5 1 3 - 1 1 - 1 1 - 1 - - - 2 - 2 - - 1 1 21
Total 14 20 9 8 4 5 7 8 3 13 4 6 4 0 5 6 4 5 0 2 1 1 129
No. Selection loci 
overlap to CNVR
4 4 1 1 - 2 2 1 1 - 2 1 - - 3 4 - - - - - - 26
However, close examination of each of these 26 overlapped regions only 
identified CNVR Cluster 154 as a plausible candidate, showing CNVR enrichment 
and selection in Chinese and Malays. The other 25 loci failed criteria as described in 
Section 3.3.3.1, in either being rare CNVR, or found in non-matching populations. 
Cluster 154 is the same CNVR identified in Section 3.3.3.1 (Figure 3.7), 
hence validated by two different datasets. The selection locus identified in the 
Chinese and Malay samples of DMERI dataset contained a selection locus of ~1.5 
Mb in size. A selection locus of smaller size at ~ 0.5Mb was identified in related 
populations (CHB, CHD, CHS, MAS & JPT) from HapMap3 or SGVP. 
 
 
Table 3.13  Distribution of the 129 merged selection loci, each with unique and non-
overlapping genomic location. Distribution is by chromosome and also by population. 
A total of 26 of these merged selection loci overlapped at least one CNVR in the 
DMERI CNVR dataset. The distribution of these 26 selection loci across every 




3.4.1 Population Diversity of CNVs in 3 Singapore Populations 
The widespread Copy Number Variation in the human genome has 
contributed to human genetic diversity and could influence phenotypic differences 
between populations. In this chapter, we investigated the various CNV attributes 
between the three Singapore populations to decipher possible functional differences 
between groups. 
Of the total 22,024 CNVs detected in the 281 samples, Indians harboured 
significantly more duplication CNVs, which is reflected in Indians having CNVs of 
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larger average size compared to Chinese or Malays. Indians also showed the highest 
number of population-specific CNVRs among the three populations. The number of 
CNVRs shared between 2 populations is the highest in Chinese and Malays, followed 
by Malays-Indians, while the lowest is found in Chinese-Indians. These observations 
parallel our early studies using mitochondrial and Y-chromosome markers (Section 
1.5), and confirm that the genetic relationship between Chinese and Malays is closer 
than that between Indians and either of these groups. This is supported by the 
genome-wide distribution of delta-values of CNVRs and FST of SNPs for the 3 
population-pairs comparison, with both delta-values and FST between Chinese-Malays 
consistently been the lowest, followed by Malays-Indians, and Chinese-Indians 
showing the highest values in a genome-wide scale (Table 3.7). A similar conclusion 
regarding genetic relationship between these 3 populations were reached in previous 
studies (Teo et al. 2009; Xu et al. 2011). 
Like other genetic polymorphisms such as SNPs and STRs, this study has 
showed that CNVs can differ greatly between populations. In fact, the majority of the 
CNVRs (70%, 1564 out of 2227) are restricted to one population only, and often at 
very low frequency.  Even if false discovery rate of rare CNVRs is taken into 
consideration (qPCR validated rare CNVRs with a false positive rate of 13.3%), 
population-specific CNVRs still amount to 1356 (61%). This non-sharing across 
populations could be due to the recent origin and/or possibly deleterious effect of 
these population-specific CNVs. The significantly larger average size of these 
population-specific CNVRs compared to the common CNVRs (Table 3.1B) also 
supported the hypothesis that they may be more deleterious and therefore kept at low 
frequencies. On the other hand, common CNVRs (frequency >5%), which are likely 
to have more ancient origin, were mostly shared between the 3 populations, 
consistent with a more ancient and neutral evolutionary histories. These common 
CNVRs shared across these 3 Asian populations are also shared with global DGV 
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CNVRs, reflecting that common CNVRs have ancient origin predating the division 
between Asians with other populations. 
The association of CNVRs shared across populations with segmental 
duplications (SDs) is in line with previous studies (McCarroll et al. 2008b; Redon et 
al. 2006). It could be explained by the association of SDs with the mutation 
mechanism Non-allelic Homologous Recombination (NAHR). NAHR in SD region 
resulted in recurrent mutations, increasing the mutation rate in specific genomic 
regions containing SDs and resulted in higher frequency for that particular CNV. This 
association supports the hypothesis that NAHR plays a role in CNV formation in 
humans, especially for common CNVs. 
We did not observe any difference in reference gene or OMIM gene overlap 
to CNVRs between these 3 populations. 
 
3.4.2 Population-specific and Population-differentiated Common CNVRs 
The allele frequency discrepancy of DNA variants such as CNVs can be 
affected by factors such as selection, genetic drift and gene flow. Nevertheless, local 
adaptation is still a major selection force to shape the discrepancy among 
geographically close populations. We have investigated both population-specific and 
highly differentiated common CNVRs in an attempt to identify candidate loci which 
could be under positive selection and get an insight of the possible adaptive 
functional differences between groups.  
The majority of the population-specific CNVRs are of low frequency, with 
only 32 such CNVRs having a population frequency of ≥ 5%. Eight are Chinese-
specific, 3 Malay-specific and 21 Indian-specific. Of the 30 CNVRs tested by qPCR, 
all were confirmed to be true positive except one, translating to a false positive rate of 
3.3% in this group of CNVRs. This false positive rate appears to be low, considering 
the reproducibility rate of CNV calls in duplicated sample are only 72.7% (Table 
2.5). This is not exactly surprising because even at low reproducibility rate, there is 
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still a 72.7% chance that the CNV would be successfully identified among a group of 
samples that harboured the CNVs. Hence, common CNVRs are less likely to be 
missed with the detection algorithm Birdsuite. 
Although the relatively small sample size of ~100 per population in this study 
might mean under-ascertainment of population-specific common CNVRs, a 
comparison of DMERI dataset to that of a much larger database of similar 
populations, SgD (Xu et al. 2011) with >1,900 individuals per population, confirmed 
the paucity of population-specific common CNVRs. Only 5 out of the above 32 
CNVRs found corresponding population-specific CNVs in SgD dataset, even using a 
liberal 1bp overlap criterion. A check in the literature revealed very few population-
specific common CNVRs have been identified to date. A study of 3,578 Koreans 
reported that only 15 out of 4,003 identified CNVRs were Korean-specific common 
CNVRs, with all frequencies less than 10% (Yim et al. 2010). The lack of population-
specific common CNVRs may be due to most de novo CNVRs being deleterious and 
being eliminated by subsequent selection (Itsara et al. 2010). This is also similar with 
the observation in SNPs that common SNPs are generally shared across populations, 
while low-frequency SNPs showed substantial geographical differentiation (Abecasis 
et al. 2012). It should be noted that the paucity is limited to common CNVRs, and not 
rare CNVRs. As this dataset has shown, there is an abundance of population-specific 
rare CNVRs, though these may be reduced when more populations and larger 
samples are studied. Hence CNVs could still be useful for population-differentiation 
studies. Compared to SNPs, it has been reported that biallelic CNPs showed greater 
population stratification when compared to frequency-matched SNPs (Campbell et al. 
2011). Furthermore, there was reported observation that structural variations as a 
whole are more specific to individuals than SNPs (Li et al. 2011). 
Of the 31 population-specific common CNVRs, 19 are located in the non-
genic regions. Only 12 overlapped known genes or uncharacterised transcripts. Of 
these, 5 are non-coding RNAs of unknown function, and 6 CNVRs overlapped within 
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introns, and hence there was no evidence of effect on coding proteins. As a whole, the 
paucity of coding gene sequence within this group of population-specific common 
CNVRs might indicate the neutral evolutionary histories of the members which allow 
them to increase in frequency. Nevertheless, these population-specific common 
CNVRs are potential selection candidates for which further epidemiological and 
functional studies could elucidate whether they are selectively non-neutral. 
Using the parameter delta-value as a measure of genetic distance of CNVRs 
between population-pairs (akin to FST), this study has identified a set of CNVRs 
whose frequencies are highly stratified in the 3 populations. The 26 qPCR carried out 
for this group of highly differentiated CNVRs confirmed all are true positives. QPCR 
also showed that there were some false negatives by microarray at sample level, 
although generally these false negatives did not affect the direction of population 
differentiation identified by microarray.  
Several of the highly differentiated CNVRs have been discussed in Section 
3.3.2.2. It is noted that many of these CNVRs are located in complex genomic 
regions, resulting in a series of adjacent CNVRs, which could show different 
directions of population differentiation. Some of them overlap with genes or gene 
family. Local genomic architecture likely is the underlying cause for the genesis of 
these CNVRs. One group has been reported to be associated with positive selection 
and rapid evolutionary turnover (Clusters 1993 and 1992). The population 
differentiation of this group could be due to their functional effects and selection, and 
hence interesting targets for future studies.  
Other CNVs known to overlap genes associated to diseases or traits, and 
pharamcogenetic genes, were also found in our list of highly differentiated CNVRs 
(Table 3.9). The marked difference in population frequencies of these genes in the 3 
Singapore populations and their associated disease/trait phenotypes might account for 
phenotypic and disease differences between the local populations, suggesting the 
potential implication of CNVs in clinical and public health practices in our local 
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context.  A list of the known function of genes overlapping some of these highly 
differentiated CNVRs can be found in Appendices 3 and 4. Future studies can be 
carried out for these candidates identified from this current hypothesis-generating 
study.  
Gene ontology enrichment analysis for the top ten percentile of the CNVRs 
differentiated between population-pairs revealed that those most enriched between 
Chinese and Malays are involved in various aspect of immune response. While the 
genes enriched in the CNVRs that showed high differentiation between Chinese-
Indians are similar to those of Malays-Indians, with cellular processes found in 
glutathione metabolism, immunity related processes and olfactory transduction. The 
enrichment of genes related immune response and sensory function has lent support 
to the suggestion of an environmental adaptive role of CNV. 
 
3.4.3 Genetic Selection of CNVR Loci 
The extensive effort of screening for evidence of genetic selection for 
CNVRs yielded one candidate located near to the gene NEGR1. This paucity could be 
interpreted as a true reflection that there are not many CNVs in the human genome 
that are under positive selection. One support of the above interpretation comes from 
the view that CNVs in the human genome are generally neutral, exist with weak or no 
phenotypic consequences and evolves under neutral evolutionary pressures (Nguyen 
et al. 2008). Several observations in the pattern of CNV distribution in the human 
genome appeared to support this view. The widespread occurrences of CNVs in 
apparently healthy individuals indicate that many CNVs confer minimal to no 
phenotypic consequence within humans. Or at least these CNVs do not have 
substantial deleterious effect. A related argument is that even if CNVs are subjected 
to purifying or positive selection, these selection forces usually lead to fixation either 
by the removal of a harmful CNV or the rapid rise in frequency of a beneficial CNV 
(Iskow et al. 2012). Thus, such selective forces cannot explain the breath of CNVs 
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currently present among human genomes. Rather the explanation for the persistence 
and extent of CNVs among human genomes, especially for intergenic CNVs, is that 
most of these CNVs have evolved under neutral evolutionary pressures. This 
hypothesis would also mean that the current pattern and frequency of these CNVs 
would have been shaped by mutation rate, genetic drift, and demographic events 
(Iskow et al. 2012). Also more recently, to explain the relative lack of adaptive 
selection in SNP studies, it was suggested that modern humans being a relatively 
young species migrated out of Africa 50,000 years ago, spanning only 2,000 
generations, though is long enough for specific adaptations to have occurred but not 
for very many such adaptations (Chakravarti 2014). This would likely explain the 
paucity of positive selection example found in this study as well. 
Although the widespread occurrence of CNV in human genomes appears to 
indicate that many CNVs are probably neutral, the effect of purifying selection is still 
indirectly visible, particularly for deletions. There is a strong skew towards rare 
CNVs or CNVs with low frequency, and there is a depletion of larger size CNVs 
(>500kb). Also, there is less gene content for deletion CNVs compared with 
duplications, and deletions are of smaller size than duplications. Karyotypic analyses 
of individuals with segmental aneuploidy have suggested that the human genome is 
more tolerant of duplication than deletion (Brewer et al. 1999), consistent with the 
stronger deleterious effect in deletion CNVs. Intuitively, since CNVs cover a larger 
extent of the genome compared to SNPs or indels, they might have a higher 
likelihood of affecting gene function and contributing to a phenotype, increasing the 
prior probability that selection has affected any particular CNV. Therefore it is 
possible that purifying selection may act more strongly on CNVs than on SNPs due to 
their size. As a result, CNVs that are still undergoing purifying selection could be 
exceedingly rare, limiting the opportunity in finding them or to study them directly. 
Another likely reason for the paucity of positive selection signals could be 
related to methodology. The working principle of HaploPS is extended haplotype 
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which is dependent on a selective sweep signal and neighbouring SNPs rising in 
allele frequency. This strategy will work only if the CNV is in linkage disequilibrium 
(LD) with flanking SNPs. But CNVs are a diverse group of variants, with many 
CNVs, especially the duplication and multiallelic ones, probably arising from 
recurrent mutations during evolutionary history. Recurrent mutations would mean 
similar CNVs can occur on different haplotype backgrounds, and the CNV is less 
likely to be in LD with neighbouring SNPs than biallelic CNVs. Similarly, 
duplication CNVs can lead to insertion into other genomic locations other than in 
tandem duplication. This will also reduce the extent of LD of the CNV with flanking 
SNPs. 
The CNV at Cluster 154 is a plausible candidate of positive selection. It is a 
biallelic deletion CNV (about 43 to 60 kb), with an extremely high deletion allele 
frequency in Chinese and Malays at 90.4% and 91%, but only 62.4% in Indians. This 
CNV is located within the genomic region identified by HaploPS to be positively 
selected not only in Singapore Chinese and Malays, but also in other Asians such as 
Beijing Han and Japanese. Interestingly, it is located 40kb upstream of NEGR1 
(Neuronal Growth Regulator 1), and is known to be associated with obesity in 
European populations (Speliotes et al. 2010; Wheeler et al. 2013; Willer et al. 2009).  
However this association has never been reported in Asians. This CNV is known to 
be in complete LD with some flanking SNPs including rs31013362 (Wheeler et al. 
2013).  Our in-house data has shown no association with obesity in Chinese nor 
Malays (sample number case/controls; Chinese, 413/519; Malays, 115/30) (Eric Yap, 
personal communication). Further studies are needed to identify the haplotype under 
selection and its allele frequencies in the 3 populations, in order to better understand 
this putative selection signal, which would shed some light on the exact candidate in 





AMYLASE GENE CLUSTER ON 1P21.1: EXAMPLES OF CNVS AND 




4.1.1 Amylase Genes as Examples of Multiallelic Copy Number Variations 
As demonstrated in the CNV database work in this thesis (Chapters 2 & 3), 
and other genome-wide CNV surveys in various populations (Ku et al. 2010; Xu et al. 
2011; Redon et al 2006; Conrad et al. 2010b), CNVs comprise a diverse set of 
variants, some of which are still less well understood than others. Much of the 
progress in the past decade has mostly focused on ‘simple’ CNVs, in which unique 
genomic segments are deleted or duplicated. Array-based platforms have been 
commonly used to analyse such variants in large cohorts, revealing associations in 
several complex diseases (see section 1.2.4.5). However, there are other classes of 
CNV that do not genotype well on array platform, and hence have not been tested for 
their relationships to human phenotypes (Chiang and McCarroll 2009). The advance 
of whole genome sequencing has similarly devoid of these classes of CNV (Abecasis 
et al. 2012; Mills et al. 2011). Chief among them are the highly multiallelic CNVs – 
the repeated segments that can vary in number in different individuals. Such 
multiallelic CNVs may be among the unstable regions of human genomes, and 
change in copy number at rates that exceed mutation rates for other classes of 
variation. In addition, observed population stratification across multiple ethnicities 
suggested an important role for multiallelic CNVs in evolution, adaptation and 
disease association (Campbell et al. 2011).  
Array-based approaches cannot resolve high copy-number differences 
because hybridisation measurements saturate at higher copy number levels and are 
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too noisy to resolve subtle copy-number differences (such as 11  versus 10 copies). 
As a result, the relevance of highly multiallelic CNVs to disease and phenotype 
generally are untested in genome-wide association studies. Compared to array-based 
platforms, quantitative real-time PCR is a more suitable method to genotype 
multiallelic CNVs because of its better precision at higher copy number (in 
comparison to array, as precision does decrease with higher copy number), 
robustness, ease to carry out in large cohort and cost-effectiveness. Several of the 
large scale disease association studies for multiallelic CNPs were carried out using 
qPCR (Gonzalez et al. 2005; Aitman et al; 2006; Fanciulli et al. 2007; Urban et al. 
2009), including a study  that showed association of AMY1 copy number with obesity 
(Falchi et al. 2014).  Recently, advances in digital PCR (dPCR) enable even better 
resolution of smaller copy number difference to be discriminated. In dPCR, a sample 
is diluted and partitioned into thousands or even millions of separate reaction 
chambers so that each contain one or no copy of the target sequence. By counting the 
number of positive versus negative partitions at the end point of PCR, the copies of a 
DNA molecule in the original sample can be calculated after correcting for Poisson 
statistics. (more information in Section 1.4.4.5). This study of genotyping multiallelic 
CNV would provide better insights into the strength and weakness of both qPCR and 
dPCR. 
The Amylase gene cluster in chromosome 1p21.1 presents an interesting 
example to illustrate different copy-number range of CNVs. Two paralogous amylase 
gene families located at this cluster, AMY1 and AMY2, are responsible for the 
production of salivary and pancreatic α-amylase, respectively. Both AMY1 and AMY2 
are multi-allelic, but AMY2 is much less variable compared to AMY1, which is known 
to be one of the most variable in the human genome in regard to copy number (Iafrate 
et al. 2004; Sudmant et al. 2010). Therefore, study of these two gene loci provides a 
contrasting example of CNVs. Both CNVs encompassing AMY1 and AMY2A were 
identified in the DMERI CNV database (Table 3.9, Figure 4.2). This locus-specific 
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study serves to verify the microarray work, and at the same time shed light on the 
extent of genetic diversity of both AMY1 and AMY2A in the three local populations. 
In addition, AMY1 copy number has been shown to be highly stratified in global 
populations and human populations traditionally consuming a high-starch diet have 
on average a higher copy number than those populations consuming a low-starch diet 
(Perry et al 2007). The presence of higher AMY1 copy numbers in populations with 
high starch diets has led to speculation that AMY1 copy number contributes to 
obesity. Supporting this idea, a recent study reported that AMY1 copy number is 
associated with obesity in both European populations and a Singapore Chinese cohort 
(Falchi et al. 2014). This report has generated further impetus to characterize the AMY 
locus in detail, and to validate the putative association in a separate Singapore 
Chinese obese cohort.  
In summary, there were three objectives in this Amylase genes study: 
1) To test the current array and qPCR methods for genotyping multi-allelic 
CNVs with high copy number and develop a novel AMY quantitation 
assay on qPCR and dPCR platforms. 
2) To explore the population diversity of AMY1 and AMY2A loci in local 
populations. 
3) To study if the recently reported association of AMY1 copy number and 
obesity could be replicated in a second Singapore Chinese cohort.  
 
4.1.2 The Structure of AMY1 and AMY2 gene families at locus 1p21.1 
At chromosome 1p21.1, multiple AMY1 (AMY1A, AMY1B, AMY1C) as well 
as AMY2 (AMY2A, AMY2B) genes exist together with a pseudogene AMYP1. The 
arrangement of genes across the locus was defined by analysis of restriction mapping 
in pedigrees (Groot et al. 1989) and the human reference genome displays a similar 
configuration (Figures 4.1 and 4.2). All genes are arranged in a head-to-tail 
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strong homology, both in exon sequences which are ~96% homologous, and in exon-
intron structure. Both genes are about 10 kb in size and contain 11 and 10 exons for 
AMY1 and AMY2, respectively. The first exon of AMY1 is present in the genomic 
sequence of AMY2 but is not transcribed (Groot et al. 1989). The pseudogene AMYP1 
lacks the first three exons compared to AMY1. The human AMY1 genes shared very 
high degrees of identity among themselves. This information was used in designing 
suitable primers for qPCR to differentiate AMY1, AMY2A, AMY2B, and to exclude the 
pseudogene AMYP1.  
 
 
Figure 4.1 Schematic representation of α-amylase gene cluster on chromosome 
1.21p.1. Genome assembly NCBI36/hg18.  (Modified from Santos et al. 2012) 
 
A ϒ-actin processed pseudogene was inserted in 5’ position of all AMY genes 
except the pseudogene AMYP1. The amount of insertions of the retroviral element is 
marked with +. Approximate locations of two segmental duplications are indicated, 








Figure 4.2 α-amylase genes cluster and local CNVs on chromosome 1.21p.1 as displayed in UCSC genome browser. Genome assembly NCBI36/hg18. Two 
groups of CNVs are identified in DMERI database, overlapping AMY2A and AMY1, of sizes 50 kb and 100 kb, respectively. Chinese in red, Malays in green, 
and Indians in blue lines representing CNV locations, with each line representing one sample. Segmental duplications are shown in lowest section. Orange 
SD, > 99% sequence similarity, the long orange SD corresponds to SD1 in figure 4.1. Light to dark yellow, 98 - 99% similarity, corresponding to SD2. Light 




Sequence comparison of the proximal promoter regions of the amylase genes 
has revealed the existence of two elements inserted into the promoter regions of all 
amylase genes except the pseudogene (Figure 4.1). The promoter region is critical in 
separating the two gene families, AMY1 and AMY2 apart. 
The first element is a 2kb γ-actin processed pseudogene inserted upstream of 
AMY2B. It shares ~89% sequence identity with mRNA of human γ actin, was found 
to be in agreement with a divergence time of 40 million years (Samuelson et al, 
1988). This signature sequence is present in all amylase genes enabling the 
evolutionary relationship between pancreatic and salivary amylases gene to be 
deduced. 
Furthermore, the γ-actin pseudogene itself is disrupted by the presence of 
retroviral elements upstream of the promoter regions of all amylase genes excluding 
AMY2B (Samuelson et al, 1988), suggesting this insertion happened after the 
duplication of other AMY genes from AMY2B.  
Evolutionary analysis of the two insertions and their inferred relationship 
when compared together with other non-human primate lineages revealed that the 
human salivary amylase gene AMY1 was derived from duplication of an ancestral 
pancreatic amylase gene AMY2, and the insertion of a retrovirus sequence is 
responsible for tissue-specific expression. The complete retroviral insertion is 
essential for tissue specificity of salivary amylase AMY1 genes, while the excised 
residual retroviral sequence is responsible for the restricted expression of AMY2A in 
the pancreas (Santos et al. 2012). 
AMY1 genes (AMY1A, AMY1B, and AMY1C) share a very high sequence 
identity which implies a relatively recent origin of duplications.  Salivary α-amylase 
is encoded by these three distinct but closely related genes, which are commonly 
referred to collectively as AMY1 since most genotyping cannot differentiate them. 
AMY1 shows extensive copy number variation ranging from 1 diploid copy of the 
AMY1 genes to as many as 20 copies (Perry et al. 2007; Santos et al. 2012; Falchi et 
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al 2014). It has been shown that the pseudogene AMYP1 and salivary genes AMY1A 
and AMY1B are much more variable in copy number than pancreatic amylase genes 
AMY2A and AMY2B. In contrast, AMY1C seems to be largely copy invariant 
(Sudmant et al. 2010).  
Salivary α-amylase catalyses the hydrolysis of the α-1,4-glycosidic bonds of 
starch, initiating carbohydrate digestion in the oral cavity. This is followed by the 
action of the two pancreatic α-amylase (encoded by AMY2A and AMY2B) acting in 
the small intestine. Copy number of AMY1 is strongly correlated with both the mRNA 
transcript and the amount of salivary α-amylase (Perry et al. 2007; Falchi at al. 2014). 
And AMY2A copy number has been shown to correlate to serum pancreatic amylase 
(Falchi et al. 2014). Although individual salivary amylase levels is also influenced by 
other factors, such as hydration status, short-term dietary habits, and psychological 
stress (Chatterton et al. 1996), they are genetically influenced by and directly 
correlate with the highly variable copy number at AMY1 (Perry et al. 2007; Falchi at 
al. 2014).  
To better understand the evolutionary context of human AMY1 copy number 
variation, Perry et al had analysed patterns of copy number variation in chimpanzees 
(Pan troglodytes) and reported that chimpanzees showed evidence of only two 
diploid AMY1 copies (Perry et al 2007). This supports the proposal that higher gene 
copy numbers at AMY1 in human compared to chimpanzees evolved as a 
consequence of a shift to a starch-rich diet (Marques-Bonet et al. 2009). Also, human 
populations traditionally consuming a high proportion of carbohydrates in their diet 
show higher copy numbers and salivary amylase activity than those consuming a low-
starch diet. Both observations lend support to the pattern of copy number variation of 
human AMY1 gene being consistent with a history of diet-related selection pressures, 





4.2 MATERIALS AND METHODS  
4.2.1 Two Study Sample Sets: DF and Obesity Sample Sets  
Two study sample sets were used in this AMY work. The same DF sample set 
used in earlier CNV database work (Section 2.2.1) was used in the population 
diversity study of AMY1 and AMY2A genes. Due to the exhaustion of some DNA 
samples, the sample size was slightly reduced by 3, now comprising 99 Chinese, 94 
Malays, and 85 Indians. 
For the study to verify putative association of AMY and AMY2A copy number 
with obesity, the Obesity (OB) study sample set was legacy collection from a 
previous DMERI project entitled ‘Obesity in SAF Enlistees: Health Profiles, Effects 
of Physical Training and Identification of Genetic Factors’.   The project was granted 
ethics approval by the DSO IRB in March 2004. Samples were collected from SAF 
volunteers with written consent between August 2004 and December 2007. The 
Control subjects have Body Mass Index (BMI) less than 23 kg/m
2
, while Obese 
subjects with BMI of at least 30 kg/m
2
. All volunteers were male, of age ranges from 
18 to 21, and of ethnicity either Chinese or Malay, with all four grandparents of 
similar race as each volunteer. This legacy sample set comprised of 519 Chinese 
controls, 413 Chinese obese, 30 Malay controls and 115 Malay obese. DNA was 
extracted from buffy coat with QIAamp DNA Mini Kit (Qiagen, Germany) and 
quantification by Nanodrop Spectrophotometer (Thermo Scientific, USA). 
  
4.2.2 Copy-Number Estimation of AMY1 and AMY2A by Quantitative Real-
time PCR   
AMY1 and AMY2A gene copy-number were estimated by duplex quantitative 
real-time PCR (qPCR) on a QuantStudio™ 12K Flex Real-Time PCR System 
(Thermo Fisher Scientific Inc., USA) with 384-well plate. The analysis software was 
QuantStudio™ 12K Flex Software version 1.1.2. Duplex reactions consisted of two 
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AMY1A, AMY1B, AMY1C Hs07226362_cn  1p21.1 1 104,198,366 Within Exon 1 FAM NFQ 101 ATGTGTCAGGGCTGAGTGTTCTGAG
AMY2A Hs04204136_cn 1p21.1 1 104,161,065 Within Intron 2 FAM NFQ 111 TTAGGTGACTTGTGTCTCCATCCGT
AMY2A Hs03342654_cn 1p21.1 1 104,155,278 5' of AMY2A FAM NFQ 85 GACGAATAGAGGGTTCTCATCCCAG
RPPH1 14q11.2 14 20,811,565 within single exon VIC TAMRA 87 GAGCTTCCCTCCGCCCTATGGGAAAA
 
assays, each with two primers and a TaqMan probe (Thermo Fisher Scientific Inc., 
USA); one specific for the target, AMY1 (Hs07226362_cn) or AMY2A 
(Hs04204136_cn), and one specific for the reference (RNase P). These two assays are 
exactly the same as those used in Falchi et al. and hence facilitated direct comparison 
of results. A different AMY2A target assay (Hs_03342654_cn) was used for the DF 
sample set, as the work was done prior to the publication of Falchi et al. This assay 
targets 5’ end of AMY2A. The primers and probe of the Taqman qPCR assay 
employed for AMY1 specifically target a region within exon 1 of the AMY1 gene, 
which is absent in the AMYP1 pseudogene, therefore ensuring specificity of the qPCR 
assay for AMY1. Details of these Taqman assays are summarised in Table 4.1. The 
context sequence of all target assays aligned to the specific target regions on the 
human genome.  
 
Table 4.1 Characteristics of Taqman Copy Number assays targeting AMY1 and 
AMY2A genes.  
 
All samples for qPCR were carried out in four replicates. For assay targeting 
AMY1, a final volume of 10ul per aliquot was used in order to achieve better 
precision to accommodate the high copy variation in AMY1, while a 4ul final volume 
was used in assays for AMY2A. Each 10 ul aliquot contained 1ul of 10ng/ul genomic 
DNA, 0.5ul each of the Taqman target assay (20x) and the reference assay RNaseP 
(20x), 5ul of Taqman genotyping master mix (2x), and 3ul of sterile water. Cycling 
condition was one cycle of 95ºC 10 min, followed by forty cycles of 95ºC 15 sec, 
60ºC 1 min. All samples were randomized for all laboratory processes, starting from 
DNA extraction to qPCR to avoid systematic bias and batch effects. 
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Real-time PCR data were analysed with QuantStudio™ 12K Flex Software 
version 1.1.2, results were then exported to CopyCaller v2.0 software (Thermo Fisher 
Scientific Inc., USA) for copy number calculation. All analysis settings selected were 
as recommended in the user guides. Diploid copy-numbers were estimated by ΔΔCt 
method using the calibrator DNA sample NA10851 (Coriell Cell Repositories, USA) 
which carries 6 copies of the AMY1 gene and 2 copies of AMY2A. NA10851 was also 
used for between-experiment normalization.  
The sample NA10851 was selected as a reference sample for several reasons. 
It is a common reference sample used in many CNV studies carried out globally 
using microarrays, and it was the calibrator in previous qPCR validation study in 
Chapter 2.  It has been compared and calibrated with several reference samples using 
both qPCR and digital-PCR, and has consistently shown good concordance and 
reproducibility. Prior to its selection, a few reference samples had been studied as a 
potential calibrators because their copy number had been independently measured 
and reported in several published studies using methods including fiberFISH and 
qPCR. These included NA18956 which was reported to carry 6 copies of AMY1 and 2 
copies of AMY2A (Falchi et al 2014); NA18972 with 14 copies of AMY1 (Perry et al 
et al 2007; Falchi et al. 2014); and NA10472 with 6 copies of AMY1 (Perry et al. 
2007). However the 14 copies of AMY1 of NA18972 was disputed by a recent study 
by Armour (personal communication, ASHG 2014) and also this study (see Table 
4.2). The samples NA18956, NA10472 and NA10851 consistently showed 6 copies 
for AMY1, but NA18956 had slightly lower copy number than the other two samples, 
possibly due to mosaicism in this cell line sample. Since NA10472 had displayed 6 
copies of AMY1 in fiberFISH and it calibrated consistently with NA10851 in both 
qPCR and dPCR platforms, NA10851 was elected as the calibrator in this study as 
well. 
A comparative CT method was used in estimating diploid copy number. The 
ΔΔCt method assumes equal amplification efficiency for the target and the reference 
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genes. PCR efficiency was evaluated for both the target assays (AMY1 & AMY2A) 
and the reference RNase P assay using a standard curve of serial dilutions of a DNA 
sample of known concentration. Log10 of the dilution factor was plotted against Ct 
mean values for each of the two assays. The slope of the line was then used to 




PCR Efficiency (%) = (E – 1) x 100 
 
Figures 4.3a and 4.3b are the real-time PCR standard curves representing 
PCR efficiencies for the qPCR assays targeting AMY1 and AMY2A, respectively. PCR 
efficiency for the AMY1 target assay and its reference (RNase P) assay was 92.76% 
and 97.44%, respectively, and for AMY2A target assay and its reference assay was 
96.56% and 98.59%, respectively. The efficiency between target and reference loci 
differ by less than 5% is considered sufficiently similar (Fernandez-Jimenez et al. 
2011). 
 
A      B 
 
Figure 4.3  Real-time PCR standard curve representing PCR efficiency. A) Taqman 
assay Hs07226362_cn targeting AMY1 and the RNaseP reference assay. B) Taqman 







4.2.3 Copy-number Estimation of AMY1 by Digital PCR   
Digital PCR was performed on Quantstudio™ 3D Digital PCR System 
(Thermo Fisher Scientific) using Digital PCR 20K Chip which contains 20,000 
reaction wells per chip, each well holds ~865 pl reaction volume. Thermal cycling 
was carried out in a Dual Flat Block GeneAmp® PCR System 9700 and analysis with 
Quantstudio™ 3D AnalysisSuite software. First the human genomic DNA has to be 
digested with appropriate restriction enzyme to break up the CNV copies. 4ul of 
genomic DNA (100ng/ul) was digested with 1ul RsaI (10U/ul) (New England 
Biolabs), with 1ul of 10x enzyme buffer in a final volume of 10ul. Digestion was 
carried out at 37ºC for 1h followed by enzyme inactivation at 65ºC for 20mins. 
Digested DNA was diluted 4x to a final volume of 40ul. 4ul of the diluted DNA 
(10ng/ul) was used in each digital-PCR reaction, which would contain 8ul of the 2x 
digital-PCR master mix, 0.8ul of 20x target Taqman assay, 0.8ul of 20x reference 
RNasaP assay, and 2.4ul sterile water to constitute a final volume of 16ul. About 
14.5ul of the dPCR reaction product was loaded per chip. Thermal cycling condition 
was 1 cycle of 96ºC 10 min, followed by 39 cycles of 60ºC 2 min 98ºC 30sec, and a 
last cycle of 60ºC 2 min. A final concentration of 2.5 ng/ul genomic DNA input into 
the dPCR chip is equivalent to approximately 750 copies/ul, which is within the 
recommended target sequence concentrations of between 200 to 2,000 copies/ul for 
successful dPCR analysis (Thermo Fisher Scientific Inc., USA).   
 
4.2.4 Statistical analysis 
Student’s t-test, Mann-Whitney test and Correlation test were carried out in 
GraphPad Prism 6. Fisher’s exact test, Cochran-Armitage trend test and power 
calculation were done in Excel XLSTAT. Logistic and linear regressions were carried 
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4.3.1 Genotyping Results 
4.3.1.1 Genotyping Results of AMY2A Copy Number in DF and OB Cohorts 
The technical challenge of genotyping increased with copy number, as 
demonstrated from the genotyping results of AMY2A and AMY1, where my data 
showed a distribution of 1 to 5 and 2 to 24 copies, respectively. The histogram of a 
CNV locus provides a good overview of the degree of robustness in estimating 
diploid copy number. Figures 4.4 A & B show the overall CNV genotype calls for the 
AMY2A locus in OB and DF sample sets, respectively. The genotypes cluster 
discretely and specific CN genotypes were clearly discernible, showing four copy 
number classes in the OB cohort and five classes in the DF cohort (Figure 4.4C & D).  
 



















































Figure 4.4 Histograms of the calculated copy number for AMY2A CNV locus, not 
rounded to integer.  A)  Taqman assay Hs4204136_cn for OB cohort comprising all 
1077 samples. B) Taqman assay Hs03342654_cn for DF cohort comprising 278 
samples. C) AMY2A CN sorted in order for the OB cohort and the clear delineation of 




4.3.1.2 Calibrating AMY1 qPCR Estimated Copy Number to dPCR Output 
The highly variable copy number of AMY1 presented a notable challenge. Its 
histogram showed a continuous distribution of calculated CN (Figure 4.5). But there 
were obvious clusters at regular intervals. It was also noted that the calculated copy 
number tended to produce a higher numerical number than expected as CN increased, 
an observation similarly noted in AMY2A where calculated CN from the comparative 
Ct method tends to increase in numerical value faster than the actual copy number 
(Figure 4.4 A & B). To validate the reliability and accuracy of qPCR results, all four 
reference samples (NA series. Coriell Repository, USA) and a series of 15 OB 
samples were genotyped with digital PCR, and the results were compared directly 





















Histogram  (AMY1 CN)
Figure 4.5 Histogram of the original calculated copy number for AMY1 in OB cohort 
comprising all 1077 samples. Taqman assay Hs07226362_cn targeting exon 1 of 
AMY1.  
 
Digital PCR is known to be more accurate than qPCR especially for 
discerning higher copy number because its measurement is by digital count, therefore 
dPCR uses a linear method in contrast to qPCR which has a logarithmic approach. At 
higher copy number, the fold change of copy 11 to 10 is 1.1 fold, a smaller fold 
change compared to copy 3 to 2 which is equivalent to 1.5 fold. The CT difference 
between adjacent copies reduces with increasing copy number, but this should not 
affect end-stage counting of dPCR where the number of positive reaction well 
difference shall remain the same whether the copy change is 3 to 2, or 11 to 10. 
Figure 4.6 demonstrates the output of three samples with increasing AMY1 copy 
number. The number of positive target reaction well increases in direct proportion to 
the number of well positive for the RNase P reference gene. 
 











Figure 4.6 Digital-PCR chip image and distribution of positive reaction assays. The 
yellow spots on the graph represent reaction wells with no amplification. Blue spots 
represent reaction wells with target AMY1 amplicons. Red spots represent reaction 
wells with reference RNase P gene. Green spots are wells that contain both AMY1 and 
reference gene amplicons. A) Sample OB273 with 2 diploid copies of AMY1. Note 
the blue and red scatter plots are of similar intensity of equal ration. B) Sample 
NA10472 with AMY1 diploid copies 6, and C) Sample NA18972 with AMY1 16 
copies, and the blue spots far outnumber the red spots. 
 
Interestingly, the correlation between dPCR estimated copy number (CN) and 
qPCR calculated CN was very high, with Pearson r=0.966, p=7.76 x 10
-11
, and 
Spearman r=0.998, p=1.65 x 10
-20
. A standard curve was constructed to correlate 
qPCR data to those of dPCR (Figure 4.7). Instead of using calculated copy number, 
the raw qPCR signal intensity delta-delta Ct (ΔΔCT) was used to plot against the 
logarithm of estimated copy number obtained from dPCR. Delta-delta CT represents 
the difference of delta CT of sample and calibrator;  
ΔΔCT  =  [(CT target – CT reference)sample – (CT target – CT reference)calibrator]  
By taking ΔCT of calibrator into consideration, this permits the normalization 
of ΔCT across different 384-well plates (interplate experimental runs). A polynomial 
line (Y=-0.0149X
2
-0.2341X+0.7617) provides the best fit correlating qPCR to dPCR 
results. Table 4.2 summarises the detailed dPCR and qPCR information of the 15 OB 
samples and 4 reference specimens used in the standard curve.  
This standard curve was used to calibrate all qPCR results with dPCR output 
for both the OB and DF cohorts, since both sample sets have undergone similar 
laboratory processes from DNA extraction to copy number genotyping. With these 
calibration and normalization, a final diploid copy number for each sample has been 





















NA10472 4 5.75 0.76 4 6.25 0.06
NA10851 4 5.59 0.75 12 6.00 0.00
NA18956 3 5.18 0.71 12 5.50 0.13
NA18972 3 16.14 1.21 12 28.63 -2.25
OB0273 3 1.95 0.29 4 1.68 1.84
OB1189 5 2.97 0.47 4 2.71 1.14
OB0662 5 4.08 0.61 4 3.93 0.61
OB0562 2 4.95 0.69 4 5.01 0.26
OB0984 3 6.00 0.78 4 6.29 -0.07
OB0129 2 6.78 0.83 4 7.52 -0.33
271 2 6.96 0.84 12 7.93 -0.38
OB1125 2 7.93 0.90 4 8.97 -0.58
OB0395 3 9.69 0.99 4 10.76 -0.84
OB0768 2 10.03 1.00 4 13.16 -1.13
OB0130 2 10.11 1.00 4 11.48 -0.94
OB0357 2 11.37 1.06 4 15.50 -1.37
OB0413 4 13.38 1.13 4 23.07 -1.94
OB0433 4 18.44 1.27 4 35.13 -2.55
OB0350 4 24.34 1.39 4 62.17 -3.37
dPCR qPCR
 





















samples) are summarised in Figure 4.8, showing a range of CN distribution from 2 to 
24 diploid copies. Although clusters of genotypes exist, the adjusted copy number 
remained as a continuous distribution across the sample set as in the original data 
(Figure 4.5). Estimation of CN genotypes in integer were accomplished by binning 
using defined thresholds to the nearest integer, which is considered as one of the 






















Figure 4.7 Standard curve correlating qPCR ΔΔCT to dPCR Log10(estimated CN) for 




















Histogram (AMY1 CN) 
Most interestingly, it was noted that all the major clusters are of even 
number, with diploid copy number 4, 6, 8, 10, and 12. While diploid odd number 
clusters formed small peaks in between the large clusters of even copy number 
(Figure 4.8). Repeated dPCR genotyping on selected OB samples per cluster 
reproduced consistent results (Table 4.2), re-affirming the overall results in Figure 
4.8. No other previous publication had reported such a phenomenon (Perry et al. 
2007; Santos et al. 2012; Falchi et al. 2014). All those previous studies of various 
sample sizes ranging from hundreds to thousands (~6,200 samples in Falchi et al. 
2014) showed histograms with an approximately normal distribution of copy number. 
This novel observation of differential even and odd diploid AMY1 copy number that 
was discovered in this study could be clarified by analysis of haplotype structures at 
the AMY1 locus. The evidence of specific AMY locus haplotype structural forms 
could be found in historical publication and two recent studies conducted by 
independent research groups presented in American Society of Human Genetics 
Meeting, Oct 2014. Therefore, this novel observation may reflect a genuine biological 
effect of AMY1 and is discussed further in the next section.  
 
 
Figure 4.8 Histogram of the transformed calculated copy number for AMY1 in OB 
cohort comprising all 1077 samples. AMY1 diploid copy number ranges from CN2 to 
24. 
 
AMY1 copy number clustered into discrete classes up till CN4 (Figures 4.8 
and 4.9). After CN4, the estimated copy number values showed a continuous 
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(Figure 4.8). Estimation of CN genotypes was done by binning using defined 
thresholds, rounding qPCR estimated CN to the nearest integer (Figure 4.9). 
However, statistical analysis was carried out using both integer copy number and the 
raw estimated copy number without rounding. In addition, the most direct raw qPCR 
signal intensity (delta-delta Ct, ΔΔCt) was also used as a continuous measurement in 











Figure 4.9  Sorted distribution of AMY1 estimated copy number of OB cohort and 
binning with defined threshold. Two samples with CN18 and CN24 not shown. 
 
 
4.3.1.3 Amylase Haplotype Structure Results in Unique Correlation between 
AMY2A and AMY1 Diploid Copy Number  
A common haplotype structure deduced 25 years ago (Groot et al. 1989; 
Groot et al. 1990) is similar to that presented in human reference sequence and are 
shown in Figure 4.1 and 4.2, respectively. Using segregation analysis of Southern 
blot hybridisation patterns in pedigrees, they defined two other AMY1 haplotypes 
(Groot et al. 1990), and suggested that a general designation 2B-2A-(1A-1B-P1)n-1C 
could describe the majority of the AMY haplotypes (Figure 4.10). The repeat 
sequence that is about 100kb in size encompassing the genes AMY1A-AMY1B-
AMYP1 and are flanked by segmental duplication designated as SD1 in Figure 4.1. 
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Figure 4.10  Structure of the human amylase haplotypes AMY*01, AMY*03, and 
AMY*05. 2b, AMY2B; 2A, AMY2A; 1A, AMY1A; 1B, AMY1B; 1C, AMY1C; P1, 
AMYP1 pseudogene. The yellow arrow indicates a 100kb homologous sequence 
which is flanked by segmental duplication listed as SD1 in Figure 4.1. (Modified 
from Groot et al. 1990) 
 
Recently, two independent research groups, Armour et al. at University of 
Nottingham, UK; and McCarroll et al. at Broad’s Institute, USA, expanded the range 
of AMY haplotypes and reported their findings in American Society of Human 
Genetic Annual Meeting in October 2014. Armour et al. used Paralogous Ratio Test 
while McCarroll et al. adopted both whole-genome-sequencing read depth analysis 
and droplet digital PCR in genotyping. Importantly, both common and rare AMY 
haplotype structures and their respective allele frequencies in European have been 
deciphered (Figure 4.11B) (McCarroll et al. 2014, Personal communication). In 
addition, the diploid copy number distributions of the AMY2B, AMY2A and AMY1 
genes were reported in three population groups, Chinese cum Japanese; Yoruban; and 
European (Figure 4.11A). These conclusions match those defined by Groot et al. 
(Figure 4.10). It is important to note that the four common haplotypes, all with odd 
copy number of AMY1 (1, 3, 5 and 7 copies), constituted a total of 90% of all AMY 
haplotypes in European (Figure 4.11B). Therefore, this clearly explains why the 
majority of AMY1 diploid copy number are even, which is corroborated with  the 
AMY1 data of this study, for both the OB and DF cohorts (DF cohort will be 





Also noted was the AMY1 copy number differential distribution between even 
and odd number are more distinct in Asians (CHB+JPT) compared to European, with 
population mode at CN6 and 8 for Asians, while CN6 for European (Figure 4.11A). 
Similar population modes are found in related Singapore populations, with Chinese 
showing mode at CN6 and CN8, Malays at CN8, and Indians CN6, in the DF cohort 
(see Figures 4.14 & 4.15, Section 4.5). Figure 4.12 shows the copy number 
distribution in 519 Chinese controls from the OB cohort. The distribution frequencies 










Figure 4.11  Structural haplotypes of AMY locus and the population distributions of 
AMY haplotypes and the diploid copy number of the three AMY genes. A) The 
distribution of diploid copy number of AMY2B, AMY2A and AMY1 in 3 population 
groups. CHB+JPT, Chinese and Japanese; YRI, Yoruba; CEU, European. B) Inferred 
haplotype structures and allele frequencies in European population. Note that a 
complete AMY2A gene would contain both the 5’ and 3’ segments, which are 
represented by the dark blue and light blue boxes, respectively. The two AMY2A 
assays used in this thesis targeted the 5’segment. (Adapted from McCarroll et al. 











Figure 4.12  AMY1 diploid copy number distribution in 519 Chinese controls from the 
OB cohort.  
 
Another interesting outcome from these common AMY haplotype structures is 
that they resulted in a unique correlation between the diploid copy numbers of 
AMY2A and AMY1. When AMY2A has a copy number of 2 (non-CNV), the AMY1 
copy number is almost always even. While AMY2A with copy number of non-2 are 
mostly associated with odd copy number of AMY1. This is clearly demonstrated in 
the scatter plot of both genotypes from OB Chinese samples (Figure 4.13). Data for 
Malay samples of OB cohort are not shown because of the small sample size, but a 
similar clustering pattern was found. When estimated copy number were rounded to 
the integer and association testing carried out, all sample groups showed significant 
association between copy numbers of AMY2A and AMY1, with AMY2A CN2 
genotype associating with AMY1 even copy numbers, while AMY2A CNVs (non-2) 
associating with AMY1 odd copy numbers (Table 4.3). Similar correlation was also 
reported by Armour et al. and Usher et al. (Armour et al. 2014; Usher et al. 2014).  
The work reported by by Armour et al. and McCarroll et al. have lent support 
to the reliability and quality of our data. Furthermore, the diploid copy number 
distribution in Chinese and Malay resembled those of CHB+JPT (Figures 4.11A & 
4.15A). In addition, the calculated haploid copy number in Chinese and Malays, ~0.4 



































































AMY2A-AMY1 CN Distribution in Chinese Obese (n=413)
Chinese Controls n=519 Chinese Obese n=413 Malay Controls OB+DF n=124 Malay Obese n=115
Count AMY2A CN Count AMY2A CN Count AMY2A CN Count AMY2A CN
AMY1 CN 2 non2 AMY1 CN 2 non2 AMY1 CN 2 non2 AMY1 CN 2 non2
even 397 12 409 even 314 3 317 even 89 3 92 even 89 3 92
odd 85 25 110 odd 75 21 96 odd 27 5 32 odd 16 7 23
482 37 519 389 24 413 116 8 124 105 10 115
Fisher's exact test: Fisher's exact test: Fisher's exact test: Fisher's exact test:
p-value (Two-tailed) <0.0001 p-value (Two-tailed) <0.0001 p-value (Two-tailed) = 0.0267 p-value (Two-tailed) =0.0004
European (Figure 4.11B).  Therefore, we proceed with the analysis for our datasets. 
The DF dataset was used in the population diversity study of AMY loci in Singapore 
populations, while the OB dataset is used for association testing to validate the 
putative association of AMY1 copy number and obesity.  
A      B 
  
Figure 4.13  The distribution of AMY2A-AMY1 diploid copy number in OB sample 
set. Copy number of AMY1 is obtained from qPCR estimated CN calibrated to the 
standard curve and without rounding to integer. A) 519 Chinese controls. B) 413 
Chinese obese samples. 
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Table 4.3  Association testings of AMY2A and AMY1 diploid copy numbers. A) 519 
Chinese controls. B) 413 Chinese obese samples. C) Combining Malay controls from 





4.3.2 Population Diversity Pattern of AMY1 and AMY2A CNVs in Singapore 
Populations 
The diploid copy number distribution of AMY1 and AMY2A were compared 
between the three Singapore populations, Chinese, Malays, and Indians, of sample 
sizes 99, 94, and 85, respectively.  The differential frequency between even and odd 
copy numbers can be found in DF cohort as well, although its effect is less marked 
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AMY2A CN2 with AMY1 even copy numbers is also noted in the DF cohort (data not 
shown).  
Mann-Whitney test indicated a statistical significant mean difference in copy 
number between Malays and Indians (CN mean difference=1.02 +/- 0.39, 95% 
confidence interval of the mean difference = 0.24 - 1.79, p=0.0112), but not in other 
population-pair comparisons (Figure 4.14D). Among the three populations, Malays 
harbor higher AMY1 copy number while Indians have lower copy number. The 
population mode in Malays is CN8, CN6 in Indians, and Chinese displays 2 modes at 
CN6 and CN8.  
 















Figure 4.14  AMY1 diploid copy number distribution in Singapore populations. A) 99 
Chinese, B) 94 Malays, and C) 85 Indians. D) Mann-Whitney tests of AMY1 CN not 
rounded to integer for the 3 populations. 
 
To further test if Chinese and Malays show any differentiation in AMY1 copy 
number, the control samples from OB cohort were combined with those from the 





















































p = 0 . 0 4 9 *
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Malays. With a larger sample size, there is a nominal significant difference of mean 
copy number between Chinese and Malays (Mann-Whitney test, p=0.049, CN mean 
difference= 0.50 ± 0.23, 95% CI of mean difference = 0.05 to 0.95 CN) (Figure 
4.15A & B). Chinese has an average copy number about 0.5 CN smaller than Malays. 
Furthermore, the larger sample size better demonstrated a distribution pattern closely 
reminiscent of those in CHB+JPT reported by McCarroll et al. (Figure 4.11A). 
 







Figure 4.15 A) AMY1 diploid copy number distribution in Chinese (n=618) and 
Malays (n=124) by combining DF and OB samples. B) Mann-Whitney tests of AMY1 
CN not rounded to integer for the same 2 populations. 
 
AMY2A is much less variable, with copy number ranging from 1 to 4 in this 
DF cohort (CN1 to 5 in the OB cohort, Section 4.3.1.1), slightly more variable than 
the range of CN1 to 3 reported in European (Falchi et al. 2014). The majority of the 
AMY2A copy numbers are 2 in all three local populations, but there is an obvious 
decrease of CN2 and a corresponding increase of non-2 copy number in Indians 
(Figure 4.16, Table 4.4). A significant difference in AMY2A copy number was noted 
between Chinese and Indians. The distribution patterns of AMY2A in Chinese and 
Malays in contrast to Indians are reminiscent of those in CHB+JPT and CEU in 
















































AMY2A CN C M I
2 94.9% 92.6% 83.5%
non-2 5.1% 7.4% 16.5%











Figure 4.16  AMY2A diploid copy number distribution in three populations. C, 99 
Chinese; M, 94 Malays; and I, 85 Indians. 
 
Table 4.4  Percentages of AMY2A diploid copy number 2 (non-CNV) versus non-2 
(AMY2A CNVs) in Chinese, Malay, and Indians. Sample sizes as in Figure 4.16. A 
significant difference in AMY2A copy number was noted between Chinese and 
Indians. 
 
The diploid copy number estimated by the qPCR and Affymetrix SNP 6.0 
microarray platforms for each DF sample were compared. The concordance rate of 
genotyping between the two platforms reflected what is expected, which is dependent 
on the number of allele copy. The overall concordance rates are 23.7% and 93.2% for 
AMY1 and AMY2A, respectively (Figures 4.17A & B). Although microarray detected 
both AMY1 and AMY2A CNV loci correctly, its copy number genotyping for AMY1 is 
highly inaccurate. Being a hybridisation platform relying on intensity for 
measurement, microarray is inherently not suitable for genotyping multi-copy CNV. 
The AMY1 and AMY2A loci have clearly demonstrated how the extent of multi-copy 
alleles could affect the robustness of genotyping. 
qPCR and dPCR provide the number of copies of AMY1 gene in the diploid 
genome without identifying the haploid alleles of AMY1. An algorithm (CoNVEM) 
was used to estimate allele frequencies (http://apps.biocopmpute.org.uk/convem/) 
(Gaunt et al. 2010). The computation of allele frequencies is based on the 
expectation-maximization algorithm and assumes Hardy-Weinberg equilibrium. The 
estimated allele frequencies of AMY1 for the three local populations are summarised 


















































































































































































































populations, while Chinese and Malays had higher allele frequency of allele copy 5 
compared to Indians (Figure 4.18A). As for AMY2A, the dominant haploid allele 
contained a single copy of AMY2A. This haploid allele decreased in frequency from 
Chinese to Malay to Indian, in direct contrast to allele with 2 copies of AMY2A, 
whose frequencies increased from Chinese to Malay to Indian (Figure 4.18B). 
 
A      B 
 
Figure 4.17  Concordance rate of diploid copy number obtained from microarray 
versus qPCR in every DF sample. Numbers highlighted in red represent the 
concordant results genotyped by both platforms. A) AMY1 CNV locus. B) AMY2A 
CNV locus. 
 
A      B 
 
Figure 4.18 Haploid Copy-number allele frequencies in the three local populations. 
Allele frequencies were estimated through the EM algorithm implemented in 
CoNVEM. A) AMY1, B) AMY2A. 
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In summary, the diploid copy number distribution of AMY1 and AMY2A in 
Chinese and Malays resemble each other, while Indians shows a different pattern.  
This difference in pattern is akin to those in CNB+JPT versus CEU (contrasting 
Figures 4.15, 4.14C & 4.11A). The difference of CNV variation in Indian versus 
Chinese and Malays is in line as in SNP differentiation (Teo et al. 2009), and in sex-
lineage markers among the three populations (see earlier work in section 1.5). This 
differentiation pattern is similarly noted in many other CNVs as shown in Chapter 3, 
reflecting the extent of genetic relatedness between the three populations, with 
Chinese and Malays genetically more related, and Indian genetically further apart. 
Nevertheless, it should be noted that at large sample size, AMY1 did show a 
significant difference in copy number between Chinese and Malays, indicating AMY1 
is a more highly stratified CNV. Among the 3 groups, the direction of genetic 
relationship has changed in AMY1 compared to AMY2 which resemble the genome-
wide average. Further discussion in Section 4.4.2. 
 
4.3.3 Association Studies of AMY1 and AMY2A Copy Number with Obesity 
One of the impetuses of embarking on this large scale genotyping of AMY 
CNVs is to validate the recent findings of a positive association whereby reduced 
AMY1 copy number was associated with increased BMI (Falchi et al. 2014). This 
finding was replicated in 6,200 subjects, comprising four European cohorts and one 
Singapore Chinese cohort.  The obesity risk (Odds Ratio, or OR) per copy reduction 
of AMY1 was reported to be 1.19 in European (95% confidence interval (CI) = 1.13 - 
1.26; p=1.46 x 10
-10
), and 1.17 in Singapore Chinese cohort (95% CI = 1.05 – 1.29, 
p=3.73 x 10
-3





). On the other hand, AMY2A copy number was reported to have no 
association with BMI or fat mass. This was an intriguing finding as it was the first 




Phenotype Control Obese Extreme  Obese Control Obese Extreme  Obese
No. 519 413 173 30 115 64
Average Age (SD) 19.4 (1.1) 19.2 (1.2) 19.3 (1.1) 19.7 (0.9) 19.4 (1.1) 19.3 (1.1)
Average BMI in kg/m2 (SD) 20.8 (2.0) 34.2 (3.6) 37.5 (2.7) 20.8 (2.2) 36.2 (4.8) 39.3 (4.2)
Min to Max BMI 15.8 - 25.2 28.1 - 49.3 32.5-49.3 17.0-24.7 28.7-51.5 33.8-51.5
Median BMI (1st-3rd quatiles) 21.0 (19.3-22.3) 33.5 (31.4-36.7) 37.2 (35.6-38.6) 20.5 (19.1-22.2) 35.1 (32.6-39.1) 38.8 (35.8-41.1)
Chinese Malay
Table 4.5 summarised sample details of the OB cohort. The definition of 
controls, obese, and extreme obese are by BMI < 23 kg/m
2, ≥ 28 kg/m2, and ≥ 32 
kg/m
2
, respectively. This study has adopted similar Taqman assays as in Falchi et al. 
for parallel comparison. Assay Hs07226362_cn targets exon 1 of AMY1 thereby 
excluding the psuedogene AMYP1 while encompassing AMY1A, AMY1B and AMY1C. 
Assay Hs04204136_cn targets intron 2 of AMY2A.  
 
 
Table 4.5  Summary information for subjects included in the OB cohort. 
 
4.3.3.1 Association Testing of AMY1 Copy Number and Obesity 
In obese Chinese, the modal copy-number was lower than in the lean (CN6, 
8, respectively), while the same trend was seen in the Malays (CN8 versus CN10) 
(Figures 4.19A & B). However, these differences did not reach statistical significance 
in statistical tests carried out for four pair-wise comparisons; controls versus obese, 
and controls versus extreme obese, for Chinese and Malay populations separately. 
The CN mean difference between each case-control set was all very small, so was the 
95% confidence interval of mean difference (Table 4.6A).  The Mann-Whitney test 
showed no significant association in all 4 groups of comparison (p>0.09, Table 4.6A). 
Logistic regression similarly indicated no significant association in all four case-
control sets (p>0.27, Table 4.6B). Linear regression was done to test if AMY1 copy 
number predicts BMI changes, and results were also negative (Table 4.6C). Statistical 
analysis was carried out on direct raw qPCR signal intensity (ΔΔCt) as a continuous 
measurement, but no association could be detected (Mann-Whitney test, p>0.05. 
Figure 4.21). The average BMI at various AMY1 copy number did not show any 


































N Av Age (SD) Av BMI (SD) β (SE) P OR (95% CI)
Chinese Controls 519 19.4 (1.1) 20.8 (2.0) 0.003 (0.028) 0.907 1.003 (0.950 - 1.059)
Obeses 413 19.2 (1.2) 34.2 (3.6)
Controls 519 19.4 (1.1) 20.8 (2.0) 0.019 (0.037) 0.598 1.020 (0.949 - 1.096)
Extreme Obeses 173 19.3 (1.1) 37.5 (2.7)
Malay Controls 30 19.7 (0.9) 20.8 (2.2) -0.087  (0.080)   0.274 0.916 (0.783 - 1.072)
Obeses 115 19.4 (1.1) 36.2 (4.8)
Controls 30 19.7 (0.9) 20.8 (2.2) -0.085  (0.086)   0.325 0.919 (0.776 - 1.088)






































Malay Controls vs Obese
Control
Obese
A      B 
Figure 4.19  AMY1 CN frequency distribution in OB cohort. A) 519 Chinese controls 
versus 413 obese. B) 30 Malay controls versus 115 obese. 
 
A      B 
 
Figure 4.20 Average BMI at different AMY1 estimated copy number. Error bar 
represents standard deviation. A) 519 Chinese controls versus 413 obese. B) 30 












N CN Mean 
Difference (SE)




Chinese Controls 519 0.0123 (0.158) -0.298 to 0.322 0.932
Obeses 413
Controls 519 0.108 (0.209) -0.302 to 0.519 0.551
Extreme Obeses 173
Malay Controls 30 0.582 (0.475) -1.537 to 0.373 0.126
Obeses 115





N Av Age (SD) Av BMI (SD) β (SE) P
Chinese 930 19.3 (1.1) 26.7 (7.2) 0.041 (.100) 0.683
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Table 4.6  Statistical tests for AMY1 CN-association analyses for four groups of 
comparison; controls-obese and controls- extreme obese in Chinese and Malays. 
Integer copy number rounded from the underlying continuous Estimated CN from 
qPCR.  A) Comparison of AMY1 CN between case-control samples and their 95% CI 












Figure 4.21  Mann-Whitney test of ΔΔCt in controls, obese, and extreme obese 
samples. Low ΔΔCt values correspond to high AMY1 copy numbers.  A) Chinese 
samples. B) Malay samples. 
 
To estimate if this study has enough statistical power to detect association as 
in Falchi’s study. It was noted that the CN mean difference between case-control 
samples in one study cohort (DESIR cohort, Falchi et al. 2014) was 0.95 with 
standard deviation of ~2.0. With these parameters, a sample size of 147 per arm 
would have 90% power. On the other hand, if the observed copy number mean 
difference and standard deviation seem in this study for the Chinese cohort is used 
(mean difference 0.0123 & SD 2.32 & 2.49), the calculated sample size required to 
detect significant difference with 90% power would be >803,000 per arm. This large 
sample size would effectively support no association.  In short, this study does not 
support the reported association between AMY1 copy number and BMI/obesity in an 
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independent Singapore Chinese cohort. A summary table comparing the different aspect of this study and the reported study (Falchi et al. 2014) can be found 
in Table 4.7. 
 
Population Cohort Gender Genotyping N Age (years) BMI (kg/m
2
) N Age (years) BMI (kg/m
2
) β (se) p OR (95% CI)
Bristish Caucasian TwinUK M / F qPCR 251 53 (47-60) ≥30 711 51 (44-59) <25 -0.26 (0.09) 3.6 x 10-3 1.30 (1.08-1.55)
French Caucasian DESIR M / F qPCR 137 55 (47-64) ≥30 1267 51 (42-59) <25 -0.16 (0.04) 7.5 x 10
-5
1.18 (1.09-1.27)
French Caucasian AOB M / F qPCR 205 36 (29-41) ≥30 358 35 (33-38) <25 -0.17 (0.04) 4.4 x 10-5 1.19 (1.10-1.29)
Singapore Chinese SP2 M / F qPCR 136 47 (37-54) ≥28 325 44 (34-51) <23 -0.15 (0.05) 3.7 x 10-3 1.17 (1.05-1.29)
Singapore Chinese OB M qPCR+dPCR 413 19 (17-23) ≥28 519 19 (17-21) <23 0.003 (0.03) 0.907 1.003 (0.95-1.06)
Singapore Malays OB M qPCR+dPCR 115 19 (17-22) ≥28 30 20 (18-21) <23 -0.087 (0.08) 0.274 1.02 (0.95-1.10)
Cases Controls Association Testing
 
Table 4.7  Summary table comparing various aspect of this present study and those reported in Falchi et al. 2014. Only case-control studies were included. 
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4.3.3.2 Association Testing of AMY2A Copy Number and Obesity 
CNV-association testing was similarly carried out for AMY2A. The 
distribution of AMY2A copy number in controls and obese samples was summarised 
in Figure 4.22. No association between AMY2A copy number and obesity was 
detected by logistic regression (Table 4.8). Mann-Whitney test using ΔΔCt as a 
continuous measurement also showed no association in all 4 case-control sample sets 
(Figure 4.22). This finding is in agreement with Falchi et al. (Falchi et al. 2014). 
 






Figure 4.22  AMY2A CN frequency distribution in OB cohort. A) 519 Chinese 
controls versus 413 obese. B) 30 Malay controls versus 115 obese. 
 








Figure 4.23  Mann-Whitney test of ΔΔCt in controls, obese, and extreme obese 
samples. Low ΔΔCt values correspond to high AMY2A copy numbers.  A) Chinese 



























Case-Control N β (SE) P OR (95% CI)
Chinese Obese-Control 413 vs 519 0.121 (0.204) 0.552 0.886 (0.594 - 1.321)
Extreme Obese-Control 173 vs 519 0.053 (0.269) 0.843 0.948 (0.560 - 1.605)
Malay Obese-Control 115 vs 30 0.369 (0.652) 0.571 1.446 (0.403 - 5.192)
Extreme Obese-Control 64 vs 30 0.156 (1.243) 0.459 1.556 (0.483 - 5.012)
 
 
Table 4.8  Logistic regression for AMY2A CN-association analyses of four groups of 
comparison; controls-obese and controls- extreme obese in Chinese and Malays. 
Integer copy number rounded from the underlying continuous estimated CN from 
qPCR.   
 
 
4.4 DISCUSSION  
The chief rationale of carrying out a detailed locus-specific study at the AMY 
locus was to illustrate the application of CNV to population diversity and its effect on 
biological traits. There were three objectives in this study: 
1) To test the current array and qPCR methods for genotyping multi-allelic 
CNVs/CNPs with high copy number and develop a novel AMY 
quantitation assay on a dPCR platform. 
2) To explore the population diversity of AMY1 and AMY2A loci in local 
populations. 
3) To study if the recent reported association of AMY1 copy-number and 
obesity could be replicated in a second Singapore Chinese cohort.  
 
4.4.1 Genotyping CNV 
The technical challenges in accurately genotyping multi-allelic CNVs/CNPs 
were well exemplified by the AMY1 and AMY2A CNVs. The genotyping performance 
of AMY2A in qPCR proved to be much more robust than AMY1. This is chiefly due to 
the smaller copy-number range of AMY2A, with diploid copy numbers ranging from 




A challenging aspect of multi-allelic copy number analysis is that the relative 
difference between copy numbers becomes smaller and more difficult to discriminate 
as copy number increases. For example, one copy increase from CN2 to CN3 
translates into a 1.5 fold change, but a single copy change at from CN10 to CN11, 
translates into a 1.1 fold change only. This means higher measurement precision is 
needed to quantify high copy-numbers. This is reflected in the observation that in 
qPCR, the ΔCt difference for 1 CN change decreases as the diploid copy number 
increases. In AMY1 genotyping, discrete classes are still callable at CN2, 3, 4 and 5, 
and qPCR measurements only become continuous after CN5 (Figures 4.8 & 4.9).  To 
increase precision at higher copy-number, one approach might be to increase the 
number of technical replicates for samples that harbor high copy-numbers. However, 
this could be difficult to implement in large-scale genotyping since a wide range of 
copy-numbers could be present in the sample set.    
Digital PCR (dPCR) is an absolute quantification method offers some 
solution to the above problem. It is an end-point PCR method, counting targets via 
single-molecule amplification across a large number of PCR replicates. The number 
of replicates determines the dynamic range of target DNA quantification, and the 
improved precision from many replicates therefore enables resolution of small 
quantity changes such as 1.1 fold change. The end-point measurement also means it is 
less affected by PCR efficiency. The dPCR platform used in this study, Quantstudio 
3D dPCR system, performed 20,000 replicates per sample. The limitation is its 
sample throughput, with a maximum 24 samples per run. Alternatively, a recently 
introduced water-in-oil droplet digital-PCR (ddPCR), which performs 20,000 
replicates on 96 samples per run, is likely to be a practical solution to high throughput 
copy-number genotyping (Hindson et al. 2011). 
This study has shown that qPCR could discriminate copy number discretely 
up to CN5, as in both AMY2A and AMY1. Despite the shortcoming of qPCR at high 
copy numbers, it still represents an attractive option for large-scale CNV genotyping 
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owing to its high throughput capabilities and the relative ease of use, as this study has 
shown. In this study, care has also been taken to minimize systematic bias and batch 
effects. All samples have been subjected to identical laboratory processes, sample 
randomization was done during genotyping, and four technical replicates were 
included per sample in qPCR. Also, validating reference samples with known copy-
number in our qPCR system ensured accuracy. The fact that this study had 
independently discovered the unique characteristic of differential frequency 
distribution between even and odd diploid copy-numbers of AMY1, and correlation 
between AMY2A and AMY1 genotypes, has re-affirmed the reliability and accuracy of 
this work. This unusual distribution of AMY1 copy-number is a novel finding which 
is markedly different from all previous publications (Perry et al. 2007, Santos et al. 
2012; Falchi et al. 2014). It is likely that the limits of CNV genotyping methods in 
earlier publications resulted in inaccuracies in establishing AMY locus CN 
frequencies. The novel finding of this study has now been corroborated by two 
presentations in ASHG 2014 meeting (Armour JA and McCarroll SA, personal 
communications). Furthermore, the population distribution can be explained from the 
underlying structural haplotypes and their allele frequencies at this locus. 
A recent small-scale study comparing various copy-number genotyping 
methods, qPCR, MLPA and PRT, had also concluded that qPCR has a reasonable 
level of accuracy although it exhibits poorer precision at high copy-number 
(Cantsilieris et al. 2014). While MLPA and PRT have been reported to be more 
precise than qPCR, they have limitations in terms of needing more optimization effort 
per target (Further details on MLPA & PRT in Section 1.4.4). Also, as both involve 
exponential amplifications, it is uncertain they can perform at the high copy numbers 
such as those in AMY1. In fact, there is no published study using these 2 methods for 
high copy number of >CN10. No large-scale CNV study has been reported with 
MLPA, and very few large-scale studies were done with PRT, hinting at possible 
limitation for large-scale genotyping.  
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Besides the challenge of quantifying copy numbers accurately in multi-allelic 
CNV, there could be other complexity related to assay design. The two 5’ nuclease 
assays used in this study have shown to be reproducible in independent laboratories. 
But in many multi-copy genomic regions, there could be inherent problems designing 
specific assays for regions of high homology. Paralogous sequence variants occurring 
within repeat copies could pose problems for non-specific primer binding, so is the 
existence of pseudogene such as the AMYP1 in the AMY locus. In addition, the 
underlying genomic structure such as segmental duplications could affect or 
complicate haplotype structure form and allele frequencies, as exemplified by the 
missed pattern of population frequencies at the AMY locus. As reference genome 
assemblies do not typically display multiple haplotypes, interpreting genotype output 
in multi-allelic CNV could be difficult. 
 
4.4.2 Population Diversity of AMY1 and AMY2A CNVs 
In general, the copy number frequency distribution of both AMY1 and 
AMY2A for Chinese resemble those of Malays, while Indians show a slightly different 
distribution from Chinese and Malays (Figures 4.14 & 4.16). For AMY1, Indians 
display a statistically significant difference for AMY1 copy number compared to 
Malays (Mann-Whitney test, p=0.0112) (Figure 4.14). And for AMY2A, Chinese and 
Indians showed significant difference (Fisher’s exact test, p=0.014. Table 4.4, Figure 
4.16). In addition, the estimated haploid allele frequencies deduced by CoNVEM 
indicated allele frequencies of major haploid allele (CN3 & CN5 for AMY1, CN1 & 
CN2 for AMY2A) tends to change as a gradient between Chinese-Malays-Indians, i.e. 
allele frequency increases or decreases in the same order (Table 4.4). Overall, for the 
copy number distribution pattern for both AMY1 and AMY2A, Chinese and Malays 




This pattern of distribution for AMY2A is similar to that of the genome-wide 
SNP differentiation (Table 3.7), and many other CNVs as shown in Chapter 3. Our 
sex-lineage markers have demonstrated a smaller genetic distance between Chinese 
and Malays, while Indians are genetically closer to European (see Table 1.3 of 
Section 1.5). Other studies have reported similar conclusion (Teo et al. 2009, Xu et al. 
2011). A general representation of the relationship among the 3 groups is in the order 
of Chinese-Malays-Indians. Their genetic distances are typically in this order; 
Chinese-Malays < Malays-Indians < Chinese-Indians, with Malays genetically closer 
to Indians than Chinese. The distribution pattern of AMY2A CNV is similar to the 
genome-wide average, and could be explained by the distance to The Most Recent 
Common Ancestor (TMRCA) and genetic drift. 
However, the distribution pattern of AMY1 CNV is different from the genome 
average. AMY1 did show a significant difference in copy number between Chinese 
and Malays when the sample size was increased (Mann-Whitney test, p=0.049) 
(Figure 4.15). Malays have the highest copy number of AMY1 while Indians have the 
lowest copy number among these 3 groups (Figure 4.14). The genetic relationship in 
AMY1 locus was in this order, Indians-Chinese-Malays, with their genetic distance 
differences as Chinese-Indians < Chinese-Malays < Malays-Indians. AMY1 is known 
to be highly stratified among global populations, and the high copy number found in 
populations with a high starch diet has been suggested as a locus under positive 
selection (Perry et al. 2007, Iafrate et al 2004). This difference in differentiation 
pattern of AMY1 in these 3 populations compared to AMY2A and the general genome-
wide pattern is an intriguing finding.  The higher copy number of AMY1 in Malays 
and lower copy number in Indians could be related to diet or other cultural adaptation.  
 
4.4.3 Obesity Association Studies with AMY1 and AMY2A CNVs 
The third objective is to study if the recent reported association of AMY1 
copy-number and obesity (Falchi et al. 2014) could be replicated in a second 
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Singapore Chinese cohort. This is important because if it could be validated, it will 
lend support to the first genetic link between carbohydrate digestion and BMI, and 
help to open a new research area. However, rigorous statistical analyses in this study 
failed to support any association between AMY1 copy number and obesity in both 
Chinese and Malays. Similarly, no association could be detected between AMY2A 
copy number and obesity in the same populations.  
The AMY2A result in this study corroborated with Falchi et al. (2014). But 
that for AMY1 was discordant between this study and Falchi et al (2014). A likely 
reason is the reliability of the AMY1 genotype data in both studies. Having genotyped 
this study (OB) cohort with the same Taqman assays as Falchi et al. has facilitated 
comparison of these two studies. It is interesting to note that Falchi et al. had failed to 
identify the eccentric distribution of AMY1 copy number in their data set, which was 
an indication of erroneous genotyping results. The AMY1 genotype data presented in 
Falchi et al. resembled a normal distribution, and the normal distribution pattern was 
consistent in all their study cohorts, suggesting some form of systematic error in their 
qPCR work. This would suggest the positive association detected could be a spurious 
outcome. 
Care has been taken in this study to minimize systematic bias and batch 
effects. Identical laboratory processes were used in all samples from the OB cohort, 
and sample randomization carried out during qPCR genotyping. These steps should 
distribute any experimental variability more uniformly across all samples, either cases 
or controls. Although qPCR copy number data did not cluster well into integer at 
higher copy, the approach of rounding qPCR measurement to the nearest integer is an 
commonly adopted approach, and an acceptable method for CNV-association testing 
(Barnes et al. 2008). The raw qPCR measurement (ΔΔCt) as a continuous parameter 
has also been used in statistical analysis for this study, and this is also a recognized 
approach (Barnes et al. 2008). Taking into consideration that qPCR measurement 
might be more variable and less precise at higher copy numbers, logistic regression 
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and Cochran-Armitage trend test have been carried out after collapsing all copy 
number ≥ 13 into a single group. But all analyses failed to show any significant 
association of AMY1 copy number and obesity nor BMI. Power calculation suggested 
the Chinese case-control sample set with >413 samples per arm should have >90% 
power to detect the effect noted in Falchi et al. 
The AMY2A result in this study corroborated with Falchi et al., which 
suggested that the positive association result for AMY1 identified in Falchi et al. could 
not be a false positive influencing from the neighboring AMY2A, but more likely the 
effect of erroneous AMY1 genotyping results. Taking all analyses into consideration, 
this study concluded that AMY1 copy number is not likely to be associated with 
obesity. A similar conclusion was reached by McCarroll’s group, who reported a 
study with 3 European cohorts, totaling >3,500 subjects, but no AMY1 copy number 
association with obesity nor BMI (Usher et al. 2014). 
In conclusion, there is now a substantial amount of evidence that supports the 
importance of multi-copy genes and human complex diseases, and many of these 
multi-copy genes reside in multi-allelic CNVs (Girirajan et al. 2011; Sudmant et al. 
2010). It is important to have a better understanding of these multiallelic CNVs. In 
addition, it has also been documented that, unlike biallelic CNVs, multi-allelic CNVs, 
especially those in segmental duplications, show poor LD with flanking SNPs 
(Campbell et al. 2011). Therefore, direct measurement of specific CNVs might be 
needed to determine the biological effect of these regions on complex diseases or 
other phenotypes. This study of multiallelic AMY loci provided some insight into the 
challenge and usefulness of doing such locus-specific targeted study. Although no 
positive association could be validated in this study, it has provided some insights to 
better understand the strength and weakness of various CNV genotyping methods, 
and a better appreciation of other challenges related to the study of multiallelic CNV, 





SUMMARY AND FUTURE DIRECTIONS 
 
5.1 Copy Number Variation in Singapore Populations and Its 
Population Genetics  
Copy Number Variation has emerged as a major source of genetic variation 
in the human genome, and contributes to human genetic diversity, diseases 
susceptibility and evolution. Cataloguing the pattern of CNV in the general 
population helps to understand its role in human phenotypic diversity. The aims of 
this work were to characterise the distribution and various attributes of CNV in our 
local populations, to better understand the population diversity and population 
genetics of this new class of DNA variants, and to investigate if any adaptive 
functional inference could be deciphered from the CNVs that are highly population 
stratified. To this end, a CNV catalogue has been established for three Singapore 
populations (100 Chinese, 95 Malays and 86 Indians) using the Affymetrix SNP 
Array 6.0 microarray. During the course of this work, it was recognised that 
experimental technologies, detection algorithms and DNA source (e.g. DNA 
extracted from cell lines versus peripheral blood (Craddock et al. 2010) all could be 
critical factors in identifying reliable CNVs.  
The final CNV catalogue adopted in this study was called by Birdsuite, 
containing a total of 22,024 CNVs which were merged into 2,227 CNVRs, and its 
quality was validated by qPCR. Common CNVRs (≥5% frequency) are likely to be 
true positives with false positive rate at 0%. However, rare & intermediate CNVR 
(<5%) CNVRs could have a false positive rate between 13.3 and 37.5%. Although 
common CNVRs are generally well detected by microarray, some extent of false 
negatives at sample level did occur in microarray, as confirmed by qPCR. But 
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importantly, this error rate is not serious enough to jeopardise the direction of 
population differentiation detected by microarray (Chapter 2). 
For the CNV identified in this study, every genome harboured about 78 
CNVs. Any 2 individuals can differ in copy number at an average 112. About 77% of 
these are common CNVs with frequency ≥5%. CNV tends to be highly skewed to 
rare frequency and small size. Deletions are generally smaller in size than 
duplications. There is also a significant depletion of gene content in deletions 
compared to duplications. All these appear to support the hypothesis that as a class, 
CNV is slightly or moderately deleterious and selection might act against changes in 
copy number, especially in deletions, as the genome is more likely to tolerate 
duplication than deletion. Common and complex CNVs are more likely to be 
associated with segmental duplications (SDs), which is also associated with CNVs of 
larger size. This supports the hypothesis that the mutation mechanism NAHR is 
involved in the formation of CNV, especially larger CNV. Furthermore, those CNVs 
associated with SDs have a significantly higher proportion of overlap with genes 
compared to the CNV not associated with SDs, which could be explained by the 
association of SDs with gene families (Chapter 2). 
In terms of genetic diversity between the three populations, there is no 
difference in the distribution of CNV numbers and other attributes such as the gene 
overlap between them. However, Indians showed significantly more duplication, and 
also harboured the highest number of population-specific CNVs among the 3 groups. 
Like SNPs, there are more CNVs shared between Chinese and Malays, and the least 
sharing between Chinese and Indians. The delta-values used to estimate population 
differentiation for CNVs reflected a similar trend as the FST used for SNP. These 
observations parallel our early studies using mitochondrial or Y-chromosome markers 
(Section 1.5), and all data suggests the genetic relationship between Chinese and 
Malays is closer than that between Indians and either of these groups (Chapter 3). 
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Although there are many population-specific CNVs in this catalogue, this 
study has confirmed that the number of population-specific common CNVs is very 
rare. Even cross-verifying with a large database of similar populations, SgD only 
identified 5 such CNVs. The lack of population-specific common CNVs lend support 
to the deleterious effect of CNV, preventing it from reaching high frequency. CNVs 
that are highly differentiated between these three populations were identified; among 
them are genes that are known to associate with diseases, and pharmacogenetic genes, 
which might help to account for disease and drug dosage differences between these 
three populations. The search of additional evidence to identify selection signal from 
these highly differentiated CNVs only uncovered a plausible CNV adjacent to 
NEGR1, with an enrichment of homozygous deletion and also a positive selection 
signal in Chinese and Malays. Interestingly, this CNV is associated with obesity in 
European populations but was never demonstrated in Asians, as in our in-house data 
that showed no association. Further work is needed to confirm the association of 
selected haplotype(s) with the deletion CNV and explore any functional differences 
between Asians and Indians for this putative selected locus (Chapter 3). 
At the inception of this work, there was no CNV data available for Singapore 
populations. Although CNV catalogues are now available in SGVP and SgD (Ku et 
al.2010, Xu et al. 2011), the dominance of rare and population-specific CNVs in all 
CNV catalogues suggest additional data will always be useful because many of the 
rare CNVs will likely be novel even in the same population. Furthermore, comparing 
this catalogue to SGVP showed an overlap of only 36.7%, confirming the value of 
additional catalogue. Direct comparison with SgD was not done because it is less 
appropriate due to platform and algorithm difference between the 2 studies. SgD used 
an assortment of arrays of lower density than Affy6.0 and hence the reported CNVs 
are generally 1 to 3 fold larger in size.  
The discovery of CES1 as a novel multallelic CNV (Chapter 2) also 
demonstrated the potential of this catalogue for further exploration and as a 
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hypothesis-generating tool. This catalogue should serve to expand CNV resources for 
Southeast Asian populations and contribute to building a global CNV map.  
 
5.2 Amylase Genes Cluster CNVs 
Active research in CNV in the past decade has led to a better understanding 
of CNV characteristics and their roles in human diseases. It is recognised that CNVs 
comprise a diverse set of variants, and some of them are not well understood because 
they are refractory to standard microarray genotyping which has been the workhorse 
of CNV association studies. One group are the multiallelic CNVs, and many of these 
CNVs could be associated with disease genes (Table 3.9). Therefore, this work later 
moved to a targeted study on the amylase genes CNV loci (AMY1 and AMY2A), using 
it to demonstrate the challenge of genotyping multiallelic CNV with different 
platforms including qPCR and dPCR. At the same time, the study also tested the 
population diversity of AMY1 and AMY2A CNVs in the three Singapore populations 
and to validate if the recent report of association between AMY1 copy number with 
obesity can be replicated in a second Singapore Chinese population (Chapter 4).  
We developed a method combining dPCR data in conjunction with qPCR 
data to establish a calibration curve specifically to translate the calculated copy 
number derived from qPCR to an estimated copy number equivalent of dPCR. Using 
this newly developed method on a sample set of >1,077 individuals, we discovered a 
novel distribution pattern of AMY1 diploid copy number with even:odd genotype 
imbalance, and also a unique correlation between the genotypes of AMY1 and 
AMY2A. This unique distribution and correlation pattern could be explained by the 
underlying haplotype structures in the amylase locus, and has been corroborated by 
two independent laboratories (Armour J, McCarroll SA, personal communications).  
Using this method, we showed that microarray has grossly underestimated 
AMY1 with a concordance rate at 23.7%, even though it detected AMY2A with a good 
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93.2% concordance, demonstrating the limitation of microarray in calling high copy 
number. The population stratification is stronger in AMY1 than AMY2A. The copy 
number distribution of AMY1 is significantly different between Malays-Indians and 
Malays-Chinese, making it one of the rare example of significant differentiation 
between Chinese and Malays.  
In the association testing of amylase genes CNVs and obesity in a Singapore 
Chinese obesity cohort (case/control=519/413), no evidence of association could be 
detected between neither AMY1 nor AMY2A copy number and obesity or BMI. The 
negative result between AMY1 and obesity is discordant with a recent report which 
claimed association in a Singapore Chinese cohort (Falchi et al. 2014). Their report of 
a normal distribution of AMY1 copy number indicated erroneous genotyping leading 
to spurious association. It also demonstrated the challenge of genotyping highly 
multiallelic CNV. 
 
5.3 Future Directions 
Affy6.0 microarray and its tailored designed algorithm Birdsuite is one of the 
highest resolution microarrays specifically designed for CNV discovery (Korn et al. 
2008, McCarroll et al. 2008). Furthermore, it has additional copy number probe 
besides SNP probes, thereby increasing the probe density and coverage along the 
human genome, particularly in SNP-poor regions such as repetitive regions or 
segmental duplications. These advantages are reflected in our dataset which has 
identified CNVs with a median size of 15kb, and on average smaller sizes than 
SGVP. However, there are still a number of limitations inherent to high resolution 
SNP microarray. These main limitations include: (1) the inability to detect copy-
neutral variation such as inversions and translocations, (2) a limited sensitivity to 
detect CNVs smaller than 10kb compared to sequence-based methods, and (3) the 
inability to determine breakpoint precisely. Resolving breakpoints precisely is 
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important as it helps to establish whether 2 alleles of indistinguishable structures are 
from the same or different ancestral mutation events, and also precisely determine the 
affected sequence and its function.  
The advent of next-generation-sequencing (NGS) technologies provides new 
promise to comprehensive screening of balanced structural variations, to exact CNV 
breakpoint characterization and to decrease the size bias inherent in microarray CNV 
detection technologies. The main advantage of whole genome sequencing 
technologies is they permit the simultaneous mapping of the entire spectrum of 
genetic variants (SNPs, indels, SVs and mobile element insertion) present in a single 
genome (more details in Section 1.4.3). However, they are much more costly than 
microarray and required substantial computational and bioinformatic support. Hence, 
applying sequencing-based methods to population-based studies are limited to large 
consortium work.  
The power of NGS was demonstrated in the releases of structural variants 
identified by the 1000 Genomes project (Abecasis et al. 2010; Abecasis et al. 2012; 
Mills et al. 2011). On the other hand, these publications also reflected a different set 
of challenges faced by NGS in discovering SVs. This is mainly due to the fact that 
short sequences produced by NGS technologies can make unique read mapping 
impossible in certain genomic regions. NGS is good for deletion but less so for 
duplication, and worse for multiallelic CNVs. Regions that are not effectively 
sequenced include GC-rich, VNTR, and repetitive regions. Deletion is easier to detect 
because they are identified by a longer than expected insert size when aligned to the 
reference genome. But NGS is unable to detect insertions that are larger than the 
insert size of the reference library. Therefore, to detect insertions or duplications of 
various sizes, several pair-end or mate-pair libraries with various insert sizes will be 
needed. And there is a technical limit to the insert size in libraries that could be 
constructed. As a result, many repetitive regions, which represent a sizable portion of 
CNVs, the multiallelic CNVs, remain refractory.  
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However, some recent development using sequence read depth coupled with 
paralogous sequence variant has enable advances in mapping these highly duplicated 
regions (Alkan et al. 2009; Handsaker et al. 2015; Sudmant et al. 2010). In addition, 
the Third Generation Sequencing (TGS) platforms using single molecule long reads 
either to map or directly sequence will hold much promise in constructing de novo 
assembly or forming scaffold to facilitate building of detail sequence with NGS. Such 
platforms included those provided by Pacific Biosciences, Nanopore and BioNano. 
As a whole, both microarray and NGS have different sets of technical 
advantages and disadvantages. Microarray will still have its role in CNVs for its cost, 
throughput, and some targeted studies in population-based studies. Both platforms 
will complement each other and a combination of approaches will be necessary for 
comprehensive whole genome analysis. 
The other important gap to be filled will be a reliable, high throughput and 
cost-effective targeted genotyping method, as reflected in Chapter 4. QPCR though 
fast and scalable, has its limitation for high copy multiallelic CNVs. Other targeted 
genotyping methods, such as MLPA, MAPH and PRT (Section 1.4.4), are not as 
scalable and require more optimisation effort. Digital PCR presents the next 
advancement as demonstrated in Chapter 4, particularly the introduction of droplet 
digital PCR (ddPCR) (Hindson et al. 2011). It involves the use of oil/aqueous 
emulsions to partition a PCR reaction into 20,000 tiny, nanoliter-volume reaction 
compartments, allowing a finer scale of copy number differentiation which is 
especially important to accurately differentiate high copy number multiallelic CNVs. 
The capability to run 96 samples simultaneously is also critical for population-based 
studies. 
In summary, this work conducted a discovery study of CNVs in 3 Singapore 
populations, investigated into common CNVs that are population-specific or highly 
stratified between these 3 populations and to study possible functional inference of 
adaptation in these groups of CNVs. The possibility of natural selection on these 
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highly differentiated CNV was also explored. In the later part of this thesis, I have 
studied the amylase genes CNVs as an example of muliallelic CNVs. This work 
demonstrated the challenge of genotyping multiallelic CNVs and provided insights 
into strength and weakness of genotyping methods. Through the development of a 
new method linking qPCR and dPCR genotyping, I discovered a novel distribution 
pattern of AMY1 diploid copy number with even:odd genotype imbalance, due to 
underlying haplotype structures. With this new method, I also studied the population 
diversity of the AMY1 and AMY2A CNV loci. This work also tested a claimed 
association between AMY1 copy number and obesity in a Singapore Chinese cohort 
and we found no evidence to support it. 
The CNV catalogue generated for the three Singapore populations has 
generated some interesting CNV candidates for future studies. The highly population 
differentiated CNV adjacent to NEGR1 with selection will need further study to 
confirm and decipher its role and the exact functional unit under selection. The 
finding of a CNV encompassing CES1 is a novel finding as population-differentiated 
CNV. The correlation of copy numbers between this CNV and its neighbouring 
CNVs with gene family members hints at a similar relationship as in the amylase 
gene locus, and is worth further exploration. Similarly, many other population-
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Taqman Assay Gene Symbol Location on Transcript or 
Gene




Chr Max_Start Max_End Max size 
(bp)
Hs03566526_cn C6 Within Intron 1 AGAGACAAAGGGTTCAGGAAGTGAT 91 789 5 41,267,255 41,277,150 9,895
Hs03900335_cn NA NA TCTTCACATTGGCTCTGCAGTCTGT 108 1834 15 45,992,538 46,001,995 9,457
Hs03724711_cn LINC00032 Overlaps - Exon 17 GTTCTTGGGCAAGGTGACTACTTCT 105 1273 9 27,220,509 27,242,785 22,276
Hs03873630_cn HEATR4 Within Intron 1 TAACAGGGAGTTGTATGATAATGAC 86 1754 14 73,070,876 73,090,732 19,856
Hs04395337_cn NA NA GCTGCATTTCTCCCGTAGGCACAGA 92 1488 11 58,566,573 58,615,474 48,901
Hs07536140_cn NA NA TGCCTGTCCAGCAGATCCACCCTGT 114 111 1 696,962 840,550 143,588
Hs07226363_cn RHD Within Exon 10 AGTCAGAGAAAATGGAGTTGAATCC 107 135 1 25,465,715 25,534,592 68,877
Hs03396518_cn THSD7B Within Intron 11 TTTCCCCAGCATTTCCTGTTTTATA 95 390 2 137,761,562 137,782,241 20,679
Hs02548088_cn TLR3 Within Exon 3 CAGCTGGAAAATCTCCAAGAGCTTC 109 732 4 187,166,418 187,374,152 207,734
Hs03266679_cn NA NA TCCTAATCTGCTGCTTCCTTTTCTT 93 984 7 8,792,410 8,832,522 40,112
Hs03798670_cn NA NA TGGGAGAAGGCACTGATGGGCTGTG 94 1540 11 133,857,095 133,977,420 120,325
Hs03821385_cn CACNA1C Within Intron 3 TCAAGAATAAGGAAGGCCAGGATAT 74 1547 12 2,105,889 2,128,667 22,778
Hs03311349_cn NA NA GAATGTGGTTCTATTCTGTGAAGGG 88 1854 15 95,618,796 95,633,191 14,395
Hs03922779_cn WWOX Within Intron 6 CTTTACCATGAATGGGAATCTTTGC 110 1938 16 76,929,941 76,942,266 12,325
Hs03118886_cn  LINC00202 Within Intron 1 GCCAATTGGGGCTGGCTTTGGTGCA 98 1357 10 27,265,910 27,268,479 2,569
Hs04566242_cn LRP1B Within Intron 2 TCAGTCATTCCAGGGAAACTATGAT 107 392 2 141,971,752 141,973,472 1,720
Hs03314032_cn NA NA GGCTTGTCTATCTGGCTTCACAAAT 80 1899 16 22,612,023 22,694,640 82,617
Hs03205971_cn (5' NEGR1) NA TGTAATTCTGAGGAGATTGACTAGT 111 154 1 72,522,941 72,583,736 60,795
Hs03342654_cn (5' of AMY2A) NA GACGAATAGAGGGTTCTCATCCCAG 85 161 1 103,910,761 103,960,907 50,146
Hs00010003_cn NA NA GAAACGATGGCCAACAGCAGCTAAT 67 1439 10 135,081,984 135,239,886 157,902
Hs03185327_cn  UGT2B17 Overlaps Intron 1 - Exon 1 ACACCAATTGGACACACGACTTACC 109 639 4 69,021,057 69,234,339 213,282
Hs03967623_cn NA NA AGTAGGTTGTAATGAAGGAAGGGCC 109 1991 17 41,006,741 41,015,665 8,924
Hs03960730_cn KANSL1 Within Intron 2 GACCATAAGTTACCGAGAACATGAC 109 1993 17 41,517,686 41,750,195 232,509
Hs03223932_cn NA NA AGGGTCATAGTTTGTACACAGGAAG 85 547 3 163,989,224 164,127,661 138,437
Hs03944240_cn NA NA GCAACCCACGCAATACACTACTGAT 101 1875 16 14,844,825 15,023,758 178,933
Hs02575461_cn GSTM1 Within Exon 1 CGGAATCCGCACCAACCAGCACCAT 82 177 1 110,025,907 110,058,147 32,240
Hs01818263_cn CES1P1 Within Exon 6 CAGTGATGGTGTCTTGTGTCTCTCA 76 1921 16 54,353,890 54,387,091 33,201
Hs07545274_cn  CYP2A6 Within Intron 1 GTCCACACTGGTCAACCCCCTGCCA 107 2076 19 46,040,709 46,072,786 32,077
Hs03367870_cn KIF26B Within Intron 2 CTACAGGTTGCATTCTTGCCTTCTT 110 249 1 243,505,830 243,509,160 3,330
Hs04206213_cn  CFHR3 Within Intron 4 GAGTATCAGCAAAATATGTTAGTTG 82 226 1 194,994,473 195,083,353 88,880
Hs04197581_cn CFHR1 Within Intron 4 GTGTTACTCCAAAGAATGTTGAATA 101 226 1 194,994,473 195,083,353 88,880
Hs03351823_cn RABGAP1L Within Intron 20 TTAGAAGCCATTCCTGTAACAATCT 88 214 1 173,062,498 173,069,074 6,576
Hs03217728_cn NA NA GCCAGTGTTCTGTTGAGCTTGGTGG 109 287 2 40,779,595 40,803,110 23,515
Hs03317369_cn NA NA CATGATAAACCCTGTGGGCAAAGCT 112 2027 18 36,512,703 36,523,810 11,107
Hs04077504_cn NA NA ACTCCTCCTGAAGCCTATTCCCTCC 100 2204 22 22,670,786 22,734,830 64,044
Hs00010004_cn  GSTT1 Within Intron 1 TCATGATCCCCACCCCTTTATTCGG 81 2204 22 22,670,786 22,734,830 64,044
qPCR Assay Information CNVR Information















Taqman Assay Gene Symbol Location on Transcript or 
Gene




Chr Max_Start Max_End Max size 
(bp)
Hs04017250_cn LOC284344 Within Intron 2 CTATTTGATTGAAATGCACCAGAGG 105 2078 19 48,388,815 48,460,022 71,207
Hs04422840_cn DNAJC15 Within Intron 1 ACTAGCAAAGCTGTTTCTCATGGAA 109 1659 13 42,497,548 42,501,093 3,545
Hs00025630_cn CD44 Within Exon 19 TGGTGAACAAGGAGTCGTCAGAAAC 90 1468 11 35,200,620 35,215,983 15,363
Hs03939200_cn CES1 Within Intron 1 TCAAAGCTGGAAGGAAGCCTGGTGA 103 1922 16 54,387,058 54,560,676 173,618
Hs03212536_cn NA NA TAATTTCACCTGCCAAAAGACGTTC 78 393 2 146,580,874 146,583,404 2,530
Hs05420023_cn WWOX Within Intron 9 AGGTTTGGAGGGAGGCCGATAGAGA 104 1939 16 77,208,496 77,251,710 43,214
Hs05458924_cn WWOX Within Intron 9 TGGCATTTATTCTGTTGTCACAGCA 73 1940 16 77,319,838 77,327,934 8,096
Hs05451936_cn NA NA AGCCATGGACAGATACCGCTTGAAG 109 1925 16 58,640,103 58,654,487 14,384
Hs03350272_cn CFHR4 Within Intron 6 CTTTCAAATGTGCAGACCACAGTTC 105 228 1 195,023,645 195,183,422 159,777
Hs03245954_cn NA NA AAGGAGATTGAAGAGTTTTCTCTGT 78 840 5 155,407,677 155,415,307 7,630
Hs04384780_cn NA NA AACAATTCCTGGATTTAAAAGGTTT 100 1411 10 82,871,310 82,879,763 8,453
Hs05846431_cn NA NA GGGTCTGGAGAGGCACGCATACTGA 101 355 2 95,094,701 95,099,193 4,492
Hs03892904_cn NA NA CAGCAGAAAGAGTCTTAGCAGTTGT 97 1726 14 27,536,375 27,591,214 54,839
Hs06768619_cn NA NA TAAGTCCTGTGATCTGAACCAATAT 104 883 6 40,174,188 40,211,285 37,097
Hs05831990_cn (5' of EDAR) NA ATGACAATTCTGCTGCCACTCTGCA 107 367 2 108,642,559 109,819,785 1,177,226
Hs03282110_cn NA NA TGTAGGAGTTAACAGCACTTTGACG 115 1385 10 58,186,381 58,196,843 10,462
Hs07156897_cn  NA NA AATGGAAATGATGAAGGAGTCTGGG 93 2064 19 21,179,648 21,191,982 12,334
Hs06932696_cn NA NA CACTAACAAGGTCACAAAGTCAGGA 107 1624 12 79,349,306 79,352,244 2,938
Hs03637577_cn  NA NA CCTGAGCCCATCTACAGCTTTATTT 87 1016 7 53,433,670 53,563,109 129,439
Hs03850423_cn NA NA TGTTCAGTGAGGCTCTGCTGGATGC 87 1650 13 22,185,775 22,192,245 6,470
Hs04506829_cn NA NA GAAGACGCGCGGGGGGCGGGGGTGG 93 2201 22 21,048,635 21,082,880 34,245
Hs06667362_cn  PIK3CA Within Intron 1 ACCAACTGGAGTTGGAGACCTGGAA 109 556 3 180,365,866 180,389,211 23,345
Hs03249301_cn  NA NA CAGCAGTCTCACACTGGCCCACTCC 109 762 5 9,954,952 9,982,909 27,957
Hs04088805_cn NA NA AATGTGGAGTTCTGTTTGACTGCTT 73 2194 22 17,006,129 17,009,153 3,024
Hs04559564_cn NA NA GAATTTGCCAAACAGGCAGCTCTCA 109 314 2 72,103,499 72,124,997 21,498
Hs00031411_cn CHRNA7 Overlaps Exon 2 - Intron 2 CTCCTGCAGATCATGGACGTGGTGA 106 1817 15 30,027,161 30,248,706 221,545
Hs02932336_cn CYP2C19 Within Intron 6 GGAAGGTGCTGCTAGTGTTCTCCTT 110 1426 10 96,548,713 96,596,764 48,051
Hs01507115_cn EDAR Overlaps Intron 6 - Exon 6 TGGGCGTGCTGGAAGGGAGACAGGG 87 367 2 108,642,559 109,819,785 1,177,226
Hs03204576_cn DNAH14 Overlaps Intron 44 - Exon 45 TACCAACTGGTGAATGTTCCATCTT 93 237 1 223,501,418 223,512,861 11,443
Hs00654324_cn  DLG2 Overlaps Intron 18 - Exon 19 CTGACGAGTTGCGGTGCTATGTTGG 73 1505 11 83,237,190 83,272,311 35,121
Hs05829783_cn NA NA TACCACTGCCCAGATCTCTAAAGCT 92 286 2 40,617,671 40,622,406 4,735
Hs02399076_cn KCNA5 Overlaps - Exon 1 TGCTTGGTAACGGGCTGCCAGAAGA 95 1548 12 5,000,615 5,033,564 32,949
Hs06704673_cn HPSE Within Exon 13 GTCTTTCGCTGACTAGCAACACTGC 103 652 4 84,352,524 84,448,376 95,852
Hs02410005_cn CTNNB1 Within Exon 5 GGAAGCTTCCAGACACGCTATCATG 89 493 3 41,229,838 41,255,648 25,810
Hs03424173_cn ERBB4 Within Intron 1 GCATGCTATCACAGTTGCTTTCGGC 104 420 2 212,889,560 212,900,070 10,510
Hs07226362_cn  AMY1A;AMY1B;AMY1C Within Exon 1 ATGTGTCAGGGCTGAGTGTTCTGAG 101 162 1 103,960,908 104,069,745 108,837















Chr Start End Size (bp) No. of 
genes
Genes Platform
CN0 CN1 CN2 CN3 CN4 CN5 CN6 CN0 CN1 CN2 CN3 CN4 CN5 CN6 CN0 CN1 CN2 CN3 CN4 CN5 CN6 CN7
111 1 696,962 840,550 143,588 4 LOC643837,FAM41C,LOC100288069,NCRNA00115Microarray 0 0 92 6 1 0 0 94 0 0 0 0 85 0 0
qPCR 0 0 77 21 1 0 0 90 3 1 0 0 82 3 0 92.1%
135 1 25,465,715 25,534,592 68,877 1 RHD Microarray 0 95 4 0 0 0 94 0 0 0 5 79 0 1 0
qPCR 0 13 86 0 0 1 25 68 0 0 5 30 50 0 0 27.0%
154 1 72,522,941 72,583,736 60,795 0 5' of NEGR1 Microarray 80 8 11 0 0 78 5 11 0 0 34 19 32 0 0
qPCR 80 19 0 0 0 78 15 0 1 0 34 38 4 9 0 82.0%
161 1 103,910,761 103,960,907 50,146 2 AMY2A, LOC648740 Microarray 0 0 98 1 0 0 0 92 2 0 0 0 79 4 2
qPCR 0 2 94 2 1 0 1 87 4 2 0 2 71 10 2 93.2%
177 1 110,025,907 110,058,147 32,240 3 GSTM1 Microarray 69 30 0 0 0 69 25 0 0 0 35 49 1 0 0
qPCR 64 30 5 0 0 62 25 7 0 0 22 49 13 1 0 90.6%
214 1 173,062,498 173,069,074 6,576 1 RABGAP1L Microarray 3 33 63 0 0 0 17 76 0 0 2 15 68 0 0
qPCR 3 38 58 0 0 0 20 73 0 0 2 18 65 0 0 96.0%
226 1 194,994,473 195,083,353 88,880 2 CFHR3 Microarray 0 10 89 0 0 0 2 7 83 2 0 6 42 37 0 0
qPCR 1 9 88 0 0 1 2 7 84 1 0 6 43 36 0 0 98.6%
226 1 194,994,473 195,083,353 88,880 CFHR1 Microarray 0 10 89 0 0 2 7 83 2 0 6 42 37 0 0
qPCR 0 15 82 2 0 2 9 82 1 0 6 44 35 0 0 95.7%
228 1 195,023,645 195,183,422 159,777 4 CFHR2,CFHR3,CFHR1,CFHR4Microarray 0 5 92 1 1 0 2 91 0 0 0 2 81 1 0
qPCR 0 5 92 2 0 0 2 91 0 0 0 2 81 1 0 99.6%
237 1 223,501,418 223,512,861 11,443 1 DNAH14 Microarray 0 0 36 0 0 0 2 30 0 0 0 0 27 0 0
qPCR 0 1 35 0 0 0 2 30 0 0 0 0 27 0 0 98.9%
249 1 243,505,830 243,509,160 3,330 1 KIF26B Microarray 0 4 94 1 0 0 0 94 0 0 0 0 85 0 0
qPCR 0 5 94 0 0 0 1 93 0 0 0 0 85 0 0 98.9%
286 2 40,617,671 40,622,406 4,735 0 - Microarray 0 0 97 0 0 0 0 92 0 0 0 0 76 0 7
qPCR 0 0 97 0 0 0 0 92 0 0 0 0 83 0 0 97.10%
287 2 40,779,595 40,803,110 23,515 0 - Microarray 0 1 98 0 0 1 15 77 0 0 0 2 83 0 0
qPCR 0 3 96 0 0 1 15 77 0 0 0 1 84 0 0 98.9%
314 2 72,103,499 72,124,997 21,498 0 - Microarray 0 4 93 0 0 1 9 82 0 0 0 0 83 0 0
qPCR 0 4 93 0 0 1 9 82 0 0 0 0 83 0 0 100.0%
355 2 95,094,701 95,099,193 4,492 0 - Microarray 0 5 92 0 0 0 0 92 0 0 0 0 83 0 0
qPCR 0 11 86 0 0 0 0 92 0 0 0 0 83 0 0 97.8%
367 2 108,642,559 109,819,785 1,177,226 10 EDAR Microarray 0 0 33 1 0 0 0 35 0 0 0 0 24 0 0
qPCR 0 0 33 1 0 0 0 35 0 0 0 0 24 0 0 100.0%
367 2 108,642,559 109,819,785 1,177,226 10 3' of EDAR Microarray 0 0 96 1 0 0 0 92 0 0 0 0 83 0 0
qPCR 0 1 95 1 0 0 0 92 0 0 0 1 82 0 0 99.3%
390 2 137,761,562 137,782,241 20,679 1 THSD7B Microarray 0 0 99 0 0 0 0 94 0 0 0 9 76 0 0
qPCR 0 1 98 0 0 0 1 93 0 0 0 10 75 0 0 98.9%
Chinese (n=10 - 99) Malays (n=15 - 94) Indians (n=16 - 85) Concorda
nce





Chr Start End Size (bp) No. of 
genes
Genes Platform
CN0 CN1 CN2 CN3 CN4 CN5 CN6 CN0 CN1 CN2 CN3 CN4 CN5 CN6 CN0 CN1 CN2 CN3 CN4 CN5 CN6 CN7
392 2 141,971,752 141,973,472 1,720 1 LRP1B Microarray 1 4 94 0 0 0 0 94 0 0 0 0 85 0 0
qPCR 1 5 93 0 0 0 0 94 0 0 0 0 85 0 0 99.6%
393 2 146,580,874 146,583,404 2,530 0 - Microarray 46 53 0 0 0 19 74 0 0 0 10 73 0 0 0
qPCR 46 43 10 0 0 19 53 21 0 0 10 34 38 1 0 74.5%
420 2 212,889,560 212,900,070 10,510 1 ERBB4 Microarray 0 0 10 0 0 0 0 15 0 0 0 8 8 0 0
qPCR 0 0 10 0 0 0 0 15 0 0 0 8 8 0 0 98.0%
493 3 41,229,838 41,255,648 25,810 1 CTNNB1 Microarray 0 0 37 1 0 0 0 23 0 0 0 0 32 0 0
qPCR 0 0 38 0 0 0 0 23 0 0 0 0 31 1 0 97.80%
547 3 163,989,224 164,127,661 138,437 0 - Microarray 79 18 2 0 0 72 20 2 0 0 17 41 27 0 0
qPCR 79 18 2 0 0 72 20 2 0 0 17 41 27 0 0 100.0%
556 3 180,365,866 180,389,211 23,345 1 PIK3CA Microarray 0 0 97 0 0 0 0 91 1 0 0 0 83 0 0
qPCR 0 0 97 0 0 0 0 92 0 0 0 0 83 0 0 99.6%
639 4 69,021,057 69,234,339 213,282 3 UGT2B15 Microarray 74 24 1 0 0 54 34 6 0 0 31 38 16 0 0
qPCR 74 24 1 0 0 54 34 6 0 0 31 38 14 2 0 99.3%
652 4 84,352,524 84,448,376 95,852 2 HPSE,COQ2 Microarray 0 0 33 0 0 0 0 32 1 0 0 0 27 0 0
qPCR 0 0 33 0 0 0 0 32 1 0 0 0 27 0 0 100%
732 4 187,166,418 187,374,152 207,734 3 TLR3,CYP4V2,FAM149AMicroarray 0 0 99 0 0 0 0 94 0 0 0 0 80 5 0
qPCR 0 0 99 0 0 0 0 94 0 0 0 0 80 5 0 100.0%
762 5 9,954,952 9,982,909 27,957 1 LOC285692 Microarray 0 0 99 0 0 0 0 94 0 0 0 9 76 0 0
qPCR 0 0 99 0 0 0 0 94 0 0 0 9 76 0 0 100.0%
763 5 9,799,299 10,053,817 254,518 1 LOC285692 Microarray 0 0 99 0 0 0 1 93 0 0 0 0 85 0 0
qPCR 0 0 99 0 0 0 1 93 0 0 0 0 85 0 0 100.0%
789 5 41,267,255 41,277,150 9,895 1 C6 Microarray 1 6 92 0 0 0 0 94 0 0 0 0 85 0 0
qPCR 1 6 92 0 0 0 0 94 0 0 0 0 85 0 0 100.0%
840 5 155,407,677 155,415,307 7,630 0 - Microarray 0 0 99 0 0 0 0 92 0 0 0 11 73 0 0
qPCR 0 0 98 1 0 0 0 92 0 0 0 14 70 0 0 98.5%
883 6 40,174,188 40,211,285 37,097 0 - Microarray 0 0 97 0 0 0 0 92 0 0 0 5 78 0 0
qPCR 0 0 97 0 0 0 0 92 0 0 0 5 78 0 0 100.0%
984 7 8,792,410 8,832,522 40,112 0 - Microarray 0 0 99 0 0 0 0 94 0 0 0 7 78 0 0
qPCR 0 0 99 0 0 0 0 94 0 0 0 7 78 0 0 100.0%
1016 7 53,433,670 53,563,109 129,439 0 - Microarray 0 0 97 0 0 0 0 92 0 0 0 5 78 0 0
qPCR 0 0 97 0 0 0 0 92 0 0 0 5 78 0 0 100.0%
1273 9 27,220,509 27,242,785 22,276 1 NCRNA00032 Microarray 0 0 99 0 0 0 5 89 0 0 0 0 85 0 0
qPCR 0 0 99 0 0 0 6 88 0 0 0 0 85 0 0 99.6%
1357 10 27,265,910 27,268,479 2,569 1 LINC00202 Microarray 0 0 99 0 0 0 0 94 0 0 0 0 77 7 1
qPCR 0 4 95 0 0 0 2 91 1 0 0 3 70 11 1 94.6%







Chr Start End Size (bp) No. of 
genes
Genes Platform
CN0 CN1 CN2 CN3 CN4 CN5 CN6 CN0 CN1 CN2 CN3 CN4 CN5 CN6 CN0 CN1 CN2 CN3 CN4 CN5 CN6 CN7
1385 10 58,186,381 58,196,843 10,462 0 - Microarray 0 0 97 0 0 0 0 92 0 0 0 7 76 0 0
qPCR 0 0 97 0 0 0 0 92 0 0 0 7 76 0 0 100.0%
1411 10 82,871,310 82,879,763 8,453 0 - Microarray 0 0 98 0 0 0 0 92 0 0 0 6 77 1 0
qPCR 0 0 98 0 0 0 0 92 0 0 0 6 78 0 0 99.6%
1426 10 96,548,713 96,596,764 48,051 1 CYP2C19 Microarray 0 0 34 0 0 0 1 35 0 0 0 0 24 0 0
qPCR 0 0 34 0 0 0 1 35 0 0 0 0 24 0 0 100.0%
1439 10 135,081,984 135,239,886 157,902 6 CYP2E1 Microarray 0 0 98 1 0 0 0 87 7 0 0 0 84 1 0
qPCR 0 0 97 2 0 0 0 84 10 0 0 0 81 4 0 97.5%
1468 11 35,200,620 35,215,983 15,363 1 CD44 Microarray 0 0 97 1 1 0 0 93 0 0 0 0 84 0 0
qPCR 0 2 91 6 0 0 0 93 0 0 0 0 84 0 0 97.1%
1488 11 58,566,573 58,615,474 48,901 1 LOC283194 Microarray 0 2 69 26 2 0 1 84 6 3 0 3 73 7 2
qPCR 0 2 63 32 2 0 1 78 13 2 0 3 72 8 2 93.5%
1505 11 83,237,190 83,272,311 35,121 1 DLG2 Microarray 0 0 34 1 1 0 0 26 0 0 0 0 36 0 0
qPCR 0 0 34 2 0 0 0 26 0 0 0 0 36 0 0 100.0%
1540 11 133,857,095 133,977,420 120,325 1 LOC283177 Microarray 0 0 99 0 0 0 7 87 0 0 0 0 85 0 0
qPCR 0 0 99 0 0 0 7 87 0 0 0 0 85 0 0 100.0%
1547 12 2,105,889 2,128,667 22,778 1 CACNA1C Microarray 0 0 99 0 0 0 0 94 0 0 0 6 79 0 0
qPCR 0 0 99 0 0 0 0 94 0 0 0 6 79 0 0 100.0%
1548 12 5,000,615 5,033,564 32,949 1 KCNA5 Microarray 0 0 34 0 0 0 1 24 0 0 0 0 33 0 0
qPCR 0 0 34 0 0 0 1 24 0 0 0 0 33 0 0 100%
1624 12 79,349,306 79,352,244 2,938 0 - Microarray 0 5 92 0 0 0 0 92 0 0 0 0 83 0 0
qPCR 0 7 90 0 0 0 0 92 0 0 0 0 83 0 0 99.3%
1650 13 22,185,775 22,192,245 6,470 0 - Microarray 0 0 97 0 0 0 0 92 0 0 0 5 78 0 0
qPCR 0 0 97 0 0 0 0 92 0 0 0 6 77 0 0 99.6%
1659 13 42,497,548 42,501,093 3,545 1 DNAJC15 Microarray 0 0 80 18 1 0 0 0 0 81 12 0 0 0 0 84 0 0
qPCR 0 0 66 21 9 2 1 0 0 76 13 2 2 0 0 84 0 0 86.6%
1726 14 27,536,375 27,591,214 54,839 0 - Microarray 0 0 97 0 0 0 0 92 0 0 0 6 77 0 0
qPCR 0 0 97 0 0 0 0 92 0 0 0 6 77 0 0 100.0%
1754 14 73,070,876 73,090,732 19,856 2 HEATR4, ACOT1 Microarray 73 26 0 0 0 45 48 1 0 0 7 77 0 1 0
qPCR 74 20 5 0 0 44 38 12 0 0 8 50 26 1 0 83.5%
1817 15 30,027,161 30,248,706 221,545 1 CHRNA7 Microarray 0 0 33 1 0 0 0 33 1 0 0 0 26 0 0
qPCR 0 1 32 1 0 0 0 33 1 0 0 0 26 0 0 98.9%
1834 15 45,992,538 46,001,995 9,457 0 - Microarray 0 18 81 0 0 0 0 94 0 0 0 0 85 0 0
qPCR 0 18 81 0 0 0 0 94 0 0 0 0 85 0 0 100.0%
1854 15 95,618,796 95,633,191 14,395 0 - Microarray 0 0 99 0 0 0 0 94 0 0 0 9 76 0 0
qPCR 0 0 99 0 0 0 0 94 0 0 1 16 68 0 0 96.8%







Chr Start End Size (bp) No. of 
genes
Genes Platform
CN0 CN1 CN2 CN3 CN4 CN5 CN6 CN0 CN1 CN2 CN3 CN4 CN5 CN6 CN0 CN1 CN2 CN3 CN4 CN5 CN6 CN7
1385 10 58,186,381 58,196,843 10,462 0 - Microarray 0 0 97 0 0 0 0 92 0 0 0 7 76 0 0
qPCR 0 0 97 0 0 0 0 92 0 0 0 7 76 0 0 100.0%
1411 10 82,871,310 82,879,763 8,453 0 - Microarray 0 0 98 0 0 0 0 92 0 0 0 6 77 1 0
qPCR 0 0 98 0 0 0 0 92 0 0 0 6 78 0 0 99.6%
1426 10 96,548,713 96,596,764 48,051 1 CYP2C19 Microarray 0 0 34 0 0 0 1 35 0 0 0 0 24 0 0
qPCR 0 0 34 0 0 0 1 35 0 0 0 0 24 0 0 100.0%
1439 10 135,081,984 135,239,886 157,902 6 CYP2E1 Microarray 0 0 98 1 0 0 0 87 7 0 0 0 84 1 0
qPCR 0 0 97 2 0 0 0 84 10 0 0 0 81 4 0 97.5%
1468 11 35,200,620 35,215,983 15,363 1 CD44 Microarray 0 0 97 1 1 0 0 93 0 0 0 0 84 0 0
qPCR 0 2 91 6 0 0 0 93 0 0 0 0 84 0 0 97.1%
1488 11 58,566,573 58,615,474 48,901 1 LOC283194 Microarray 0 2 69 26 2 0 1 84 6 3 0 3 73 7 2
qPCR 0 2 63 32 2 0 1 78 13 2 0 3 72 8 2 93.5%
1505 11 83,237,190 83,272,311 35,121 1 DLG2 Microarray 0 0 34 1 1 0 0 26 0 0 0 0 36 0 0
qPCR 0 0 34 2 0 0 0 26 0 0 0 0 36 0 0 100.0%
1540 11 133,857,095 133,977,420 120,325 1 LOC283177 Microarray 0 0 99 0 0 0 7 87 0 0 0 0 85 0 0
qPCR 0 0 99 0 0 0 7 87 0 0 0 0 85 0 0 100.0%
1547 12 2,105,889 2,128,667 22,778 1 CACNA1C Microarray 0 0 99 0 0 0 0 94 0 0 0 6 79 0 0
qPCR 0 0 99 0 0 0 0 94 0 0 0 6 79 0 0 100.0%
1548 12 5,000,615 5,033,564 32,949 1 KCNA5 Microarray 0 0 34 0 0 0 1 24 0 0 0 0 33 0 0
qPCR 0 0 34 0 0 0 1 24 0 0 0 0 33 0 0 100%
1624 12 79,349,306 79,352,244 2,938 0 - Microarray 0 5 92 0 0 0 0 92 0 0 0 0 83 0 0
qPCR 0 7 90 0 0 0 0 92 0 0 0 0 83 0 0 99.3%
1650 13 22,185,775 22,192,245 6,470 0 - Microarray 0 0 97 0 0 0 0 92 0 0 0 5 78 0 0
qPCR 0 0 97 0 0 0 0 92 0 0 0 6 77 0 0 99.6%
1659 13 42,497,548 42,501,093 3,545 1 DNAJC15 Microarray 0 0 80 18 1 0 0 0 0 81 12 0 0 0 0 84 0 0
qPCR 0 0 66 21 9 2 1 0 0 76 13 2 2 0 0 84 0 0 86.6%
1726 14 27,536,375 27,591,214 54,839 0 - Microarray 0 0 97 0 0 0 0 92 0 0 0 6 77 0 0
qPCR 0 0 97 0 0 0 0 92 0 0 0 6 77 0 0 100.0%
1754 14 73,070,876 73,090,732 19,856 2 HEATR4, ACOT1 Microarray 73 26 0 0 0 45 48 1 0 0 7 77 0 1 0
qPCR 74 20 5 0 0 44 38 12 0 0 8 50 26 1 0 83.5%
1817 15 30,027,161 30,248,706 221,545 1 CHRNA7 Microarray 0 0 33 1 0 0 0 33 1 0 0 0 26 0 0
qPCR 0 1 32 1 0 0 0 33 1 0 0 0 26 0 0 98.9%
1834 15 45,992,538 46,001,995 9,457 0 - Microarray 0 18 81 0 0 0 0 94 0 0 0 0 85 0 0
qPCR 0 18 81 0 0 0 0 94 0 0 0 0 85 0 0 100.0%
1854 15 95,618,796 95,633,191 14,395 0 - Microarray 0 0 99 0 0 0 0 94 0 0 0 9 76 0 0
qPCR 0 0 99 0 0 0 0 94 0 0 1 16 68 0 0 96.8%
1875 16 14,844,825 15,023,758 178,933 11 NPIP Microarray 0 0 54 43 2 0 0 60 32 2 0 0 0 44 37 4 0 0
qPCR 0 0 44 48 7 0 0 51 36 4 3 0 0 22 43 15 4 1 83.8%







Chr Start End Size (bp) No. of 
genes
Genes Platform
CN0 CN1 CN2 CN3 CN4 CN5 CN6 CN0 CN1 CN2 CN3 CN4 CN5 CN6 CN0 CN1 CN2 CN3 CN4 CN5 CN6 CN7
1899 16 22,612,023 22,694,640 82,617 0 - Microarray 0 0 99 0 0 0 0 87 7 0 0 0 85 0 0
qPCR 0 0 99 0 0 0 0 87 5 2 0 0 85 0 0
1921 16 54,353,890 54,387,091 33,201 1 CES1P1 Microarray 16 56 27 0 0 20 41 33 0 0 8 32 45 0 0
qPCR 16 61 22 0 0 20 48 26 0 0 8 32 45 0 0
1922 16 54,387,058 54,560,676 173,618 2 CES1, CES5A Microarray 0 0 0 99 0 0 0 0 92 1 0 0 0 0 0 83 0
qPCR 0 1 22 60 16 0 0 26 47 19 0 1 0 1 43 30 9
1925 16 58,640,103 58,654,487 14,384 0 - Microarray 0 10 89 0 0 0 0 93 0 0 0 0 84 0 0
qPCR 0 10 89 0 0 0 0 93 0 0 0 0 84 0 0
1938 16 76,929,941 76,942,266 12,325 1 WWOX Microarray 0 98 1 0 0 0 94 0 0 0 9 75 0 1 0
qPCR 0 2 97 0 0 0 7 87 0 0 9 25 51 0 0
1939 16 77,208,496 77,251,710 43,214 1 WWOX Microarray 0 1 98 0 0 0 0 93 0 0 0 0 84 0 0
qPCR 0 1 98 0 0 0 0 93 0 0 0 0 84 0 0
1940 16 77,319,838 77,327,934 8,096 1 WWOX Microarray 0 1 97 0 0 1 8 84 0 0 0 3 81 0 0
qPCR 0 1 96 1 0 1 8 84 0 0 0 3 81 0 0
1991 17 41,006,741 41,015,665 8,924 0 - Microarray 37 62 0 0 0 25 69 0 0 0 1 83 0 0 1 0 0
qPCR 0 37 47 15 0 0 25 43 25 1 0 3 6 45 24 6 1
1993 17 41,517,686 41,750,195 232,509 4 KANSL1 Microarray 0 0 99 0 0 0 0 89 5 0 0 0 28 27 30 0 0 0
qPCR 0 1 98 0 0 0 0 87 3 4 0 0 10 24 21 25 4 1
2027 18 36,512,703 36,523,810 11,107 0 - Microarray 7 37 55 0 0 12 51 30 0 0 25 40 19 1 0
qPCR 7 39 53 0 0 12 54 27 0 0 26 41 17 1 0
2064 19 21,179,648 21,191,982 12,334 0 - Microarray 0 0 97 0 0 0 0 92 0 0 0 5 78 0 0
qPCR 0 0 96 1 0 0 0 92 0 0 0 5 76 2 0
2076 19 46,040,709 46,072,786 32,077 1 CYP2A6 Microarray 3 16 80 0 0 1 21 72 0 0 0 4 80 1 0
qPCR 3 19 77 0 0 1 25 67 1 0 0 5 79 1 0
2078 19 48,388,815 48,460,022 71,207 3 LOC284344 Microarray 5 45 49 0 0 7 44 42 0 0 3 8 73 0 0
qPCR 5 47 47 0 0 7 44 42 0 0 3 9 72 0 0
2194 22 17,006,129 17,009,153 3,024 0 - Microarray 0 0 99 0 0 0 0 94 0 0 0 8 77 0 0
qPCR 0 0 99 0 0 0 0 94 0 0 0 8 77 0 0
2196 22 17,004,365 17,150,527 146,162 2 USP18,GGT3P Microarray 0 0 99 0 0 0 0 94 0 0 0 0 84 1 0
qPCR 0 0 99 0 0 0 0 94 0 0 0 0 84 1 0
2201 22 21,048,635 21,082,880 34,245 0 - Microarray 0 0 97 0 0 0 0 92 0 0 0 1 78 4 0
qPCR 0 0 97 0 0 0 1 91 0 0 0 3 72 7 1
2204 22 22,670,786 22,734,830 64,044 4 GSTTP1 Microarray 42 57 0 0 0 34 58 0 1 0 19 63 2 0 0
qPCR 42 46 11 0 0 34 42 11 6 0 19 31 30 4 0
2204 22 22,670,786 22,734,830 64,044 GSTT1 Microarray 42 57 0 0 0 34 58 0 1 0 19 64 2 0 0
qPCR 42 46 11 0 0 34 42 17 0 0 19 31 35 0 0






cytoband genes CNVR overlap 
with
Biological Function
111 1p36.33 LOC643837 whole gene hypothetical protein LOC284591, mRNA. Function unknown.
FAM41C whole gene family with sequence similarity 41, member C (FAM41C), long non-coding RNA. Function unknown.
LOC100288069 part of the gene uncharacterized LOC100288069, long non-coding RNA. Function unknown.
NCRNA00115 whole gene non-protein coding RNA 115. Function unknown.
249 1q44 KIF26B intron 1 kinesin family member 26B (KIF26B), mRNA. Essential for embryonic kidney development. Plays an important role in the compact adhesion between 
mesenchymal cells adjacent to the ureteric buds, possibly by interacting with MYH10. This could lead to the establishment of the basolateral integrity of the 
mesenchyme and the polarized expression of ITGA8, which maintains the GDNF expression required for further ureteric bud attraction. Although it seems to 
lack ATPase activity it is constitutively associated with microtubules (By similarity).
392 2q22.1 LRP1B intron low density lipoprotein receptor-related protein 1B, mRNA. LRP1B belongs to the low density lipoprotein (LDL) receptor gene family. These receptors play a 
wide variety of roles in normal cell function and development due to their interactions with multiple ligands (Liu et al., 2001). Sequence Note: A 
downstream AUG is annotated as the start codon because, as with the mouse homolog, extension of the 5' boundary of the CDS to an upstream AUG would 
eradicate the signal peptide for this receptor protein.
789 5p13.1 C6 intron 1 complement component 6 (C6), mRNA. This gene encodes a component of the complement cascade. The encoded protein is part of the membrane attack 
complex that can be incorporated into the cell membrane and cause cell lysis. Mutations in this gene are associated with complement component-6 
deficiency. Transcript variants encoding the same protein have been described.
1273 9p21.2 NCRNA00032 3' of gene long intergenic non-protein coding RNA 32 (LINC00032), long non-coding RNA. Function unknown.
1540 11q25 LOC283177 3' of gene uncharacterized LOC283177, long non-coding RNA. Function unknown.
 




Note: Red background  represents Chinese-specific common CNVRs. Green background represents Malay-specific common CNVR., Blue background 









cytoband genes CNVR overlap 
with
Biological Function
390 2q22.1 THSD7B intron thrombospondin, type I, domain containing 7B (THSD7B), mRNA. Diseases associated with THSD7B include alcohol dependence, and pancreatic cancer. An 
important paralog of this gene is SPON2.
420 2q34 ERBB4 intron 1 v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4 (ERBB4), transcript variant JM-a/CVT-2, mRNA. This gene is a member of the Tyr protein 
kinase family and the epidermal growth factor receptor subfamily. It encodes a single-pass type I membrane protein with multiple cysteine rich domains, a 
transmembrane domain, a tyrosine kinase domain, a phosphotidylinositol-3 kinase binding site and a PDZ domain binding motif. The protein binds to and is 
activated by neuregulins and other factors and induces a variety of cellular responses including mitogenesis and differentiation. Multiple proteolytic events 
allow for the release of a cytoplasmic fragment and an extracellular fragment. Mutations in this gene have been associated with cancer. Alternatively spliced 
variants which encode different protein isoforms have been described; however, not all variants have been fully characterized. 
732 4q35.1,4q35.2 TLR3 whole gene The protein encoded by this gene is a member of the Toll-like receptor (TLR) family which plays a fundamental role in pathogen recognition and activation of 
innate immunity. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. They recognize pathogen-associated 
molecular patterns (PAMPs) that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective 
immunity. The various TLRs exhibit different patterns of expression. This receptor is most abundantly expressed in placenta and pancreas, and is restricted 
to the dendritic subpopulation of the leukocytes. It recognizes dsRNA associated with viral infection, and induces the activation of NF-kappaB and the 
production of type I interferons. It may thus play a role in host defense against viruses. Use of alternative polyadenylation sites to generate different length 
transcripts has been noted for this gene.
CYP4V2 whole gene encodes a member of the cytochrome P450 hemethiolate protein superfamily which are involved in oxidizing various substrates in the metabolic pathway. 
It is implicated in the metabolism of fatty acid precursors into n-3 polyunsaturated fatty acids. Mutations in this gene result in Bietti crystalline 
corneoretinal dystrophy.
FAM149A whole gene family with sequence similarity 149, member A, transcript variant 1, mRNA. Function unknown
762 5p15.2 LOC285692 5' of gene uncharacterized LOC285692, long non-coding RNA. Function unknown.
1357 10p12.1 NCRNA00202 non-protein coding RNA 202. Function unknown.
1547 12p13.33 CACNA1C intron Calcium channel, voltage-dependent, L type, alpha 1C subunit (CACNA1C), mRNA. This gene encodes an alpha-1 subunit of a voltage-dependent calcium 
channel. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization. The alpha-1 subunit consists of 24 transmembrane 
segments and forms the pore through which ions pass into the cell. The calcium channel consists of a complex of alpha-1, alpha-2/delta, beta, and gamma 
subunits in a 1:1:1:1 ratio. There are multiple isoforms of each of these proteins, either encoded by different genes or the result of alternative splicing of 
transcripts. The protein encoded by this gene binds to and is inhibited by dihydropyridine. Alternative splicing results in many transcript variants encoding 
































Chr Start End Size (bp) genes #_gen
es
Biological Function
Highest delta in C_M population-pair
1754 14 73,070,876 73,090,732 19,856 HEATR4, 2 HEATR4 (HEAT repeat containing 4). Diseases associated with HEATR4 include epididymitis.
ACOT1 ACOT1 (acyl-CoA thioesterase 1). Diseases associated with ACOT1 include human immunodeficiency virus infectious disease, and epididymitis. Acyl-CoA 
thioesterases are a group of enzymes that catalyze the hydrolysis of acyl-CoAs to the free fatty acid and coenzyme A (CoASH), providing the potential to 
regulate intracellular levels of acyl-CoAs, free
fatty acids and CoASH. Active towards fatty acyl-CoA with chain-lengths of C12-C16 (By similarity).  
1488 11 58,566,573 58,615,474 48,901 LOC283194 1 hypothetical protein LOC283194
1563 12 11,111,991 11,143,141 31,150 TAS2R43, 2 TAS2R43 belongs to the large TAS2R receptor family. TAS2Rs are expressed on the surface of taste receptor cells and mediate the perception of bitterness 
through a G protein-coupled second messenger pathway (Conte et al., 2002). Gustducin-coupled receptor immplicated in the perception of bitter compounds 
in the oral cavity and the
gastrointestinal tract. Signals through PLCB2 and the calcium-regulated cation channel TRPM5. Activated by the
sulfonyl amide sweeteners saccharin and acesulfame K. In airway epithelial cells, binding of bitter compounds
increases the intracellular calcium ion concentration and stimulates ciliary beat frequency. May act as
chemosensory receptors in airway epithelial cells to detect and eliminate potential noxious agents from the
airways . 
PRH1-PRR4 PRH (proline-rich protein HaeIII subfamily). PRP's act as highly potent inhibitors of crystal growth of calcium phosphates. They provide a protective and 
reparative environment for dental enamel which is important for the integrity of the teeth.
192 1 147,291,426 147,606,824 315,398 LOC388692 1 hypothetical protein LOC388692
214 1 173,062,498 173,069,074 6,576 RABGAP1L 1 RABGAP1L (RAB GTPase activating protein 1-like) . Diseases associated with RABGAP1L include esophageal squamous cell carcinoma, and esophagitis.
362 2 97,507,179 97,528,142 20,963 ANKRD36B 1 (ankyrin repeat domain 36B) is a protein-coding gene. Diseases associated with ANKRD36B include melanoma, and acral lentiginous melanoma.




7 Olfactory receptors interact with odorant molecules in the nose, to initiate a neuronal response that triggers the perception of a smell. The olfactory receptor 
proteins are members of a large family of G-protein-coupled receptors (GPCR) arising from single coding-exon genes. Olfactory receptors share a 7-
transmembrane domain structure with many neurotransmitter and hormone receptors and are responsible for the recognition and G protein-mediated 
transduction of odorant signals. The olfactory receptor gene family is the largest in the genome. The nomenclature assigned to the olfactory receptor genes 
and proteins for this organism is independent of other organisms..
Appendix 4: The known functions of the Genes that overlap with CNVRs Highly differentiated between Chinese and Malays (Table3.8A). 
 
 








Chr Start End Size (bp) genes #_gen
es
Biological Function
Highest delta in M_I population-pair.
1993 17 41,517,686 41,750,195 232,509LOC644246,LRRC37A,KIAA1267,ARL17B4 Unknown function
226 1 194,994,473 195,083,353 88,880 CFHR1 2 CFHR1 (complement factor H-related 1). This gene encodes a secreted protein belonging to the complement factor H protein family. Might be involved in 
complement regulation. Can associate with lipoproteins and may play a role in lipid
metabolism. Mutations in this gene are associated with an increased risk of atypical hemolytic-uremic syndrome. 
CFHR3, It binds to heparin, and may be involved in complement regulation. Mutations in this gene are associated with decreased risk of age-related macular 
degeneration, and with an increased risk of atypical hemolytic-uremic syndrome. 
894 6 66,456,203 66,463,931 7,728 EYS 1 EYS (eyes shut homolog (Drosophila)). Required to maintain the integrity of photoreceptor cells. The product of this gene contains multiple epidermal growth 
factor (EGF)-like and LamG domains. The protein is expressed in the photoreceptor layer of the retina, and the gene is mutated in autosomal recessive retinitis 
pigmentosa. Multiple transcript variants encoding different isoforms have been found for this gene. 
2078 19 48,388,815 48,460,022 71,207 PSG4,LOC284344,
PSG9
3 The human pregnancy-specific glycoproteins (PSGs) are a family of proteins that are synthesized in large amounts by placental trophoblasts and released into 
the maternal circulation during pregnancy. Molecular cloning and analysis of several PSG genes has indicated that the PSGs form a subgroup of the 
carcinoembryonic antigen (CEA) gene family, which belongs to the immunoglobulin superfamily of genes.
1754 14 73,070,876 73,090,732 19,856 HEATR4,ACOT1 2 As above table
1847 15 82,331,742 82,334,554 2,812 ADAMTSL3 1 A Disintegrin-Like And Metalloprotease Domain With Thrombospondin Type I Motifs-Like 32.
236 1 221,083,948 221,090,227 6,279 DISP1 1 Dispatched Homolog 1 (Drosophila). Functions in hedgehog (Hh) signaling. Regulates the release and extracellular accumulation of cholesterol-modified 
hedgehog proteins and is hence required for effective production of the Hh signal. The pattern of cellular proliferation and differentiation that leads to normal 
development of embryonic structures often depends upon the localized production of secreted protein signals. Cells surrounding the source of a particular 
signal respond in a graded manner according to the effective concentration of the signal, and this response produces the pattern of cell types constituting the 
mature structure. A novel segment-polarity gene known as dispatched has been identified in Drosophila and its protein product is required for normal 
Hedgehog (Hh) signaling. This gene is one of two human homologs of Drosophila dispatched and, based on sequence identity to its mouse counterpart, the 
encoded protein may play an essential role in Hh patterning activities in the early embryo.
1992 17 41,750,187 42,144,468 394,281 NSF,ARL17B,NSFP
1,LRRC37A2,LRRC
37A,ARL17A
6 NSF (N-ethylmaleimide-sensitive factor). Required for vesicle-mediated transport. Catalyzes the fusion of transport vesicles within the Golgi
cisternae. Is also required for transport from the endoplasmic reticulum to the Golgi stack. Seems to function as
a fusion protein required for the delivery of cargo proteins to all compartments of the Golgi stack independent
of vesicle origin. 










Chr Start End Size (bp) genes #_gen
es
Biological Function
Highest delta in C_I population-pair
1993 17 41,517,686 41,750,195 232,509LOC644246,LRRC37A,KIAA1267,ARL17B4 As above
1754 14 73,070,876 73,090,732 19,856 HEATR4,ACOT1 2 As above
226 1 194,994,473 195,083,353 88,880 CFHR3,CFHR1 2 As above
894 6 66,456,203 66,463,931 7,728 EYS 1 As above
1847 15 82,331,742 82,334,554 2,812 ADAMTSL3 1 As above
2078 19 48,388,815 48,460,022 71,207 PSG4,LOC284344,PSG9 3 As above
1031 7 66,266,764 66,282,667 15,903 TYW1 1 TYW1 (tRNA-yW synthesizing protein 1 homolog (S. cerevisiae)).  Probable component of the wybutosine biosynthesis pathway. Wybutosine (yW) is a 
hypermodified guanosine found in phenylalanine tRNA adjacent to the anticodon that stabilizes
codon-anticodon interactions in the ribosome. In yeast, the homolog of this gene is essential for the synthesis
of wybutosine.
1992 17 41,750,187 42,144,468 394,281NSF,ARL17B,NSFP1,LRRC37A2,LRRC37A,ARL17A6 As above





Note: As above, refer to earlier tables for Chinese-Malays, or Malays-Indians. The gene functions have been listed in earlier 2 tables of Appendix 4. 
